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The ventricles of the heart are the chambers responsible for pumping blood into the 
lungs as well as the entire body. In these chambers of the heart, the working myocytes are 
termed ventricular cardiomyocytes (vCMs). Diseases associated with the ventricular chambers 
of the heart such as ventricular fibrillation, myocardial infarction and cardiomyopathy would 
ultimately affect the properties and functions of these vCMs. Limited supply (Peeters et al., 1995) 
and the lack of regenerative capacity of adult human vCMs limit their utility for in vitro studies 
(Mummery, 2005). Therefore, a vCM-specific in vitro model would be a useful tool for the 
development of therapies for ventricular chambers-associated diseases. In addition, the vCM in 
vitro model can also be used in cardiotoxicity drug screening, to screen newly developed drugs 
for ventricular pro-arrhythmic liability.  
In this study, human embryonic stem cells (hESCs) are used as the source of 
cardiomyocytes (CMs). However, cardiac differentiation of hESCs gives rise to all three subtypes 
of CMs. In addition, these hESCs-derived CMs are phenotypically immature, closest to fetal or at 
best, neonatal CMs in characteristic. To facilitate the fractionation of vCMs from a pool of mixed 
hESCs-derived CMs, an MYL2 specific knock-in reporter line was developed. MYL2 has been 
reported to be specifically expressed in vCMs and not atrial cardiomyocytes (Bird, 2003; Zhang 
et al., 2011). The knock-in line was generated with homologous-recombination technique with 
the aid of a novel genome editing tool: transcription activator-like effector nuclease (TALEN). 
Two reporters (mCherry and Gaussia Luciferase) and one selectable marker (neomycin 
resistance) were knocked into the last exon of MYL2 gene, behind the coding sequence of the 
gene. PCR and Southern blotting confirmed that the targeting construct was inserted at the 
correct site. Immunohistochemistry and FACS analysis, together with karyotype data, also 
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confirmed that the knock-in lines are pluripotent and do not show any gross chromosomal 
aberrations. 
Functional validation of this novel reporter line necessitates a robust hESCs cardiac 
differentiation protocol. Therefore another major part of the present study was to optimize a 
previously used in-house CM differentiation protocol to one that is more robust and 
reproducible. Over nine iterations, the KP protocol was optimized. The final version of the 
protocol consistently generated beating embryoid bodies and monolayer of cardiomyocytes by 
day 9 of differentiation. 
Using this optimized protocol, two newly generated MYL2 knock-in reporter lines 
(H9V15 and H9VC16) were differentiated into CMs to validate their functionality. Quantitative 
PCR data from mRNAs extracted from these knock-in CMs showed strong inter-reporter and 
reporter–MYL2 gene expression correlation. Fluorescence microscopy analysis indicated that 
mCherry was expressed in knock-in CMs starting from day 15 of differentiation. In addition, CMs 
positive for mCherry and resistant to neomycin expressed significant levels of MYL2 and 
negligible expression of MYL7 (a gene expressed in immature vCMs and atrial CMs). Gaussia 
luciferase was also stably expressed in MYL2-expressing cells. Taken together, the novel MYL2 
knock-in reporter lines are fully functional as designed.  
The third part of this study makes use of the knock-in CMs to generate biomimetic 
cardiac tissue constructs: engineered heart muscles (EHMs), to study CM maturation in a three-
dimensional tissue construct. A number of factors were tested for their ability to enhance EHMs 
maturation in vitro. These factors included auxotonic stretching, pre-load variation, extracellular 
calcium variation, electrical stimulation and in vitro aging. The in vitro aging experiment 
revealed a number of up-regulated and down-regulated genes as well as microRNAs as EHMs 
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developed in vitro; these are elaborated in Chapter 5. Auxotonic stretching, pre-load variation 
and extracellular calcium variation were not found to improve EHM maturation in vitro, in that 
all EHMs in all experimental groups showed negative force-frequency response, similar to fetal 
CM behavior. Electrical stimulation was found in this study to enhance EHM maturation in that 
calcium handling, force frequency and Isoprenaline/carbachol response of these EHMs were 
improved in the experimental group versus the control group. The mCherry-positive CMs also 
appeared to be more aligned in the electrically stimulated group than in the control group.  
Finally, the cell line was used in two further applications: (1) the development of a vCM-
specific differentiation protocol, and (2) the investigation for the effects of cardio-active drugs in 
EHMs. With this new protocol, more than 45% mCherry positive population was routinely 
obtained with each round of differentiation. The pilot drug testing experiment also revealed 
quantitative luciferase data to be a useful predictor for EHM contractile forces under normal 
conditions.  
In summary, novel MYL2 knock-in reporter lines were developed successfully in this 
study. These lines would be useful tools for identifying and enriching vCMs, allowing for in vitro 
studies of this CM subtype. In addition, electrical stimulation was identified as the modality of 
choice for improving CM maturation in vitro. These new tools and insight will guide future 
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The heart consists of two upper atrial chambers and two lower ventricular chambers. Atria 
serve as blood collection points whereas ventricles serve as pumps. The walls of the heart 
comprise three main layers: the epicardium, myocardium and endocardium (figure 1.1-1). It is 
the myocardium layer that contracts and makes up the atria and ventricles. The myocardium, in 
turn, consists of a number of components: cardiomyocytes (CMs), extracellular matrices, blood 
vessels, lymphatic vessels, nerves and interstitial cells (of Cajal) (Filipoiu, 2014). CMs in the atria 
are accordingly termed atrial cardiomyocytes (aCMs), whereas those in the ventricles are 
termed ventricular cardiomyocytes (vCMs). The third CM subtype: the nodal CMs are located at 
the sinoatrial (SA) and atrioventricular (AV) nodes at the right atrium. 
 
 





Atrial and ventricular cardiomyocytes differ in their electrophysiology and molecular 
biology (Ng et al., 2010). Ventricular CMs (vCMs) have action potentials with lower resting 
potential, higher amplitude and longer phase 2 (figure 1.1-2). This is due to the differential 
expressions of ion channels on the cell surface membranes of the two CM subtypes (Ng et al., 
2010). Details on each of the ion channels responsible for each phase of the action potentials 
are available elsewhere (Ng et al., 2010). The main differences in molecular biology of the two 
different subtypes are summarized in table 1.1-1 (Ng et al., 2010).  
 
 
Figure 1.1- 2 Action potentials of (A) Atrial CMs versus (B) Ventricular CMs 
 
Parameter Atrial cardiomyocytes Ventricular cardiomyocytes 
Transcription factor HRT1 HRT2 
IRX4 
Contractile protein MYL7 MYL2 
Gap junctions CX40 CX43 
Membrane protein Sarcolipin - 
Secretory protein/peptides Atrial natriuretic factor (ANF)  
 
Table 1.1- 1 Differences in molecular biology of atrial CMs versus ventricular CMs 
 
The study described in this thesis aims to develop an in vitro model for the vCMs of the 
heart. Such a model will be useful as there is a limited supply of adult human vCMs (Peeters et 
al., 1995) for use in research since adult human vCMs are difficult to obtain and they also have 
very little regenerative capacity (Mummery, 2005). The availability of vCM in vitro model would 
facilitate more preclinical studies aimed at developing new therapies such as cell-based therapy 





compromised. In addition, such model will also be useful as cardiotoxicity screening platforms 
for new drugs, especially in detecting their ventricular pro-arrhythmic liability (Cavero and 
Holzgrefe, 2014; Vunjak Novakovic et al., 2014). Current cardiotoxicity screenings employ animal 
models which are suboptimal in predicting human responses.  
Human embryonic stem cells (hESCs) are used in the present study as the source of CMs. 
Previous reports have described successful attempts of differentiating these cells into 
contractile CMs in vitro (Wei et al., 2012; Yang et al., 2008; Zhang et al., 2011; Burridge et al., 
2011; Elliott et al., 2011; Laflamme et al., 2007; Paige et al., 2010; Lian et al., 2012; Zhang et al., 
2012). Yet despite the encouraging data reported in these publications, reproducibility remains 
to be an issue in this laboratory and others. Until today, researchers in the field continue to 
publish their own methods of generating CMs, indicative of the difficulties encountered in 
adopting protocols already published by their contemporaries.  
The first part of the thesis describes efforts to develop a more robust and reproducible 
cardiac differentiation protocol in order to improve CM yield. An optimized protocol was 
obtained after nine rounds of iterations; the final version of this protocol consistently generated 
contractile embryoid bodies and CM monolayer by day 9 of differentiation.  
The second part of the thesis describes the development of a reporter line which would 
facilitate the identification of and enrichment for vCMs from a mixture of hESCs-derived CM 
subtypes. From table 1.1-1, there are four possible genes to target for this purpose. However, 
out of the four, only MYL2 gene has been described to be expressed specifically in vCMs (Bird, 
2003; Zhang et al., 2011). HRT2 is also expressed in endothelial and vascular smooth muscle cells 
(Xin et al., 2007). IRX4, although important for ventricular genes regulation, has not been found 
to be sufficient to confer ventricular identity (Bruneau et al., 2001). Therefore, in this study, 
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MYL2 gene is used as a marker to identify vCMs. The MYL2 knock-in line was designed to have 
two reporters (mCherry, Gaussia luciferase) and one selectable marker (neomycin resistance) 
inserted into the last exon and behind the coding sequences of the MYL2 gene. Endogenous 
expression of MYL2 gene in knock-in hESCs will lead to stoichiometric expression of the inserted 
foreign genes, thus enabling enrichment for vCMs through neomycin selection or cell sorting for 
mCherry positive CM population by fluorescent activated cell sorting (FACS). In addition, Gaussia 
luciferase expression would also enable real-time monitoring of vCMs development in vitro.  
The subsequent parts of the thesis describe attempts at improving the phenotypic 
maturation of hESCs-derived CMs as these cells are relatively immature – they are closest in 
phenotype to human fetal CMs (Cao et al., 2008; Snir et al., 2003). Immaturity of these hESCs-
derived CMs limits their potential in applications such as cell therapy and drug screening. In the 
present study, different in vitro modalities were attempted to improve the phenotypic 
maturation of hESCs-derived CMs: (1) three-dimensional versus monolayer culture; (2) 
continuous culture for 90 days in vitro (aging); (3) electrical and/or mechanical stimulation and 
(4) treatment with different extracellular calcium concentrations. CM maturation was 
determined by assessing the expression of reporter genes, contractile forces, calcium handling 
capacity, force-frequency response as well as responses to isoprenaline and carbachol 
stimulations. The results from these investigations are described in detail in Chapters 4-5 of this 
thesis.  
The final chapter of the thesis provides a general discussion to unify the different research 
findings from this study.   
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A number of bioactive molecules were investigated for their ability to direct human 
embryonic stem cells (hESCs) differentiation towards cardiomyocytes (CMs). Over 9 iterations, it 
was determined that the synergistic effect of BMP4, Activin A and BIO-acetoxime (a GSK-3α/β 
inhibitor) for phase 1; Wnt inhibitor and p38/MAPK inhibitor for phase 2 efficiently drove 
cardiac differentiation, generating beating embryoid bodies (EBs) or CM monolayer by day 9 of 
differentiation.  
Once contractile CMs were obtained, they were dissociated into single cell suspension 
(or “trypsinization”) and combined with human foreskin fibroblasts (HFFs) at a preset cell ratio. 
This mixed cell suspension was then resuspended in a collagen gel for casting in molds to make 
engineered heart muscle (EHM) rings. Enzymatic composition as well as trypsinization 
techniques affected CM yield as they varied CM viability from 25.7% to 70.13% post-digestion. 
The cell ratio of CMs to HFFs was also found to affect the functionality of the EHMs. EHMs made 
from 70% CMs and 30% HFFs generated significantly higher forces than those made from 50% 
CMs and 50% HFFs (0.226 ± 0.045mN vs 0.093± 0.018 mN, respectively; p<0.05, n=4, data is 
presented as mean ± SEM).  
 In sum, a robust differentiation protocol was successfully developed over nine 
iterations to efficiently generate CMs from hESCs in nine days. Enzymatic composition used as 
well as trypsinization techniques are critical for maintaining viability of trypsinized CMs and 30% 




It is widely accepted that the adult heart has limited regenerative capacity (Mummery, 
2005). Events leading to cell loss or dysfunction, such as myocardial infarction (MI), are mostly 
irreversible and may result in progressive heart failure and mortality. Progressive heart failure is 
a burgeoning public health problem and despite advances in the medical field, prognosis for 
patients with heart failures remains poor. Heart transplantation still is the gold standard of 
treatment for these patients. However, lack of donors presents a major challenge to this 
approach.  
Cell therapy and tissue engineering present an alternative approach to the problem. 
However, to be clinically relevant, large amounts of cardiomyocytes, CMs (in the order of 109) 
will be needed. Human pluripotent stem cells (hPSCs), given their pluripotency and inherent 
capacity for indefinite cell renewal, present a potential solution. Unfortunately as will be evident 
in the following sections, state-of-the-art methods of differentiating hPSCs to CMs are still 
rather inefficient and are hard to reproduce. This part of the thesis therefore describes work 
that aims to generate a robust cardiac differentiation protocol to enable downstream 
investigations utilizing CMs.  
The development of such a differentiation protocol hinges on the understanding of 
cardiac embryonic development as well as its molecular events in vivo. Therefore, much of the 
following literature review will focus on the different steps of cardiac embryogenesis. Once a 
robust differentiation protocol was developed, the next step was to optimize the protocol for 
generating single cell suspension of CMs (or “trypsinization”). An inefficient trypsinization 
protocol could lead to massive cell death and reduce CM yield for downstream experiments.  
 Introduction and Literature review 2.2.
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There are four contiguous stages of cardiogenesis in mammals: (1) mesoderm formation, 
(2) mesoderm patterning, (3) cardiac mesoderm formation and (4) cardiomyocyte maturation 
(Willems et al., 2009). Cardiogenesis is a highly dynamic process that is tightly regulated by the 
interactions of multiple signaling pathways, some of which will be briefly discussed below. Good 
in-depth reviews on cardiac development have been published elsewhere (Abu-Issa and Kirby, 
2007; Olson, 2006; Olson and Schneider, 2003) 
Mesoderm formation 
Cardiogenesis in mammals starts prior to gastrulation, whereby a number of cells 
destined to be heart cells are scattered throughout the pre-gastrula epiblast (Guzzo et al., 2007). 
Gastrulation begins with the signaling of the transforming growth factor β (TGF-β) family 
member NODAL signaling in the proximal epiblast, which keeps BMP4 expression in the adjacent 
extra-embryonic ectoderm, which then in turn induces canonical Wnt signaling in the proximal 
epiblast (Burridge et al., 2012). Soon after, Wnt expression gets restricted to the posterior 
epiblast only, due to the expression of Wnt antagonist Dkk1 and the NODAL antagonists LEFTY1 
and CER1 (CER1 is also Wnt and BMP signaling inhibitor) in the anterior visceral endoderm. Cells 
destined to be heart cells then ingress and migrate through the Primitive Streak (PS) antero-
laterally, going through epithelial-mesenchymal transition (EMT) to form mesodermal cells 
expressing markers such as T (Brachyury) and Mixl1. Early mesodermal precursor cells migrate 
through PS from posterior region of low activin and high BMPs towards anterior region of low 
BMPs and high activin (Sumi et al., 2008). Just before migration however, these cells transiently 
activate the basic helix-loop-helix transcription factor mesoderm posterior 1 (Mesp1) to enter 
cardiac mesodermal lineage (Bondue et al., 2011; Wu, 2008). Mesp1 has been termed the 
 Embryonic heart development 2.2.1.
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“master regulator” of cardiac lineage specification, more specifically in cardiac progenitor 
specification or cardiovascular lineage commitment (Bondue and al, 2008; Bondue and Blanpain, 
2010). 
 Mesoderm Patterning and Cardiac Mesoderm Formation 
Once the cells reach the anterior position, they have become fully committed to the 
cardiac lineage (Sumi et al., 2008). Mesp1 triggers the expression of cardiac mesodermal 
markers which include Nkx2-5, Tbx5, Hand1/2, Gata4, Mef2c, Myocd, Foxh1 and Isl1 (Bondue 
and Blanpain, 2010; Dierickx et al., 2012). In mice, Nkx2-5 is important for the interpretation of 
patterning signals within the primitive heart tube and is likely to act in tandem with Tbx5 during 
formation of both the atrial and left ventricular compartments (Mummery et al., 2012). The 
cardiac mesoderm gives rise to the first heart field (FHF), second heart field (SHF), endocardium, 
and the pro-epicardial mesenchyme. The differentiation of FHF proceeds ahead of the 
differentiation of SHF, a process regulated by Bmp4. Meanwhile, SHF is still proliferative and 
regulated by hedgehog and canonical Wnt signaling (down-regulation) (Dierickx et al., 2012). 
FGF and Notch signaling come into play once heart fields have been established, controlling 
proliferation and fate determination of cardiac progenitor cells (CPCs) (Dierickx et al., 2012). 
Specifically, Notch induces the expression of Wnt5a, Bmp6, and Sfrp1, which altogether serve to 
increase the proliferation of CPCs (Chen et al., 2008). 
Cardiomyocytes terminal differentiation 
A number of pathways have been reported to regulate CM terminal differentiation 
during cardiogenesis. Firstly, Hedgehog signaling and canonical Wnt signaling are down-
regulated, thus stopping proliferation of CPCs and initiating their differentiation (Dierickx et al., 
2012). In addition, down-regulation of canonical Wnt signaling induces Wnt11 expression, thus 
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switching on non-canonical Wnt signaling (Dierickx et al., 2012). BMP signaling is also needed for 
terminal differentiation by maintaining Tbx20 expression (Shi et al., 2000; Walters et al., 2001). 
Nkx2-5 and Tbx5 associate with members of GATA family of zinc finger transcription factors 
(GATA4/5/6) and with serum response factor (SRF) to activate cardiac structural genes, such as 
actin, myosin light chain, myosin heavy chain (MHC), troponins and desmins (Mummery et al., 
2012). Tbx5 also cooperates with Nkx2-5 to activate expression of atrial natriuretic factor and 
the junctional protein connexin 40 (Mummery et al., 2012). In addition, SRF regulates the 
expression of microRNAs essential in heart development such as miR-1 and miR-133 (Chen et al., 
2006; Zhao et al., 2005). The P38-MAPK pathway regulates the activation of myocyte enhancer 
factor 2c (Mef2c), which in turn regulates cardiac muscle structural genes (Mummery et al., 
2012). Altogether, these different regulatory factors and pathways direct the differentiation of 
CPCs to neonatal stage CMs. These cells are still somewhat proliferative and the process is 
modulated by factors such as IGF1, activating the PI3K/AKT signaling pathway (Evans-Anderson 
et al., 2008). The maturation of CMs beyond this point, however, has not been fully elucidated.  
In conclusion, cardiogenesis in the embryo is governed by precise spatial and temporal 
regulations, as well as interactions of four main signaling pathways: nodal/activin/TGFβ, Wnt, 
BMP, and FGF. In vitro differentiation from hPSCs to CMs is thought to follow similar trends as in 















































































There are many published protocols describing methods to differentiate hPSC to CMs. 
Some methods are using two-dimensional (monolayer) technique while some others are using 
three-dimensional (EB) technique. Regardless of the different technical details, all protocols 
have four similar stages: (1) maintenance of PSCs; (2) differentiation of PSCs to mesodermal cells; 
(3) cardiac lineage specification; and (4) cardiomyocytes proliferation and maturation. 
Differences lie in the techniques in generating the EBs, growth factors/inhibitor cocktail and 
basal media used as well as their time of application and/or removal. Outlined below are some 
of the more common methods used in literature. 
Co-culture with endoderm 
This method attempts to recapitulate the in vivo differentiation environment and was 
first described by Mummery et al. (2003) with subsequent improvement by Passier et al. (2005). 
HESCs and/or hiPSCs were co-cultured with mitomycin-C inactivated visceral endoderm-like cell 
line (END-2) and contractile foci of beating cells were observed within 12 days of culture, with 
about 85% of CMs being ventricular-like in nature as determined through electrophysiological 
measurements. Although this method is relatively inefficient, it consistently induced 
cardiomyocyte (CM) differentiation, indicating the importance of factors secreted/depleted by 
adjacent anterior endoderm in cardiac lineage induction. This protocol served as a model to 
optimize later differentiation protocols. Some enhancements to the protocol involved removing 
serum from the differentiation medium, adding ascorbic acid (Passier et al., 2005), removing 
insulin (Freund et al., 2008), adding low concentration of p38 MAPK signaling inhibitor (Gaur et 
al., 2010; Graichen et al., 2008) and adding prostaglandin I (Xu et al., 2008). These modifications 
have increased the CM differentiation efficiency up to 25 %. 
 Differentiation of hPSCs to CMs  2.2.2.
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2D (monolayer) and 3D (EB)-based Differentiation Techniques 
EB-based differentiation is the most widely-used method to differentiate hPSCs to CMs. 
EBs are three-dimensional spheroids with an inner layer of ectoderm-like cells and a single outer 
layer of endoderm. They are named so to reflect their similarity to early post-implantation 
embryos. Cells in EBs differentiate into derivatives of the three primary germ layers: endoderm, 
mesoderm and ectoderm. Earliest generation of CMs from EBs was seen in mouse EBs 
generated from mouse embryonic stem cells (mESCs) and mouse embryonal carcinoma cells in 
1985. Typically, these cells were dissociated into single cells and aggregated in hanging drops on 
the lids of petri dish to form EBs. Over time, a fraction of the EBs would develop spontaneously 
beating foci containing CMs (Doetschman et al., 1985).  
First few efforts to replicate this method in the hESCs, however, showed that unlike 
mESCs, hESCs tend to die upon single-cell isolation, thus making human EB formation less 
straightforward. The earlier attempt of successful CMs differentiation were from EBs derived by 
collagenase IV treatment: hESC colonies were detached from feeder layer into clumps of 3 to 20 
cells and grown in suspension on non-adherent petri dish (Kehat et al., 2001). In these EBs, cell-
cell contacts induce mesodermal and early cardiac markers (Tran, 2009). Typically after a few 
days, the EBs were transferred to 0.1% coated culture dish for attachment and beating foci were 
observed 4 days post plating. Similar technique (spontaneously differentiating EBs) was also 
utilized to generate CMs from human induced pluripotent stem cells (hPSCs) (Gai, 2009; Nelson, 
2009; Zhang et al., 2009). Despite the low efficiency of this protocol (lower than 1% CMs 
formation), electrophysiological analysis showed that all three subtypes of CMs were generated: 
atrial, nodal and ventricular CMs (He et al., 2003; Kehat et al., 2001; Xu et al., 2002). Other than 
the low differentiation efficiency, this technique is hampered by significant line-to-line 
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variability and low rate of reproducibility. This was caused by the use of undefined media 
components, heterogeneous EB sizes as well as different culture conditions in different labs. 
Improvements to this early protocol require better-defined culture conditions and generation of 
EBs with uniform sizes. 
Some groups tried to overcome the problem of EB size heterogeneity by forced 
aggregation methods in which defined numbers of enzymatically adapted hPSCs were seeded 
into low-attachment U- or V-well bottomed multi-well plates and aggregated with or without 
the aid of centrifugation (Burridge et al., 2007; Ng et al., 2005; Ungrin et al., 2008). In this 
method, EB sizes can be controlled by varying the number of cells seeded into each well. Stem 
Cell Technologies combined this idea with silicon wafer based micro-fabrication technology to 
commercially produce AggreWells. This method, though attractive, is unfortunately still not 
suitable for large scale production as it is rather expensive and time consuming. Other methods 
to keep the EB sizes uniform include micro-well EBs (Khademhosseini et al., 2006; Mohr et al., 
2006; Mohr et al., 2010) and micro-patterned EBs (Bauwens et al., 2008; Peerani et al., 2007). 
These methods focus on limiting the size of clonal growth of each hPSC colony such that upon 
manual scraping of hPSC colony from the substrate, uniform size EBs would be generated. 
However, these approaches necessitate the use of micro-engineering technologies that are not 
publically accessible (Mummery et al., 2012). 
Serum-free media have recently been preferred over serum-containing media since 
there is lot-to-lot variability in serum that might affect the reproducibility of a protocol. To 
circumvent this problem, some groups opt to use serum-free media such as APEL (Stem Cell 
Technologies, Vancouver, BC, Canada) (Elliott et al., 2011), StemPro-34 (Invitrogen) (Yang et al., 
2008), homemade media such as the selenium-transferrin based media (Wei et al., 2012) or the 
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Burridge RPMI+PVA media (Burridge et al., 2011) (similar to APEL). Growth factors and/or 
pathway inhibitors can be added at specific time-points into these serum free media to direct 
the stochastic differentiation process towards the cardiac lineage. Some factors that have been 
shown to improve the efficiency of differentiation include: (1) BMP4 addition from day 0-4 
(Takei et al., 2009); (2) WNT3A or GSK3β-inhibitor addition for the first 24 (Lian et al., 2012) or 
48 hours (Tran et al., 2009); (3) addition of inhibitors of Wnt signaling such as IWR1 from day 4-6 
(Ren et al., 2011) or IWP2/4 from day 3-5 (Lian et al., 2012) or Dkk1 from day 3-5 (Paige et al., 
2010) and (4) addition of p38/MAPK inhibitor SB203580 from day 4-6 (Gaur et al., 2010). 
Furthermore, factors such as G-CSF (Shimoji et al., 2010) and L-ascorbic acid (Cao et al., 2011) 
have been demonstrated to improve cardiac differentiation by enhancing CPCs proliferation 
whereas IGF and IGF2 were shown to enhance the hPSC-derived CM proliferation (Burridge et 
al., 2012; McDevitt et al., 2005). Different groups have used different combination of factors at 
different concentrations and time points in their protocol. Some protocols are discussed in 






Group Primitive streak 
formation 
Mesoderm induction Cardiac specification and  
terminal differentiation 
Efficiency 





1% Selenium Transferrin medium + 
P38-MAPK inhibitor  
SB 203580 (5 µM) 
Day 5-13: 
1% ST medium + P38-MAPK inhibitor 
SB 203580 (5 µM) 
 
Day 13 onwards: Plated on 0.1% 
gelatin coated plates in DMEM+2% FBS 
~22%  
β-MHC (+) 




StemPro 34 + 
BMP4 (10 ng/ml) 
5% CO2/5% O2 
/90% N2 
Days 1–4:  
StemPro34 + 
BMP4  
(10 ng/ml) + 
bFGF (5 ng/ml) + 
activin A  
(3 ng/ml) 
5% CO2/5% O2 
/90% N2 
Days 4–8:  
StemPro34+ 
VEGF (10 ng/ml) + 
human DKK1 (150 ng/ml) 
 
Days 8 onwards: 
VEGF+ DKK1+ bFGF. 
5% CO2/5% O2/90% N2 (until day 12) 
40-50% 
CTNT+ cells 






BMP4 (25 ng/ml)+ 
bFGF (6 ng/ml) 
Day 1-2: 
RPMI+B27+ 
Activin A  
(100 ng/ml) 
Day 3-5: RPMI+B27+ 
Noggin (250 ng/ml) 
 
Day 5-8: RPMI+B27+ 
DKK1 (200 ng/ml) + 
Retinoic acid inhibitor (1 µM) 
 
Day 8 onwards:RPMI+B27+ 








RPMI + PVA ( 4 mg/ml)+ 
1-thioglycerol (400µM) + 
hr-insulin (10µg/ml) + 
BMP4 (25ng/ml) + 
FGF2 (5ng/ml) + 
1x chemically defined 






Day 4 onwards: 
RPMI + 
1-thioglycerol (400µM ) + 
hr-insulin (10µg/ml) + 












Day 0-2: Low Insulin-APEL + 
Insulin (1µg/ml) + BMP4 (20-40ng/ml ) + 
Activin A (20ng/ml) + VEGF (30ng/ml )+ 
SCF (40ng/ml ) + WNT3a (50-80ng/ml)  
Day 3-onwards: 
LI-AEL without growth factors 
~96.4% 
contracting 








Group Primitive streak 
formation 
Mesoderm induction Cardiac specification and  
terminal differentiation 
Efficiency 
Laflamme, M.A. et al 
(2007) 
(2D) 
Day 0-1: RPMI+B27+ 
activin A (100ng/ml) 
Day 1-5: RPMI+B27+ 
BMP4 (10ng/ml) 
Day 6 onwards: 
RPMI + B27 
~30% 
 
Paige, S.L. et al 
(2010) 
(2D) 
Day 0-1: RPMI+B27+ 
Activin A (100 
ng/ml)+ 
Wnt3a (100 ng/ml) 
Day1-5: 
RPMI+B27+ 
BMP4 (10 ng/ml) 
Day 5-11: RPMI+B27+ 
DKK1 (200 ng/ml) 
~48% 
sarcomeric MHC (+) 












RPMI+B27 (-insulin) + 









Zhang, J. et al 
(2012) 
(2D) 




Day 0 - 1: 
RPMI+ B27 (-insulin) 
Matrigel overlay + 
Activin A (100 ng/ml) 
Day1-5: 
RPMI + B27(-insulin)+ 
BMP4 (10ng/ml)+ 
bFGF (5 ng/ml) 





Table 2.2.2-2 Summary of published monolayer based cardiac differentiation protocol 
 
 
Although each study reported moderate to high differentiation efficiencies, 
reproducibility remains an issue in the field. Sometimes, a given protocol and cell line can yield 
significant differences from one experiment to the next in the same laboratory. This 
inconsistency is one of the major setbacks for advancement in the field. A robust and 
reproducible protocol that is applicable to the majority of cell lines is very much needed to fully 







Immunostaining and action potential analysis reveal that hPSC-derived CMs are mostly 
heterogeneous in nature: nodal-like, atrial-like and ventricular-like action potentials can all be 
observed from these CMs (Mummery et al., 2003). The phenotypes of all three CM subtypes 
correspond to their fetal or at most neonatal counterparts. It is interesting to see that different 
protocols generate different proportions of CM subtypes. EB-based protocols generate almost 
equal proportions of the three subtypes while co-culture protocols seem to generate a majority 
of ventricular-like cells based on morphological and electrophysiological parameters (Mummery 
et al., 2003; Rajala et al., 2011). 
HPSC-derived CMs show automaticity and have fetal type: (1) ion channel expression 
(Beqqali et al., 2006); (2) electrophysiological signals with slower action-potential upstroke and a 
relatively depolarized maximum diastolic potential (Brito-Martins et al., 2008; Davis et al., 2011; 
He et al., 2003); (3) gene expression patterns and (4) physical phenotypes (Cao et al., 2008). 
They express expected ionic currents, such as fast sodium current, L-type calcium current, 
pacemaker currents, as well as transient outward and inward rectiﬁer potassium currents (Brito-
Martins et al., 2008; Mummery et al., 2003; Rajala et al., 2011). Among the cardiac-specific 
transcription factors expressed are GATA4, NKX2-5, ISL1, TBX5, TBX20, and MEF2C (Kehat et al., 
2001; Norström et al., 2006; Xu et al., 2002; Xu et al., 2009; Yoon et al., 2006). Structural 
proteins such as sarcomeric proteins α-actinin, cardiac troponins T and I, atrial- and ventricular 
myosin light chains (MYL7 and MYL2); desmin, tropomyosin and gap junction proteins are also 
expressed (He et al., 2003; Mummery et al., 2003; Xu et al., 2002; Xu et al., 2009). Similar to 
adult CMs, contraction in hPSC-derived CMs is a caused by a rise in intracellular calcium 
concentration (Mummery et al., 2003; Sartiani et al., 2007). However, due to the immature 
 Phenotypic Status of hPSC-Derived CMs 2.2.3.
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sarcoplasmic reticulum in hPSC-derived CMs, intracellular calcium handling in these cells differs 
from their adult counterparts. It has been postulated that hPSC-derived CMs lack the expression 
of phospholamban and calsequestrin, which are two of the main intracellular calcium handling 
proteins (Binah et al., 2007; Dolnikov et al., 2005; Sartiani et al., 2007).  Also, unlike the 
characteristic response of a typical mature cardiomyocyte whereby contraction amplitude 
increases in response to drug-increased stimulation (i.e., the force-frequency relationship), 
hPSC-derived CMs have been reported to respond in the opposite manner and display negative 
force-frequency behavior (Kehat et al., 2002). 
Morphologically, hPSC-derived CMs have less deﬁned rod shape and display very low 
frequency of multi-nucleation (<1%) compared to adult human CMs (20%) (Snir et al., 2003). 
Ultra-structurally, hPSC-derived CMs show clearly identifiable sarcomeres with A, I, and Z bands 
and intercalated discs with gap junctions and desmosomes, similar to the adult CMs, although 
the myoﬁbrillar and sarcomeric organization indicate an immature phenotype in the stem cell-
derived population (Kehat et al., 2001; Liu et al., 2007; Snir et al., 2003; Yoon et al., 2006). 
Mitochondria are also present in these cells in the vicinity of the sarcomeres (Rajala et al., 2011). 
  The immaturity of hPSC-derived CMs provided a good platform to study CM maturation 
in vitro. Furthermore, since MYL2 has been reported to be a marker of mature ventricular CMs 
(Franco et al., 1999; Kubalak et al., 1994; Segev et al., 2005), the MYL2 knock-in reporter line 






Culture environment plays an important role in CM maturation. Studies have shown 3-
dimensional (3D) culture in proteinaceous matrix to be superior to monolayer approach for 
maturation of CMs (Tiburcy et al., 2011; Zhang et al., 2013). In comparison to monolayer culture, 
the CMs in 3D culture: (1) appeared to be more rod-shaped (Tiburcy et al., 2011) and had longer 
sarcomeres (Zhang et al., 2013); (2) showed significantly higher conduction velocities (Zhang et 
al., 2013); (3) had higher frequency of bi-nucleation (Tiburcy et al., 2011);  (4) expressed higher 
levels of genes expressed in adult CMs such as CASQ2, SERCA2 and the contractile genes cTnT, 
αMHC, and MYL2 (Zhang et al., 2013); (5) expressed higher levels of adult CMs proteome, 
tropomyosin isoforms, desmin and M-type creatine kinase (Tiburcy et al., 2011); as well as (6) 
exhibited significant positive inotropy with isoproterenol treatment (Schaaf et al., 2011; Tiburcy 
et al., 2011). In addition, CMs cultured in 3D exhibited decreased expressions in ANP and CARP 
proteins and had higher responsiveness to triiodothyronine (T3) treatment, indicative of tissue 
maturation (Akins et al., 2010). As such, a three-dimensional culture system in the form of 
previously reported engineered heart muscles (EHMs) (Soong et al., 2012; Tiburcy et al., 2014) 
will be used for downstream study of maturation. 
  





HESCs were scaled up with manual passaging onto Matrigel-coated 
10cm dishes, making sure that each passaged fragment had similar 
sizes. 5 days later, hESCs were treated with 1mg/ml Dispase at 370C 
for 6 minutes and washed 3 times in DMEM/F12 basal media. HESC 
colonies were dislodged carefully from culture surface using cell scraper and transferred to low 
attachment 6 well plates to form embryoid bodies (EBs) overnight in hESC medium without 
bFGF. On the next day (d1 of differentiation), the culture medium was changed to CARM + 5µM 
SB203580. On day 5 of differentiation, the culture medium was changed to fresh CARM + 5µM 
SB203580 and kept until day 9 when the culture medium was changed to CARM only. 
Contraction of EBs was monitored from day 10 of differentiation onwards.  
 
Burridge 2011 protocol 







 Materials and Methods  2.3.
 Differentiation of hESCs to immature CMs - Embryoid body (3D) approach 2.3.1.
CARM medium 
DMEM (4.5g/L glucose) 




Table 2.3.1-1 Composition 











into single cells 
with TrypLE 
Express and 
seed into V-well 















in 5% O2 
Change 
medium to 
RPMI + Insulin 
















Change medium every 3 days. 
Once contracting, use RPMI + PVA 
or RPMI + Insulin 
Figure 2.3.1-1 Burridge 2011 protocol 
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RPMI + PVA Medium 
RPMI 1640 
400µM 1-thiglycerol 




1% chemically defined lipids 
1µM Y27632 








1% chemically defined lipids 
 
Table 2.3.1-2 Components of media used in Burridge protocol 
 
KP 3D protocol (unpublished) 
This protocol was first developed to improve differentiation efficiency of the then in 
house protocol. KP 3D protocol was optimized by experimenting on the differentiation media 
components, their concentrations and time of applications during differentiation. The final 








Phase 1 Medium 
RPMI 1640 
4mg/ml PVA 
200µM Ascorbic acid 





50ng/ml Activin A 
20ng/ml bFGF 
1% chemically defined lipids 
2µM Y27632 
Phase2 Medium  
RPMI 1640 
1x B27 minus insulin 
1x Penicillin/Streptomycin 

















1x Penicillin/Streptomycin  
 
Table 2.3.1-3 Media composition used in KP 3D protocol  














into single cells 
with 0.05% 
Trypsin/EDTA and 






























Change medium every 2 days. 
Once contracting, B27 (+) medium 
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Lian 2012 protocol 





KP 2D protocol (unpublished) 
This protocol is a derivation of KP 3D protocol. Each version is exactly the same as the 
3D counterpart, in terms of differentiation media compositions and time-points of media 
change. The only difference in the 3D and 2D protocols was that the phase 1 to 4 differentiation 
media used in 3D protocol had to be diluted 1: 4 to be used in 2D differentiation protocol.  
Hudson (in press, 2014) protocol 







 Differentiation of hESCs to immature CMs - Monolayer (2D) approach 2.3.2.
Figure 2.3.2-1 Lian 2012 protocol timeline 




RPMI 1640 with Glutamax 
200µM Ascorbic acid 
1mM Sodium Pyruvate 
1x Penicillin/Streptomycin 
1x  B27 
Mesodermal Medium  
Base medium 
1µM CHIR 
5 ng/ml BMP4 
9 ng/ml Activin A 







Table 2.3.2-1 Media composition used in Hudson protocol 
 
 
Generation of EHMs molds 
Shown on figure 2.3.3-1 is the technical drawing of small circular molds used to cast 
EHMs. Briefly, polydimethylsiloxane (PDMS, or silicone), was poured into a 6cm diameter glass 
petri dish to 0.5cm depth and allowed to crosslink at room temperature overnight. On the next 
day, 4-polytetrafluoraethylene (Teflon®) molds in the form of donuts were arranged on top of 
the semi cross-linked PDMS. Each Teflon® donut was put together with a straw insert and PDMS 
stick inside the donut and more PDMS was poured onto the glass dish to reach the upper 
surface of the Teflon® donut. The PDMS was let to crosslink at room temperature to get rid of 
small bubbles overnight before being baked at 600C oven for 3 hours. 
Generation of auxotonic stretchers 
Auxotonic stretchers were made from PDMS by injecting into pre-made Teflon® molds 
as shown on figure 2.3.3-2. The PDMS was allowed to crosslink overnight at room temperature 
before being baked at 600C oven for 3 hours the next day. After the PDMS was fully cross-linked, 
the resulting stretcher can be extracted from the mold. 
 
  







Figure 2.3.3-1 Technical drawing of EHM molds for casting 
 (Tiburcy et al., 2014) 
Figure 2.3.3-2 Auxotonic stretchers 
A – Teflon® casting molds for auxotonic stretcher 
B – Technical drawing of auxotonic stretcher 
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Cardiomyocytes dissociation to single cell suspension 
A few methods were employed: (1) collagenase I (with or without Y27632) followed by 
“Accutase mix”; (2) collagenase I followed by trypsin in differing concentration; (3) “Accutase 
mix” with prior PBS wash – PBS composition was varied in this case. Collagenase I (Sigma) was 
reconstituted to a final concentration of 2mg/ml in 20% FBS in PBS with calcium and magnesium. 
“Accutase mix” was really Accutase mixed with trypsin/EDTA diluted to a final concentration of 
0.125% and DNAse I diluted to a final concentration of 20µg/ml. 
 
Method 1 and 2: collagenase I (with or without Y27632) was added to cardiomyocytes 
and incubated at 370C for 30 minutes. Y27632 is a cell-permeable small molecule Rho-associated 
kinase (ROCK) inhibitor (Ishizaki et al., 2000). Cardiomyocytes (CMs) were washed with PBS (+) 
once, triturated to break down to small clumps and transferred to a 50ml Falcon tube. Culture 
flask was washed again with PBS (+). CMs were then centrifuged at 1000rpm for 4 minutes and 
the pellet resuspended and incubated for 5-10 minutes at 370C in pre-warmed “Accutase mix” 
or differing concentration of trypsin to produce single cell suspension. Trypsin was deactivated 
by addition of FBS-containing media.  
Method 3: CMs were incubated in either PBS (-) or PBS (+) for 5 minutes at room 
temperature before incubating with “Accutase mix” for 5-10 minutes at room temperature. PBS 
(+) contains 2mg/L CaCl2, 2mg/L MgCl2-6H2O, 4mg/L KCl, 4mg/L KH2PO4, 160 mg/L NaCl, 
43.2mg/L Na2HPO4-7H2O, 20mg/L D-Glucose and 0.72mg/L sodium pyruvate. Enzymes were 





Generation of engineered heart muscles (EHMs) 
 
Master mix components for  
4x small EHMS 
Volume 
(µl) 
Bovine Collagen I (5.83 mg/ml) 322 
2x DMEM 322 
0.1 M NaOH 52 
HFF = 1.753x106 cells 
Cardiomyocytes = 5.26x106 
1408 
Total volume of master mix 2104 
   Table 2.3.3-1 Composition of EHM master mix 
 
 
EHMs are cardiac muscle tissue-mimetic constructs generated by growing CMs and 
human foreskin fibroblasts (HFFs) in a collagen matrix. The cell-in-matrix suspension was cast in 
a ring format using the above mold to make EHM rings. Table 2.3.3-1 lists the composition of 
master mix for every 4 molds in 6 cm glass beaker. Typically, each EHM would contain 0.4 mg of 
collagen and a total of 1.5x106 cells (CMs + HFFs mixture). All components for master mix 
(except CMs and HFFs) were kept on ice to facilitate uniform ring formation. 450 µl of master 
mix was pipetted into each mold and allowed to condense in CO2 incubator at 370C for 1 hour. 
Subsequently, 6 ml of pre-warmed SFMM medium was added into the dish. Media was changed 
the next day and every other day subsequently. Figure 2.3.3-3 shows the process of EHMs 
condensation inside the mold for the first 3 days post-casting. Once fully condensed, EHM rings 
were transferred manually using pipet tips to pre-sterilized auxotonic stretchers. Figure 2.3.3-4 
shows an EHM ring cultured on such stretcher. 
 
SFBM medium 
485ml Iscove  
45mg L-Ascorbic acid 2-phosphate 











 Table 2.3.3-2 Media composition in EHM casting and culture 







EHM rings force measurement 
 
 
 Measurements of EHM contractile forces  2.3.4.
Figure 2.3.3-3 EHMs formation (Tiburcy et al., 2014) 
 
Figure 2.3.3-4 EHM ring on auxotonic 
stretcher. Scale bar = 5mm 
Figure 2.3.4-1 EHM ring stretched in organ bath of contraction setup  
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Isometric forces were measured inside an organ bath supplied by Föhr Medical 
Instruments GmbH (FMI) under a fixed frequency (1.5-2.5Hz) and 200mA field stimulation in 
modified tyrode solution. Tyrode solution contains: 120mM NaCl, 5.36mM KCl, 0.2mM CaCl2, 
1.05mM MgCl2, 22.62mM NaHCO3, 0.42mM NaH2PO4, 1 g/L glucose and 0.1g/L ascorbic acid. 
Briefly, EHM rings were stretched gradually to increase their preload according to Frank-Starling 
law in presence of physiological 1.8mM Ca2+. The Frank starling law describes the positive 
relationship of cardiac muscle stretch and its contractility, up to an optimum length (Iaizzo, 
2009). Thus stretching was stopped once the max-min plot showed plateau phase, which is 
indicative of the sarcomeric optimal length being reached. The EHMs were washed with fresh 
tyrode solution to bring down the calcium concentration back to 0.2mM.  
The calcium response experiment was carried out at Frank Starling length to assess 
cardiomyocytes calcium handling capacity. EHMs were stimulated at 200 mA and 1.5 Hz and 
their forces at increasing calcium concentration (0.2 mM – 4.0 mM) were recorded. Stimulation 
was stopped after the contractile force at 4.0mM calcium was recorded and the EHMs were 
washed with fresh tyrode. To measure the force frequency behavior, EHMs were stimulated at 
constant current of 200 mA at their Frank-Starling length and in presence of 1.2 mM Ca2+. The 
stimulation frequency was changed from 1 Hz to 3 Hz at interval of 5 minutes per frequency. The 
forces generated by EHMs were recorded.  
To assess the responses to β-adrenergic stimulation, EHMs were stimulated at 200 mA 
current, 1.5 Hz frequency in presence of 0.8 mM Ca2+. Isoprenaline was then added to the organ 
bath at a final concentration of 1 µM. Following washing step with fresh tyrode, a muscarinic 
receptor agonist, carbachol, was added to a final concentration of 10 µM.  
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The labor intensive nature of EHM casting and transfer prevented the system to be used 
for high throughput analysis. Since high throughput analysis was necessary for maturation 
studies of the project, we turned to 3D-printing technology to automate molds and stretchers 
production.  
Printing casting plates 
Casting plate was printed with Objet 3D printer from Stratasys, using tango black 
material for the poles and veroclear for the rest. The plate was washed for a week in water and 
then sterilized by autoclaving before use. The V-bottom design around the poles allowed for 
automatic EHM ring transfer onto the poles for auxotonic stretching. 
 
 
Statistical significance was calculated using Prism 5.0 (Graphpad) with the student t-test or 
ANOVA when applicable. Bonferroni's Multiple Comparison Test comparing all groups was used 
as post-hoc test when ANOVA was employed.   
 
 Automation of casting and transfer 2.3.5.























































In house protocol 
The in-house SB protocol forms EBs at high frequency of 
success. However, there were a number of challenges: (1) 
the EBs formed were of different sizes (figure 2.4.1-1), (2) 
the EBs tend to coalesce to form bigger EBs and (3) the 
differentiation efficiency was low (about 10 - 20 % 
beating EBs by day 21 of differentiation).  
Burridge 2011 protocol 
Reproducing Burridge 2011 protocol was found empirically to be challenging due to a 
number of factors: 
1. The protocol required enzymatic cell passaging to single cells on a strict timescale of every 
3 days using feeder cells-conditioned media. All hPSCs lines used in this study (MBJ5, Hes3, 
and H9) differentiated spontaneously when cultured in conditioned media. 
2. The protocol required day (0) to day (2) of differentiation to be carried out in a hypoxic 
chamber, which is not available in this laboratory.  
3. Extensive cell death was observed during EB formation step, resulting in non-uniform EB 
sizes 
4. EB formation step was not always successful for yet unknown reasons 
5. Strictly following the published protocol resulted in cystic EBs. Unfortunately, these EBs 
were not beating even with extended period of culture (≥ 20 days).  
 
Shown in figure 2.4.1-2 are images of EBs derived with Burridge protocol, with different 
starting number of hPSCs.  
 
 Results 2.4.
 Optimization of EB-based cardiac differentiation protocol 2.4.1.
Figure 2.4.1-1 EBs generated by in house 
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Figure 2.4.1-2 The Burridge protocol allows the generation of uniformly-sized EBs, depending on the number of 
cells seeded per well. Scale = 500µm 




KP 3D protocol 
A new protocol, (KP protocol) was developed to improve the then in house 
differentiation protocol efficiency. The protocol was first conceptualized by combining the 
Burridge and Lian protocols and adapting it to a 3D format. To form EBs with similar sizes, 
Burridge’s forced aggregation method was employed. Table 2.4.1-1 shows the diameters of EBs 
formed from different numbers of cells seeded per well using the Burridge and KP protocols on 
day 5 of differentiation. Similar to the Burridge protocol, the first iteration of the KP protocol 
resulted in morphologically cystic EBs, yet no beating was observed. Version 9 is the most robust 
version of the protocol in generating beating EBs as well as bioengineered heart muscles (BHMs). 







Table 2.4.1-2 summarizes the different versions of the KP 3D protocol. Over 9 iterations, 
the protocol improved cardiac differentiation efficiencies from 0% - 100%. Differentiation 
efficiency was measured with the following formula  
Efficiency (%) = Number of beating EBs
Total number of EBs ∗ 100 
 
 
Number of cells 
per well 
Burridge’s protocol/ µm 
(Mean ± SD) 
KP’s protocol /µm  
(Mean ± SD) 
5000 283.14 ± 36.86 87.20 ± 8.92 
10000 232.26 ± 37.04 118.29 ± 11.85 
25000 450.69 ± 46.56 370.18 ± 45.29 
50000 661.38 ± 35.81 540.23 ± 22.31 




Days 0 1 2 3 4 5 6 7 8 9 10 >10 
V1 
 
2 µM CHIR + 400µM 1-
thiglycerol + 4 mg/ml PVA + 
10µg/ml hr-insulin + 25 ng/ml 
BMP4 + 5ng/ml FGF2 + 1% 






400µM 1-thiglycerol + 
10µg/ml hr-insulin + 1% 
chemically defined 
lipids 
400µM 1-thiglycerol + 
10µg/ml rh-insulin 
1% chemically defined lipids   
+ 5 µM  IWP2 
400µM 1-thiglycerol + 10µg/ml rh-insulin 






5 µM BIO + 400µM 1-
thiglycerol 
4 mg/ml PVA +  





1% chemically defined lipids +  
150 ng/ml DKK1 + 5 µM SB203580 
400µM 1-thiglycerol + 10µg/ml rh-insulin 
1% chemically defined lipids + 150 ng/ml DKK1  
 
Efficiency: No EBs 
V3 
 
2 µM BIO + 400µM 1-thiglycerol 
4 mg/ml PVA + 10µg/ml rh-insulin 
40 ng/ml BMP4 + 5ng/ml FGF2 + 40 ng/ml Activin A 
1% chemically defined lipids + 2µM Y27632 
2% B27 (-) + 150 ng/ml DKK1  
+ 5µM SB 203580 
400µM 1-thiglycerol 
10µg/ml rh-insulin 
1% chemically defined lipids + 










D(-1): matrigel overlay + 2µM 
BIO 
Scrape colonies to make EBs 
2% B27 (-) + 10 ng/ml BMP4 + 
 5 ng/ml bFGF + 25 - 100 ng/ml 
Activin A 
2% B27 (-) + 150 ng/ml DKK1 + 5 µM SB203580 2% B27 (+) Efficiency: ≤1.7% 
V5 
 
2 µM BIO + 400µM 1-thiglycerol 
4 mg/ml PVA + 1 µg/ml rh-insulin 
20 ng/ml BMP4 + 5ng/ml FGF2 + 40 ng/ml Activin A 
1% chemically defined lipids + 2µM Y27632 
2% B27 (-) + 2 – 5 µM IWP4 + 5 µM  SB 
203580 







Efficiency 0 1 2 3 4 5 6 7 8 9 10 >10 
6 
2 – 5 µM BIO + 400µM 1-thiglycerol 
4 mg/ml PVA + 1 µg/ml rh-insulin 
20 ng/ml BMP4 + 5ng/ml FGF2 + 40 ng/ml Activin A 
1% chemically defined lipids + 1µM Y27632 
2% B27 (-) +  
2 µM IWP4 or 25 – 50 nM C59 + 5 µM  SB 
203580 






25nM C59 33% 
50nM C59 16.7% 
3µM BIO 
50nM C59 62.5% 
2µM IWP4 80% 
25nM C59 100% 
2 µM BIO 
2µM IWP4 100% 
25nM C59 100% 
50nM C59 85.7% 
 
V7 
2 µM BIO + 400µM 1-thiglycerol 
4 mg/ml PVA + 1 µg/ml rh-insulin 
20 ng/ml BMP4 + 5ng/ml FGF2 + 50 ng/ml Activin A 
1% chemically defined lipids + 1µM Y27632 
2% B27 (-) +  
2 – 5 µM IWP4 or  
25 – 50 nM C59 +  
with or without 5 µM  SB 203580 
2% B27 (-) 
Efficiency: 




5µM IWP4 76.7% 
25nM C59 
- 66.7% 
5µM SB 96% 
50nM C59 
- 10.34% 
5µM SB 96.7% 
 
V8 
2 µM BIO + 400µM 1-thiglycerol 
4 mg/ml PVA + 1 µg/ml rh-insulin 
20 ng/ml BMP4 + 5ng/ml FGF2 + 50 ng/ml Activin A 
1% chemically defined lipids + 1µM Y27632 +  
1mM Sodium pyruvate 
2% B27 (-) +  
25 nM C59 + 5 µM  SB 203580 2% B27 (-) 





2 µM BIO + 400µM 1-thiglycerol 
4 mg/ml PVA + 1 µg/ml rh-insulin 
20 ng/ml BMP4 + 20 ng/ml FGF2 +  
50 ng/ml Activin A 
1% chemically defined lipids + 2 µM Y27632 +  
1mM Sodium pyruvate + 200 µM Ascorbic acid 
2% B27 (-) + 5 µM IWR1 + 5 µM  SB 203580 
+ 200 µM Ascorbic acid 
2% B27 (-) +  
5 µM IWR1 +  
5 µM  SB 203580   
+ 200 µM Ascorbic acid 
+ 1 µM BMS453 
2% B27 (+) +  
5 µM IWR1 + 
5 µM  SB 
203580  





Table 2.4.1-2 Different versions of KP 3D protocol.  
Version 8-9 was validated for more than 5 times in independent experiments per version. 
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In the initial phases of the study reported in this thesis (before the optimization of CMs 
trypsinization protocol), quantification of differentiation efficiency in 2D format was challenging 
in this laboratory due to a number of reasons: FACS analysis of alpha-actinin staining required 
cardiomyocytes monolayer to be trpysinized prior to fixing and staining. This trypsinization step 
was found to be detrimental to cells, killing almost 50%-70% of cardiomyocytes. This high 
amount of cell death subsequently affected the alpha-actinin staining result. Therefore, analysis 
of beating efficiency was done by qualitative observation. Video clips of contracting CM 
monolayer are included in a CD accompanying this thesis.  
Lian 2012 protocol 
In the Lian protocol, extensive cell death occurred after the addition of GSK3 inhibitor (BIO 
or CHIR). Strictly following the published protocol did not generate contractile CMs. Thus the 
Lian protocol was optimized in this laboratory; the optimization steps taken were:  
1. Varying hPSCs culture density 4 days before the start of differentiation (d(-4)) 
2. Varying length of CHIR treatment on d0 - d1 of differentiation (from 20 – 24 hours) 
3. Varying concentration of CHIR and BIO 
4. Varying concentration of IWP4 on d3 of differentiation 
 
The following parameters were determined empirically to give the most efficient 
differentiation using Lian protocol, leading to the generation of beating cells in all wells of NUNC 
12 well plates: 
1. Cell density of  7.5x105 H9 hESCs per well of 12 well plate on d(-4) 
2. Treatment length of strictly 22 hours with 12µM CHIR 
3. Adding a 1:1 mixture of spent and fresh B27(-) medium, with final concentration of 5µM 
IWP4 
 
 Optimization of 2D differentiation protocol  2.4.2.
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Although the Lian protocol was optimized, having to differentiate in 12 well plates was 
time consuming, especially when differentiating large numbers of CMs (in the order of 106) at a 
time. There was a need to scale up the system. Adapting the Lian protocol to T25 and T75 tissue 
culture flasks required further rounds of optimization with regards to cell seeding density. It was 
noted that different hESCs lines (H9, H9V15 and H9VC16) required different cell density on day 4 
before the start of differentiation (d(-4)). H9 and H9V15 required 1.6x105 cells/cm2; while 
H9VC16 required 1.6x105 –2.2x105 cells/cm2.  
Control Ms IgG Alpha-actinin 
   
 
Table 2.4.2-1 The Lian protocol generates >80% α-actinin (+) cardiomyocytes 
 
The Lian protocol was used as the main 2D differentiation protocol as it routinely 
generated >80% alpha-actinin positive CMs (table 2.4.2-1). However, for unknown reasons, the 
differentiation efficiency was suddenly lost after a few good rounds of differentiation. It was 
hypothesized that trypsin-passaging of hESCs might have changed the characteristics of hESCs 
over time thus reducing the efficiency of the Lian differentiation protocol. This prompted the 






The Hudson protocol (Hudson et al, in press) uses trypsin-passaged hESCs cultured on 
HFFs feeder cells for maintenance. This protocol was the main protocol used in the Zimmermann 
lab in Göttingen for CMs differentiation from hESCs. H9 and H9V15 were more adaptable to 
trypsin passaging and culture on HFFs. H9VC16, however, was less adaptable and adaptation 
process to HFFs feeder frequently resulted in spontaneous differentiation. This hampered 
immediate utilization of the Hudson protocol. When healthy looking colonies were finally 
obtained on HFFs, strictly following the protocol did not generate beating cells. The protocol had 
to be optimized. 
The first modification of the Hudson protocol involved using hESCs cultured on MEFs 
instead of on HFFs but this modification did not generate any contractile CMs. A different culture 
medium was then used to culture hESCs from the 4th day prior to differentiation to the day just 
before differentiation (d(-4) to d(-1)) and cell density on d(-1) was optimized further. The cell 
density for H9 and H9V15 was most optimal at 4x106 cells/T25 flask and H9VC16 at 4.5x106 
cells/T25 flask. Furthermore, hESCs were best cultured on MEFs in normal hESCs medium 
instead of Matrigel in mTeSR1 medium prior to differentiation. In other words, the d(-4) to d(-1) 
step of the Hudson protocol had to be omitted.   
Following these modifications, the Hudson protocol proved to be robust, consistently 
generating CMs. However, differentiation efficiencies also dropped as the hESCs passage 
number increased, similar to the observation with the Lian protocol. It was found that over time, 
later passages of hESCs required higher cell density for previously observed differentiation 
efficiencies to be achieved. H9VC16 of passage 13 and above required 1.6x107 cells/T75 flask in 
comparison with earlier passages (1.35 - 1.4x107/T75).   
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KP 2D protocol 
This protocol was optimized in parallel to hESCs trypsin adaptation to HFFs feeder for 
the Hudson protocol. Extensive cell death was observed with the use of the KP 3D protocol 
Phase 1 medium (table 2.4.1-3) for monolayer-based differentiation. Thus different dilutions of 
phase 1 medium were tested. Empirically, 4x dilutions of version 8 and 9 of KP 3D phase 1 
medium was found to be most optimal for monolayer-based differentiation on T25 tissue culture 
flasks (>80% success of all differentiation efforts). Phase 1 medium from version 8 of KP 3D 
protocol was diluted in B27 (-) medium + 1mM sodium pyruvate without ascorbic acid whereas 
Phase 1 medium from version 9 was diluted in B27 (-) + 1mM sodium pyruvate + 200µM ascorbic 
acid. Beating was routinely observed from day 8-10 of differentiation.  
 
Control Ms IgG Alpha-actinin 









Table 2.4.2-2 The Hudson protocol generates >75% α-actinin (+) cardiomyocytes 
 
 























Trypsinization of cardiomyocytes 
CM trypsinization to generate single cell suspension is important for downstream 
experiments. Suboptimal trypsinization technique could result in loss of up to 70% CMs. First 
attempts to digest CMs involved the use of collagenase I for 30 minutes at 370C followed by 
trypsinization with 0.25% trypsin/EDTA for 10 minutes at 370C. This resulted in only 25.7% viable 
CMs.  
10µM Y27632, a rho-associated protein kinase (ROCK) signaling pathway inhibitor, was 
then added into collagenase I; and the effective trypsin concentration in “Accutase mix” (AM) 
was reduced from 0.25% to 0.125%. These changes almost doubled the viability of trpysinized 
CMs to 46.99% ± 5.2% (mean ± SD), as can be seen from bar A in figure 2.4.3-1. Further 
decreasing effective trypsin (T) concentration from 0.125% to 0.05% further improved the 
viability of trpysinized CMs to 65.09% ± 16.1% (mean ± SD).  
It was observed that collagenase I digestion step could be eliminated thus reducing 
trypsinization process from 45 to 20 minutes. Bar C and D in figure 2.4.3-1 show the viability of 
trpysinized CMs when only AM containing 0.05% Trypsin/EDTA + 20µg/ml DNAse I was used. 
Methods C and D differed in the PBS used for washing and the medium used to deactivate the 
digestion enzymes. Method C used PBS (-) to wash the cells whereas D used PBS (+); and C used 
FBS-containing media to deactivate the enzymes while D used serum-free PBS (+) solution. 
Method D was the most optimal, generating 70.13% ± 11.9% (mean ± SD) live CMs post-
digestion. However, the difference was not statistically significant to the results obtained from 
method C.  





Figure 2.4.3-1 CM viability post trypsinization was improved over 4 iterations 
 
 
Effect of composition of EHMs 
The cardiomyocytes (CMs) were then tested for their ability to self-assemble in a 
collagen matrix to form contractile tissue constructs: the engineered heart muscles (EHMs). 
Different ratios of CMs to HFFs (100%: 0% to 50%: 50%) were tested to investigate the optimal 
ratio for highest force generation. EHMs containing 90% and 100% CMs did not condense 
properly to form compact tissues; these EHMs did not contract and were excluded from 
contraction experiment.  
EHMs condensation, i.e. aggregation of the cells and establishment of cell-cell-
connections within the collagen matrix, is a prerequisite for EHM contractile force generation. A 
minimum of 25% HFFs was empirically determined to be critical for EHMs condensation. 
Comparing EHMs containing 30% HFF and 50% HFF, 30%-HFF EHMs significantly (p<0.05, n=4) 
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beat with higher contractile forces: 0.226 ± 0.045mN vs 0.093± 0.018 mN (mean ± SEM). Thus 











n = 4 per group
Ca2+ (mM)
* *













Figure 2.4.3-2 Forces comparison between 30%HFF-EHMs and 50%HFF-EHMs 
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A number of parameters were optimized for printed plate: (1) shape of wells (round and 
oval); (2) materials for poles; (3) diameter of poles; (4) cleaning protocol and; (5) volume of 
master mix. Beating EHMs were obtained successfully when plate was made from veroclear and 
poles from tango black. Poles with 1.3mm diameter allowed better visualization of EHM 
contraction than 1.5mm (1.5 mm is the diameter of auxotonic poles). Cleaning procedure prior 
to plate sterilization was very critical to the success of experiment. Immersing in water for at 
least two weeks, with agitation and daily water change, followed by ethanol and UV sterilization 
was optimal in generating healthy EHMs post casting. Finally, only a max of 200µl of master mix 





As evident from figure 2.4.4-1, EHMs casted in oval shaped wells (n=4) gave EHMs which beat 
with higher force than those casted in round shaped wells. The significance of this difference, 
however, could not be calculated as EHMs casted on round shaped wells snapped during force 
measurement.   
 Printed plate parameters and handling affects functionality of EHMs 2.4.4.
Figure 2.4.4-1 Forces of EHMs casted on round and oval shaped printed wells 
n = 4 per group 
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3-dimensional approach to cardiac differentiation 
HESCs can be differentiated towards CMs using 3D (EB) or 2D (monolayer) approach. The 
EB approach necessitates the formation of uniformly sized EBs. The conventional in house EB 
formation protocol generated non-uniform EB sizes which tend to coalesce to form bigger EBs. 
Furthermore, this protocol resulted in low cardiac differentiation efficiency: only 10% – 20% of 
all differentiated EBs were beating by day 21 of differentiation. 
The Burridge 2011 protocol appeared to offer a simple and efficient approach to make 
uniform-sized EBs via the forced aggregation method. However, the protocol did not generate 
beating EBs. In addition, extensive cell death was observed during EB formation step, resulting 
ultimately in non-uniform EBs. Initially, it was thought that the high concentration of insulin at 
10 µg/ml in the RPMI+PVA medium might prevent efficient cardiac differentiation. It was 
observed previously from the in-house protocol that EBs grown in medium containing 20% 
KnockOut™ serum replacement (KOSR) failed to differentiate towards CMs. KOSR has a high 
level of insulin at approximately 100 mg/l, resulting in an approximately 20 µg/ml in 20% 
solution (Odorico et al., 2004). Thus insulin was removed from RPMI+PVA medium and the 
Burridge protocol was repeated. EBs failed to form in absence of insulin (as reported in KP 3D 
version 2). Removing PVA from the mix also resulted in no EB formation. Therefore, although the 
Burridge 2011 protocol did not result in successful cardiac differentiation, it introduced an 
efficient technique for EB formation, as well as the insight that PVA and insulin are both critical 
for human EB formation. In addition, from experimentation on initial cell seeding number, an 





This initial understanding of EB formation led to further experimentation leading to the 
development of final KP 3D protocol. It was observed that adding a GSK3 inhibitor, 2 µM BIO, 
and 40 ng/ml activin A to the RPMI + PVA mix (as in KP 3D version 3, table 2.4.1-2) resulted in 
cell death during EB formation, which explains the smaller diameter of EBs generated with KP 3D 
v3 protocol (table 2.4.1-1). However, despite cell death, some EBs were observed to be beating, 
and the method improved the cardiac differentiation efficiency from 0% to 6.25%. This initial 
finding highlighted the importance of canonical Wnt signaling, as well as the importance of 
having both Activin A and BMP4 to synergistically activate TGFβ signaling for cardiac 
development. The improvement in cardiac differentiation efficiency might also be attributed to 
the use of a Wnt signaling inhibitor Dkk1 together with p38/MAPK inhibitor SB203580 from day 
4-8 of the differentiation (instead of RPMI+FBS medium in Burridge 2011 protocol). Despite this 
initial success, the low differentiation efficiency indicated that there was still something in the 
medium which might inhibit cardiogenesis. 
Armed with this knowledge, the next iteration involved experimentation with the 
concentrations of some of the active components. In comparison to version three of the KP 3D 
protocol, BIO concentration was kept the same at 2 µM, BMP4 concentration was reduced from 
40 ng/ml to 20 ng/ml; activin A concentration was kept constant at 40 ng/ml and the rh-insulin 
concentration was reduced from 10 µg/ml to 1 µg/ml. Also, since Dkk1 had to be used at very 
high concentrations of 150 ng/ml in version three to four, the cost became prohibitively 
expensive. Therefore, instead of Dkk1, KP 3D version five onwards made use of small molecule 
Wnt signaling inhibitors IWP4, C59 and IWR1 (Chen et al., 2009). In version five of KP 3D protocol, 
two different concentrations were tested: 2 µM and 5 µM IWP4. The p38/MAPK inhibitor 
SB203580 was kept at the same concentration as in version three to four at 5 µM. With these 
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modifications in place, cardiac differentiation efficiency was increased significantly in 
comparison to version three. 46.7% and 35.7% of all differentiated H9 EBs, were beating with 
2µM IWP4 and 5µM IWP4 treatment, respectively. HES3 EBs showed higher differentiation 
efficiencies: 75% and 100% of all differentiated EBs were beating with 2 µM IWP4 and 5 µM 
IWP4 treatment, respectively.  
A couple of reasons could be behind this observed improvement: (1) insulin 
concentration was too high in version 3 at 10 µg/ml and this somehow inhibited phase 1 of 
cardiac differentiation; (2) the ratio of 20 ng/ml of BMP to 40 ng/ml of activin A was more 
optimal than 40 ng/ml of BMP4 to 40 ng/ml of activin A and (3) IWP4 at the 2 different 
concentrations tested (2µM and 5µM) was more effective than 150 ng/ml Dkk1. It has been 
understood that insulin inhibits cardiac differentiation in the early stages of END-2 cell co-culture 
cardiac differentiation system (Xu et al., 2008). A recent publication by Lian et al (2013) also 
support our observation that 10 μg/ml insulin at day 0 fully blocked the synergistic effects of 
activin A and BMP4 in cardiac differentiation as it inhibits cardiac mesoderm differentiation of 
hPSCs. 
Version six of the KP 3D protocol kept concentrations of insulin, BMP4 and activin A at 
the same level as version five. The ROCK inhibitor (Y27632) concentration was reduced from 
2µM to 1µM and BIO was varied from 2 – 5 µM. For phase 2 of the differentiation, on top of 
2µM and 5µM IWP4, a new Wnt inhibitor “C59” was tested at 25nM and 50nM. Generally, lower 
concentrations of BIO (2µM – 3µM) in phase 1 media gave better differentiation efficiencies, 
generating 62.5% – 100% beating EBs from all differentiated EBs. 5µM BIO gave 16.7% – 50% 
beating EBs. When 2µM BIO was used in phase 1 of differentiation, EBs treated with 50nM C59 
in phase 2 of the differentiation showed lower differentiation efficiencies than EBs treated with 
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25nM C59 and 2µM IWP4. EBs treated with 2µM IWP4 and 25nM C59 were all beating while 
only 85.7% of all EBs treated with 50nM C59 were beating. When 3 µM BIO was used in phase 1, 
80%, 100% and 62.5% of all EBs were beating when treated with 2 µM IWP4, 25nM C59 and 
50nM C59, respectively. When 5 µM BIO was used in phase 1, 50%, 33% and 16.7% of all EBs 
were beating when treated with 2 µM IWP4, 25nM C59 and 50 nM C59, respectively. Altogether, 
the result indicated that insulin at 1 µg/ml, BMP4 at 20 ng/ml, Activin A at 40 ng/ml, Y27632 at 
1µM and BIO at 2µM were optimal for phase 1 of cardiac differentiation. For phase 2 of 
differentiation, 2µM IWP4 or 25nM C59 was more optimal than 50nM C59. 
Version seven investigated the importance of p38/MAPK inhibition in phase 2 of cardiac 
differentiation. Activin A concentration was now increased from 40 ng/ml to 50 ng/ml in phase 1 
media and for phase 2 of differentiation, 25nM and 50nM C59 was tested with or without 5µM 
SB203580. For comparison, 2µM IWP4 + 5µM SB203580 and 5µM IWP4 + 5µM SB203580 groups 
were also tested. The result indicated that the p38/MAPK inhibitor SB203580 was needed for a 
more efficient cardiac differentiation. 66.7% and 96% of all differentiated EBs were beating after 
25nM C59 and 25nM C59 + 5µM SB203580 treatment, respectively. Treatment with 50 nM C59 
and 50 nM C59 + 5 µM SB203580 generated 10.34% and 96.7% beating EBs, respectively from all 
differentiated EBs. Finally, from all differentiated EBs, 86.7% and 76.7% of EBs were beating after 
treatment with 2µM IWP4 + 5µM SB203580 and 5µM IWP4 + 5µM SB203580, respectively. C59 + 
SB203580 treated EBs gave higher percentages of beating EBs than those treated with IWP4 + 
SB203580. Thus, it can be inferred that C59 could be a more effective Wnt inhibitor than IWP4. 
This prompted the use of 25 nM C59 + 5 µM SB203580 for phase 2 of cardiac differentiation 
from version eight onwards. 
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Version eight of the protocol consolidated knowledge gained to date. Multiple rounds of 
differentiation showed consistently high EBs differentiation efficiencies (>90%) with version 8 of 
the protocol. Also, it was empirically observed that addition of sodium pyruvate to a final 
concentration of 1mM reduced the extent of cell death during EB formation step. It has been 
known that GSK3β phosphorylates pyruvate dehydrogenase thus inactivating it; this results in 
mitochondrial dysfunction and possibly cell death (Hoshi et al., 1996). GSK3β inhibition, 
conversely, will lead to glycogen synthase and pyruvate dehydrogenase (PDH) activation, 
resulting in increased mitochondrial respiration. In addition, 8 – 24 hours of GSK3 inhibition has 
been reported to result in an approximately twofold increase in glucose uptake due to a similar 
increase in protein expression of the facilitative glucose transporter 1 (GLUT1) (Buller et al., 
2008). Taken together, GSK3 inhibition seems to increase cellular glucose uptake and 
metabolism. This theory could explain the observed cell death when BIO-acetoxime (GSK3β 
inhibitor) was used in phase 1 media. Cell apoptosis was subsequently ameliorated when 1mM 
sodium pyruvate was added into phase 1 media. The cells could have been metabolizing glucose 
at such a fast rate upon GSK3β inhibition by BIO that glucose was rapidly depleted in the 
medium; the cells could be dying due to starvation in absence of pyruvate supplement.  
Version nine (final version) of the protocol serves to further fine-tune the KP 3D protocol 
by increasing bFGF concentration to 20 ng/ml in order to further enhance cell proliferation in the 
early phase of differentiation. To reduce oxidative stress in the culture system during enhanced 
cell proliferation, 200µM of ascorbic acid was added into phase 1 media. Addition of ascorbic 
acid has been shown to improve cardiac differentiation in a number of studies (Burridge et al., 
2012; Burridge et al., 2011; Cao et al., 2012; Kattman et al., 2011) possibly due to  increasing 
collagen synthesis that might enhance proliferation of cardiovascular progenitor cells (Burridge 
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et al., 2014; Cao et al., 2012).  A recent publication by Burridge et al (2014) also highlighted the 
use of ascorbic acid in E8 medium for the culture of hPSCs, thus postulating an additional role of 
ascorbic acid in cardiac differentiation. Furthermore, another report pinpointed the role of 
ascorbic acid as a regulator of DNA methylation in embryonic stem cells by Tet enzymes 
(Blaschke et al., 2013). Thus ascorbic acid might in itself serve to regulate a number of genes 
which altogether serve to enhance cardiac differentiation.  
 In addition, the Wnt inhibitor used in phase 2 of differentiation was changed from C59 
to IWR1. IWR1 has been reported to block Wnt signaling pathway more efficiently as it inhibits 
downstream Wnt responses whereas IWP2 and 4 inhibit novel Wnt production; there could still 
be some residual Wnt responses observed with the use of IWPs. Detailed mechanisms of these 
two different classes of Wnt inhibitors have been well reviewed elsewhere (Chen et al., 2009). 
Recently, IWR1 has been demonstrated to play an important role in ventricular cardiomyocyte  
(vCMs) subtype specification (Karakikes et al., 2014; Weng et al., 2014) Thus the Wnt inhibition 
step was prolonged from 3 days (day 3-6 of differentiation) to 7 days (day 3-10 of differentiation). 
Furthermore, 1µM BMS453 was added from day 6-8 of differentiation in the hope of promoting 
differentiation towards vCM subtype (Zhang et al., 2011), together with the use of IWR1. This 
part will be further elaborated in Chapter 5. In addition, insulin was added back into the medium 
starting from day 8-10, to promote cardiac progenitor proliferation. Using this latest version of 
the protocol, 100% all formed EBs routinely started to beat by day 9 of differentiation. 
2-dimensional approach to cardiac differentiation 
If the success of 3D differentiation protocols hinged on the successful formation of 
uniformly-sized EBs, the success of 2D differentiation protocols was found to depend strongly on 
the cell seeding density on day 0 of differentiation. Cell density had to be just right: sub-
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confluent culture did not differentiate efficiently towards CMs and similarly, over-confluent 
culture also often failed to be differentiated to CMs. Cell-to-cell signaling could be at the root of 
this observation. Bauwens et al (2008) explained that the maintenance of hESCs pluripotency is 
enhanced in larger colonies due to an antagonistic interaction between secreted factors from 
pluripotent hESCs and the extra-embryonic endoderm cells, which regulates Smad1 activation 
(Peerani et al., 2007). Increased hESCs density leads to higher levels of secreted BMP antagonists 
(such as GDF3) by these cells, thus promoting self-renewal, as well as the expression of neuro-
ectodermal markers Pax6 and nestin via the reduction in Smad1 activation (Bauwens et al., 2008; 
Pera et al., 2004). However, lower hESCs densities render the hESCs more susceptible to BMP-2 
secreted by extra-embryonic endoderm. BMP2 will activate Smad1 and self-renewal of hESCs 
will be suppressed instead.  As such, hESCs cultured in low density tend to differentiate towards 
endodermal lineages (higher Gata6/Pax6 ratio), whereas hESCs cultured in high density tend to 
differentiate towards ectodermal lineages (Bauwens et al., 2008). 
In the effort to reproduce the Lian protocol, a number of challenges were encountered: 
there was (1) a drift in optimal cell seeding density; (2) failure to replicate the protocol when 
fresh RPMI + B27 (-) + 5 µM IWP4 was added on the third day of differentiation (mixture of spent 
and fresh media was required instead). As described above, it was also observed experimentally 
that as hESCs grew older, a more dense seeding density was required on day 0 of differentiation 
to achieve previously observed differentiation efficiencies. Enzymatic passaging methods of 
hESCs (collagenase or trypsin-based) have been reported to promote chromosomal aberrations 
in hESCs lines that had originally been propagated with manual methods over as few as 23 
passages (Mitalipova et al., 2005). In addition, the same authors also reported that hESCs 
passaged with bulk passaging methods (cell-dissociation reagent based and/or enzymatic based) 
74 
 
demonstrated an increase in the expression of early differentiated genes, indicating that these 
methods had compromised the undifferentiated hESCs normal gene expression profile 
(Mitalipova et al., 2005). Therefore, the observed drift in optimal seeding density might be 
caused by bulk passaging and high density culture conditions; which might have affected the 
gene expression profiles of hESCs used in this study such that it affected the “balance point” in 
which the cells define their optimal cell density on day 0 of differentiation.  
It is still not understood how mixing spent media with fresh RPMI + B27 (-) + 10µM IWP4 
in 1:1 ratio promotes the differentiation process. Presumably, the differentiating cells secreted 
bio-active factors into the media, which, when in combination with 5µM IWP4, effectively tuned 
the signaling pathways efficiently to enhance cardiac differentiation in the differentiating cell 
population.   
Cardiomyocyte trypsinization protocol 
The first attempt of CMs isolation with collagenase I and 0.25% trypsin/EDTA resulted in 
25.7% viable CMs. CM viability was observed to increase as trypsin concentration was decreased, 
reaching about 47% ± 5.2% when the trypsin concentration was halved in conjunction with the 
use of Accutase mix. CM viability was further enhanced to 65.1% ± 16.1% as trypsin 
concentration was further lowered to 0.05%. Thus it appears that trypsin concentration plays a 
major role in CM viability post digestion.  
 However, experimental observations indicated that trypsin concentration was not the 
only parameter determining CM viability post-digestion. It was observed that the state of 
cardiomyocytes just before trypsinization was more important – the CMs had to be quiescent 
prior to trypsinization. In house protocol for isolating rat CMs from rat EHMs involve the use of 
0.035 mg/ml Liberase Blendzyme III (Roche) and 30 mmol/L BDM (2,3-butanedione monoxime) 
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at 37 °C for 60 min.  The use of BDM improved isolated cell number, viability and morphology 
and is effective in that respect. However, BDM use is also associated with a number of 
disadvantages: BDM acts as a non-specific phosphatase in the isolation solutions and especially 
in culture media. Prolonged perfusion with BDM may result in cells with better morphology, but 
cells either enter a state of terminal contracture and die, are not excitable, or have significantly 
altered cellular electrical properties once BDM was removed (Verrecchia and Herve, 1997; 
Watanabe et al., 2001; Wolska and Solaro, 1996). Thus different CM trypsinization methods 
were explored. However, the most effective protocol was the simplest, necessitating only 5 
minutes of CM incubation in PBS (+) at room temperature prior to trypsinization. There is very 
low level of calcium in PBS (-) or PBS (+), thus contractile forces of the CMs are reduced following 
PBS wash. At this point, trypsinization into single cell suspension with Accutase will result in 
minimal CM death. This current protocol led to improved CM viability post digestion to around 
70% ± 11.9%.   
In vitro cardiac tissue mimetic - Engineered Heart Muscles (EHMs) 
The heart is composed of different cell types: cardiac fibroblasts and cardiomyocytes 
(majority); endothelial cells; vascular smooth muscle cells (VSMCs); macrophages and neurons 
(Banerjee et al., 2007; Baudino et al., 2006; Camelliti et al., 2005; Harvey and Rosenthal, 1999; 
Zimmermann, 2011). All cellular components interact collectively and dynamically with the 
extracellular matrix to regulate cardiac mechanical, biochemical and electrophysiological 
functions (Baudino et al., 2006). In this light, in order to construct a functional in vitro model of 
heart tissue, one needs to incorporate these different components accordingly. Published 
reports have demonstrated the indispensable role of non-myocytes fraction for the generation 
of functional cardiac tissue patch (Kim et al., 2010; Naito et al., 2006; Zimmermann et al., 2006; 
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Zimmermann and Eschenhagen, 2003). Some groups used fibroblasts (Soong et al., 2012; Tiburcy 
et al., 2014), while some others used endothelial cells and/or smooth muscle cells (Liau et al., 
2011; Naito et al., 2006; Narmoneva et al., 2004).  
In this study, fibroblasts were used to represent the non-myocyte fraction due to two 
main reasons (1) they form the majority of the non-myocyte fraction in native human hearts and 
(2) they produce extracellular matrix for tissue growth and maintenance (Zimmermann, 2011). 
During EHM casting, collagen type-I was used as the matrix to hold the different cells together, 
as the native human heart contains mostly collagen type I and III (Zimmermann, 2011). 
Interestingly, the observed experimental results seem to recapitulate the in vivo conditions, with 
30% fibroblast-containing EHMs contracting with higher forces than 50% fibroblasts-containing 
EHMs (Banerjee et al., 2007). EHM contractile forces also increased with increasing extracellular 
calcium concentrations, and they responded well to isoprenaline stimulation. As such, EHMs 
could be used as in vitro model of the heart tissue for downstream studies of hPSC-derived CM 
maturation.  
3D-printing technology for the automated formation of EHMs 
3D-printing technology allows immediate prototyping of ideas. In this study, 3D-printing 
was used to print a semi-automated plate system which enabled EHMs casting and transfer to 
auxotonic stretchers to be done in automatic and seamless manner. Unfortunately, although 
veroclear and tango black were biocompatible materials, the support and binding materials were 
not. It was observed that leeching of residual support material to culture medium was cytotoxic. 
In addition, the tango black material did not provide the same mechanical properties to the 
conventionally used PDMS, thus altering the properties of 3D-printed stretchers. The utility of 
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this technology depends on future optimizations on the plate design as well as printing materials 
and sterilization techniques. Due to the time limitation, this effort was discontinued.  
Concluding remarks 
Cardiogenesis is a tightly regulated process governed by precise spatial and temporal 
regulation, as well as interactions of four main signaling pathways: nodal/activin/TGFβ, Wnt, 
BMP, and FGF. However, in vitro recapitulation of these events are as not as straightforward. 
Successful in vitro cardiac differentiation protocols do not stop at simply incorporating these 
pathways at specific timings in the regime. Special attention to: (1) techniques used in 
maintenance of pluripotent hPSC culture (Burridge et al., 2014), (2) EB sizes for 3D-based 
differentiation, (3) hPSC density on day 0 of differentiation for 2D-based differentiation, as well 
as (4) the compositions of differentiation media is of utmost importance and can make or break 
the differentiation protocol at hand.   
In this part of the study, both 3D and 2D differentiation protocols for CM generation 
from hESCs have been successfully optimized. With the new protocol described here, it is 
possible to generate 100% beating EBs and monolayers by day 9 of differentiation.   
Similar attention to detail is also needed for the generation of a functional in vitro heart 
tissue model: the EHM tissue constructs. Successful in vitro engineering of functional heart 
muscles pivots on the understanding of native heart components and their respective functions. 
Additionally, efficient trypsinization protocol of CMs can improve CM yield, which is the 
bottleneck in making large numbers of EHMs for downstream studies. In this study, a simple yet 
efficient CM trypsinization protocol has been successfully developed. In addition, early 
experiments with EHMs composition indicated 30% HFFs: 70% CMs ratio to be the most optimal 
for EHM formation.   
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State-of-the-art cardiomyocyte differentiation protocols result in a heterogeneous 
population of cardiomyocytes (CMs) and other cell types (Burridge et al., 2014; Mummery et al., 
2012; Rajala et al., 2011). This heterogeneity is suboptimal for downstream experiments as it can 
affect the accuracy of results from studies aimed at investigating just a specific subtype of CMs.   
To enable enrichment for ventricular cardiomyocytes (vCMs), an MYL2 knock-in line was 
generated by homologous recombination mediated by a novel genome editing technology, TAL-
effector Nucleases (TALENs). A targeting vector was cloned and electroporated along with 
forward and reverse TALENs to generate the recombinant knock-in line.  
Efficiency of homologous recombination was determined by PCR and ranged from 5.33% 
- 27.2%, depending on the wild type pluripotent stem cell line used. A few clones were chosen 
for Southern blotting to validate successful homologous recombination event and Southern blot 
showed positive heterozygous knock-in at the gene locus of interest. FACS and 
immunohistochemistry data showed that knock-in lines are positive for pluripotency markers 
SOX2, OCT3/4, NANOG, TRA-1-60 and SSEA4. Karyotyping data also showed no gross 
chromosomal aberrations.  
Initial validation experiments revealed that MYL2 was expressed later than day 14 of 
differentiation. RNA from knock-in CMs (day 18 – 90 of differentiation) was extracted for 
quantitative PCR (qPCR) experiment to assess correlation between the expression level of MYL2 
and inserted reporters.  QPCR data showed that reporter genes were expressed in high 
correlation to MYL2 gene. Each reporter gene’s expression was also highly correlated with the 




MCherry expression was observable from day 18 of differentiation onwards in CM 
monolayer culture. In the engineered heart muscles (EHMs), mCherry expression was observable 
from day 24 of differentiation onwards. MCherry expression was observed to increase 
qualitatively with time, with day 90 of differentiation EHMs showing significantly brighter signal 
than day 24 of differentiation EHMs. MCherry-positive CMs were sorted out with FACS and their 
RNA extracted for qPCR experiment. QPCR data showed that mCherry-positive CMs expressed 
significantly higher level of MYL2 gene than mCherry-negative CMs (p ≤ 0.001). Treating knock-in 
CM monolayer with G418 for one week resulted in enrichment for mCherry-positive CMs, 
indicating that knock-in CMs expressed neomycin resistance gene. Finally, Gaussia luciferase (G. 
Luc) was also expressed as early as day 21 of differentiation in CM monolayer as well as in EHMs. 
G. Luc expression increased with time, with a maximum level of expression observed on day 45 
of differentiation in EHMs. 
It was observed that CMs derived from H9VC16 (a knock-in line in which the PGK-HygroR 
cassette was removed) expressed significantly higher level of mCherry than H9V15-derived CMs 
(p ≤ 0.001). However, G. Luc and neomycin resistance (NeoR) reporter genes expression did not 
differ significantly between H9VC16 and H9V15 (parental line of H9VC16 with PGK-HygroR 
cassette still intact). 
In conclusion, the engineered MYL2 knock-in reporter lines are functional as designed with 
the three knocked-in foreign genes being expressed in significant correlation with the MYL2 gene. 
These novel reporter lines can function as an enrichment tool for vCMs, thus allowing for 




Human embryonic stem cells (hESCs)-derived ventricular cardiomyocytes (vCMs) are of 
interest in the field of cardiovascular research. Diseases involving the ventricular chambers of 
the heart will ultimately affect the vCMs. A pure population of vCMs would enable in vitro 
studies of these diseases, as well as studies aimed at developing potential therapies for them. 
Yet, supply of vCMs is limited and when they become available, the yield is often 
insufficient as these cells are terminally differentiated and have lost most of their proliferative 
capacity. With unlimited proliferative potential, hESCs becomes an attractive source of CMs. Yet, 
hESCs give rise to immature CMs from all different subtypes (more on this in chapter 4 of this 
thesis). Therefore, an enrichment tool for hESCs-derived vCMs will be useful and relevant for this 
field of research. A homogenous population of vCMs would also provide in vitro toxicology data 
with higher accuracy and predictive power, especially for assessing drug-induced ventricular pro-
arrhythmic events. 
There have been a few reports describing attempts at deriving a relatively homogenous 
population of vCMs. Zhang et al. (2011) reported the role of retinoic acid (RA) in CMs subtype 
specification, with RA agonist increasing the proportion of atrial-like CMs to 94% and RA 
inhibition (by using RA inhibitor BMS 189453) increasing the proportion of ventricular-like cells 
to 83%. Müller et al. (2010) transfected mouse embryonic stem cell (mESC) line with eGFP which 
expression was under the control of MYL2 promoter and enhancer element of CMV. As 
mentioned previously, MYL2 gene is expressed in vCMs but not atrial CMs (Bird, 2003; Zhang et 
al., 2011), thus prompting its use as vCM marker in this laboratory and others. MYL2 promoter 
sequence -497 to +70 relative to transcription start site has also been used to drive the 
expression of GFP reporter using recombinant adenoviral constructs (Bizy et al., 2013; Huber et 
 Introduction and Literature review 3.2.
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al., 2007). These approaches employed standard transfection technique, which although is 
simpler than homologous recombination strategy, carries with it inherent disadvantages. 
Compared with standard transfection strategy, homologous recombination enables a 
better control of the targeting construct integration site and it reduces the likelihood of the 
targeting construct integrating into multiple locations in the genome. Site-specific knock-in will 
also result in a more consistent level of expression of the transgenes from generation to 
generation (Koch Institute for integrative cancer research at MIT, 
http://ki.mit.edu/sbc/escell/models/knock).  
To generate a multifunctional reporter line, a multicistronic reporter construct has been 
designed in the present study. This construct contains two reporters: a fluorescent protein 
mCherry (mChr) and bioluminescence enzyme Gaussia Luciferase (G.Luc); and a selectable 
marker: Neomycin resistance (NeoR). For simplification purpose, these three inserts will 
henceforth be referred to as “reporters.”  
This reporter construct was designed such that all reporters are transcribed along with 
the MYL2 gene. As such, the levels of their expressions should be in stoichiometric ratio with the 
endogenous level of MYL2 gene expression, thus enabling real time monitoring of MYL2 gene 
expression.  
Having a multicistronic targeting construct with three reporters side-by-side, a cleaving 
strategy during translation was needed. Traditionally, internal ribosomal entry site (IRES) has 
been used for multicistronic vectors. However, IRES is relatively large at around 600 base pairs. 
In addition, the expression of the downstream cistron strongly depends on its specific location 
relative to the IRES and hence this system might not be dependable as the downstream coding 
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sequence often suffers from much lower levels of expression than the upstream sequence 
(Trichas et al., 2008). As such, IRES usually does not provide equivalent levels of expression of 
the genes separated by its elements (Trichas et al., 2008). There was a need for an alternative.  
The use of 2A peptides has recently been favored over IRES. The 2A sequences are 
relatively short peptides (about 20 amino-acids long, depending on the virus of origin) containing 
the consensus motif Asp-Val/Ile-Glu-X-Asn-Pro-Gly-Pro. They cause “ribosomal skip” during 
translation as they prevent the formation of a peptide bond between the penultimate glycine 
and the last proline residue (Donnelly et al., 2001). The ribosome would skip to the next codon 
during translation, with the nascent peptide cleaving between the glycine and proline residue of 
the 2A peptide. After cleavage, the short 2A peptide remains fused to the C-terminus of the 
'upstream' protein, while the proline is added to the N-terminus of the 'downstream' protein.  
There are four types of 2A peptides, each derived from different virus: foot-and-mouth 
disease virus, equine rhinitis A virus, Thosea Asigna virus and porcine teschovirus-1. Of the four 
aforementioned types, the one derived from porcine teschovirus-1 (P2A) has the highest 
cleavage efficiency as tested in three commonly used human lines, zebrafish embryos and adult 
mice (Kim et al., 2011). Advantages of using 2A peptide have been well reviewed by de Felipe 
and colleagues (de Felipe et al., 2006). This superiority over IRES has prompted the use of P2A 
sequence in our targeting vector.  
Having the targeting vector at hand, the appropriate method of getting this vector into 
the hESCs genome had to be identified. In hESCs, chemical methods of transfection generated 
homologous clones 10–5 of the time (Eiges et al., 2001). However, attempts using ExGen500 and 
FuGene-6 for homologous recombination into the human POU5F1 gene resulted in no resistant 
colonies to selection drugs (Zwaka and Thomson, 2003). When these authors employed 
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electroporation method however, they obtained 103 G418-resistant clones, 28 of which (27%) 
were demonstrated to be positive for homologous recombination through PCR and Southern 
Blotting. This recombination efficiency was further improved to almost 40% when they used a 
second targeting vector with a longer 3' homologous arm. The same authors further reported a 
26:1 ratio of stable transfected clones to homologous recombination events for the POU5F1 
construct when hESCs were electroporated with a DNA construct containing a neo cassette 
under the control of the tk promoter. A lower ratio of 50:1 was reported for transfection of 
the HPRT1 vector (Zwaka and Thomson, 2003).  
In recent years, the advancement in genome engineering technology has made available 
more tools for improving homologous recombination efficiency. Zinc Finger Nucleases (ZFNs) 
technology gained popularity as a mediator of homologous recombination process in the mid-
21st century. This technology is a development of initial work by Chandrasegaran and colleagues 
(Kim et al., 1996). ZFNs can be engineered to introduce a double stranded break into the desired 
target gene locus, thus stimulating gene targeting 102 - 104 fold by activating cellular DNA repair 
pathways (Cathomen and Joung, 2008). Although this improved efficiency is highly desirable, the 
technology also carries with it some drawbacks. One of the most concerning drawbacks is the 
cytotoxic effect of ZFNs due to off-target effects; this has been reported in several studies (Alwin 
et al., 2005; Beumer et al., 2006; Bibikova et al., 2002; Miller et al., 2007; Porteus, 2006; 
Szczepek et al., 2007). In addition, designing ZFNs to bind to specific sequences of the DNA can 
be rather challenging (Ramirez et al., 2008) as the binding specificity of ZFNs array assembly 




A more recent advancement in genome editing technology came in the form of 
transcription activator-like effector endonucleases (TALENs). TALENs, like ZFNs, consist of DNA 
binding modules coupled to FokI endonuclease (Boch and Bonas, 2010; Boch et al., 2009; 
Christian et al., 2010; Moscou and Bogdanove, 2009; Li et al., 2011; Mahfouz et al., 2011; Miller 
et al., 2011). The DNA-binding modules originate from plant pathogens Xanthomonas. Each 
module consists of a tandem repeat of 34 amino acids and is nearly identical to the others 
except for the residues at position 12 and 13, which are termed repeat variable diresidues 
(RVDs). These RVDs are the ones conferring nucleotide binding specificity of the module (Boch et 
al., 2009; Moscou and Bogdanove, 2009). “NI” binds to A; “HD” to C; “NN” or “NK” to G and “NG” 
to T (Boch et al., 2009). In this way, DNA binding region can be engineered to target a specific 
site of known sequences in the genome.  
Some studies have reported the efficiencies of non-homologous end joining (NHEJ)-
induced mutagenesis mediated by TALENs of up to 45% of transfected cells (Miller et al., 2011; 
Mussolino et al., 2011). In addition, TALENs have been shown to edit the genome with low 
toxicity (Mussolino et al., 2011). The most attractive advantage of using TALENs over ZFNs is the 
apparent lack of context dependence and 1:1 correspondence of RVDs with a specific nucleotide 
pair (Carlson et al., 2012). This is in contrast to ZF modules, where there is redundancy of ZFs for 
a given triplet of base pairs. This redundancy is further complicated with contextual interaction 
within the ZFNs array assembly (Carlson et al., 2012). Thus engineering DNA binding specificity is 
more straightforward in TAL effector than ZFs.  Very recently, another genome editing tool 
becomes available: CRISPR/Cas technology (Jinek et al., 2012). However, the use of this 
technology as genome editing tool was only gaining popularity midway through this project. 
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Therefore, in this study, TALENs were used to enhance homologous recombination efficiency to 
generate the knock-in cell line described herein.  
 Once a stable MYL2 knock-in reporter line was obtained, this line would be 
differentiated to CMs and the reporter genes expression would be analyzed. In particular, the 
faithfulness of the reporter genes expression, i.e. the degree of correlation between their 
expressions and the expression of MYL2 gene as well as to one another, would be examined in 
this part of the study. Finally, the effects of removing PGK-Hygromycin cassette from the knock-




Preparing  5’ and 3’ homology arms to MYL2 gene 
MBJ6, HES3, and H9 hESCs genomic DNA (gDNA) were extracted using Qiagen DNeasy® 
Blood and Tissue kit. The sequences flanking about 1kb 5’ and 3’ from the stop codon of MYL2 
gene were PCR amplified using Expand Long Template PCR System from Roche. The cycling 
protocol for the amplification is as follows:   
Step Temperature (0C) Time (s) Cycle 



















150 + 20 per cycle 
20x 
Final elongation 68 480 1x 
Cooling 4 ∞ 1x 
 
Table 3.3.1-1  PCR amplification protocol for MYL2 homology arms 
 
 
Adding 5’-LoxP and 3’ LoxP sites to PGK-Hygro selection cassette 
MHC-Luc plasmid contains PGK-Hygro cassette and was obtained from Dr. William Sun. 
The PGK-Hygro cassette was amplified using long primers named Phlox (forward and reverse), 
which contain LoxP sequence as well as complimentary bases to the template of interest. For 
this PCR amplification, Expand High Fidelity enzyme by Roche as well as 5% DMSO additive was 
used. Product obtained was 1.83kb in length. PCR product of LoxP-PGK-Hygro-LoxP (herein, 
“Phlox”) was cut from the gel and extracted using Qiaquick gel extraction kit from Qiagen. The 
cycling parameters are as follows: 
 
 Materials and Methods  3.3.
 Cloning of targeting plasmid 3.3.1.
97 
 
Step Temperature (0C) Time (s) Cycle 





























120 + 10 per cycle 
15x 
Final elongation 72 480 1x 
Cooling 4 ∞ 1x 
 
Table 3.3.1-2 PCR amplification protocol for adding LoxP to PGK-Hygro 
 
 
Cloning MYL2 PCR product into TOPO vector 
Once MYL2 PCR product was obtained at suitable amount, they were cloned into pCR™ 
2.1-TOPO® vector which was part of Invitrogen’s TOPO® TA Cloning® Kit. Different molar ratio of 
PCR inserts: vector ration was tested for efficient transformation into TOP10 chemically 
competent of TG1 electrocompetent cells. The general methodology is outlined below: 
Chemical transformation Electrical transformation 
1. Prepare PCR products and mix with commercial 
vector as per manual 
1. Prepare PCR products and mix with commercial 
vector as per manual 
2. Take out 4ul of this mix and put into TOP10 
chemically competent cells 
2.   Take out 2ul of this mix and put into 50µl TG1 
electro-competent cells 
3. Incubate on ice for 30 minutes 3.    Transfer mixture to 1mm cuvette 
4. Heat shock cells at 420C for 45s without shaking 4.  Transform with 10 µF capacitance, 600Ω resistance 
and 1800V voltage 
5. Put back on ice immediately and recover with 
250µl SOC medium 
5.   Within 10s, add 950µl of recovery medium into the 
cuvette and resuspend well 
6. Incubate at 370C for 1hour with 200rpm shaking 6.    Transfer to culture tube and incubate tube at 370C 
for 1hour with 250rpm shaking 
7. Spread 100µl of cells per ampicillin selection 
plates and incubate overnight 
7.    Spread 100µl of cells per ampicillin selection plate 
and incubate overnight 
 
Table 3.3.1-3 Protocol of Chemical and Electrical transformations 
 
White colonies were picked from TOPO-MYL2 selection plates and grown overnight at 370C with 
200rpm shaking frequency in LB medium. Plasmids were then extracted from the bacterial cells 
using Qiaprep spin miniprep kit from Qiagen. To confirm successful cloning of MYL2 into pCR™ 
2.1-TOPO® vector, restriction digest with EcoRI-HF was carried out. True transformant clones will 
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generate 3 bands: 6.278kb, 2.365kb and 3.913kb. Once positive clones are identified, their 
plasmids were sent for sequencing to check for mutations at MYL2 insert.  
Generating targeting vector – Self Assembly Cloning 
The targeting vector consists of three parts: (1) homology arms to endogenous MYL2 
gene, (2) reporters cassette, and (3) loxP flanked-selection cassette PGK-HygroR. To combine all 
three parts of the targeting vector, self-assembly cloning (SAC) method as previously reported 
was employed (Matsumoto and Itoh, 2011). In short, each insert of interest is to be PCR 
amplified two times using two pairs of primers that would generate “sticky-ends” either only on 
5’ end or 3’ end of the insert. PCR amplicons from the same template but different sets of 
primers would be termed sister amplicons (A and B; C and D; E and F). Each sister amplicon 
together with its respective primers are outlined in table 3.3.1-4; and the cycling parameters of 
PCR reactions used to amplify amplicons are outlined in table 3.3.1-5. All amplifications were 
done using High Fidelity Phusion Hot Start II enzyme in presence of 5% DMSO additive. 
 
 
Table 3.3.1-4 Details of primers and templates used for PCR amplification of inserts for SAC 
 
Sister amplicons would be denatured and reannealed back together such that each 
insert would have sticky ends on both 5’ and 3’ ends.  The sticky ends of first insert would 
complement the sticky ends of the second insert, those of the second will complement those of 
the third; and the third will complement the first thus sticking all inserts together to form a 
nicked vector. Upon successful transformation into bacterial hosts, these nicks would be sealed 
off and functional nick-free plasmids are generated.  
 
 Reporters insert Phlox MYL2 homology arms 
Primers used Primer 1-2 and 2-1 (A)  
Primer 1-1 and 2-2 (B) 
Primer 3-2 and 4-1 (C) 
Primer 3-1 and 4-2 (D) 
Primer 5-2 and Primer 6-1 (E) 
Primer 5-1 and Primer 6-2 (F) 




Table 3.3.1-5 PCR amplification parameters of different inserts for SAC 
 
 
Nicked SAC plasmids were transformed into TOP10 chemically competent cells. For each 
transformation experiment, 20 colonies or more were picked and screened using restriction 
digest and DNA sequencing. All picked colonies were first digested with NheI for 2 hours (to 
show presence of MYL2 homology arms), followed by SalI-HF for 2 hours (to show presence of 
reporters insert) and finally with NdeI for another 2 hours (to show presence of Phlox). At each 
digestion step, an aliquot was taken out of the reaction and analyzed by gel electrophoresis. A 
positive clone would show bands at the following lengths: 
1. After NheI:  6.071kb and 4.629kb 
2. After SalI-HF:  4.629kb, 3.216kb, 2.855kb 
3. After NdeI: 4.629kb, 2.855kb, 1.616kb, 1.600kb 
 
Generation of TALENs expression vectors 
TALENs were commercially generated by Life Technologies. They were designed to 
target the last exon of MYL2 gene just before the stop codon. In this laboratory, each of the 
forward (F-) and reverse (R-) TALEN construct was cloned into pEF6-expression vectors. To 
amplify F- and R- TALEN plasmids, 1.5µl of each F- and R- TALEN plasmids was mixed with 25µl  
E. Cloni cells. This mixture was transferred immediately into 1cm cuvette and electroporated 
with the same parameter as previously described  (table 3.3.1-3) for electroporating TG1 electro-
competent cells. After 1 hour incubation, cells were spread onto Kanamycin selection plates. 10 




Initial denaturation:  
980C, 240s, x1 
Initial denaturation:  
980C, 90s, x1 
Initial denaturation:  
980C, 180s, x1 
Denaturation: 980C, 30s 
Annealing: 620C, 90s             x25 
Extension: 720C, 85s 
Denaturation: 980C, 30s 
Annealing: 580C, 30s             x25 
Extension: 720C, 60s 
Denaturation: 980C, 30s 
Annealing: 620C, 80s              x25 
Extension: 720C, 225s 
Final extension: 720C, 300s, 1x Final extension: 720C, 300s, 1x Final extension: 720C, 600s, 1x 
Cooling: 40C, ∞ Cooling: 40C, ∞ Cooling: 40C, ∞ 
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clones from F- and R- TALEN plates were picked for scaling up. The plasmids from these clones 
were then extracted from the cells using Qiagen miniprep kit, and digested with HindIII and NotI 
to check for the presence of TALEN inserts. Presence of insert will be indicated by a band at 
3.075kb. 100ng of plasmids from positive clones F2 and R2 were used as templates in PCR 
amplification of the F- and R- TALEN sequences with high fidelity hot start II Phusion polymerase 
using TAL-5 and TAL-3 primers. The cycling parameter is outlined below: 
Step Temperature (0C) Time (s) Cycle 











Final elongation 72 300 1x 
Cooling 4 ∞ 1x 
 
Table 3.3.1-6 PCR amplification parameters to generate F- and R- TALEN PCR products 
 
 
The resulting F- and R-TALEN PCR products were loaded onto agarose gel for gel 
electrophoresis and the appropriate band at 3.075kb was cut and gel purified with Promega 
Wizard® SV Gel and PCR Clean-Up System. To clone F- and R- TALENs into expression vector, a 
single “A” overhang was first added onto extracted PCR products using Dream Taq polymerase 
from Thermo Scientific. This fresh PCR product was mixed with pEF6-TOPO vector from 
Invitrogen as per supplier’s manual and transformed into TOP10 chemically competent cells. 10 
clones each were picked from F- and R- TALEN selection plates and grown overnight in 
2xTY+ampicillin medium at 370C with 200rpm shaking. Plasmids from cultured clones were 
extracted using Qiagen miniprep kit and further digested with SpeI and NheI to determine if F- 





Throughout this project, a number of feeder cells were used: (1) CF1 mouse embryonic 
fibroblasts (MEFs) (Millipore), (2) hygromycin resistant MEFs (Millipore), (3) DR4 MEFs (ATCC), (4) 
Puromycin-resistant MEFs (Stem cell technologies), (5) HFFs (ATCC) and (6) normal human 
dermal fibroblasts (NHDF) (Lonza). All mouse fibroblasts and human fibroblasts were cultured in 
MEF medium and HFF medium, respectively. The compositions of each medium are outlined in 
table 3.3.2-1.  
MEF medium 
440ml DMEM with 4.5g/L glucose 
5ml 100x Penicillin-Streptomycin-Glutamine 
5ml 100x NEAA (100x) 
50ml FBS 
HFF medium 
415ml DMEM with 4.5g/L glucose 
5ml 100x Penicillin-Streptomycin-Glutamine 
5ml 100x NEAA (100x) 
75ml FBS  
Add bFGF to a final concentration of 5ng/ml when above passage 28 
   
 
 
MEF culture – thawing frozen stock  
While in Singapore, CF1 MEFs (normal and hygromycin resistant) at p3 was obtained 
commercially from Millipore, while HFFs were obtained commercially from ATCC. While in 
Göttingen, Germany, MEFs were derived from mouse embryos by the animal facility staff and 
immediately passed to the laboratory in a test tube for propagation.  
The protocols for MEFs and HFFs culture are very similar; they only differ in the culture 
medium compositions. In short, frozen vial of cell was thawed quickly inside a 370C water bath. 
Partially thawed vial was then sprayed with 70% ethanol and brought inside sterile biosafety 
hood. Once the vial was opened, 1ml of pre-warmed culture medium was added drop-wise into 
the vial, with shaking after addition of each drop. The cell mixture was then aspirated into a 15 
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ml falcon tube. Fresh 8 ml of pre-warmed culture medium was added into the cell suspension 
and the cells were pelleted down by centrifuging at 250 xg for 4 minutes at room temperature. 
At the end of centrifugation, the supernatant was aspirated, and the cells were resuspended by 
pipetting up and down gently in 5 ml of culture medium. Cell number was counted using 
hemocytometer.  Once the cell number was obtained, the cells were seeded onto tissue culture 
flask at a density of 10-15x104/cm2. For MEFs and HFFs maintenance, 20 ml and 35 ml of culture 
medium was added per T75 flask and T175 flask, respectively. Cells were then allowed to grow 
to 80-90% confluence by incubating in 370C incubator. The culture medium was changed every 3 
days for cells maintenance.  
 
Propagation of MEFs 
MEFs and HFFs were routinely passaged when they reach about 80-90% confluence. 
Briefly, confluent cells were first incubated in PBS (-) (PBS without Ca2+ and Mg2+) for 3 minutes 
at room temperature to aid cell detachment. Subsequently, cells were digested for 5 minutes at 
370C with pre-warmed 0.05% trypsin/versene (5ml and 10ml per T75 and T175 flask, 
respectively). The trypsin was then deactivated by the addition of pre-warmed fresh MEFs/HFFs 
culture medium (10ml and 20ml per T75 and T175 flask, respectively), and the cell mixture 
triturated up and down with pipet to break the cell clumps. Afterwards, cell suspension was 
transferred to 50 ml Falcon tube and centrifuged at 250 xg for 4 minutes at room temperature. 
MEFs and HFFs were seeded back onto tissue culture flasks pre-coated with 0.1% gelatin at a 
density of 10-15x104/cm2. The culture medium was changed every 3 days for maintenance.  
Inactivation of MEFs and HFFs 
In Singapore, MEFs and HFFs were mitotically inactivated by Mitomycin C (Kyowa). In 
Göttingen, Germany, MEFs and HFFs were inactivated by gamma rays irradiation. Briefly, 
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Mitomycin C (MMC) was resuspended in water to a final concentration of 2 mg/ml and then 
filter-sterilized. This stock solution was then added into fresh MEFs/HFFs medium to a final 
concentration of 20 µg/ml.  
Beginning with 90%-confluent layer of MEFs and HFFs, spent MEFs/HFFs medium was 
removed from the flask and replaced with fresh MEFs/HFFs medium containing MMC (10ml and 
15ml per T75 and T175 flask, respectively). MEFs/HFFs were incubated in this medium for 2 
hours 45 minutes in CO2 incubator for mitotic inactivation. Subsequently, inactivation medium 
was removed from the flask(s) and the cells were washed 3 times with PBS (-). During the last 
washing step, the cells were incubated in PBS (-) for 3 minutes before trypsinization with pre-
warmed 0.05% trypsin/versene. After cell number was obtained, cells were resuspended at 
5x105/ml of freezing medium (90% FBS + 10% DMSO) and aliquoted at 1ml per cryovial. Cryovials 
were then transferred to -800C freezer in a pre-cooled cell freezing containers (CoolCell) or 
Nalgene Mr. Frosty (Thermo Scientific). The next day, frozen vials were transferred to liquid 
nitrogen tank or -1500C freezer for storage.   
For gamma rays inactivation, 90%-confluent MEFs/HFFs were first washed and 
incubated in PBS (-) for 3 minutes, trpysinized with 0.05% trypsin/EDTA and resuspended in cold 
MEFs/HFFs medium at cell density of 8x106 cells/10ml medium. Cell suspension was transferred 
to 15ml Falcon tubes and kept on ice prior to gamma irradiation. Cells were then irradiated with 
60 Gray of gamma rays (MEFs) or 30 Gray of gamma rays (HFFs) at room temperature. Irradiated 
MEFs/HFFs were then frozen in freezing medium at -800C overnight before they were 






Throughout this study, H9 (WiCell), HES3, MBJ5 and MBJ6 (hiPSCs) lines were used. 
MBJ5 and MBJ6 were derived from BJ fibroblasts with RNA reprogramming method (Mehta et al., 
2014). HPSCs were cultured on feeder cells (MEFs or HFFs) for maintenance.   
Cell culture media composition 
hESCs medium 
390ml DMEM/F12                                                                       5ml 100x NEAA 
100ml KOSR                                                                                  910µl 55mM 2-mercaptoethanol 
5ml 100x Penicillin-Streptomycin-Glutamine 
*Add bFGF to a final concentration of 10ng/ml just before using 
hESCs recovery medium 
25 ml FBS 
25 ml hESCs medium without bFGF 
200 µl Matrigel 
hESCs freezing medium 
mFreSR™ for stock hESCs 90% FBS+10% DMSO for working hESCs 
 
Table 3.3.3-1 Compositions of hESCs cell culture media 
 
 
Thawing and freezing of hPSCs 
A frozen vial of hPSCs was taken out from the liquid nitrogen tank and thawed quickly in 
370C water bath. Partially thawed vial was sterilized with 70% ethanol and brought into biosafety 
hood. 1ml of pre-warmed hESCs medium was then added drop-wise with shaking into the vial 
and the cell suspension was transferred into 15ml Falcon tube. 8 ml of hESCs medium was 
further added drop-wise into this cell suspension before centrifugation at 200xg for 4 minutes at 
room temperature. HPSCs were then resuspended in hESCs medium + 10µM Y27632 (ROCK 
inhibitor) and plated onto feeder-coated or matrigel-coated culture dishes.  
Feeder-dependent propagation and freezing of hPSCs 
Mitotically-inactivated feeder cells were seeded on tissue culture dishes pre-coated with 
0.1% gelatin at a density of 1.6x105cells/cm2. On the next day, each undifferentiated hPSC colony 
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was cut manually into small grids or squares and each small square of hPSC fragment was 
transferred onto this feeder layer at a maximum of 50 pieces per 6cm dish. If hPSCs were to be 
frozen, these pieces were transferred into cryo-vials filled with mFreSR™ at maximum of 70 
pieces/vial.  
Alternatively, hPSCs were trypsin-passaged onto feeder cells. Briefly, a rho-associated 
protein kinase (ROCK) signaling pathway inhibitor, Y27632, was added to hPSCs on culture dishes 
to a final concentration of 10µM and allowed to incubate for 1 hour in the CO2 incubator before 
trypsinization. Subsequently, hPSCs were washed with PBS (-) for 3 minutes at room 
temperature before trypsinization with 0.05% Trypsin/Versene or 0.05% Trypsin/EDTA for 4 
minutes at 370C. Once hPSCs were dissociated from culture dishes, hESCs recovery media was 
added to the culture dishes to deactivate the trypsin. Culture dishes were washed with hESCs 
medium and the cell suspension was passed through 40µm cell strainer before being transferred 
to a falcon tube for centrifugation at 200xg for 4 minutes. HPSCs pellet was resuspended in 
hESCs medium + 10µM Y27632 and seeded at 1.2-1.5x104 cells/cm2. The culture medium was 
changed the next day to hESCs medium without Y27632. The culture medium was added at 5ml 
per 6cm dish; 10ml per 10cm dish and 15 ml per T75 tissue culture flask. For maintenance, the 
culture medium was changed daily until hPSCs reached 80%-90% confluence. If hPSCs were to be 
frozen, a determined cell number was centrifuged and resuspended in mFreSR™ at a density of 
2x106/ml. hPSCs were then frozen at 1ml per vial in -800C freezer overnight before transferring 
to liquid nitrogen tank for storage.   
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Preparation of F- and R- TALEN plasmids and targeting vector 
Transformed Top10 chemically competent cells carrying plasmids with the following 
inserts of interest were scaled up in 1L LB + 100µg/ml Ampicillin for maxiprep: (1) SAC5 (2) F7-
TALEN and (3) R2-TALEN. Plasmids were extracted using Purelink Hi-pure plasmid filter maxiprep 
kit and precipitator modules from Invitrogen, Life Technologies and subsequently digested with 
restriction enzymes to confirm presence of inserts of interest. SAC5 was sequentially digested 
with NheI-HF, SalI-HF and NdeI, while F-TALEN and R-TALEN were each double-digested with 
SpeI and NheI-HF. Once the expected restriction digest profiles were obtained for all three 
plasmids, 100 µg of SAC5 was linearized with BglII at 370C for 4 hours followed by phenol 
chloroform extraction. The resulting SAC5 pellet was dissolved in 40µl of sterile water overnight 
at room temperature. To check if BglII digestion was complete, 5µl of the digestion product was 
size-fractionated with gel electrophoresis.  
HPSCs electroporation for generation of knock-in line 
Before electroporation, hPSCs on tissue culture dishes were incubated with 10 µM 
Y27632 for 1 hour at 370C. During incubation, a DNA mix was prepared in a total volume of 300 
µl PBS (-); this mix consists of 40 µg linearized SAC5, 5 µg F7-TALEN and 5 µg R2-TALEN. At the 
end of 1 hour incubation with Y27632, hPSCs were washed with PBS (-) for 3 minutes at room 
temperature before trypsinization with 0.05% trypsin/versene at 370C for 4 minutes.  
To inactivate trypsin, three times the volume of hESCs recovery medium was added into 
each dish. Cell suspension was then passed through 40µm cell strainer before cell counting. 
4x107 cells were pelleted down and resuspended in 450µl hESCs medium + 10 ng/ml bFGF + 
10µM Y27632. 300µl of the DNA mix was then added into this cell suspension and the resulting 
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mixture transferred to 0.4cm electroporation cuvette for electroporation with the following 
parameters: 320 V voltage, 200 µF capacitance, ∞ Ω resistance and 4 mm cuvette size.  
The experimental time constant and voltage were noted down and within 10 seconds of 
electroporation, hPSCs were recovered by adding 1 ml of hESCs medium + 10ng/ml bFGF + 10µM 
Y27632 (complete hESCs medium) into the cuvette. Electroporated cell suspension was 
immediately transferred into 7 ml of complete hESCs medium in a Falcon tube and seeded back 
at a density of 5x106 cells/dish. Each dish was pre-coated the day before with 1x106 hygromycin-
resistant MEFs. These dishes were incubated for two days in a CO2 incubator. On day 3 onwards, 
the culture medium was changed daily to hESCs medium + 10ng/ml bFGF without Y27632 until 
the hPSCs reached 80% confluence. 
Selection and screening for positive clones 
Once 80% confluence was reached, the culture medium was changed daily to hESCs 
medium + 10ng/ml bFGF + 50 µg/ml hygromycin B. HESCs culture was maintained in this way 
until hygromycin-resistant colonies were big enough for manual passaging.  
Each hygromycin-resistant colony was cut manually and the pieces transferred to (1) one 
OCD pre-coated with mitotically inactivated MEFs (1.6x105 cells/OCD) for maintenance; and (2) 
one well of 24 well plate pre-coated with hESCs qualified Matrigel. The pieces on Matrigel-
coated plate were allowed to grow until 90% confluence so that their genomic DNA could be 
extracted in sufficient amount using DNeasy Blood & Tissue Kit from Qiagen. Genomic DNA from 
each hygromycin-resistant colony was then PCR-amplified using MYL2KI-F and MYL2KI-R primers 
with Taq DNA polymerase, 5% DMSO and 2mM MgCl2 additive with the cycling parameter (table 
3.3.4-1). Knock-in hPSCs should generate a band at 1.794kb (henceforth positive clones) while 
negative clones would not generate any bands. 
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Step Temperature (0C) Time (s) Cycle 











Final elongation 72 420 1x 
Cooling 4 ∞ 1x 
 
Table 3.3.4-1 PCR cycling parameters for screening positive knock-in clones 
 
 
Positive clones were further scaled up for Southern blotting while negative clones were 
disposed of. For Southern blotting, 15µg of genomic DNA (gDNA) from positive clones was first 
digested with NdeI at 370C for 4 hours. Subsequently, this digested gDNA was extracted using 
phenol-chloroform method and reconstituted in 35 µl of water. Reconstituted gDNA was loaded 
onto 1% agarose gel and run in TBE buffer at 110V for 2½ hours before being soaked in dH2O 
containing SYBR green for 45 minutes for subsequent DNA bands visualization under UV 
exposure.  
Genomic DNA on the gel was then depurinated, denatured and neutralized as per 
manufacturer’s recommendations to prepare for DNA transfer. Afterwards, gel was equilibrated 
in 20x SSC; nylon membrane in 2x SSC and the transfer sandwich was assembled for transfer of 
gDNA onto nylon membrane overnight. On the next day, gDNA was cross-linked onto the nylon 
membrane through exposure to UV light at 120mJ before being prepared for hybridization by 
incubating in Easyhyb DIG buffer (Roche) for 45 minutes at 450C (for Nde500L probe) or 47.50C 
(for Nde508L probe).  
While the membrane was being primed for hybridization, a hybridization mix was 
prepared. Briefly, DIG-labeled probe (either Nde500L or Nde508L) was mixed with 50µl of H2O, 
denatured at 990C for 5 minutes and immediately chilled on ice before being transferred into 
pre-warmed Easyhyb DIG buffer. This hybridization mix was added onto the membrane at the 
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end of membrane priming step for overnight incubation. On the next day, nylon membrane was 
washed sequentially with low stringency buffer, high stringency buffer and washing buffer 
before blocking with blocking solution (Roche) and addition of primary antibody solution (ant-
DIG-AP). Finally, the membrane was washed and equilibrated with detection buffer before the 
addition of ready to use CDP-star to show bands of interest for imaging.  
 
Preparation of Cre-recombinase plasmid 
Cre recombinase was obtained commercially from Addgene as “Cre-IRES-Puro” 
(Catalogue number 30205) and streaked onto LB + 100µg/ml Ampicillin agar plate. To obtain 
sufficient amount of plasmids for transfection, a colony was picked and scaled up in LB + 
100µg/ml ampicillin overnight. Extracted plasmid was confirmed for presence of Cre-
recombinase by restriction digest experiment. In short, the extracted plasmids were first double-
digested with AscI and NdeI before subsequent digestion with XhoI. Positive clone would yield 
bands at 7.903kb and 1.329kb after the first double digest and 1.329kb, 1.868kb and 6.035kb 
after XhoI digestion. 
H9V20 transfection with Cre-IRES-PuroR 
5x6cm tissue culture dishes were pre-coated the day before with inactivated Puromycin-
resistant MEFs at 1x106 MEFs/dish. H9V15 was trpysinized into single cells and seeded onto 
these culture dishes at seeding density of 3x105 cells/dish. On the next day, the culture medium 
was changed to hESCs medium + 10ng/ml bFGF without Y27632. Meanwhile, 517 µl of 
DMEM/F12 was mixed with 33µl Fugene HD transfection reagent and incubated at room 
temperature for 5 minutes. 100 µl of this diluted Fugene was set aside in a new tube for control 
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dish while to the remaining, 4 µg of Cre-IRES-Puro plasmid was added. Plasmid-Fugene HD 
mixture was incubated at room temperature for 40 minutes. Subsequently, 100 µl of diluted 
Fugene was added into a control dish while 100 µl of the plasmid-Fugene-HD mixture was added 
into each of the 4x 6cm dishes drop-wise, with swirling of dish after the addition of every drop. 
Time of addition was recorded.  
24 hours later, the culture medium was changed to hESCs medium containing 1µg/ml 
puromycin. This puromycin selection medium was applied again on the 48th hour post-
transfection. On the 72nd hour post transfection, the culture medium was changed back to hESCs 
medium + 10ng/ml bFGF. For hESCs maintenance, the culture medium was subsequently 
changed every 2 days and culture was maintained until puromycin-resistant colonies were big 
enough for manual passaging (7days).  
Selection for successfully transfected clones 
Forty clones were picked and each clone was passaged manually onto (1) one OCD pre-
coated with irradiated MEFs, and (2) one well of 24-well plate pre-coated with Matrigel. The 
culture medium was changed daily and seven days later, cells on Matrigel were trpysinized and 
their gDNA extracted using Qiagen DNeasy Blood and Tissue Kit.  
Three rounds of independent PCR amplification were carried out to check for successful 
removal of floxed PGK-hygromycin cassette in the knock-in line. The first PCR used Luc-F and 
qPCR-WT-R primers; a band would show at 2.775kb and 1.021kb for non-excised clones and 
successfully excised clones, respectively. The second PCR made use of Luc-F and Seq-hyg-R2 
primers; a band would show at 1.723kb for non-excised clones, while no bands would show for 
successfully excised clones. The third PCR was used to check if cre-IRES-puro was integrated into 
the knock-in line genome. For this third PCR, Puro-F and Puro-R primers were used and cre-IRES-
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puro integration into the genome would be indicated by a band at 516bp. Each PCR cycling 
parameters are outlined below: 
Step Temperature (0C) Time (s) Cycle 











Final elongation 72 180 1x 
Cooling 10 ∞ 1x 
 
Table 3.3.5-1 Cycling parameters for PCR1 and PCR2 to screen for successfully excised clones 
 
 
Step Temperature (0C) Time (s) Cycle 











Final elongation 72 120 1x 
Cooling 10 ∞ 1x 
 




Karyotyping and sequencing 
Karyotyping was done by The DNA Diagnostic & Research Laboratory (DDRL) at KK 
Women’s and Children’s Hospital (KKH). HPSCs were passaged manually onto Matrigel-coated 
tissue culture dish and this dish was delivered to KKH for analysis. 
For sequencing, gDNA was extracted from knock-in hESCs and sent directly for 
sequencing to 1st BASE or Axil Scientific using primers KIgDNA-F and KIgDNA-R. Alternatively, 
gDNA was PCR amplified using the same primers, run on gel electrophoresis with band of 
interest at 2.595kb cut and gel purified before sending it to Seqlab (Germany) for sequencing. 
PCR amplification was done with high fidelity hot start Phusion DNA polymerase using 5% DMSO 
as additive. The cycling parameters are as follows: 
 In vitro characterization of knock in lines 3.3.6.
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Step Temperature (0C) Time (s) Cycle 











Final elongation 72 360 1x 
Cooling 4 ∞ 1x 
 
Table 3.3.6-1 PCR cycling parameters for gDNA sequencing 
 
Pluripotency markers – immunofluorescence staining and FACS 
Knock-in hPSCs cultured on mitotically-inactivated MEFs on OCDs were fixed in 4% 
paraformaldehyde (PFA) at room temperature for 15 minutes. The colonies were washed three 
times with PBS (-) before incubation with blocking buffer for 30 minutes at room temperature. 
For Tra-1-60 and SSEA4, the blocking buffer without Triton-X100 was used while for Oct3/4, 
Nanog and Sox2, the blocking buffer containing 0.1% Triton-X100 was used. The blocking buffer 
consisted of 5% goat serum + 1% bovine serum albumin (BSA) in PBS (-).  
Primary antibodies were then diluted in blocking buffer to desired concentration (table 
3.3.6-2) and incubated with the hPSCs at 40C overnight. The next day, the dishes were washed 
three times with PBS (-) before incubation with Hoechst 33342 and secondary antibody for 1 
hour at room temperature. Hoechst counterstain and secondary antibodies (goat anti rabbit 
Alexa 546, goat anti mouse Alexa 488) were all diluted 1:1000 in blocking buffer. Subsequently, 
dishes were washed three times with PBS (-) and mounted with coverslips for imaging.  
Pluripotency markers – FACS analysis 
The procedure of staining for FACS analysis is very similar to immunofluorescence 
staining protocol. The difference lies in the cells being stained as colonies for 












Tra-1-60 1:50 1:100 Mouse 
PBS(-) 
5% goat serum 
1% BSA 
With or without 
0.1% Triton X-100 
Oct3/4 1:50 1:100 Mouse 
Nanog  1:50 1:100 Rabbit 
SSEA4 1:200 1:400 Mouse 
Sox2 1:50 1:100 Rabbit 
IgG isotype control 1:1000 1:1000 Mouse 
IgG isotype control 1:2000 1:2000 Rabbit 
 
Table 3.3.6-2 List of primary antibodies used for pluripotency immunofluorescence staining 
 
 
All reporter genes were analyzed at transcript level as well as protein level (except for 
NeoR). Analysis was done either in monolayer (2D) or in EHMs (3D) format. For EHMs format, 
wild type H9 hESCs as well as knock-in lines H9V15 and H9VC16 were differentiated to CMs and 
cultured on culture dishes until day 18. CMs were digested into single cells on day 18, mixed with 
human foreskin fibroblasts (HFFs) in collagen I matrix to form EHMs in the molds. EHMs were 
transferred to auxotonic stretchers on day 21 and cultured in SFMM as described in chapter 2. 
Total RNA was extracted at each different time points from day 18-90 of differentiation and 
expressions of MYL7, MYL2, mChr, NeoR, G.Luc and CASQ2 were analyzed with qPCR. Ct values 
from all samples were normalized to their respective GAPDH expression. MChr protein 
expression was analyzed by fluorescence microscope while G.Luc protein expression was 
analyzed using luciferase assay.  
Microscopy analysis of knock-in CM in 2D and 3D format 
Differentiated CMs from H9 and H9V15 or H9VC16 either in 2D or EHM format were 
analyzed by fluorescence microscope for mChr expression from day 18-90 of differentiation. 2D 
analysis was done with an Xcellence rt (Olympus) microscope whereas 3D analysis was done 
with a SteREO Lumar.V12 (Zeiss). 
  Validation of gene expression and transcription of MYL2 knock-in reporter line 3.3.7.
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Live cell FACS of knock-in CMs 
Differentiated CMs from H9V15 and H9VC16 were cultured on Matrigel until day 30 of 
differentiation and trypsinized into single cell suspension for live cell FACS sorting. MCherry 
positive population was gated and sorted for. Total RNA was extracted from mChr (+) and mChr(-) 
CMs and qPCR was performed to analyze MYL7, MYL2 and CASQ2 expression levels in each 
sample. Ct values were normalized to the respective GAPDH expression level in each sample. 
Investigation for effective Neomycin concentration 
H9V15 and H9VC16 knock-in hESCs were differentiated to CMs and cultured to day 15 of 
differentiation. On day 15, CMs were digested into single cells and reseeded on Matrigel-coated 
dishes at density of 2.5x105 cells/well of a 12-well plate in B27 (+) medium.  On day 27 of 
differentiation, selection medium containing different concentrations of G418 was applied to the 
CM monolayer (0 - 50 µg/ml). Cells were cultured in this selection medium for a week; with 
medium change every other day. On day 35 of differentiation, selection medium was changed 
back to B27 (+) without G418 and CMs were cultured for additional 9 days, with media change 
every other day. On day 44 of differentiation, cells were imaged by fluorescence microscopy for 
mChr signal, before trypsinization and total RNA extraction. Finally, qPCR analysis was carried 
out for MYL7 and MYL2. All qPCR data was normalized to respective GAPDH expression level in 
all samples. 
Luciferase assay 
EHMs as well as CM monolayers from H9 wild type and knock-in H9V15 and H9VC16 
were cultured until day 90 of differentiation. Culture media were changed every three days and 
media samples were collected at day 21, 24, 27, 30, 45, 60, 75 and 90 of differentiation. Assay 
was carried out in white 96-well plate using GloMax® 96 microplate luminometer with dual 
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injectors from Promega. BioLux® Gaussia Luciferase Flex assay kit from NEB was used and assay 
was carried out as per manufacturer’s recommendations. In short, 20 µl of medium sample was 
pipetted into each well of the 96-well plate and the injector was set with the following 
parameters: 50 µl of injection volume, delay between injection and measurement of 40s and 10s 
of integration time. 
 
Data is presented as mean ± standard error mean (SEM). Statistical analyses were 
performed with Student’s t-test (2-tailed) or ANOVA when applicable followed by post-hoc 
Bonferroni's Multiple Comparison test. Results were considered to be significant at p ≤ 0.05 (*); 
very significant at p ≤ 0.01(**) and extremely significant at p ≤ 0.001 (***). Correlation studies 
were carried out using Prism 5.0.  
  Statistical analysis 3.3.8.
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MYL2 and Phlox PCR products 
PCR amplification for MYL2 homology arms was most efficient with long template PCR 
DNA polymerase (Roche) and 5% DMSO additive. Product obtained was 2.347kb in length (figure 
3.4.1-1 and -2). “Phlox” insert was obtained readily with High Fidelity (HF) Expand DNA 








To clone MYL2 PCR product into the expression vector pCR™ 2.1-
TOPO® vector (Invitrogen), four different insert: vector molar ratios 
were tested (1:1, 5:1, 10:1, 50:1). Of the four ratios tested, 5:1 ratio 
gave the most number of transformants on the selection plates. Ten 
clones each were picked from chemically competent and electro-
competent groups and scaled up for plasmid analysis.  
 
 Results 3.4.




















Figure 3.4.1-2 MYL2 PCR was more efficient 
with Long Template PCR DNA Polymerase 
(Roche) 
DMSO  
(-) (-) (+) (+) 





Figure 3.4.1-1 Addition of DMSO improved 




The PCR result showed that the chemically competent group (C1 – C10) showed three 
positive transformants (in red) out of ten picked clones while the electrically competent group 
(E1 – E10) showed one positive transformant out of ten picked clones. Clones C1, C3, C5, E1, E3 
and E5 were sent for sequencing to check for mutations.  
Sequencing result showed that clone C1 from chemically competent group had no 
mutations and therefore it was used for subsequent experiments (henceforth pCR2.1-MYL2-C1).  
 
Targeting construct generation by self-assembly cloning (SAC) 
Strictly following published SAC protocol did not yield desired construct. It was 
determined empirically that denaturation and annealing of sister amplicons had to be done in 
cycles (ten cycles), instead of one cycle as per published protocol. In addition, denaturation 
period had to be extended and an extra annealing step at 700C had to be added before the slow 
cooling step. A further incubation at 40C for 2 hours was also found to be necessary for 

















C1 C2 C3 C4 C5 C6 C7 C8 C9 C10 
E1 E2 E3 E4 E5 E6 E7 E8 E9 E10 
Figure 3.4.1-4 pCR2.1-MYL2 after digestion with EcoRI 
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Of 48 transformant clones picked, only one clone showed expected restriction digest 
profile (SAC5). Illustrated on the next page is the diagram of SAC5 together with its restriction 
digest result. SAC5 was sent for DNA sequencing and the results showed no mutations on SAC5. 









Generation of TALEN expression vector 
 Figure 3.4.1-7 shows the diagram of a TALEN plasmid (forward TALEN has the same map 
as reverse TALEN). After transformation into TOP10 chemically competent cells, 9 transformants 
each were picked for F- and R-reverse TALENs. These transformants were scaled up and their 
plasmids extracted for a double digest with HindIII and NotI to confirm the presence of TALEN 
insert. Positive transformants would yield 2 bands at 3.057kb (TALEN insert) and 2.582kb (other 
half of the plasmid). 
Figure 3.4.1-6 Plasmid map of SAC5 
Sequential digest should yield fractions: 
1. After NheI:  6071bp and 4629bp 
2. After SalI-HF:  4629bp, 3216bp, 2855bp 
3. After NdeI: 4629bp, 2855bp, 1616bp, 1600bp 
 
 
                                   














Nhe I Sal I Nde I 
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Once positive clones were identified, F- and R- TALENs were PCR amplified using the 
positive plasmids as template, the expected 3.075kb band was cut, gel extracted and purified. 3´ 
Adenine overhang was then added to this extracted PCR products before they were mixed with 
pEF6-TOPO vector. pEF6-F- and R- TALENs were transformed into TOP10 chemically competent 
cells. Shown in figure 3.4.1-9 is the diagram of pEF6-TALEN vector. Constructs inserted in the 
right orientation would generate a band at 2.288kb while those inserted in the wrong 
orientation would generate a band at 852bp. This is because there are 33 bases from SpeI digest 
site to the start of TALEN sequence and there are 819 bases from NheI digest site to the end of 
TALEN sequence.  
For F-TALEN construct, one out of ten (F7) picked clones had the construct inserted in 
the right orientation (positive clones), while for R-TALEN construct, there were six positive 
clones out of ten picked clones (R1, R2, R4, R5, R8, R9). Plasmids from F7 and R2 were sent for 
sequencing and the result showed no mutations in both sequences. Thus, pEF6-TALEN-F7 and 
pEF6-TALEN-R2 were the TALEN expression vectors used for homologous recombination. 
 
 
Figure 3.4.1-7 TALEN plasmid map 
2.5 
1 
Figure 3.4.1-8 HindIII and NotI double digest 









    
 
HPSCs colony morphology 
Shown in figure 3.4.2-1 is the typical morphology of manually-passaged human 
pluripotent stem cells (hPSCs) colony grown on mitotically inactivated mouse embryonic 
fibroblasts (MEF) feeder layer: the colonies look roundish and flat, with clear edges. Manually-
passaged hPSCs grown on Human Foreskin Fibroblasts (HFFs) look slightly different, a little bit 
irregularly shaped instead of roundish, although still flat and having distinct edges.  
Trypsinized hPSCs grow at a faster rate than mechanically passaged hPSCs and shown in 
figure 3.4.2-3 is the typical appearance of trypsinized hPSCs grown on inactivated MEFs feeder. 
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Figure 3.4.1-10 TALEN restriction digest 








           
 
  
Validation of TALEN expression constructs and the targeting vector 
Before electroporating hESCs with F- and R- TALENs as well as the targeting vector, a 
validation round of restriction digest was carried out to make sure that the right vectors were 
used. Figure 3.4.3-1 below shows that the restriction digest profiles of pEF6-F7-TALEN and pEF6-
R2-TALEN as well as targeting vector SAC5 are as expected. Figure 3.4.3-2 shows that 
linearization of SAC5 was complete prior to electroporation. 
 Generation of knock-in line 3.4.3.
Figure 3.4.2-1 Manually cut hPSC colonies on 
inactivated MEFs, ready for passaging 
Figure 3.4.2-2 Manually cut hPSC colonies on 
inactivated HFFs, ready for passaging 
Figure 3.4.2-3 Trypsinized hPSCs on inactivated 
MEFs, ready for passaging 
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HPSCs electroporation 
Different hPSCs line used gave rise to different numbers of hygromycin B-resistant 
colonies. Tabulated below are the experimental values of voltage of time constant of each 
electroporation experiment. HPSCs were viable after electroporation (figure 3.4.3-4) and 
reached 80-90% confluence in 4-5 days (figure 3.4.3-3). Hygromycin B selection caused extensive 
cell death, but resistant colonies started to be visible 5 days after hygromycin selection (figure 
3.4.3-6). Good-sized hygromycin-resistant colonies, such as shown in figure 3.4.3-5 were 
manually passaged and propagated for maintenance and PCR screening. 




MBJ5 317 3.8 
Hes3 319 3.5 
H9 318 3.6 
 











Generuler 1kb DNA ladder 
F7 R2 NheI NdeI SalI 
-HF 
Figure 3.4.3-1 Restriction digest profile of TALEN F7, 





Figure 3.4.3-2 BglII completely 
linearized SAC5 
Bgl-II 









            
  
Efficiency of homologous recombination (HR) 
Listed in table 3.4.3-2 is the summary of 3 independent efforts in generating knock in 
line from various hPSCs lines. Only very few MBJ5 clones could be scaled up as majority of MBJ5 
PCR positive clones senesced after a few passages.  
 
hPSCs Colonies picked 
PCR positive 
colonies 
Efficiency of HR 
through PCR (%) 
Colonies scaled up for 
southern blot 
Colonies positive by 
southern blot 
MBJ5 162 44 27.2 3 2 
Hes3 11 1 9.09 1 1 
H9 75 4 5.33 4 4 
 
Table 3.4.3-2 Summary of homologous recombination efficiency 
 
Figure 3.4.3-3 Electroporated hPSCs just before 
Hygromycin B selection 
Figure 3.4.3-4 Maintenance of knock-in hESCs and 
selection of positive clones 
Figure 3.4.3-6 Electroporated hPSCs 5 days after 
Hygromycin B selection 
Figure 3.4.3-5 Electroporated hPSCs 12 days after 




As can be seen from table 3.4.3-2, the HR efficiency varied widely across different 
attempts (5.33% - 27.2%). Nevertheless, each round successfully generated at least one positive 
HR clone as screened through PCR. Shown below is the diagram of endogenous MYL2 gene in 
the knock-in line and wild type hPSCs. DIG labeled probe was designed to target the 3’ end of the 
homology arm for southern blot analysis. Therefore, NdeI-cut knock-in gDNA would give a band 






             
 
 DIG labeled probe 
  
   

















Figure 3.4.3-8 Southern blot of 
MBJ5 knock in clones V43 and 
V74 showed that they contain 
both knock-in and wild type 
allele (heterozygous knock-in) 









Figure 3.4.3-9 Southern blot of H9 knock-in clones. All 
screened clones have both knock-in and wild type alleles 
(heterozygous knock-in) 
Figure 3.4.3-7 Schematic diagram showing hybridization site of Nde500L and Nde508L to gDNA of knock in line 
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Out of 44 MBJ5 knock-in clones (positive through PCR 
screening), 3 were scaled up for southern blot: V43, V74 and 
V167. Figure 3.4.3-8 shows that V43 and V74 are both 
heterozygous knock-in, showing bands corresponding to both 
wild type allele (6.352kb) and knock-in allele (2.223kb). V167 
did not show any bands for either wild type or knock-in allele. 
This could be due to the insufficient amount of starting gDNA 
used for Southern blotting.  
 
V167 senesced after 10 passages and could not be further propagated. V43 and V74 also 
grew very slowly, taking up more than 1 month to reach confluence, whereas HES3 and H9 took 
1 week. This slow growth rate of the generated knock-in cells prevented their use for 
downstream experiments.  
Homologous recombination was repeated, this time using HES3 as the starting 
population. Unfortunately, HES3 generated only one knock-in clone (H3V9) and it was deemed 
too risky as this clone might carry mutations. While waiting for karyotyping and sequencing 
result of H3V9, HR was repeated using H9 hESCs.  Four putative clones from H9 screened 
positive through PCR and the successful knock-in was confirmed by Southern blotting. All four 

















Figure 3.4.3-10 Southern blot of 





When knock-in CMs were first analyzed, it was noted that the reporters’ expression was 
not as strong as expected. There have been reports which suggested that the presence of strong 
constitutive promoter driving the expression of selection marker might interfere with the 
endogenous enhancer/promoter elements and affect the physiological expression of the gene or 
neighboring genes (Calegari and Waskow, 2014). This possibility prompted the use of Cre-
recombinase to remove the floxed PGK-Hygromycin cassette in the knock-in line. H9V15 was 
transfected with Cre-IRES-Puro as outlined in the methods section. Puromycin-resistant colonies 
were propagated for PCR to identify colonies in which the PGK-Hygromycin selection cassette 
has been successfully removed.  
40 colonies were screened with PCR and out of these 40, 38 showed a band at 1.021kb 
for PCR1, indicating that the PGK-Hygromycin cassette had been floxed out in these clones. For 
PCR2, gel appeared mostly empty, very faint bands were seen at 1.723kb for 18 clones, 
indicating that in these clones, the PGK-Hygromycin cassette had not been removed. Combining 
this result with result from PCR1, this means that 18 of these clones were not pure, that they 
contain some non-floxed cells. First round of PCR3 showed that all clones had Cre-IRES-Puro 





 PGK-Hygromycin cassette was removed using Cre-recombinase 3.4.4.




















Colony 16, henceforth H9VC16, was chosen for downstream experiments. Shown below 
are gel pictures showing results of PCR1-3 from H9VC16, indicating that its PGK-Hygromycin 
cassette had been floxed out, with minimal (or possibly, negative) integration of Cre-IRES-Puro in 
the genome (since H9V15 also showed a very faint band at 500bp, this might be an unspecific 
band). 







C16 SAC5 C16 SAC5 
Figure 3.4.4-4 Result of PCR1 and 
PCR2 from H9VC16 indicated that 
PGK-HygroR cassette has been 














Figure 3.4.4-5 Result of PCR3 from 
H9VC16 indicated that there is no 
genomic integration of Cre-IRES-Puro  






* * * * * * * * * * * * * * * * * * 
Figure 3.4.4-2 Result of PCR2 from all clones with SAC5 as negative control. Faint bands are labeled with asterisks 






Figure 3.4.4-3 Result of PCR3 from selected clones with SAC5 as negative control 
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Knock in lines have normal karyotypes 
Shown on the left is the karyotype of the 
knock-in line derived from HES3: H3V9. 
H9VC16 was also sent for karyotype analysis.  
Analysis undertaken by the Cytogenetics 
Laboratory in KKH indicated that there are 
no major chromosomal aberrations both in 
H3V9 and H9VC16.  
gDNA sequencing gave inconclusive result  
Genomic DNA from H9V15 and H9VC16 were sent for sequencing. The resulting 
sequences, however, did not align 100% with the expected sequence. The results are tabulated 
below:  
Cell line Match to expected sequence 
H3V9 98% using KIgDNA-F and 97% using KIgDNA-R 
H9V15 98% using KIgDNA-F and 97% using KIgDNA-R 
H9V20 99% using KIgDNA-F and 97% using KIgDNA-R 
 
Table 3.4.5-1 Percentage match of knock-in gDNA to expected sequence 
 
 
H3V9 H9V15 H9V20 
Position Mutation Position Mutation Position Mutation 
1228 GAC 1172 TG 1203 CT 
1246 Insertion of T 1228 Insertion C or G 1226 GA 
1252 Insertion of G 1230 GA 1233 Insertion A 
1265 Insertion of C 1258 Insertion A or G 1241 CG 
1281 C  T 1261 Insertion C or G 1243 Insertion T 
1314 T  G 1264 GC 1252 Insertion G 
1331 C  G 1281 CT 1256 GA 
1353 Insertion of G 1282 TC 1259 Insertion G 
1371 AC 1287 Insertion T 1267 Insertion A 
1385 CT 1310 AC 1275 Insertion C 
  1312 Insertion T or C 1279 AT 
 Knock-in lines are pluripotent and have no chromosomal aberrations 3.4.5.
Figure 3.4.5-1 H3V9 karyotype 
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  1334 CT 1281 CT 
H3V9 continued H9V15 continued H9V20 continued 
Position Mutation Position Mutation Position Mutation 
  1366 CG 1282 TC 
  1371 AC 1294 Insertion C 
  1377 CG 1298 GA 
  1385 CT 1301 Insertion A 
  1394 CG 1317 CG 
    1321 TA 
 
Table 3.4.5-2 List of mutations from direct sequencing of gDNA. Highlighted in red are the mutations that are 
common between the three different reporter cells lines 
 
 
This experiment was not repeated due to time constraints, as at the time, the author had to 
relocate to Germany for the second half of the study.  
 
Knock-in lines are pluripotent 
Shown below are the representative results of knock-in lines stained with pluripotency markers. 
The results indicated that despite having gone through a number of manipulations, the knock-in 
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First attempts at investigating mChr expression from day 10 – 14 of differentiation had 
failed to detect its expression and it was thought that the knock-in line was not functional. 
However, when 43 days old EHMs (figure 3.4.6-1) were observed by chance under a Lumar 
microscope, mChr expression was observed, leading to a new understanding that the failure of 
previous attempts stemmed from the fact that MYL2 expression appeared later in human CMs. 
Thus a time series experiment was carried out in which mChr expression was analyzed every 
three days starting from day 18 – 60 of differentiation. Day 90 EHM videos are provided in the 
supplementary CD with this thesis.  
 
 
Figure 3.4.6-1 Fused EHMs, showing positive mCherry signal. Scale = 1mm 
 










Figure 3.4.6-2 EHMs under 561 nm excitation (left) and bright field (right) at different time points. MCherry expression increased with time in culture.  
Scale = 1 mm. 
A – H9 EHM on day60      D – V15 EHM on d30 
B – V15 EHM on day24 E – V15 EHM on d45 
C – V15 EHM on day27 F – V15 EHM on d60 
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MChr expression was observable from day 24 of differentiation in EHMs, or 6 days after 
CMs digestion into single cells and EHMs casting (figure 3.4.6-2). Interestingly, mChr expression 
level seemed to indicate forces generated by the corresponding EHMs. Older EHMs expressed 
brighter mChr signal qualitatively and they also beat with significantly higher forces (figure 3.4.6-
4). Day 90 EHMs beat with the highest forces at maximum of 1.96 ± 0.156 mN, followed by day 
60 EHMs at 1.38 ± 0.127 mN, day 45 EHMs at 1.06 ± 0.087 mN and lastly day 30 EHMs at 0.271 ± 
0.019 mN   (figure 3.4.6-3).  Day 90 EHMs corresponded to 72 days post EHM casting, since 
EHMs were casted on day 18 of differentiation. 
 
 






















Figure 3.4.6-4 Maximum H9V15 EHM forces at different time points.  




To assess whether the mChr signal was specific, lambda scan was performed with a 
confocal microscope. Emission was observed at the expected wavelength around 610 nm (figure 
3.4.6-5).  
CMs trypsinized on day 18 of differentiation were also seeded back onto Matrigel at high 
and low density for prolonged in vitro monolayer culture until day 90 of differentiation. CMs 
cultured in different cell densities showed different morphologies, as well as mChr expression 
pattern (Figure 3.4.6-6).   
On day 45 and day 60 of differentiation, CMs were digested into single cells and 
subjected to live-cell sorting with FACS for mChr expression analysis. At both time points, the 
mean fluorescence intensity of CMs derived from H9VC16 was significantly higher than those 
derived from H9V15 (figure 3.4.6-7), indicating that removal of PGK-hygromycin cassette 
resulted in higher expression of reporter gene, in this case mChr. Strong CM contractions 
mCherry 
Excitation = 587 nm  
Emmision =610 nm  
Figure 3.4.6-5 Lambda scan of H9V15 CM indicated that emission signal is specific for mCherry 
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resulted in the CM monolayer detaching from the culture surface around day 80 of 
differentiation, thus there was no live-cell FACS data for day 90 monolayer CMs. 
 
  
561 nm excitation brightfield overlap 
Figure 3.4.6-6 mCherry expression in H9 CMs and H9V15 CMs reseeded back at  
A – High density and B – Low density. Scale = 50 µm 
Figure 3.4.6-7 Mean fluorescence intensity of H9VC16-CMs is higher than that from 










H9 wild type CMs H9V15 knock-in CMs H9VC16 knock-in CMs 
Day 45 
   
Day 60 
   




1.2% 56.5% 70.6% 
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Knock-in CMs from H9V15 and H9VC16 showed G418 resistance up to 50 µg/ml (figure 
3.4.7-1). Extensive cell death was observed in wells with higher concentration of G418, with only 
very bright mChr (+) cells surviving ≥30 µg/ml G418. Weak mChr (+) cells could only tolerate a 
maximum of 20 µg/ml G418. 
 
  Neomycin resistance gene was expressed in knock-in cardiomyocytes 3.4.7.
Figure 3.4.7-1 H9VC16 CMs after G418 selection. Scale bar = 50µm. 






Knock-in CMs secreted G.Luc into the culture medium, thus generating luminescence 
when appropriate substrate was added. G.Luc expression increased markedly in the first 9 days 
post EHMs casting and peaked at day 45 of differentiation (day 24 of differentiation) at 3.3x106 
RFU for H9VC16 CMs and 2.25x106 RFU for H9V15 CMs. Knock-in CMs cultured in monolayer 
format also show similar trend for G.Luc expression, although the sharpest increase in 
expression was delayed from day 30 to day 45 of differentiation (appendix 4.1).  
 
  
 Gaussia Luciferase was expressed in knock-in cardiomyocytes 3.4.8.
Figure 3.4.8-1 Gaussia Luciferase expression in EHMs at different time points  






Pair Correlation coefficient ( Pearson r) R
2 P value Significance 
MLC2v and mCherry 0.9335 0.8714 0.0021 ** 
MLC2v and NeoR 0.9882 0.9765 <0.0001 *** 
MLC2v and G.Luciferase 0.7812 0.6102 0.0381 * 
MLC2v and MYL7 0.8759 0.7672 0.0097 ** 
mCherry and NeoR 0.9750 0.9506 0.0002 *** 
mCherry and G.Luciferase 0.9460 0.8948 0.0013 ** 
NeoR and G.Luciferase  0.8563 0.7332 0.0139 * 
 
Table 3.4.9-1 Correlation of reporter genes to MYL2 and to each other are significant 
 
Figure 3.4.9-1 shows the qPCR result of MYL2, MYL7, together with the three reporter 
genes from EHMs harvested at different time points. MYL2 started to be expressed on day 18, at 
about 0.04x the expression level of GAPDH. This expression level was about 50x lower than the 
expression of MYL7. There was a dip of expression from all genes assessed on day 21. From day 
























 Expression of reporter genes was correlated to the endogenous expression level 3.4.9.
of MYL2 gene 
Figure 3.4.9-1 Relative expression of genes in H9V15 EHMs at different time points.  






expression remained stable while there was a dip in MYL7 expression. Expression of all genes 
increased steadily from day 30 – 45 of differentiation, with MYL2 expression during this period 
being 2x higher than the MYL7 expression. There was a decrease in all genes expression from 
day 30 – 45 of differentiation, with MYL7 decreasing at a higher rate than MYL2. Finally, all genes 
expression increased steadily to reach a level of expression similar to that observed between day 
45 and day 60 of differentiation. In addition, the graph also showed that the expressions of MYL2 
and reporter genes are very closely correlated. This correlation was found to be significant with 
p-values ranging from 0.0381 to <0.0001 (table 3.4.9-1). The expression of each reporter gene 
was also significantly correlated to each other with p-values ranging from 0.0139 to <0.0001 
(table 3.4.9-1). Similar trend was obtained when all gene expression data was normalized to 
both GAPDH as well as the gene’s respective fold change on day 18 (appendix 4.2). 
 
To determine if FACS sorting for mCherry signal is efficient for vCMs enrichment, mChr(+) 
and mChr(-) fractions from H9V15 and H9VC16 CMs were sorted and their total RNA was 
extracted. Figure 3.4.10-1 showed relative expression levels of a number of marker genes from 
H9V15 CMs, normalized to GAPDH. The data implied that vCMs sorted out were still immature, 
as they still express a high level of MYL7. MCherry FACS sorting was also specific for vCMs as the 
MYL2 expression in mChr(+) cells was significantly higher than in mChr(-) cells. The sorting 
process was very stringent as cells expressing low levels of mChr were gated out. This was 
evident from the fact that the mChr(-) cells still showed detectable expression of MYL2. Finally, 
 MYL2 positive cells (ventricular cardiomyocytes - vCMs) can be enriched by live 3.4.10.
FACS sorting as well as Neomycin selection 
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reporter gene expressions were expressed at a similar level to MYL2. Similar level of marker 
genes expression was observed with H9VC16 CMs (figure 3.4.10-2).  
 
 
Figure 3.4.10-1 Relative mRNA expression levels in mChr(+) and mChr(-) CMs sorted from H9V15 CMs.  
MChr(+) CMs expressed significantly higher level of MYL2 than mChr(-) CMs. 




Figure 3.4.10-2 Relative mRNA expression levels in mChr (+) and mChr (-) CMs sorted from H9VC16 CMs.  
MChr(+) CMs expressed significantly higher level of MYL2 than MYL2(-) CMs. 



















































Total RNA from surviving H9VC16 CMs post G418 selection was extracted and converted 
to cDNA for qPCR of MYL7 and MYL2. The result indicated that there was significant enrichment 
for vCMs with increasing G418 concentration from 10 µg/ml to 50 µg/ml. Averaged MYL2 
expression was significantly higher in the CMs monolayer treated with 30µg/ml and 50µg/ml 
G418 than with 10µg/ml. The analysis also indicated that CMs were still relatively immature, as 




Figure 3.4.10-3 Relative mRNA expression levels in selected H9VC16 CMs.  
Significant enrichment for vCMs was obtained with 30 µg/ml and 50 µg/ml G418. 



































In the present study, MYL2 knock-in reporter lines were generated from 3 different hPSC 
lines using homologous recombination (HR) technique with the aid of a genome editing tool, 
TALENs. The cloning of targeting vector was accomplished successfully using self-assembly 
cloning method (Matsumoto and Itoh, 2011), with slight modification of the denaturing and re-
annealing step of sister amplicons.  
HR efficiencies differed depending on the stem cell line used, with H9 showing the 
lowest HR efficiency at 5.33% from 75 clones screened. HES3 HR efficiency was higher at 9.09% 
from 11 hygromycin resistant clones. MBJ5 showed the highest HR efficiency at 27.2% from 162 
clones screened. It must be pointed out that there were more than 75 hygromycin resistant 
clones for H9 HR experiment. Thus the low efficiency of 5.33% might be attributed to the higher 
frequency of negative clones being picked from the parent dishes for propagation and/or not 
enough clones being screened. The same cannot be said for hES3 HR experiment, however, as 
there were only a total of 11 hygromycin resistant clones from the HES3 HR experiment. This low 
number might be attributed to the fact that only 2.5x107 cells were used, in comparison to 
4.0x107 cells for the other two hPSC lines. 
Initially, the MYL2 reporter knock-in line was to be derived from MBJ6, the human 
induced PSCs (hiPSCs). However, for yet unknown reasons, the knock-in lines derived from MBJ6 
stopped proliferating after passage 10, preventing their use for downstream experiments. It is 
postulated that knocking-in a rather large of DNA piece (around 3kb) into a specific gene locus 
might have interfered with global physiological gene expression, leading to cell cycle arrest. 
However, this phenomenon was puzzling as it was specific to MBJ6, a hiPSC line; no such effect 




the knock-in lines derived from hESCs lines were more susceptible to spontaneous 
differentiation than their corresponding wild-type hESCs. As such, it was harder to maintain the 
knock-in lines in the pluripotent state. Outside this susceptibility, knock-in lines behaved very 
similarly to their wild-type counterparts, staining positive for pluripotency markers, showing no 
chromosomal aberrations, as well as maintaining the ability to be differentiated towards CMs. 
Thus the phenomenon observed in MBJ6-derived knock-in lines might be due to an incomplete 
reprogramming process of the parental BJ cells to the pluripotent state.  
It was also observed that the genomic sequencing data of H9V15, an H9-derived knock-in 
line, revealed many mutations in the middle part of the sequence. The sequencing primers 
KIgDNA-F and KIgDNA-R would give a product of 2.595kb in length. The earliest mutation was 
observed at position 1172 from 5‘- end of KIgDNA-F, which is beyond the accuracy range for the 
primer (a primer has accuracy range of about 850bp). In addition, PCR reaction could also 
introduce mutations in the PCR products to be sequenced. Adding another pair of sequencing 
primers somewhere in the mid-region of the sequence of interest should improve the accuracy 
of the sequencing data. Nevertheless, since the cDNA sequencing results showed no mutations 
in the cDNA of the knock-in lines, the reporters should be expressed as designed, if there were 
no other confounding factors in the system. Indeed as has been described in this chapter, this 
was the case.   
In conclusion, with the aid of TALENs, a number of MYL2 knock-in reporter lines have 
been successfully generated. These lines should allow for enrichment as well as real time 
monitoring of ventricular CMs development, amongst other potential applications. The use of 
TALENs reduced the need to screen hundreds of colonies before positive transgenic clones could 
be identified.  In comparison to Thomson and Zwaka’s report in 2003, the approach taken here 
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was most similar to the POU5F1 knock-in experiment whereby a construct containing 
a neo cassette under the control of the tk promoter was introduced to hESCs. The authors 
reported a 26:1 ratio of stable transfected clones to HR events (Zwaka and Thomson, 2003). 
Using TALENs in this study, at the lowest HR efficiency of 5.33%, we obtained four homologous 
recombinant clones from screening 75 clones (similar to a ratio of 18.75:1). At the highest HR 
efficiency, 44 homologous recombinant clones were obtained from screening 162 colonies 
(similar to a ratio of 3.68:1). Thus TALENs improved homologous recombination events in hESCs. 
Furthermore, TALENs also did not contribute to cytotoxicity, or gross chromosomal aberrations 
in the knock-in clones.  
Through in vitro aging experiment, it was observed that the three knocked-in reporters 
were expressed in close correlation with MYL2 gene (figure 3.4.9-1). The earliest mChr signal was 
observable on day 24 of differentiation in the EHMs; this corresponded to MYL2 gene expression 
at 10x lower than that of GAPDH. On day 24 of differentiation, the G. Luc signal was around 
1x105 RFU, around 5x higher than the background signal from the wild-type CMs. Knock-in CMs 
were also resistant to G418 treatment up to 50 µg/ml.  
The correlation of MYL2 gene expression with each of the reporter was shown to be 
significant (p ≤ 0.05 for G. Luc; p ≤ 0.01 for mCherry and p ≤ 0.001 for NeoR). Lambda scan also 
showed that observed red fluorescence was specific for mChr with emission signal detected 
exclusively around 610nm, i.e. the theoretical emission wavelength of mCherry. While mChr 
reporter provides a qualitative real time signal for vCMs, G. Luc reporter provides a quantitative 
one. By day 30, knock-in CMs generated G. Luc signal 3 orders of magnitude higher than the wild 
type CMs (figure 3.4.8-1). Taken together, the data demonstrated reporter genes were well 
expressed in the knock-in CMs.  
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G418 selection of up to 50 µg/ml enabled enrichment for very bright mChr (+) CMs. 
However, considerable cell death was observed in cultures treated with higher concentrations 
(30 – 50 µg/ml) of G418. In fact, some mChr (+) CMs have been observed to float (and selected 
against G418) after a few days of antibiotic treatment. This was puzzling at first since NeoR gene 
was expressed as shown through qPCR data (figure 3.4.9-1). NeoR expression correlation to 
MYL2 gene was also the strongest (p ≤ 0.001).  
Presumably, G418 killed the MYL2 (-) cell population, which included not only the matrix 
producing non-myocytes, but also the other CMs subtypes (atrial and nodal). These MYL2 (-) 
cells, however, might have been tightly coupled to MYL2 (+) cells. Thus killing these cells might 
have resulted in detachment of the closely coupled MYL2 (+) adjoining cells from the cell culture 
surface.  
General protocols for G418 killing curve experiment require sub-confluence of cells 
before antibiotic selection. However, directly differentiated CMs in tissue culture flasks tend to 
be tightly coupled to one another. The need for trypsinization and subsequent CM replating at 
20-25% confluence conflicted with the original purpose of including this reporter in the knock-in 
line, i.e. to provide a one-step enrichment method for MYL2 positive cells from a mixed cell 
populations following a directed cardiac differentiation from hPSCs. Due to time limitation, G418 
selection on CMs derived from 3D-differentiation method was not performed, thus the effect of 
selection on suspension culture of CMs could not be determined. 
When comparing the reporter genes signals from H9V15 CMs versus H9VC16 CMs, it was 
observed that H9VC16 CMs expressed mChr at higher intensities than the H9V15 CMs (figure 
3.4.6-7). This data is in agreement with literature which suggested that the strong expression of 
constitutive PGK promoter in PGK-Hygromycin selection cassette might interfere with the 
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endogenous enhancer/promoter elements and affect the physiological expression of the gene or 
neighboring genes (Calegari and Waskow, 2014). Although the G. Luc expression was higher in 
H9VC16 CMs (figure 3.4.8-1), this difference was not shown to be statistically significant. 
However, considering that on day 21, H9VC16 EHMs expressed lower level of G. Luc, it might be 
the case that H9VC16 EHMs contained fewer MYL2 (+) CMs, but that each of these CM produced 
more G. Luc than each of the MYL2 (+) H9V15 CM. This resulted in overall higher level of G.Luc 
expression (albeit not statistically significant) in H9VC16 EHMs from day 27 onwards, in 
comparison with H9V15 EHMs. Only if this presupposition holds, can we make the conclusion 
that the removal of the PGK-Hygromycin selection cassette resulted in a higher level of reporter 
gene expression. 
Although qPCR data indicated a slight dip in MYL2 and all reporter genes expression from 
day 45 – 60, this dip in expression at protein level was only observed with G.Luc signal (figure 
3.4.8-1). MChr signal was observed to increase in intensity through time in culture (figure 3.4.6-
2). Due to the qualitative nature of mCherry signal, however, no definitive conclusion could be 
made yet on the correlation of mChr signal with EHM contractile forces.  
The G. Luc expression level on day 90 of differentiation was relatively similar to day 60. 
However, the contractile forces of day 90 EHMs were on average 42% higher (1.96 ± 0.16 mN vs 
1.38 ± 0.13 mN) than the forces of day 60 EHMs. Considering G. Luc expression to be proxy of 
MYL2 gene expression, this increase in contractile forces must be attributed to other sources 
besides MYL2 contractile protein density in the CMs. Nevertheless, the in vitro aging experiment 
gave us insights on the expression pattern of MYL2. The gene starts to be expressed strongly in 
CMs cultured as EHMs from day 24 of differentiation. This expression increased steadily until its 
peak expression on day 45 of differentiation. Beyond day 45, MYL2 expression level reached a 
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plateau. As such, it can be inferred that MYL2 is probably a good proxy for vCM early 
development up until day 45 of differentiation. Beyond day 45, MYL2 expression level does not 
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It is widely accepted that hPSC-derived cardiomyocytes (CMs) are phenotypically immature, 
akin to fetal CMs (Cao et al., 2008; Snir et al., 2003). This part of the thesis summarizes efforts to 
mature hESCs-derived CMs in vitro. The first attempt used a combination of growth factors, 
auxotonic mechanical conditioning and extended culture period of 3 months. The contractile 
forces as well as reporter genes expression generally increased over time of culture; this was 
described in the previous chapter. Day 30, 45, 60 and 90 EHMs beat with an average of 0.229 ± 
0.019 mN, 0.869 ±0.087mN, 1.09 ±0.13mN and 1.62 ±0.16mN, respectively.  
This chapter focuses on the dynamic regulation of EHM transcriptomes as they aged in vitro. 
A multitude of genes were up-regulated and down-regulated over time in culture. Up-regulated 
genes included many associated with the extracellular matrix development and remodeling, 
regulation of developmental processes and cardiac morphogenesis, potassium transport, lipid 
and ions binding and transport, and cell adhesion. Down-regulated genes were functionally 
clustered around cell proliferation, some cell signaling cascade and carbohydrate metabolism.  
The second approach involved electrical stimulation in conjunction with auxotonic stretching 
at basal (60 mm inter-pole distance) or at greater extension lengths (66 mm, 72 mm and 84 mm). 
66 mm was found to be the maximum tolerable distance; anything farther was detrimental to 
the function of CMs inside the EHMs. Of all different electrical stimulation protocols tested, the 
following protocol was found to enhance CM maturation the most in EHM format: 8V basic 
square wave with 2 days each of the following frequencies: 1Hz, 1.5Hz, 2Hz and 2.5Hz. EHMs 
stimulated with the latter protocol showed (1) higher EC50 values than the control group of 
unstimulated EHMs (0.8 mM vs 0.6 mM Ca2+); (2) more positive force-frequency response from 




to cardioactive drugs: isoprenaline (89.2% vs 5.5% in unstimulated EHMs) and carbachol (36.5% 
vs 4.4% in unstimulated EHMs). 
 These experiments demonstrated that in vitro manipulations could enhance the 
maturation level of cardiac tissue mimetic constructs (EHMs), but current in vitro protocols still 
fell short in generating CMs with the with the degree of maturity expected of CMs in vivo.   
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At the phenotypical and transcriptional level, human pluripotent stem cell (hPSC)-derived 
cardiomyocytes (CMs) are most similar to fetal CMs (Cao et al., 2008; Snir et al., 2003); more 
specifically, the ones from primary heart tube (Fijnvandraat, 2003). This fact makes the use of 
hPSC-derived CMs suboptimal for number of applications such as drug screening and cell therapy 
due to their immature electrophysiology and mechanical properties (Chen et al., 2009). There is 
a need to improve the maturation level of hPSC-derived CMs in vitro, and this chapter describes 
different attempts to reach this goal. 
3-dimensional CMs culture as engineered heart muscle constructs (EHMs), coupled with 
auxotonic stretching, has been shown to improve terminal differentiation and maturation of 
CMs in vitro in comparison with the monolayer (2D) culture approach (Tiburcy et al., 2011; Zhang 
et al., 2013). However, there are still reported signs of CM immaturity in EHMs (Schaaf et al., 
2011). Thus, there is a need for further development for in vitro maturation techniques.  
A number of maturation methods have been reported in literature and they will be explored 
in greater depth in the literature review section below. Before delving into these protocols, 
however, it is useful to understand what the term “mature” entails. 
 
Excellent reviews on CM maturation are available (Robertson et al., 2013; Yang et al., 
2014). In this thesis, some of these parameters will be summarized; some other important 
factors not yet covered in the reviews will also be outlined. Readers are referred to Chapter 2 
section 2.2.3 for the phenotypes of hPSC-derived CMs.  
 Introduction and literature review 4.2.




Cell behavior, structure and morphology 
 Adult CMs are generally rod-shaped/cylindrical, with length-to-width ratio of 7 to 9.5 
(Gerdes et al., 1992). The relatively large CM size plays an important role in action potential (AP) 
propagation and maximal rate of depolarization (Vmax = dV/dtmax) (Spach et al., 2004). Adult CMs 
have well organized and long sarcomeres, with relaxed state length of around 2.2 µm (Bird, 
2003). They show the typical periodic Z-lines, M lines and the transverse-tubule network 
opposed tightly to terminal cisternae forming dyads (Lieu et al., 2009; Ziman et al., 2010). T-
tubules in adult vCMs are closely apposed to the sarcoplasmic reticulum (SR) to facilitate calcium 
Induced calcium release (CICR) events, thus promoting coordinated contraction throughout the 
entire cytoplasm. In addition, adherens junctions marked by N-cadherin are localized to 
intercalated disks of adult CMs to promote cell-to-cell attachment; and gap junctions in the 
same location containing connexin 43 serve to enhance conduction velocity (Angst et al., 1997). 
In human neonates, CMs continue to proliferate in the first few months after birth: only 
around 25% neonatal CMs are binucleate (Laflamme and Murry, 2011). Adult human CMs 
however, are mostly multinucleate as they replicate their DNA without cytokinesis. The great 
majority of adult CMs have exited the cell cycle, with only 1% annual turn-over at the age of 25 
to 0.45% at the age of 75 (Bergmann et al., 2009). In these cells, hypertrophic growth 
predominates; with circa 30-40 fold size increase in both rodents and humans (Laflamme and 
Murry, 2011). 
 The cytoplasm of adult CMs is filled with contractile proteins and mitochondria 
(Robertson et al., 2013); myofibrils make up 40% - 52% (Barth et al., 1992; Tashiro et al., 1990) 
and mitochondrial volume makes up 15% - 40% of the total CM volume (Barth et al., 1992; 
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Hattori et al., 2010; Schaper et al., 1985; Sulkin et al., 2014; Tashiro et al., 1990). In addition, 
mitochondria of the adult CMs are more elongated with higher membrane potential and well-
structured lamellar cristae arranged in crystal like lattice pattern (Schaper et al., 1985). This 
improved structural organization leads to higher oxidative capacity and lower levels of reactive 
oxygen species (ROS) production in adult CM mitochondria (Yang et al., 2014). Notably, the 
mitochondria permeability transition pores (MPTPs) are closed in adult CMs (Yang et al., 2014).  
 Metabolically, fatty acid oxidation accounts for 90% of acetyl-CoA production and 60% – 
80% of ATP production (Huss and Kelly, 2005; Yang et al., 2014) in adult CMs, indicating their 
preference for oxidative metabolism and their dependence on oxygen (Giordano, 2005; Harris 
and Das, 1991).   
Electrophysiology and calcium handling 
During the first few years of life, CMs increase 2.4-fold in size, yet AP duration (APD) only 
increases by around 20% (Lakatta and Sollott, 2002; Roberts and Wearn; Zak, 1974). The 
different AP characteristics of all hPSC-derived CMs have been excellently reviewed elsewhere 
(Chen et al., 2009a). Adult CMs generally have hyperpolarized maximal diastolic potential (MDP) 
around -85mV (Drouin et al., 1998), relatively long APD (Schram et al., 2002), and extremely fast 
maximum rate of depolarization dv/dt (max) or Vmax around 300 V/s (Robertson et al., 2013). In 
addition, adult vCMs are generally quiescent and do not exhibit spontaneous phase 4 
depolarization (Schram et al., 2002). The left ventricle of myocardium in humans has been 
shown to have a conduction velocity of 0.3 to 1.0 m/s (Yang et al., 2014). 
A recent study in zebrafish by Hou, et al. (2014) demonstrated that early in development, 
action potentials were initiated via a calcium current through L-type calcium channels (LTCC). As 
the heart develops, there was a switch in the ventricular AP to a sodium-driven upstroke, while 
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the atrial AP remained LTCC-driven. In the adult state, APs are initiated by sodium current, both 
in the atria or ventricles (Hou et al., 2014). Thus, there is an increased dependence in sodium 
channels for AP initiation in adult hearts, at least in the zebrafish. 
Donald M. Bers (2002) has described cardiac excitation-contraction coupling in great 
detail. A number of membrane proteins are important for excitation-contraction coupling in 
adult CMs. The intracellular Ca2+ concentration is reduced by calcium clearance from the cytosol 
mediated by SERCA (sarcoplasmic reticulum Ca2+ ATPase pump), the sarcolemmal sodium-
calcium exchange pump, the sarcolemmal Ca2+-ATPases and/or mitochondrial Ca2+ uniport (Bers, 
2002). Calcium import into the cytosol, on the other hand, is mostly driven by calcium induced 
calcium release (CICR) events from the sarcoplasmic reticulum (SR). In fact, the SR contributes 
around 70% of the total calcium release from adult CMs (Bers, 2002). CICR mostly acts through L-
type calcium channels (LTCC), transmembrane calcium channels located in T-tubules, and 
ryanodine receptors (RYRs) (Bers, 2002). These proteins lie in close proximity to each other in 
the region termed the “calcium cleft” (Bers, 2002). RYRs are coupled to triadin, junctin and 
calsequestrin in the luminal side of SR, thus they also act as intra-SR calcium sensor (Bers, 2002). 
Contractile forces, cytosolic proteins and extracellular matrix  
The beating force of adult human and rat myocardium has been reported to be around 
44 ± 11.7 mN/mm2 and 56.4 ± 4.4 mN/mm2 respectively (Hasenfuss et al., 1991). Adult CMs beat 
along a single axis with a positive force-frequency relationship, i.e. faster pacing frequency will 
result in increased beating force (Bers, 2002; Dolnikov et al., 2006). In addition, they also exhibit 
post-rest potentiation: calcium uptake is increased during resting phase after rapid pacing. 
Treatment of adult CMs with isoprenaline (beta receptor agonist) would generally lead to 
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chronotropic and inotropic responses, while treatment with carbacholine (muscarinic receptor) 
would lead to the opposite: reduced heart rate and contractile forces.  
Adult CMs show isoform specificity in their expression of titin, troponin and MHC. Unlike 
their younger counterparts, adult CMs express a shorter and stiffer form of titin of 3000 kDa 
(N2B), which aids in the regulation of passive tension (Lahmers et al., 2004; Opitz et al., 2004; 
Warren et al., 2004). Adult CMs also contain the cardiac troponin I (cTnI) instead of the slow 
skeletal troponin I (ssTnI) isoform (Bhavsar et al., 1991; Hunkeler et al., 1991; Sabry and Dhoot, 
1989; Saggin et al., 1989). CTnI contributes to decreased calcium sensitivity for contraction in 
adult CMs, in comparison with complexes containing ssTnI (Metzger et al., 2003; Reiser et al., 
1994; Siedner et al., 2003). Therefore, a decrease in extracellular calcium sensitivity is predictive 
for improved CM maturation. Very recently, the cTnI: ssTnI isoform ratio has been proposed as a 
CM-maturation signature (Bedada et al., 2014). In adult CMs there is also more β-MHC (myosin 
heavy chain) isoform than α-MHC, the latter being more prevalent in fetal hearts (Xu et al., 
2009). The increased abundance of the slower β-isoform might contribute to the observed 
postnatal heart rate decrease.  
With regard to cell-extracellular matrix attachment proteins, adult CMs were found to 
attach efficiently to laminin and type IV collagen, but weakly to fibronectin (Borg et al., 1984). In 
contrast, neonatal CMs were demonstrated to attach to collagen I, III and IV, fibronectin and 




Parameters Immature cardiomyocytes Mature cardiomyocytes 
Morphology 
Cell shape Circular Rod-shaped 
Membrane 
capacitance 17.5±7.6 pF ≈150 pF 
Sarcomere 
Structure Disarrayed; Non-periodic Z lines 
Highly organized; 
Periodic Z-lines 
Length ≈1.6 µm ≈2.2 µm 
Myofibrillar 
isoform 
Titin N2BA N2B 
Troponin I ssTnI cTnI 
MHC β > α β >> α 
T-tubules No Yes 
Mitochondria 
Irregular reticular network in 
cytoplasm; occupies a small 
fraction of cell volume 
Regularly distributed; 
occupies ≈ 20% - 40% of 
cell volume 
Metabolic substrate Glucose  Fatty acid 
Multinucleation Mononucleated ≈25% multinucleated 








≈−60 mV ≈−90 mV 
Automaticity Spontaneous contraction Quiescent 
E-C coupling 
Partially developed; 
Contraction depends on trans-





Force frequency response Negative Positive 
Contractile force ≈nN range/cell ≈µN range/cell 
Gap junction distribution Circumferential Polarized to intercalated disks 
Conduction velocity ≈0.1 m/s 0.3 – 1.0 m/s 
Responses to β-adrenergic 
stimulation 
Chronotropic response; 




Table 4.2.1-1 Summary of differences between immature and adult cardiomyocytes.  




CMs are regulated by differing environmental signals during embryonic development in 
vivo. Amongst these factors are mechanical cues, electrical fields, soluble factors as well as 
dynamic composition and characteristics of extracellular matrices. These factors in turn may 
determine spatial organization and induce tissue morphogenesis (Henderson and Chaudhry, 
2011; Nuccitelli, 1992). Therefore, most successful in vitro maturation approaches attempt to 
recapitulate the in vivo environment in order to mature CMs in culture. Methods to enhance CM 
maturation can use either monolayer or three-dimensional culture approach. Once a culture 
system is determined, state-of-the-art maturation techniques can be broadly grouped into 5 
different approaches: (1) in vitro aging, (2) physical manipulation, (3) electrical pacing, (4) 
biochemical treatment and (5) co-culture with other cell types (often in combination with other 
techniques).  
In vitro aging 
In vivo, human neonatal CMs developed over 6 – 10 years to the reach their adult phenotype 
(Peters et al., 1994). Practical constraints limit in vitro aging experiment for similar duration. 
Nevertheless, long term culture has been used as the most instinctive way to enhance CM 
maturation in vitro. HPSCs-derived CMs have been reported to exhibit morphological and 
ultrastructural maturation as well as withdrawal from cell cycle within 60 days of in vitro culture 
(Snir et al., 2003). CMs were shown to be more elongated and bigger in size, myofibril 
morphology, organization and density were also improved, with A, I and Z bands being observed 
in older CMs. The gap junction proteins connexin 43 and 45 were also expressed (Kehat et al., 
2002). T tubules, however, were still absent in these CMs.  More recent publications (Kamakura 
et al., 2013; Lundy et al., 2013) using 180 day old and 80 – 120 day old hPSC-derived CMs, 
 Old is better than young  4.2.2.
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respectively, have also supported these observations. Kamakura et al. (2013) continued to 
culture their CMs for 1 year and noted that M bands “were finally detected in 360-day old EBs,” 
although the level of expression was still lower than that in the adult heart. Lundy et al. (2013) 
also reported a 10-fold increase in the fraction of multinucleated CMs. In a separate study, 
electrophysiology of hESCs-derived CMs was shown to mature over 3-month culture period 
(Sartiani et al., 2007). Figure 4.2.2-1 captures the essence of quantitative and qualitative changes 
in the different currents during maturation. Lundy et al (2013) also reported similar 
electrophysiological behavior with their older hPSC-derived CMs: late-stage CMs were shown to 
have hyperpolarized maximum diastolic potentials (MDP), increased action potential amplitudes, 
and faster upstroke velocities. 
 
 
Figure 4.2.2-1 Schematic representation of ionic currents measured in hESCs, early and late CMs. Image is 
reproduced from (Sartiani et al., 2007) with permission. 
 
 
Additionally, 80 – 120 day old CMs were shown to beat with shortening magnitude 
double that of the younger (20 – 40 day old) CMs. Their contraction kinetics was also slower in 
comparison to the early stage cells (Lundy et al., 2013). Furthermore, these authors reported an 
increase in calcium release and reuptake rates with no change in the maximum contraction 
amplitude. Despite the encouraging results from in vitro aging experiments, the nature of the 
Developmental maturation is illustrated 
by gray triangles, indicating an increase in 
the current density and by a dashed 
stripe, which represents the slowing 
activation rate for If. Presence of INa has 
been described (Satin et al., 2004). 
Abbreviations: ICa,L, L-type calcium 
current; If, pacemaker current; IK1, inward 
rectifier potassium current; IKr, rapid 
delayed rectifier potassium current; INa, 




experiments prevents time-effective in vitro CM maturation. In addition, despite 1 year of 
culture, hPSC-derived CMs still did not reach the maturity level of adult CMs in vivo (Kamakura et 
al., 2013).  
Physical manipulation 
 
A number of approaches fall into this category:  
1. Varying the mechanical properties of the attachment substrate  
 
Hazeltine and colleagues (2012) seeded hPSC-derived CMs on polyacrylamide hydrogels 
of varying stiffness from 4.4 – 99.7 kPa. Contraction stress was found to increase with substrate 
stiffness. Strain, beating rate and morphology, however were not significantly affected. CMs 
seeded on all 4 different substrate stiffness nevertheless responded to isoprenaline stimulation, 
indicating presence of beta adrenergic receptors. A similar result was reported by Rodriguez et al. 
(2011) who cultured neonatal rat ventricular CMs on micro-fabricated arrays of flexible posts of 
different stiffness. It was found that CMs cultured on stiffer substrates developed 6-fold greater 
twitch forces but slower twitch velocity. In addition, CMs on stiffer arrays were found to exhibit 
more mature myofibril structure, as they had longer sarcomeres and wider Z-bands. 
Furthermore, the CMs cultured on stiffer arrays also showed improved intracellular calcium 
levels during a twitch, indicating better intracellular calcium storage capacity. 
2. Attachment surface engineering for anisotropic cell attachment 
 
Some groups have taken the approach of using biomimetic topographical cues. CM 
shape has been shown to regulate sarcomere alignment (Bray et al., 2008), and cell alignment 
has been shown to improve when cells are cultured on patterned substrates (Au et al., 2009; 
Wang et al., 2011). Kim et al. (2010b) constructed an anisotropically nanofabricated substrate of 
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polyethylene glycol patterned with ridges and grooves ranging from 150 to 800 nm wide, 
designed to closely reproduce a nanoscale structure of the myocardial extracellular matrix 
composed of aligned fibrils around 100 nm in diameter. Each CM spanned >10 nano-ridges and 
was shown to align along the direction of the topographical cue. Aligned CMs exhibited cell 
geometry, conduction velocity, and Cx43 expression more similar to that of the native heart. In a 
more recent attempt, surface topography and substrate stiffness approaches were combined 
(Wang et al., 2011). Morphology and orientation of neonatal rat ventricular CMs were mainly 
influenced  by nano-grooved structures, whereas the contractile function of the CMs was 
regulated by both surface topography and substrate stiffness, with better contraction on the soft 
substrate with deep grooves (Yang et al., 2014). 
3. Mechanical conditioning 
In another set of experiments, neonatal rat CMs were seeded in neutralized collagen I 
into 3-dimensional engineered heart tissues (EHTs) which were then subjected to phasic 
unidirectional stretch for 6 days (Fink et al., 2000). The authors showed that atrial natriuretic 
factor (ANF) was up-regulated by 98% and alpha-sarcomeric actin by 40%. In addition, stretched 
EHTs developed hypertrophic CMs with increased cell length and width, longer myofilaments, 
and increased mitochondrial density. The CMs in stretched EHTs also showed marked 
improvement in structural organization, being arranged into parallel arrays of rod-shaped cells. 
Finally, stretched EHTs demonstrated significant improvements in contractile forces. Stretched 
EHTs beat with 2 – 4 fold higher forces both under basal conditions and after stimulation with 
calcium or isoprenaline.  
More recently, hESCs-derived CMs were exposed to cyclic equiaxial mechanical stretch 
at 0.5 Hz with pulsation of 10–25% elongation of cells for 24 h (Foldes et al., 2011). CMs 
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stretched for 24 hours showed increase in cell size (1.6-fold, P < 0.001) and percentage of CMs 
showing organized sarcomere structure (P < 0.001). Mechanically stretched CMs also showed 
significantly higher mRNA expression levels of αMHC + βMHC and ANF (P < 0.05 and 0.001 vs. 
unstretched control, respectively, triplicate determinations). The ratio of α/β-MHC, however, 
was not found to change significantly with stretching. These results were in accordance with 
those of another study (Tulloch et al., 2011), which demonstrated that uniaxial mechanical stress 
conditioning resulted in 2-fold increase in alignment of CMs and matrix fibers as well as 
enhanced myofibrillogenesis and sarcomeric banding. The cyclic stress conditioning also induced 
CMs hypertrophy (2.2-fold) and proliferation rates (21%). 
 
Electrical stimulation 
In hESCs-derived CMs, electrical stimulation led to longer action potential duration and 
higher caffeine-induced calcium flux (Martherus et al., 2010). Also, it has been reported that 
electrically stimulated hESCs-derived CMs had higher level of Kir2.1 expression (Deng et al., 
2000). In another study, hPSC-derived CMs were cultured in 3-dimensional format and 
electrically paced with either progressively increasing stimulation frequency from 1 Hz to 3 Hz or 
from 1 Hz to 6 Hz over 1 week of culture at 3-4V/cm (Nunes et al., 2013). The authors 
demonstrated that electrical stimulation enhanced CMs sizes and phenotype, with the ones 
paced up to 6 Hz showing better results than the ones paced up to 3 Hz. In particular, 
electrically-stimulated CMs showed significantly more rod-like cells, enhanced CMs self-
organization with presence of Z disks, I bands, H zones, and desmosomes. The number of H 
zones per sarcomere, the ratio of I bands to Z discs and the desmosome density were shown to 
increase significantly with increasing frequency of stimulation (Nunes et al., 2013). The same 
authors also described down-regulation of NPPA, NPPB, MYH6 and up-regulation of KCNJ2 in 
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their electrically stimulated CMs, implying maturation of these CMs. Electrically stimulated CMs 
also exhibited lower proliferation rates, improvements in electrical properties, electrophysiology 
and calcium handling properties. A more recent study employed a more modest electrical 
stimulation frequency (Hirt et al., 2014). The authors mixed hiPSCs-derived CMs with fibroblasts 
to form engineered heart tissues (EHTs) and subsequently paced the EHTs with biphasic pulses 
of 4 ms and field strength of 2V/cm from day 4 post-casting onwards, at 2 Hz for the first week 
and 1.5Hz thereafter (Hirt et al., 2014). In comparison with the non-paced group, the paced EHTs 
were found to beat with 1.5x higher forces, and contained more anisotropically aligned CMs with 





To test the effects of hormones on CM differentiation, hESCs-derived CMS were 
subjected to 100 μM angiotensin II or 10 μM α-adrenergic phenylephrine (PE) treatment for 48 
hours (Foldes et al., 2011). The authors found that CMs treated with PE had a significant increase 
in cell area (1.8-fold, P < 0.0001), cell volume (2-fold, P < 0.001) and fraction of CMs with 
organized sarcomeres (3.8-fold, P < 0.0001). Messenger RNA and protein expression of ANF (2.1-
fold, P < 0.001) were also increased in PE-treated CMs, in comparison with untreated CMs.  CMs 
treated with angiotensin II also showed increase in cell size (1.2-fold, P < 0.05), fraction of CMs 
with organized sarcomere structure and αMHC, βMHC, and ANF mRNA levels). The level of 
increase for each parameter, however, was less than that observed with PE. The ratio of α/β-
MHC was also not found to change significantly with PE or angiotensin treatment.  
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Thyroid hormone has an indispensable role in maintaining normal heart function (Klein 
and Ojamaa, 2001). T3 has also been reported to modulate the developmental titin isoform 
switch in cultured fetal rat CMs from fetal isoform N2BA (>3200kDa) to adult isoform N2B 
(3000kDa) (Kruger et al., 2008), indicating that the hormone promotes CM maturation. In ovine 
background, T3 was demonstrated as a prime driver of CM maturation (Chattergoon et al., 2012). 
T3 treatment increased the expression levels of phospho-mTOR, atrial natriuretic peptide (ANP) 
and SERCA2a. In additional, T3 treatment also increased CM width by 14%, bi-nucleation rate by 
31% and p21 protein expression by 200%. T3-treated CMs also showed a decrease in 
proliferation by 39% and a decrease of cyclin D1 protein expression by 50% (Chattergoon et al., 
2012). The role of T3 is not limited to CM maturation, however. The hormone has also been 
shown to promote CM differentiation from mouse embryonic stem cells (Lee et al., 2010). T3 
treatment improved CM yield as well as up-regulation of a number of cardiac markers such as 
Nkx2.5, MYL2, αMhc and βMhc (Lee et al., 2010). Furthermore, T3-treated CMs displayed more 
adult-like electrophysiology and calcium homeostasis: they had more negative resting 
membrane potential (−74.72 ± 4.12 mV; P < 0.05) and higher expression of Serca2a and RyR2 
(Lee et al., 2010). T3-treated CMs also had larger peak amplitude of calcium transients, F/F0 
(2098 ± 208.30); higher maximal upstroke velocity, F/F0/sec (3.38 ± 0.32 vs. 1.17 ± 0.10) and 
maximal decay velocity, F/F0/sec (−1.34 ± 0.08 vs. −0.34 ± 0.09) (Lee et al., 2010).  
The effect of another hormone, relaxin (RLX), was tested in mouse neonatal CMs in 
primary culture (Nistri et al., 2012). The authors found that RLX affected cell proliferation, 
enhancing it at 2 and 12 hours yet inhibiting it at 24 hrs. RLX also induced the expression of 
Gata4, Nkx2-5, cx43, troponin T and Hcn4 ion channel at both the mRNA and protein level. 
Furthermore, RLX-treated CMs showed ultrastructural and electrophysiological maturity.  
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In another paper, transgenic mice overexpressing insulin growth factor receptor (Igf1R) 
in the heart were reported to exhibit cardiac hypertrophy (McMullen et al., 2004). The 
transgenic mice also had enhanced systolic function at 3 months of age, which was maintained 
at 12-16 months of age. Thus it seems that IGF1 might enhance CM maturation in vitro.  
2. miRNA 
 
MiR-1 has been identified as a potential modulator of CM maturation (Fu et al., 2011). 
Indeed, miR-1 overexpression decreased action potential duration (APD) and hyperpolarized 
both the resting membrane potential and the maximum diastolic potential in hESCs-CMs, due to 
increased Ito, IKs, and IKr, and decreased If. Furthermore, miR-1 was demonstrated to improve 
calcium transient amplitude and kinetics. MiR208 is yet another miRNA identified as a CM 
maturation modulator. This has been shown to be involved in thyroid hormone responsiveness 
and myosin isoform switching (Callis et al., 2009; van Rooij et al., 2007). 
Co-culture with other cell types 
Using genetically purified early hESCs-CMs, Kim et al (2010a) showed that non-CMs are 
required for the development of expression of some intracellular calcium handling proteins. 
Presence of non-CMs was demonstrated to enhance ion channel development (HCN4) and CMs 
electrophysiological maturation. Non-myocyte fraction has been shown to be critical for 
functionality of 3-dimensional culture of hPSC-derived CMs (Tiburcy et al., 2014). Defined non-
myocyte fraction (fibroblasts) was demonstrated to enhance the maturation of CMs inside the 
EHTs, which were measured through higher contractile force of 9.8±0.9 nN/CM, higher EC50 for 
calcium, and enhanced inotropic response to isoprenaline. In addition, there was evidence for 
cell cycle withdrawal, increased actinin protein expression per CM; and reduction in MYL2/MYL7 
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double positive CMs fraction. Taken together, non-myocyte fraction seems to improve the 
maturation of the CMs in EHTs by improving their functionality.  
 
Total RNA and microRNA sequencing 
At day 18 of differentiation, H9V15 and H9VC16 CMs were digested into single cells and 
mixed with HFFs in collagen I matrix to make EHMs. These EHMs were cultured in vitro for 90 
days in presence of VEGF, IGF, FGF and auxotonic stretching but no electrical stimulation. RNA 
samples were extracted from these EHMs on day 30, 45, 60 and 90 of differentiation and then 
sent for RNA and small RNA sequencing experiment. The raw data was provided by the DNA 
Microarray and Deep-Sequencing Facility, Göttingen.  
The raw data was analyzed by the author of this study in Singapore using Partek 
Genomics Suite® on trial version. Firstly, an ANOVA table was created to determine the 
probability values which would indicate that the differential gene expression observed was not a 
stochastic effect. Genes with false discovery rate (FDR) ≤ 0.001 and absolute log2fold change 
value ≥ 3.000 were shortlisted for further analysis.  
 
H9VC16 EHMs were transferred to printed auxotonic stretchers of varying inter-pole 
distances: 60mm (normal), 66mm, 72mm, and 84mm. Three different sets of experiments were 
 Materials and Methods 4.3.
 Temporal in vitro maturation in maturation medium 4.3.1.
 Increasing pre-load resistance for EHMs 4.3.2.
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carried out (table 4.3.2-1). CMs level of maturation was assessed through EHM force 
measurements, force frequency response and calcium handling capacity (EC50). 
Experiment number Treatment 
1 60mm for 2 weeks; 72mm for 1 week; 84mm for 1 week 
2 60mm for 8 days; 66mm for 9days; 72mm for 8 days 
3 60mm for 5 days; 66mm for 2 weeks 
 
Table 4.3.2-1 Passive mechanical stretch (increasing CMs preload) procedures 
 
H9VC16 EHMs were transferred to 60mm printed auxotonic stretchers and cultured for a 
minimum of 2 weeks. They were then paced with ION Optix C-Pace EP Culture Pacer with square 
bipolar pulses at 5 – 8V with 5ms duration in between pulses. Frequency of pulse was adjusted 
manually to 1Hz, 1.5Hz, 20Hz and 2.5Hz. Each frequency was applied to EHMs for one or two 
days per frequency. The level of CM maturation was assessed through the expression level of 
reporter genes, EHM contraction force measurement, EHM force-frequency response as well as 
calcium handling capacity (EC50).   
 
In a few experiments, the preload of H9VC16 EHMs were gradually increased from 60mm to 
84mm across three weeks of culture in vitro. EHMs were first cultured on 60 mm printed 
auxotonic stretchers for a week, before being transferred to 72 mm stretchers. A week later, 
these EHMs were transferred again to 84 mm stretchers and kept at this distance for another 
week of culture. EHMs were electrically stimulated as per section 4.3.3 whilst being stretched at 
84 mm. In another set of experiments, EHMs were electrically stimulated whilst being stretched 
at 72 mm or 66 mm.  
 Electrical stimulation of EHMs 4.3.3.
 Increasing preload and electrical stimulation 4.3.4.
174 
 
Data is presented as means ± standard error mean (SEM). Statistical analyses were 
performed with Student’s t-test (2-tailed) or ANOVA when applicable, with post-hoc Bonferroni's 
Multiple Comparison test. Results were considered to be significant at p ≤ 0.05 (*); very 
significant at p ≤ 0.01(**) and extremely significant at p ≤ 0.001 (***).   
 Statistical analysis 4.3.5.
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Fused EHMs as on figure 3.4.6-1 were set on electrophysiology viewing chamber and 
impaled with glass electrodes. The following figures show the typical action potentials obtained. 
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 Results 4.4.




-70.3 ± 1.50 mV 
Average action potential 
amplitude (APA) 
106.5 ± 0.70 mV 
Average maximum speed 
of depolarization (dV/dt) 
169.66 ± 2.26 V/s 
Average APD40 147.05 ±  9.48 ms 
Average APD90 202.61 ± 10.43 ms 
Average RMP -60.57 ± 1.77 mV 
Average APA 99.81 ± 4.04 mV 
Average dV/dt 72.41 ± 12.93 V/s 
Average APD40 108.4 ± 6.74 ms 
Average APD 90 171.75 ± 8.11 ms 
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Using FDR ≤ 0.001 and the absolute value of Log2Ratio (treatment/control) ≥ 3 as initial 
cut off criteria, 4900 genes were shortlisted for further analysis. A column statistics was then 
generated for these genes to facilitate hierarchical clustering and the generation of Self 
Organizing Map (SOM) in the form of heat map. The profile trellis function was also used in this 
study to display the different patterns of gene expression from different samples. The profile 
trellis enables simple identification of the group of genes which displayed a certain pattern of 
expression. In this particular experiment, the different samples were obtained from EHMs of 
different age. Thus a continuously increasing pattern shown on profile trellis e.g. sub-profile 17 
of figure 4.4.2-2 on the next page would indicate genes which were continuously up-regulated as 
EHMs aged in vitro for a period of 90 days.  
The heatmap shown in figure 4.4.2-1 of the RNA-sequencing results shows genes that 
were up- and down-regulated through time in culture (red shows higher expression and blue 
shows lower expression). From the heat-map, one can see that there are more genes that are 
up-regulated than down-regulated the longer EHMs were cultured. Almost all of the gene 
functions and site of expressions outlined below are adapted from GeneCards® database at 
www.genecards.org as well as gene ontology module of Genomics Suite® software, unless stated 
otherwise. Up-regulation and down-regulation fold changes for mRNA expressions are quoted as 
log2foldchange values, unless stated otherwise. Thus three times down-regulation refers to 
eight times absolute fold change.  






















































































































































































































































































Figure 4.4.2-2 shows the different types of expression patterns of the 4900 shortlisted 
genes, across different time points (day 30, 45, 60 and 90). Genes which showed continuous 
differential up-regulation or down-regulation from day 30-90 of culture will be further analyzed. 





Genes belonging to profile 3 showed a general down-regulation in gene expressions through 
time in culture, with steepest gradient from d60 – 90 of differentiation. Data was sorted for ratio 
of log2 expression on d60 vs d90 of >= 2.0, indicating greater than 4 absolute fold change in 
expression. Gene ontology was also filtered for p-value of enrichment < 0.05. The full list of 
genes together with their normalized level of expression is available in appendix 5.1.  
Gene Ontology Gene list and Sites of expression/Functions 
Carbohydrate catabolic 
processes 





Transporters ATP4A, COX7A1, ATP6V1G  proton transporters 
CHRNA3, TMEM38, ATP1B4, KCNV2, and ABCB1  other transporters 
Signal transducer MSX2, expressed in atrio-ventricular canal cells (Seddon et al., 2004),  
heart tube and cardiomyocyte-like progenitor cells (Tate, 2010) 
Cell adhesion 
molecules 
PROM1 (expressed in cardiomyocytes progenitors),  
CDH13,  
SELP (expressed in atrioventricular node cells)  and  
RND2 (expressed in cardiac crescent and cushion mesenchymal cells) 
 





Genes in profile 4 showed steady down-regulation as EHMs age in vitro.  
 
Gene Ontology Gene list and Sites of expression/Functions 
Cell-cell signaling EREG  positively regulates cell proliferation and mitosis,  
CRHBP, GRIA1, TRH, TFAP2C, STC1, HOXA11, FGFBP1, COMT, CHRNA9 and ADCY8 
Extracellular matrix reorganization and Ca2+-ion binding MMP3 
Transporters SLC16A6  monocarboxylate transporter and symporter, 
SLC2A2  facilitative glucose transporter 
Lipid-binding 
proteins 
APOA2  involved also in cellular lipid catabolic process and cholesterol import, 
SORL1 
Membrane proteins CLDN6, NLGN4Y and KIRREL3 
 




Genes in this profile group showed down-regulation of genes as EHMs aged from d30 – 60. The 
down-regulated genes then show steadily low expression from d60 – d90.  
Gene Ontology Gene list and Sites of expression/Functions 
Antiporter activity SLC4A9  anion-anion antiporter activity 
Bicarbonate transporter SLC4A9, SLC24A3, SLC4A8, SLC26A9 
Membrane-associated transporters CNGA2, SLC4A9, SYP, KCNK16, TRPC3, TRPA1, GJD2, SYT10, ATP13A4, 
SLC4A8, GABRB2, SLC24A3 and SLC26A9 
Glucose transports regulation IL1B, OSTN 
Short-chain fatty acid metabolic process IRG1 and THNSL2 
Striated muscle tissue development ALDH1A2, EYA1 and  
RXRG  also involved in fatty acid storage 
Lipid-binding protein CLVS2, SYP, SH3GL2, SYT14, VNN1, CADPS, YBX2 and ALDH1A2 
Cell-cell adhesion regulatory genes IL1B, L1CAM and DPP4 
Cell-cell signaling genes IL1B, TRHDE, SALL1, KCNK16, GJD2, ADCY2, ABAT, GABRB2 and CORT 
 
Table 4.4.2-3 Gene ontology of genes which belong to profile 5 
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Profile 9 shows sharp down-regulation in EHMS day 30-45, steady expression in EHMs day 45-60 
and further down-regulation in day 60-90.  
 
 
Gene Ontology Gene list and Sites of expression/Functions 
Cation transporters KCNQ2, CHRNB4, CCR7 
Anion transporters ABCC3, SLC6A18, CRYM, SLC51B 
Very-low-density lipoprotein assembly protein and 
cholesterol-binding 
SOAT2 
Positive regulation of glycoprotein biosynthetic 
process 
CCR7 and SLC51B 
 
Table 4.4.2-4 Gene Ontology of genes which belong to profile 9 
 
 
Profile 10 shows sharp down-regulation from day 30-45 EHMs and steady low level of expression 
beyond day 45 of differentiation.  
 
 
Gene Ontology Gene list and Sites of expression/Functions 
G-protein coupled receptor signaling pathway NPVF, GUCA1C, PDC and NPFFR1 
Channel proteins CYBB, PANX3, CACNA2D2, GABRQ, and CACNA1D 
Signaling receptor activity proteins TAS2R42, NPFFR1, OR51Q1, PTCHD2, GABRQ, CCRL2, GPR64, 
HNF4G 
Gap junction hemi-channel protein PANX3 
 










Genes in this profile were up-regulated rather sharply from day 30-45 of differentiation which 
continued up to day 90 in culture.  
 
 
Gene Ontology Gene list and Sites of expression/Functions 
Signal transduction APLN, GPR116, ANGPT2, NRK, RAPGEF5, CXCR4, COL15A1, CASQ2, KIT, PDE3A, 
GRAP, ELTD1, RHOJ, TNFSF10, ACKR3, ARHGDIB, ARHGAP18, F2RL3, RASSF9, F2R, 
RASL12, FZD4 HTR2B, KITLG, GNG2, RAMP2, SPARC, TLR4, TEK, AKR1C3, ENTPD1, 
EFEMP1, DLC1, FAT4, F2RL1, PTN, ACTG1, HEY1, CTHRC1, RAB15, PLCE1, P2RX1, 
DIRAS3, PLCL2, DCBLD2, NRP2, PRKD3, RALA, NEK6, RAB7L1, RAB31, HOMER3, 
RAB23, YES1, GFPT1, IQGAP1, MAP4K4. 
Negative regulation of cell 
proliferation 
OGN  regulator of left ventricular mass (Petretto et al., 2008), 
CDH5, NRK, F2R, DLC1, ETS1 and CD9 
Heart development and 
cardiac progenitor 
differentiation 
KIT, RAMP2, SPARC, TEK, FBN1, PLCE1 and NRP2 
calcium-mediated signaling CXCR4, CASQ2, HTR2B and PLCE1 
calcium ion binding CD93, CDH5, PCDH12, CASQ2, EDIL3, ELTD1, PLSCR4, MMP16, SPARC, SYT4, 
EFEMP1, FAT4, FBN1, PLCE1, PLCL2, TPM4 and IQGAP1 
Phospholipid translocation ATP8B1 and ATP10D  
A cell-surface membrane protein: 
Mediates cell-cell adhesion, linkages of transmembrane proteins to cytoskeleton, Ca2+ and carbohydrate 
binding. 
CD93 
An endogenous ligand for G-protein coupled APJ receptor:  
Regulates heart contractile forces, cardiac tissue remodeling, inhibits adenylylcyclase, increases 
intracellular calcium and activates extracellular signal-regulated kinases (ERKs), PI-3K, AKT and p70S6 
kinase (S6K1).  
At the cellular level, apelin signaling participates in cell relaxation (smooth muscle cells), migration and 
proliferation, as well as contraction in cardiomyocytes (Audigier, 2006). 
APLN 
Cell-cell junction proteins CDH5, CLDN5, CXCR4, GJA4, PCDH12, ESAM 
Cell adhesion, regulates transient increase in intracellular calcium 
concentration 
MCAM 
Basement membrane protein: stabilizes muscle cells in the heart COL15A1 
 







Genes which belong to this profile showed a rate of increase less steep than genes which belong 
to profile 16 from day 30-45 of differentiation but the final level of expression at d90 of 
differentiation was higher than those genes which belong to profile 16.  
 
 
Gene Ontology Gene list and Sites of expression/Functions 
Angiogenesis PGF, DLL4, PIK3CG, PLXND1, TIE1, PLXDC1, RASIP1, CYP1B1, ACVRL1, COL8A2, 
WARS, EFNA1, GPR124, HTATIP2, SRPX2, S1PR1, ITGA5, VASH1 and ERAP1 
Regulation of cell motility 
and migration 
MMP9, DLL4 and HGF 
Regulation of localization LPL, MMP9 
Lipid metabolic process ELOVL2, PTGIS, CYP1B1, PLA2G4A, C2CD4B, PIK3CG, PPARG, TRIB3, SNAI2, IGF2, 
NR3C1 and PDP1 
Biological adhesion POSTN, ISLR, COL14A1 and PIK3CG 
Negative regulation of 
cardiac contractility 
PIK3CG, POSTN 
NOTCH signaling pathway DLK1, DLL4, SNAI2, CCND1, ADAM17 and POSTN 
Regulation of cardiac 
muscle tissue growth 
GATA6, FOXP1 
 





Genes belonging to this profile showed a general up-regulation of genes, with a rather level 
expression from d30 – d45 post-differentiation in vitro, but rapid up-regulation from d45 to d90 
post-differentiation in vitro. The full list of genes which belong to this profile is available in 








TGFBR3, ADAMTS4, CILP2, COL6A6; 
SMOC and ADAMTS5 (both expressed by mature cardiac fibroblasts) 
Regulation of heart 
developmental processes 
TGFBR3, TBX18 and SOX9 (altogether regulate TGFβ, BMP and Wnt signaling pathways) 
Low-density lipoprotein 
binding 
COLEC12 and SCARF1; these genes mediate the uptake of modified LDL into cells for 
degradation 
Cell adhesion molecules B4GALT1 mediates cell-cell, cell-matrix interactions (by binding to specific 
oligosaccharide ligands on cells or matrix), as well as lactose biosynthesis;  
CBLN1 mediates cell-cell interactions and is expressed in atrio-ventricular canal cells 
(Seddon et al., 2004) 
 
Table 4.4.2-8 Gene Ontology of genes which belong to profile 18 
 
Profile 22 
Genes in this profile group showed up-regulation from day 30-45, steady level of expression 




SOX18 Heart tube development, endocardial cell differentiation and 
outflow tract morphogenesis. 
CHST1, BGN and CHST15 Glycosaminoglycan biosynthesis 
PDGFB, SPRY1, P2RY1, KDR and PDGFRA ERK1 and ERK2 cascade regulatory genes 
CD34, LYVE1, COL12A1, PCDH1, PODXL Cell adhesion genes 
RASSF2 Cell cycle arrest 
SPARCL1, PCDH1, FAT3and PCDHA7 calcium ion binding genes 
PIEZO2 and SLC40A1 Cation transport 
ANO1 Regulation of membrane potential 
XIRP2, ZFPM2, SOX18 Heart development 
XIRP2, PDGFB, EPS8 and FHL3 Actin and cell-cell junction cytoskeleton organization 
P2RY1,  PDGFRA Regulation of cytosolic calcium concentration 
P2RY1 Positive regulation of carbohydrate metabolic process 
P2RY1, PDGFB, KDR, ZEB2, and PDGFRA MAPK cascade 
 







Genes in this profile showed continuous and steady up-regulation of genes throughout in vitro 
culture, with higher rate of up-regulation in late phase of culture (d60 – 90). Complete list of 
genes which belong to this category is available in appendix 5.3.  
Gene Ontology Gene list and Sites of expression/Functions 
Extracellular matrix 
processes 
COL1A1, COL5A1, TRAM2, CHST2, CSPG4, and PDGFRB (altogether for collagen and 
glycosaminoglycan biosynthesis) 
ADAMTS2, ADAMTS7, CILP, ECM2, TENC1, OLFM2A, PXDN, SPON1 and VWF (altogether to 
organize and up-regulate the expression of extracellular matrix proteins) 
PXDN also plays a role in mediating peroxidative reactions in the cardiovascular system 
(Shin et al., 2003). 
Cell adhesion SORBS3, COL5A1, ECM2, ITGA8, ITGA  expressed in endocardium, heart atrium and 
ventricle as well as pericardium  
SPON1  expressed in heart atrium 
STAB1  expressed in intercalated discs in heart muscle and endocardium 
KIAA1462, PCDHGA10, PCDHGB6, PCDHGC3, RAPH1, APBA1 and VWF. 
Cardiac 
morphogenesis 
NOTCH1 (heart valve, coronary vasculature and atrium formation) and HEG1 (atrium 
formation) 
Heart rate regulation AVPR1A and EPAS1 
Transporters ABCC9 and KCNJ8  Potassium transport 




ARHGEF28, DTNBP1, FAM101B, FGD5, FMNL3, INF2, PDGFRB and WASF2 
Signaling pathway 
regulation 
Serine/Threonine (TGFβ) signaling pathway by NOTCH1, DAB2 and ITGA8 
Wnt signaling pathway by NOTCH1,COL1A1, DAB2 and GPRC5B 
MAPK signaling cascade by CSPG4, DAB2, PDGFRB, SASH1 and SORBS3 
 












Profile 24 of figure 5.4.1-3 shows genes that are expressed in a relatively steady level up until 
day 60 of differentiation with sudden rapid up-regulation from day 60 onwards.  
Gene Functions 
CD36 TGFβ binding, thrombospondin receptor activity, lipid binding, storage and transport, positive 
regulation of cellular metabolic process and protein phosphorylation, positive regulation of 
MAPK cascade (together with HIPK2, EGFR, PRKD2, TGFB1 and INSR), I-kappaB kinase/NF-
kappaB signaling, positive regulation of reactive oxygen species metabolic process and cell 
adhesion (together with SFRP2, MYO10, PRKD2 and GSK3B), regulation of nucleocytoplasmic 
transport, as well as ions transmembrane transport. 
SCN7A A voltage gated sodium channel: 
Regulates membrane depolarization during action potential generation, maintains sodium ion 
homeostasis. Strongly expressed in adult human heart (http://www.nextprot.org/). 
GPC4 Connects cells to heparin sulphate proteoglycan in the ECM, aids in cellular lipid metabolic 
process 
HSPG2 Binds to glycosaminoglycan, involved in cardiac tissue development, cellular lipid and organic 
acid metabolic process 
TTYH3 A large-conductance Ca2+-activated chloride channel: 
Plays a role in Ca2+ signal transduction.  
KCNMB2 A negative regulator of Ca2+-activated K+-channel KCNMA1 
ENG, HIPK2, ULK1, EGFR, DYRK1B, PDK4, CAMK4, 
RPS6KA2, MAST4, WNK1, PRKD2, MAPK7, LATS1, PAK2 
and GSK3B 
Serine/threonine kinases, DYRK1B and GSK3B are involved 
in syncytium formation by plasma membrane fusion of 
myoblasts. 
PEAK1, EGFR, DYRK1B and INSR Tyrosine kinases 
BCL2, EGFR, TGFB1, RPS6KA2, JMY, and LATS1 Regulation of cell cycle process, the genes in bold 
negatively regulate mitotic cell cycle. 
 










Micro RNA (miRNA) expressions across different time points can be summarized by a 
heat map and profile trellis (figure 4.4.3-1 and -2). Based on the patterns of expression, up-
regulated miRNAs belonging to profile 6 and 9 as well as down-regulated miRNAs belonging to 
profile 4 and 7 would be further analyzed. As each miRNA targets a large set of genes, only 
miRNAs that are expressed highly (>1000 copies at day 30 for down-regulated miRNAs or at day 
90 for up-regulated miRNAs) and showed significant level of up- or down-regulation (> 8x) will be 
analyzed. These miRNAs are underlined in the following table. Unlike the mRNA expression data 
format above (log2fold-change data), the fold change of miRNA quoted below is the absolute 
fold change. Table 4.4.3-1 summarizes all miRNAs that are up-regulated as EHMs aged in vitro. 













































































Table 4.4.3-1 List of up-regulated miRNAs 

















































































































































































































































Out of miRNAs in profile 6, hsa-miR-10a-5p shows the highest level of expression at day 
90 at 78198 copies (12.62x higher in day 90 vs day 30 EHMs). The miRNA targets cardiac muscle 
cell differentiation genes (down-regulating TBX5 and up-regulating GATA6) and biosynthetic 
process genes (up-regulating ELOVL2, NFIX, and NR5A2). Next on the list with high level of 
expression at 44812 copies (11.87x higher in d90 vs d30 EHMs) is hsa-miR-146b-5p. It down-
regulates cell-cell signaling gene STC1 and up-regulates biological adhesion and signaling gene 
PCDH1. In addition, it up-regulates voltage-gated sodium channel gene involved in cardiac 
muscle cell action potential: SCN3B; actin filament bundle assembly genes ABL2 and GAS7 and 




Figure 4.4.3-3 Dot plot of normalized read counts of hsa-miR-146b-5p in EHMs at different time points.  
Box plots show interquartile range, with line showing median and whiskers symbolizing 10% to 90% range 
 
Hsa-miR-483-3p targets a number of signal transduction genes, down-regulating RAB3B 
(8.89x) and SHC3 (6.29x) and up-regulating GUCY1B3 (3.59x), HIPK2 (3.98x), DLC1 (4.78x), KITLG 
(7.85x), IGF1 (10.45x) and PDGFB (13.43x). IGF1 and PDGFB also regulate polysaccharide 



















regulates cell proliferation and MAPK cascade. Hsa-miR-483-3p down-regulates protein–binding 
gene involved in vesicular traffic RAB3B (8.89x). The table below summarizes the gene 
ontologies of all genes targeted by miR-214, while the following table summarizes the gene 















TFAP2C (16.33x)  
SALL1 (6.57x)  
 
Up-regulation:  




FMNL3 (5.96x)  
PGF (29.43x) 
Up-regulation: 
TRPS1 (4.24x) RUNX1 
(4.79x) SULF1 (4.79x) 
MECOM (4.92x) SEMA3D 







TRPS1 (4.24x)  
RUNX1 (4.79x)  
SULF1 (4.79x) MECOM 
(4.92x) 
BMP8A (7.67x) 























































PDGFB  (13.43x) 
SULF2 (9.72x) 






COL9A3  (4.53x) 
ITGB8 (4.41x) 






















protein kinase B 
signaling 












CCR7 (6.11x)  





negative regulation of 




Positive regulation of 
Wnt Signaling pathway 
Plasma membrane part Receptor signaling protein serine/ 












































Positive regulation of 
cell cycle 


















Table 4.4.3-3 Gene Ontology of genes targeted by hsa-miR-98-5p 
 
Hsa-miR-582-5p targets genes that are involved in heart development: SFRP2, SALL1, 
FOXF1, MEF2D, FOXC1, FBN1, HHEX and NOTCH1. It also up-regulates cell-cell junction proteins 
DLC1, EPS8 and FZD4; up-regulates TGFβ signaling pathway, transmembrane receptor protein 
tyrosine kinase signaling pathway ADAM12, Wnt signaling pathway (TBX18, SFRP2, SOX9 and 
NOTCH1) and down-regulates BMP signaling pathway (SFRP2 and NOTCH1).  
 
Profile 9 
Hsa-miR-3613-5p shows highest level of fold change at 15.46x higher in d90 vs d30 EHMs. 
It targets metabolic regulating genes: such as the lipid metabolic process regulators, up-
regulating IGF1R (2.59x), RORA (2.48x), SAMD8 (2.03x) and down regulating PDK1 (2.59x). It also 
regulates glucose metabolic process by up-regulating RORA (2.48x) and down-regulating PDK1 
(2.59x). In addition, it also regulates lipid transport by up-regulating RUNX1 (4.79x). Finally, it up-
regulates vasculature development genes RUNX1 (4.79x), VASH2 (3.13x) and RAP1B (2.39x) and 
cell surface receptor signaling pathway transducers TRPS1 (4.24x) and IGF1R (2.59x).  
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Second highest fold-change, at 8.23x higher in d90 vs d30 EHMs was shown by hsa-let-
7d. Interestingly, hsa-let-7d-5p belongs to the same family as hsa-miR-98-5p (a highly expressed 
miRNA from profile 6): the let-7 family. Other miRNAs in profile 9 that belong to this family 
include: hsa-let-7i-5p, hsa-let-7c-5p and hsa-let-7b-5p. Incidentally, these miRNAs belong to top 
6 of most highly expressed miRNAs in profile 9. Thus, the gene ontology for let-7 family is the 
same as those of hsa-miR-98-5p and can be found on table 4.4.3-3.   
An exception in the cut off process was made for miRNA hsa-miR-199b-5p, which shows 
a high level of expression in day 90 EHMs at 40695 copies and 7.11x fold change with respect to 


















































































Figure 4.4.3-4 Dot plot of normalized read counts of hsa-let-7f-5p in EHMs at different time points.  









































Up-regulation:     
ITGA4 (9.99x)      with KIT and PDPN also mediate  
MYH9 (2.10x)      cell-cell adhesion 
 
Table 4.4.3-4 Gene Ontology of genes targeted by hsa-miR-199b-5p 
 
One miRNA that showed up with separate Partek flow® analysis was hsa-miR-425-5p 
with expression profile shown below. The genes targeted by this miRNA enrich to a number of 









Figure 4.4.3-5 Dot plot of normalized read counts of hsa-miR-425-5p in EHMs at different time points.  























































































































































Table 4.4.3-6 List of down-regulated miRNAs 
 
 
Table 5.4.3-5 summarizes all miRNAs that were down-regulated as EHMs aged in vitro. However, 
there were only 2 miRNAs in which expression at day 30 EHMs is more than 1000 copies and fold 
change to expression on day 90 EHMs is more than 8 fold. In this light, the cut-off copy number 





Using new cut-off value for copy number of 500, hsa-miR-493-3p and -5p showed the 
highest fold-change (37.23x and 31.79x, respectively) to expression at day 90 EHMs. Hsa-miR-
493 targets genes which enrich for:  
1. Heart morphogenesis: COL5A1 (+3.01x) and NCOR2 (+2.43x) 
2. Proteoglycan binding: GPC6 (+5.34x) and COL5A1 (+3.01x) 
3. Growth-factor binding: LTBP2 (+4.91x), COL5A1 (+3.01x) and IGF1R (+2.59x) 
4. calcium- and calmodulin-dependent protein kinase complex (+2.78x) 
 
Hsa-miR-127-5p and -3p are the next 2 miRNAs showing highest fold change (d30 
expression vs d90 expression) at 36.32x and 31.79x respectively. Unfortunately, the genes hsa-
miR-127 targets do not intersect with the pool of 4900 mRNAs with known expression profiles in 
EHMS at different time points, thus their ontologies could not be derived.  
The last miRNA meeting cut off criteria is hsa-miR-411-5p. Interestingly, the top 50 gene 
ontologies point to embryonic eye development. More relevant gene ontologies of the targeted 
genes include:  
1. Cardiovascular system development: SP2 (+2.32x) 
2. TGFβ-receptor signaling pathway: HIPK2 (+3.98x) and SP1 (+2.11x) 
3. Sodium-bicarbonate symporter activity of SLC4A7 (+3.66x) (log2 fold change)  
4. Iron ion transmembrane transport: SCARA5 (-3.33x) 
5. Lipid binding proteins: SYT4 (+6.40x), APOLD1 (+5.12x) and PREX1 (+3.01x). Together with 
FZD4 (+8.75x), APOLD1 is involved in lipid transport.  
6. Wnt signaling pathway, calcium modulating pathway: FDZ4 (+8.75x). Together with HIPK2 






Using the new cut-off criteria, two miRNAs were further analyzed. The first one is hsa-miR-
184 with 13.02x down-regulation from d30 to d90 EHMs. Genes targeted by hsa-miR-184 enrich 
for: 
1. Extracellular matrix part RUNX1 (+4.79x) and the elastic fiber ELN (+4.32x) 
2. Cell proliferation: RUNX1, ELN and NCOR2 (+2.43). NCOR2 also binds Notch. 
3. Regulation of store-operated calcium entry: STC2 (+2.02x) 
4. Intracellular sterol/cholesterol/lipid transport: NUS1 (+2.41x) 
 
The second miRNA is hsa-miR-302d-3p, with 10.48x down-regulation from d30 to d90 EHMs. 









































79 genes, please refer to 
appendix 5.5 
Regulation of transcription, 
DNA-templated 
55 genes, please refer to 
appendix 5.6 
 
Table 4.4.3-7 Gene ontology for genes targeted by hsa-miR-302d 
 
 
When miRNA data was analyzed again with Partek flow®, 2 further miRNAs were 







Figure 4.4.3-6 Dot plot of normalized read counts of hsa-miR-4461 in EHMs at different time points.  










Calcineurin complex and Ca2+-dependent 
protein serine/threonine phosphatase activity 






























Unfortunately there is no list of genes targeted by hsa-miR-6087 available in literature 

































Figure 4.4.3-7 Dot plot of normalized read counts of hsa-miR-6087 in EHMs at different time points.  
Box plots show interquartile range, with line showing median and whiskers symbolizing 10% to 90% range 
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Experiment 1 (06.01.2014) 
HES2 cardiomyocytes were mixed with human foreskin fibroblasts (HFFs) at 2:1 ratio and 
casted in “rat molds,” so-called as these molds were originally made for making rat EHM tissue 
constructs from rat CMs. Culture media used was “cardiac differentiation” medium containing 
Biochrom Iscove’s basal media with 20% FBS, 1x NEAA, 1x PSG, ascorbic acid and 2-
mercaptoethanol. At end of experiment, the remaining 2 stimulated EHMs were so thin they 
were not used for contraction experiment.  
Stimulation Frequency (Hz) Period (days) 







3 (6 EHMs) 
3 (4 EHMs left) 
3 (2 EHMs left) 
3 (2 EHMs left) 
3 (2 EHMs left) 
 




 Electrical stimulation improved force frequency and isoprenaline/carbachol 4.4.4.
response of cardiomyocytes in EHMs 
Figure 4.4.4-1 Electrically stimulated EHM rings 
showed rougher surface and areas of thinning 
(arrows)   
 
A – After 1 week of stimulation 
B – After 2 weeks of stimulation 
C – Control (unstimulated EHM) at same time 









EHMs were digested with collagenase I for 1 hour at 370C followed by 0.25% 
Trypsin/EDTA at 370C for 5 minutes. EHM2 recovered 3.98E5 cells, out of which 27.4% was viable 
(1.091E5 live cells) while EHM3 recovered 2.13E5 cells, out of which 31% was viable (6.61E4 
viable cells). To analyze the CM fraction of the isolated cells, alpha-actinin staining was carried 
out. Isolated cells were fixed in 1% paraformaldehyde (PFA) at room temperature for 15 minutes 
followed by 90% methanol at -200C for 10 minutes, washed with PBS before staining with alpha-
actinin (Sigma) antibody and analyzed with FACS. The data showed that CM fraction in isolated 
cells were around 30% - 40%. To make one EHM, 3E6 total cells were used: 66.7% of these were 
CMs and 33.3% of these were HFFs.  
 Mouse isotype control EHM2 EHM3 
% FITC positive 0.9% 33.1% 37.8% 
α-actinin positive cell numbers - 36112 25000 
 
Table 4.4.4-2 Alpha-actinin staining result of cells extracted from electrically stimulated EHMs 
 
Experiment 2 (23.04.2014) 
EHMs were cast in “mouse molds” on day 27 of differentiation and transferred onto 
auxotonic stretchers 3 days later. Electrical stimulation was only applied 2 weeks after EHMs 
were transferred onto auxotonic stretchers to promote cells consolidation and matrix 
remodeling. EHMs were cultured in serum free maturation media (SFMM). 
 
Stimulation Frequency (Hz) Period (days) 











Table 4.4.4-3 Electrical stimulation parameters for experiment 3 
 
 
At the end of electrical stimulation, media were sampled from all groups for G. 
Luciferase expression. The result is summarized in table 4.4.4-4 below. EHMs were also analyzed 









There was an increase of 1.66x fold in the luciferase signal in H9V15 EHMs and 3.80x fold 
in H9VC16 EHMs. This is consistent with earlier data that H9VC16 showed higher expression of 
reporter genes. This also indicated that MYL2 expression was enhanced with electrical 
stimulation. This quantitative data was also reflected in the mCherry expression data as 
illustrated in table 4.4.4-5 below. Electrically stimulated EHMs in both H9V15 and H9VC16 lines 
showed brighter mCherry signal than the non-electrically stimulated EHMs.  
 
Table 4.4.4-5 Electrically stimulated V15 and C16 EHMs showed higher mCherry expression than non-stimulated 
EHMs 
H9 EHMs H9V15 EHMs H9VC16 EHMs 
Control Control Stimulated Control Stimulated 
1.80E+04 1.25E+06 2.87E+06 3.30E+05 2.49E+06 
2.08E+04 1.53E+06 1.75E+06 1.32E+06 
4.18E+06 
2.73E+06 
Average 1.94E+04 1.39E+06 2.31E+06 8.25E+05 3.13E+06 
Fold change w.r.t 
control NA 1.66 3.80 
 







Shown in figure 4.4.4-2 is a graph showing forces generated by C16 EHMs (control vs 
electrically stimulated). Throughout all concentrations of extracellular calcium used, electrically 
stimulated EHMs generated less force than the non-stimulated EHMs. This difference however, 
was not determined to be statistically significant (P = 0.0595). Forces were transformed with 
respect to the maximal forces to generate a percentage of maximal force graph. From this graph, 
the calcium concentration which corresponds to 50% of maximal forces can then be determined 
(EC50 value).  From figure 4.4.4-3, it appears that the EC50 from both electrically and non-
electrically stimulated C16 EHMs did not differ very much; both were around 0.35 mM Ca2+.  
 
 
Figure 4.4.4-2 Electrically stimulated EHMs contracted with lower forces than non-electrically stimulated EHMs 
  

















N -electrically stimulated C16 EHMs 








Figure 4.4.4-4 Electrically stimulated EHMs showed more positive force-frequency response than non-electrically 
stimulated EHMs 
 
To assess CM maturation, one can also look at the force-frequency response, as shown 
in figure 4.4.4-4. Interestingly, as compared to the non-electrically stimulated group, the 
electrically stimulated group showed more statistically significant positive force frequency 
relationship. At 3Hz stimulation frequency, the EHM contractile forces from the non-electrically 
stimulated group plunged to 14% lower (vs 2.1% in electrically stimulated group) than their 
beating forces at 1 Hz. There was a slight positive force frequency relationship at 2Hz of 
   







































Electrically stimulated C16 EHMs 
Non-elec ically stimulated C16 EHMs 
Electrically stimulated C16 EHMs 
Non-electrically stimulated C16 EHMs 
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stimulation in the electrically stimulated group, resulting in an increase of 1.8% the force 
generated at 1Hz stimulation. This, however, might be contributed to arrhythmic contractions 
observed at 1Hz. Nonetheless, the fact that there was only a drop of 2.1% in contractile forces 
when stimulation frequency was increased to 3Hz from 1Hz showed that there was some degree 
of maturation in the CMs of electrically stimulated EHMs.  
Another way to assess CM maturation is by measuring their response to β-
adrenoreceptor agonist isoprenaline and cholinergic agonist carbachol. C16 EHMs responses to 
these drugs are summarized in figure 4.4.4-5. Electrically stimulated group showed higher 
inotropic response to isoprenaline (131.67% vs 109.51%). This difference however, was not 
shown to be statistically significant. The carbachol response was also stronger in the electrically 
stimulated EHMs. Following carbachol treatment, the beating force of electrically stimulated 
EHMs decreased by 11.06% in comparison to the non-stimulated group, which decrease was 
only 6.43%.  
Altogether the data demonstrated that although electrical stimulation caused cell death 
in the EHMs; the maturation level of surviving CMs was much more enhanced that those CMs in 
non-electrically stimulated group. This was determined by more expression of contractile 
protein MYL2, more positive force-frequency response, as well as better response to beta 
adrenergic and muscarinic receptor stimulation. However, this degree of maturation was not 






Figure 4.4.4-5  C16 EHMs response to isoprenaline and carbachol 
 
 
Experiment 1 (07.07.2014) - gradual 20% stretch per week 
EHMs were casted in “mouse-molds,” transferred onto 60 mm printed stretchers 3 days 
later and cultured in SFMM. EHMs were kept at 60 mm for 1 week before being transferred to 
72 mm stretchers. EHMs were maintained at 72 mm for another week before being transferred 
further to 84 mm stretchers. The “mechanical-stretch only” group was cultured at 84mm while 
the “mechanical stretch and electrical stimulation” group was paced on the next day with the 
following parameters: 
Stimulation Frequency (Hz) Period (days) 











Table 4.4.5-1 Electrical stimulation parameters for experiment 1 
 
 
 Cardiomyocytes in EHMs can tolerate a maximum of 10% increase in strain  4.4.5.
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All EHMs generated no appreciable force at the end of the experiment and when looked 
under fluorescence microscope, showed no mCherry positive cells 











Table 4.4.5-2 mCherry signal from H9 and C16 EHMs (mechanical only vs mechanical + electrical stimulation) 
 
Experiment 2 (22.07.2014) concurrent with experiment 3 – total of 20% stretch 
EHMs were casted in “mouse-mold,” transferred to 60 mm printed stretchers 3 days 
later and cultured in SFMM. 8 days later, EHMs were transferred to 66 mm printed stretchers 
and maintained on these stretchers for 9 days. Afterwards, EHMs were transferred to 72 mm 
printed stretchers and electrically stimulated on the next day with the following parameters: 
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Stimulation Frequency (Hz) Period (days) 











Table 4.4.5-3 Electrical stimulation parameters for experiment 2  
 
At the end of the experiment, all EHMs with just mechanical stimulation on 72mm 
stretchers had snapped. 72mm electrically-stimulated EHMs showed only few visible mCherry 
positive cells (table 4.4.5-4).  




Only mechanically treated (act as fluorescent 
bakground control only) 
H9 72mm 







72mm All snapped by the end of experiment 
 
 
Table 4.4.5-4 mCherry signal from V15 EHMs (non-stimulated vs stimulated) 
208 
 
Shown in figure 4.4.5-1 is the G.Luc expression profile of H9 wild type EHMs and H9V15 
knock-in EHMs. The profile shows reduction in signal as EHMs were stretched from 60 mm to 
72mm (20% stretch). Electrical stimulation also seems to reduce the signal generated, with 60 
mm stimulated EHMs generating similar G.Luc signal to 72 mm non-stimulated EHMs. 
Altogether, the data indicated that electrical stimulation and passive 20% mechanical stretch 
either resulted in reduced expression of MYL2, or death in CMs containing MYL2. There are no 
error bars as biological replicates of EHMs were pooled into 1 well for electrical stimulation. RFU 
signal was averaged to the number of EHMs in the well. 
                  
Figure 4.4.5-1 Gaussia Luciferase expression of stimulated H9 and V15 EHMs 
 
Figure 4.4.5-2 on the next page is similar to figure 4.4.4-2 in that electrically stimulated EHMs 
beat with lower forces than the non-mechanically stimulated ones. Of note, the red and green 
line, corresponding to electrically stimulated H9V15 EHMs stretched to 72 mm and electrically 
stimulated H9 EHMs stretched to 72 mm did not generate any appreciable forces. Interestingly, 
H9 EHMs which were over-stretched during the Frank Starling sarcomeric length optimization 
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step of contraction experiment showed the same effect, hinting that stretching EHMs to 72 mm 
was probably over stretching the CMs, leading to cell death. From the EC50 curve (figure 4.4.5-
3), we see that electrically stimulated EHMs were less sensitive to extracellular calcium 
concentration (EC50 = 0.8mM Ca2+) in comparison with the non-electrically stimulated EHMs 
(EC50 = 0.6mM Ca2+). This is probably indicative of more utilization of CTnI instead of the more 
calcium sensitive ssTnI (section 4.2.1). Interestingly, the wild type H9 EHMs showed higher 
contractile forces with even higher EC50 value at 0.9mM Ca2+. 
 
Figure 4.4.5-2 Electrically stimulated EHMs contracted with lower forces than non-electrically stimulated EHMs. 
20% increase in preload was sufficient to abolish contractions in EHMs 
 
 
Figure 4.4.5-3 Electrical stimulation lessened calcium hypersensitivity in V15 EHMs at 60mm 
    







    
  
    
    
    
   






           




    
  
    
    
    
   












Non-electrically stimulated H9 EHMs at 60mm  
Non-electrically stimulated V15 EHMs at 60mm  
Electrically stimulated V15 EHMs at 60mm  
Electrically stimulated H9 EHMs at 72mm  
Electrically stimulated H9 EHMs at 72mm  
Electrically stimulated H9 EHMs at 60mm 
(overstretched during Frank-Starling) 
Non-electrically stimulated H9 EHMs at 60mm  
Electrically stimulated V15 EHMs at 60mm  
Electrically stimulated H9 EHMs at 72mm  
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Again, figure 4.4.5-4 is similar to figure 4.4.4-4 in that electrically stimulated H9V15 
EHMs showed much less negative force-frequency response in comparison with the non-
electrically stimulated group. For this graph, the statistical significance was calculated in 
comparison with non-stimulated H9V15 EHMs, not the wild type EHMs. There was an increase in 
contractile forces by about 20% when stimulation frequency was increased from 1Hz to 2Hz for 
the electrically stimulated group; whereas there was a drop of about 10% in the non-stimulated 
group. As stimulation frequency was further increased from 2Hz to 3Hz, the electrically 
stimulated group exhibited a drop in contractile forces by about 16.5%; whereas the non-
stimulated group exhibited 22% drop in forces.  
 
 
Figure 4.4.5-4 Electrical stimulation induced a more positive force-frequency response in V15 EHM at 60mm 
 
In addition, electrically stimulated H9V15 EHMs showed more significant response to 
isoprenaline (+89.2% vs +5.5% in non-stimulated EHMs) and carbachol (-36.5% vs -4.4% in non-
stimulated EHMs).  
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Figure 4.4.5-6 Electrical stimulation improved response to cardioactive drugs 
 
Taken together, the results from this experiment supported the earlier hypothesis that 
electrical stimulation served to enhance CM maturation in the EHMs in that it improved calcium 
handling, force-frequency, as well as responses to isoprenaline and carbachol treatments. From 
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Experiment 3 (22.07.2014) – 10% stretch 
Experiment 3 was very similar to experiment 2. The only difference being that the 72mm 
step was omitted: EHMs were maintained at 60mm for 5 days, transferred to and maintained at 
66mm for 10 days before starting electrical stimulation. Electrical stimulation parameters were 
as follows:  
Stimulation Frequency (Hz) Period (days) 











Table 4.4.5-5 Electrical stimulation parameters for experiment 3 
 
The luciferase data below shows that in absence of electrical stimulation, there was not much 
difference in the expression level between EHMs stretched with 60mm or 66mm poles. In 
presence of electrical stimulation, however, a slight drop was observed in luciferase expression. 
This difference, however, was not shown to be statistically significant.  
 
 
Figure 4.4.5-7 Gaussia Luciferase expression of stimulated H9 and C16 EHMs 
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Table 4.4.5-6 Electrical stimulation lowered mCherry signal in C16 EHMs. (Dotted white circles indicate position of 
printed poles) 
 














Table 4.4.5-6 shows that mCherry signal was observed in EHMs stretched to 66mm, 
indicating that stretching to 66mm was not detrimental to CMs in the EHMs. Electrical 
stimulation, however, seems to cause CM death to a certain extent in that the electrically 
stimulated EHMs showed less mCherry signal than the non-electrically stimulated ones. It is 
interesting to note that CMs in electrically stimulated EHMs appeared to be more aligned (red 
cells appeared to be more anisotropic than those in non-electrically stimulated group), hinting 
that electrical stimulation might lead to improved sarcomeric organization. 
       
 
Figure 4.4.5-8 Electrical stimulation and 10% increase in preload lowered contraction force in C16 EHMs 
 
Shown above are the contraction force curves for all EHMs: electrically stimulated ones 
are represented by the darker colors (black for H9; blue for H9VC16 stretched with 60mm wide 
poles; and red for H9VC16 stretched with 66mm wide poles). The corresponding EHMs which 
were not electrically stimulated are represented in the lighter colors. From the graph, it can be 
observed that EHMs stretched with 60mm-wide poles beat with higher forces than those 
stretched with 66mm-wide poles. It is also apparent that electrically stimulated EHMs beat with 
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lower forces than the non-electrically stimulated EHMs. This trend was reversed for H9 EHMs 
however; the electrically stimulated EHMs were beating with higher forces than the non-
electrically stimulated group. 
 
 
Figure 4.4.5-9 10% increase in preload further worsened calcium hypersensitivity;  
5V stimulation was not sufficient to lessen calcium hypersensitivity. 
 
When % of maximal force was generated, EC50 values of H9VC16 EHMs stretched with 
60mm-wide poles did not differ very much between the electrically stimulated and non-
stimulated group around 0.7 mM Ca2+. For H9VC16 EHMs stretched with 66mm-wide poles, 
however, the electrically stimulated EHMs showed higher EC50 value of about 0.48 mM Ca2+ vs 
the non-electrically stimulated group at around 0.4 mM Ca2+. In general, EHMs stretched wider 
at 66mm showed more extracellular calcium hypersensitivity than those stretched at 60mm 
distance. Consistent with the contraction data, electrical stimulation enhanced calcium handling 
in H9 wild type EHMs, with electrically stimulated EHM having EC50 value of 1.0 mM Ca2+ and 
non-electrically stimulated EHM having EC50 value of about 0.78 mM Ca2+. 
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Figure 4.4.5-10 Force frequency response of electrically stimulated vs non-stimulated EHMs 
 
The force-frequency response was rather puzzling, with electrically stimulated group 
showing more negative force-frequency response than the non-electrically stimulated group. 
The light blue line represents the non-electrically stimulated group at basal stretching distance 
of 60mm wide: it remains constant at all stimulation frequencies tested. This was because the 
EHMs could not be paced in the organ bath during measurement. It is interesting to note that 
H9VC16 EHMs (be it electrically stimulated or not; or stretched at 60mm/66mm), all beat with 
only 30% of its forces at 1Hz with 3Hz stimulation, unlike the results of previous electrical 
stimulation experiments. At 2Hz, comparing the electrically stimulated EHMs, EHMs stretched at 
66mm showed less drop (27%) in contractile forces than the ones stretched at 60mm (50%).  
H9 EHMs again supported initial data: the electrically stimulated EHM showed positive 
force-frequency behavior from 1Hz to 2Hz, and a slight negative behavior from 2Hz to 3Hz. 
However, the EHMs still beat with higher force at 3Hz than it did at 1Hz stimulation. The non-
electrically stimulated H9 EHM showed no change as stimulation was increase from 1Hz to 2Hz, 
but slight negative response from 2Hz to 3Hz. For H9 EHMs, the electrically stimulated EHM also 
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fared better during isoprenaline stimulation (with about 150% increase in force) than the non-
electrically stimulated EHM (75% increase). With carbachol treatment, electrically- as well as 
non-electrically stimulated H9 EHMs exhibited about 50% drop in contractile forces. Non-
electrically stimulated H9VC16 EHMs at 60mm and 66mm both showed a more moderate 
increase in contractile force of around 15% after isoprenaline stimulation. The electrically 
stimulated EHMs, however, showed higher increase, with E. stim 60 mm group showing about 
45% increase and the E. stim 66mm group showing about 25% increase. In general, the 60mm 
groups had better response to carbachol than the 66mm groups. M. stim 60 mm showed 10% 
drop after carbachol treatment; while E. stim 60 mm group showed 22.5% drop. M. stim 66 mm 
showed only 5% drop, whereas E. stim 66 mm showed 15% drop following carbachol treatment.  
Taken together, for this experiment, 60mm stretch seems to be optimal for the EHMs in 
terms of MYL2 expression, contractile forces, EC50 values, as well as responses to isoprenaline 
and carbachol. Force frequency response seems to favor the 66mm group, however. In this 
experiment, electrical stimulation seemed to fail in maturing the CMs in the EHMs, with the sole 
exception of H9 EHMs. CMs in electrically stimulated H9 EHMs apparently showed more advance 
maturation, in terms of contractile forces, EC50 value, force-frequency response as well as 
responses to isoprenaline and carbachol. The data on H9 was not conclusive however; as there 
was only 1 EHM per group for H9 EHM (these EHMs were initially only used as negative control 
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In vivo, CMs take 6 – 10 years to the reach their adult phenotype (Peters et al., 1994). 
This time frame is impractical to adopt in the laboratory. Thus in this chapter, in vitro techniques 
to enhance CM maturation in a time-effective manner were investigated.  
Many investigators in the field have turned to biomimetic approaches to enhance their 
CMs maturation. Such approaches are: 
1. In vitro aging techniques (Kamakura et al., 2013; Kehat et al., 2002; Lundy et al., 2013; Snir 
et al., 2003) 
2. Varying the mechanical properties of CMs attachment surface (Hazeltine et al., 2012; 
Rodriguez et al., 2011); 
3. Engineering anisotropic CMs attachment surfaces (Au et al., 2009; Bray et al., 2008; Kim et 
al., 2010b; Wang et al., 2011); 
4. Mechanical conditioning/stretching (Fink et al., 2000; Foldes et al., 2011; Tulloch et al., 
2011) 
5. Electrical stimulation (Deng et al., 2000; Hirt et al., 2014; Martherus et al., 2010; Nunes et 
al., 2013) 
6. Hormonal stimulation (Chattergoon et al., 2012; Foldes et al., 2011; Klein and Ojamaa, 
2001; Kruger et al., 2008; Lee et al., 2010; McMullen et al., 2004; Nistri et al., 2012) 
7. Micro-RNA (Callis et al., 2009; Fu et al., 2011; van Rooij et al., 2007)and 
8. Co-culture with other cell types (Kim et al., 2010a; Tiburcy et al., 2014) 
 
Each approach was either used singularly, or in combination with each other. Studies 
employing these techniques have reported advanced CM maturation phenotypes, such as 
enlarged rod-shaped CMs, progressive exit from cell cycle, improved ultrastructural organization, 
action potential phenotypes, calcium current density and up-regulation of ion channels. Despite 
these encouraging reports, a few things were always missing: quiescent state of ventricular CMs, 




fast conduction velocities, fast maximum rate of depolarization and relatively long APD. Thus 
current techniques were only generating intermediately mature CMs.  
In this chapter, two in vitro maturation methods were investigated. The first attempt 
involved in vitro passive aging for a period of 3 months; this was combined with auxotonic 
mechanical conditioning and treatment with IGF-1, VEGF and FGF but not electrical stimulation 
in attempt to mature CMs in EHMs. The RNAs from these EHMs at different time points (day 30, 
45, 60 and 90 post-differentiation) were sequenced in order to better understand the 
transcriptomic events taking place as EHMs aged over time in culture. The second attempt used 
electrical stimulation in combination with growth factors (as in the first attempt) and auxotonic 
stretching either at basal width of 60mm or wider (66mm, 72mm or 84mm).  
MRNA and miRNA sequencing data from the passive aging experiment showed that 
down-regulated genes mainly enriched for:  
(1)  Cell proliferation 
(2)  ERKs, PI-3K, Akt and p70S6 kinase (S6K1) signaling cascades as well as  
(3)  Carbohydrate metabolism. 
 
Up-regulated genes, on the other hand, enriched to mainly 10 biological activities: 
(1) Cardiac development, morphogenesis and contractile forces;  
(2) Extracellular matrix development, assembly and remodeling;  
(3) Ion and lipid binding and transport (calcium ion included);  
(4) Cytoskeletal reorganization;  
(5) Wnt, MAPK and I-kappaB kinase/NF-kappaB cascade;  
(6) Heart rate;  
(7) Cell-cell junction proteins;  
(8) Calcium-mediated signaling;  
(9) Fat metabolism; and 
(10) Negative regulation of cell proliferation. 
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As such, the RNA-Seq and small RNA-Seq data suggested an improved level of 
maturation of the CMs in the EHMs over 3 months culture period as seen from reduced 
proliferation capacity, metabolic substrate preference, structural organization and expression of 
calcium handling proteins.  
Of particular interest are the following up-regulated genes: FOXP1, GATA6, TBX18, and 
NOTCH1. In mice, Foxp1 has been reported to control CMs proliferation through different 
mechanisms in the endocardium and myocardium (Wang and Morrisey, 2010; Zhang et al., 2010). 
When expressed in the CMs, Foxp1 restricts CM proliferation autonomously by repressing its 
direct target Nkx2.5 (Wang and Morrisey, 2010). When expressed in the endocardium however, 
Foxp1 enhances CMs proliferation by repressing Sox17, which is a known repressor of Wnt/β-
catenin signaling (Zorn et al., 1999). As such, Foxp1 activation causes the derepression of Wnt/β-
catenin signaling, which results in increased expression of the important mitogens for 
proliferation: Fgf16 and Fgf20 (Wang and Morrisey, 2010).  
Gata6 is expressed in the mesoderm and the endoderm and appears to be required for 
the maturation of cardiac phenotype, at least in the Xenopus and murine backgrounds (Peterkin 
et al., 2003). In these non-myogenic tissues, gata6 regulates the secretion of cardiogenic signals 
which may in turn, regulate the maintenance but not initial induction of Bmp4 and Nkx2 family 
expressions (Loose and Patient, 2003; Peterkin et al., 2003). Gata6 loss-of-function resulted in 
heartless phenotype in Xenopus background and morphogenetic defects in murine background; 
heartless phenotype in murine background was observed only with concomitant knock-out of 
gata4 (Nemer and Horb, 2007; Zhao et al., 2008). Tbx18 has been described to be expressed in 
CMs derived from proepicardial organ (Cai, et al., 2008). These CMs are migratory and make 
substantial contribution to CMs in ventricular septum, atrial and ventricular chambers of the 
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heart (Cai et al., 2008). In a separate study, Wiese et al. (2009) found that Tbx18 was required to 
establish the large head structure of the mouse sinoatrial node from mesenchymal precursors. 
Notch1 has been described as a regulator of cardiac stem cells growth and commitment to the 
CM lineage (Urbanek et al., 2010). Inhibition of the Notch pathway in newborn mice resulted in 
impaired cardiomyogenesis and dilated myopathy followed by high mortality (Urbanek et al., 
2010). The up-regulation of FOXP1, GATA6, TBX18 and NOTCH1 could imply the role of these 
factors in directing CM maturation, i.e. these four factors could be “maturation” factors. It will 
be interesting to see the impact of adding these four factors into immature population of CMs.   
Figure 4.4.1-1 and -2 show that fused EHMs had low maximal diastolic potentials (MDP) 
averaging at around -70.6mV. This value is rather close to the adult CM MDP which is around   
-85mV (Drouin et al., 1998). The maximal rate of depolarization (Vmax) of fused EHMs action 
potential (AP), however, was still rather slow at 169.66 V/s, almost twice lower than that of the 
adult CMs (around 300 V/s). In terms of contractile forces, EHMs generated a maximum of 1.96 ± 
0.16 mN (mean ± SEM) by day 90 of differentiation (day 72 after EHMs casting). Adult 
myocardium strip twitch tension has been reported to be around 44 ± 11.7 mN/mm2 (Hasenfuss 
et al., 1991). Using “mouse molds,” we routinely generated EHMs with total cross sectional area 
of about 0.5 mm2 (unpublished in-house data). Thus the oldest EHMs (90days of differentiation) 
beat with a maximum of about 4mN/mm2, or eleven times lower than the reported data by 
Hasenfuss et al. The EHMs were also autonomously contracting.  
Taken together, the data indicated that in vitro aging, in conjunction with IGF-1, VEGF 
and FGF treatment matured CMs in the EHMs only to an intermediate stage. Thus another 




The first round of electrical stimulation experiments was carried out in serum-containing 
media and resulted in progressive thinning of EHMs over time, which eventually led to snapping. 
It was postulated that electrical stimulation generated too much reactive oxygen species or 
other cytotoxic by-products that were detrimental to the cells. However, alpha actinin staining 
indicated that CMs fraction was still around 32.2% - 36.9%, which is a normally observed 
percentage of CMs after collagenase I digestion (unpublished in-house data). So it seems that 
the electrical stimulation could be killing the fibroblasts in the EHMs instead.  
The second experiment with electrical stimulation used lower voltage (6V instead of 8V) 
and shorter stimulation protocol (a total of 9 days stimulation instead of 15 days as in first 
protocol). With this second attempt, there was still cell death but much less than that observed 
in the first attempt. In general, the data showed that CM maturity was enhanced in the 
electrically stimulated group but all EHMs were still showing extracellular calcium 
hypersensitivity.  
In further experiments, electrical stimulation was carried out in parallel with increasing 
the preload (stretching EHMs to an increased length). It was observed, however, that a gradual 
increase of 20% strain per week was too much for the CMs; they were overstretched and 
consequently stopped beating, possibly due to CM rupture following overstretching. Gradual 10% 
strain per week to a total of 20% strain was also found to be too much for the CMs. Indeed, the 
CMs could only tolerate a total strain of 10%.  
Without electrical stimulation, EHMs stretched from 60mm to 66mm did not show any 
decrease in average G. Luc signal. The 66mm-EHMs were also still beating nicely with prominent 
mCherry expression. With electrical stimulation, however, 66mm EHMs seemed to express less 
G. Luc signal. This might be due to CM death caused by electrical stimulation.  
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When only the 60mm EHMs group were analyzed for the electrically stimulated group, 
experiment batch 22.07.14 EHMs showed more maturity in terms of the degree of calcium 
hypersensitivity than the EHMs from batch 23.04.14. The difference between these two 
experiments is in the voltage used during electrical stimulation: batch 22.07 used 8V while batch 
23.04 used 6V. In addition, the stimulation duration was less in batch 22.07 at 8 days versus 
batch 23.04 which was 9 days. However, there was still quite a significant degree of cell death 
observed with the 22.07.14 electrical stimulation protocol. Thus it was thought that lower 
stimulation voltage at 5V and shorter stimulation protocol of 5 days would reduce the 
occurrence of cell death. Five volts of electrical stimulation was observed to be insufficient to 
pace the EHMs. Despite the low voltage used, some degree of CM death was still observed. 
Consequently, in comparison with the 60 mm non-electrically stimulated group, the 60 mm 
electrically stimulated EHMs beat with weaker forces, showed similar level of extracellular 
calcium hypersensitivity, and displayed very negative force frequency response. The only sign 
that the electrically stimulated EHMs were more mature than the non-stimulated ones was the 
fact that the electrically stimulated EHMs showed better responses to isoprenaline and 
carbachol treatments. In short, 5V stimulation for 5 days was not enough to induce phenotypical 
changes in CMs inside EHMs to drive them towards maturation. Protocol 4.4.4.-3 proved to be 
the best amongst all protocols tested. However, the EHM contractile forces were still very low at 
an average of around 0.33mN.  
From this chapter, it was observed that the in vitro maturation methods tested so far 
only enhanced the maturation of CMs within EHMs to an intermediate level. A robust protocol 
which enhances in vitro maturation of CMs within EHMs to the level expected as in vivo remains 
to be optimized.  
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In this chapter, the effects of increasing concentrations of extracellular calcium (Ca2+) on 
EHM maturation were investigated. In addition, the utility of IWR1 to induce ventricular subtype 
specification during cardiomyocytes differentiation was tested against IWP4. Finally, EHMs 
generated with knock-in cardiomyocytes (CMs) were used as in vitro model for cardiac tissue 
and their responsiveness to chronic treatment with cardioactive drugs (endothelin-1, 
noradrenaline, IBMX, metformin and gemfibrozil) were investigated.  
MYL2, G. luciferase and mCherry were expressed proportionally to the concentrations of 
extracellular Ca2+ (up until 1.2mM), beyond which, MYL2 gene expression reached a plateau. 
Functional contractile forces were detected when extracellular Ca2+ was ≥ 0.8mM. EHMs 
cultured in 1.2mM – 2.0mM Ca2+ beat with similar forces (about 0.52 – 0.54 mN) and these 
forces were about twice the average forces of EHMs cultured in 0.8mM Ca2+ (about 0.26 mN). 
EC50 values did not differ significantly in beating EHMs (0.4mM – 0.57mM) and they also 
exhibited negative force-frequency relationship beyond 2Hz stimulation. Despite the observed 
increasing response to isoprenaline and carbachol with increasing extracellular Ca2+ 
concentrations up to 1.6mM, these differences were not statistically significant. Taken together, 
10 days in vitro EHMs culture with 1.2mM – 1.6mM extracellular calcium was beneficial to the 
functionality of the EHMs. However, this alone was not sufficient to drive the cardiomyocytes 
maturation in these EHMs.  
Using the mCherry positive fraction as an indicator for ventricular CMs fraction, it was 
empirically determined that 5µM IWP4 or IWR1 at 2.5 and 5 µM concentrations did not 
significantly alter the ventricular CMs fraction. 5 µM IWP4, 2.5 µM IWR1 and 5 µM IWR1 gave 




The description for each drug tested in this part of the study will be further elaborated in 
the introduction and discussion part of this chapter. It was observed that EHMs treated with 
endothelin-1 (ET-1) expressed more luciferase, followed by those treated with IBMX and 
noradrenaline (NA). However, treatment with NA right-shifted the EHMs’ EC50 values the most 
(0.8 – 0.95 mM Ca2+), followed by treatment with ET-1 (0.7 – 0.75 mM Ca2+) and IBMX (0.62 – 
0.72 mM Ca2+). The responses to isoprenaline were generally dose-dependent for EHMs treated 
with ET-1 and IBMX but not for NA whereby the intermediate concentration of 100nM showed 
the maximal response. EHMs treated with Metformin expressed higher level of luciferase than 
those treated with Gemfibrozil. Metformin treated EHMs also expressed more luciferase with 
higher doses of Metformin, which was opposite in trend to the Gemfibrozil treated EHMs. EHMs 
treated with Gemfibrozil, however, showed a more right-shifted EC50 values and better 
isoprenaline response than the Metformin treated ones (EC50 = about 0.7 – 0.8mM vs 0.67 – 
0.73mM Ca2+).  
In all of the EHMs tested so far, mCherry signal was a good indicator for contractile function. 
G. Luc signals gave quantitative measurements which were more sensitive than mCherry. With 
prior calibrations, G.Luc read-out could be correlated with contractile forces under normal 
conditions. With drug treatments, however, there could be other factors outside MYL2 gene 
expression that could potentially regulate contraction of the EHMs, thus G.Luc and mCherry 
signals might not correlate significantly with the corresponding strength of EHM contractions. 
Nevertheless, the MYL2 knock-in line generated in this study and described in this thesis 
presents itself as a useful tool for identifying ventricular CMs and for predicting their 




From the previous chapter, it was understood that mechanical conditioning, electrical 
stimulation, biochemical stimulation and in vitro aging were not sufficient to drive hESCs-derived 
CM maturation towards the adult phenotype. Thus one more approach was tested, i.e. to vary 
extracellular calcium concentration in the EHM culture media.  
In addition, this part of the thesis aims to look at the different functionalities of the 
knock-in cell line. One immediate use of the cell line was in the development of a ventricular 
subtype specific differentiation protocol. Recently, the Wnt inhibitor IWR-1 has been shown to 
play a key role in ventricular subtype CM specification from HES-2, H7 and H1 hESCs lines 
(Karakikes et al., 2014) as well as hiPSCs line and H9DF hESCs line (Weng et al., 2014). In addition, 
retinoid signaling has also been demonstrated to regulate this process (Zhang et al., 2011).  
Other than small molecules, miRNAs have also been used to direct CM differentiation 
and specification towards ventricular CMs. One such miRNA is miR-499; this was used to 
enhance ventricular specification of hESCs-derived CMs while miR-1 was used to promote 
electrophysiological maturation of these ventricular CMs (Fu et al., 2011). Very recently, one 
group combined these 2 miRNAs with miRNAs 133 and 208 to reprogram non-myocytes to 
cardiomyocyte-like cells in situ, these reprogrammed cells were reported to significantly improve 
cardiac function following myocardial infarction in an animal model (Jayawardena et al., 2014). 
These CM-like cells were also found to have morphological and functional properties of mature 
adult ventricular CMs (Jayawardena et al., 2014). In this study, this miRNA approach was not 
attempted. Instead, the role of IWR1 in CM subtype specification during hESCs cardiac 
differentiation will be investigated. 
 Introduction and literature review 5.2.
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Finally, the functional potential of the knock-in line as a drug screening platform was 
investigated in a pilot study of drug screening using noradrenaline (also known as 
norepinephrine), endothelin-1, metformin, IBMX and Gemfibrozil. Noradrenaline (NA) has been 
reported to increase ventricular mass; ratios of ventricular weight to ventricular volume and 
body weight (around 50%); as well as ratio of ventricular RNA: protein levels (Kaddoura et al., 
1996; Newling et al., 1989). NA was also demonstrated to exert its hypertrophic effect through 
increasing endogenous Endothelin-1 mRNA levels (Kaddoura et al., 1996). However, high 
concentrations of NA at 50μM and 100μM have been reported to cause a shift from hypertrophy 
to apoptosis (Jain et al., 2014). At these high concentrations, NA altered cellular and nuclear 
morphology as well as mitochondrial membrane potential thus increasing the production of 
reactive oxygen species in the CMs which subsequently led to caspase dependent activation of 
cell death (Jain et al., 2014). 
3-Isobutyl-l-methylxanthine (IBMX) has been shown to be a potent competitive 
nonselective phosphodiesterase (PDE) inhibitor (Beavo et al., 1970; McNeill et al., 1973; 
Peytremann et al., 1973; Terasaki and Brooker, 1977) and nonselective adenosine receptor 
antagonist (Daly et al., 1987). PDE inhibitors such as IBMX block the PDE-mediated hydrolysis of 
the 3’-phosphodiester bond in cyclic nucleotides such as cyclic adenosine monophosphate 
(cAMP) thus generating the corresponding inactive form (Essayan, 2001). Accumulation of cAMP 
in the cell leads to the activation of protein kinases; inhibition of TNF-alpha (Deree et al., 2008; 
Marques et al., 1999) and synthesis of leukotriene (Peters-Golden et al., 2005); as well as  
reduced inflammation and innate immunity (Peters-Golden et al., 2005). Increased cAMP levels 
also leads to an increase in junctional conductance in the heart (De Mello, 1989) and protein 
phosphorylation in sarcolemmal slow-Ca2+ channel leading to increased Ca2+ inward current (Isi) 
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(Reuter, 1983; Reuter and Scholz, 1977) and increased contractile force. Being an adenosine 
receptor antagonist, the effects of IBMX on isometric force of contraction closely mimics those 
of isoprenaline (Korth, 1978). IBMX-induced positive inotropic response begins at 10 µM to 
reach a maximum of 400% increase from basal level of contraction with treatment at 300 µM; 
Isoprenaline treatment resulted in similar inotropic response but at much lower concentrations 
at 1nM – 100nM (Brückner et al., 1985). In the above-mentioned studies, however, IBMX was 
only applied for a short term (minutes). In this study, the effect of chronic (10 days) EHMs 
treatment with IBMX was investigated.  
Metformin has been a conventional therapy for patients with type 2 diabetes (Inzucchi, 
2005). Patients who have both diabetes and heart failure exhibit preserved systolic function but 
impaired left ventricular relaxation (Piccini et al., 2004) which eventually result in maladaptive 
ventricular remodeling (Parsonage et al., 2002). This could be due to hypertension, diabetic 
microcirculatory disease, oxidative stress, and the deleterious influences of hyperglycemia and 
insulin resistance on inflammatory mediators, growth factors, vascular endothelial function, and 
the renin-angiotensin system (Inzucchi, 2005). The effect of chronic Metformin treatment on 
generated from normal knock-in CMs was investigated in this chapter. 
Gemfibrozil belongs to fibrates group of drugs; it is a potent lipid regulating drug whose 
major effects are to increase plasma high density lipoproteins (HDL) and to decrease plasma 
triglycerides (TG) (Saku et al., 1985). Gemfibrozil is also a ligand for peroxisome proliferator–
activated receptors isoform alpha (PPARα) (Forman et al., 1997), which modulates genes 
involved in the β-oxidative degradation of fatty acids (Takano et al., 2000). In addition, 
Gemfibrozil has been shown to ameliorate cardiac remodeling events in obese and hypertensive 
rats through its antioxidant activity (Singh et al., 2011). This antioxidant property, along with its 
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anti-inflammatory property (Adabag et al., 2009) has sparked an interest whether Gemfibrozil 
could prevent or delay the development of atrial fibrillation in heart disease patients. 
Unfortunately, it was not found to reduce 4-year incidence of atrial fibrillation in men who have 
coronary heart disease (Adabag et al., 2009). In this study, the effects of Gemfibrozil treatment 
for 10 days on normal EHMs were investigated.  
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Day 15 H9VC16 cardiomyocytes were mixed with HFFs (75%: 25%) to form EHMs. EHMs 
were cultured in normal SFMM medium from the day of casting for three days before they were 
transferred to auxotonic stretchers. On the next day, the medium was changed to SFMM 
medium but the base medium of SFMM was changed to DMEM without calcium instead of RPMI 
1640. EHMs were cultured in DMEM SFMM without calcium for two days before starting the 
calcium response experiment.  
Six different concentrations of calcium were applied to the EHMs (0mM – 2.0mM) for 
ten days before analysis; thus analysis was carried out on day 30 of differentiation. Analysis of 
expression of mCherry (mChr) and Gaussia luciferase (G.Luc), as well as contraction experiments 
were carried out to determine the effects of varying calcium concentration on cardiomyocytes in 
tissue-mimetic three dimensional EHM format.  
 
Two Wnt inhibitors, IWP4 and IWR1, were tested for their capacity to differentiate 
knock-in hESCs to ventricular cardiomyocyte (vCMs). On day 30 of differentiation, efficiency of 
the differentiation protocol was assessed through the expression of knocked-in reporter genes. 
In brief, the beating layer of cardiomyocytes was dissociated into single cells and counted. Live 
cells were analyzed by FACS to determine the percentage of mCherry-positive cells in the 
population. In addition, G.Luc expression was normalized to cell number to get RFU per cell. 
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Cardiomyocytes were trypsinized and mixed with human foreskin fibroblasts (HFF) in a 
collagen matrix on day 15 of differentiation at (3:1) ratio to make EHMs. On day 18 of 
differentiation, EHMs were transferred onto auxotonic stretchers and maintained in culture for 
seven days. After one week maintenance on auxotonic stretchers, five different drugs were 
tested on these EHMs. Drug-containing SFMM media were changed daily and G.Luc secreted 
into the medium was assayed at different time points (1, 3, 7, and 10 days of drug treatment) to 
assess acute (≤7 days) and chronic (>7 days) drug response. The response to drug treatment was 
also assessed through the analysis of contractile force, reporter gene expression (proxy for MYL2 
expression), force frequency measurement, as well as isoprenaline and carbachol response.  
 
Data is presented as means ± standard error mean (SEM). Statistical analyses were 
performed with Student’s t-test (2-tailed) or ANOVA when applicable, using post-hoc Dunnett's 
Multiple Comparison test or Bonferroni's Multiple Comparison test. Results were considered to 
be significant at p ≤ 0.05 (*); very significant at p ≤ 0.01(**) and extremely significant at p ≤ 
0.001 (***).  
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Table 5.4.1-1 mCherry expression increased in EHMs cultured in increasing calcium concentrations (up to 1.6mM) 
 
From table 5.4.1-1 above, we can see that mCherry positive cells are sensitive to 
external calcium concentration. When EHMs were cultured in SFMM containing 0mM Ca2+, they 
did not beat and there were no observable mCherry expression under fluorescence microscope. 
EHMs cultured in 0.4mM Ca2+ were beating albeit very weakly; this could be explained by the 
presence of only few bright mCherry positive cells in these EHMs (table 5.4.1-1). In general, as 
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the external Ca2+ concentration was increased from 0.4mM – 2.0mM, more mCherry positive 
cells were observed in the corresponding EHMs.  
 
 
Figure 5.4.1-1 More luciferase was expressed by EHMs cultured in higher concentrations of calcium (up to 1.6mM) 
 
Figure 5.4.1-1 above shows that there was a gradual increase in the expression of 
luciferase as extracellular Ca2+ concentration was increased, reaching a plateau at 1.6mM – 
2.0mM Ca2+. 0.4mM – 2.0mM Ca2+ significantly increased the luciferase expression in the EHMs 
in comparison with 0mM Ca2+ (the level of statistical significance is shown as * above the 
respective bars). However, in comparison with EHMs cultured in 0.4mM Ca2+, only 1.2mM – 
2.0mM Ca2+ significantly increased the level of luciferase expression. Beyond 0.8mM Ca2+, the 
increase in luciferase expression was not shown to be statistically significant. Interestingly, the 
increase of Gaussia luciferase expression from 0.0mM – 1.2mM Ca2+ was found to be linear and 
could be fitted to the equation 𝑦 = (584000)𝑥 + 43930 with 𝑅2 = 0.9989  (when the mean of 
each group is considered) or 𝑅2 = 0.9274  (when all replicates were considered individually). 
Shown below are the forces generated by the EHMs cultured in different Ca2+ concentration for 
10 days.  
  























Figure 5.4.1-2 Forces of EHMs cultured in different Ca2+ concentrations 
 
From the graph above, 0 – 0.4mM Ca2+ seems to generate EHMs with negligible forces. 
This is reminiscent of the earlier data whereby EHMs cultured in Ca2+ free media did not appear 
to be beating and that there were no observable mCherry positive cells observed in these EHMs. 
The EHMs cultured in 0.4mM Ca2+ were beating very weakly with few mCherry positive cells 
observed under the fluorescence microscope. Interestingly, EHMs cultured in 0.4mM Ca2+ were 
showing luciferase expression about 4.96x the level of expression of EHMs cultured in Ca2+ free 
medium. Yet this number of ventricular CMs appeared to be insufficient to generate appreciable 
contractions in the EHMs.  
The graph also shows that EHMs cultured in 1.2 – 2.0mM Ca2+ beat with similar forces 
(around 0.52 – 0.54 mN) and these forces were about twice the average forces of EHMs cultured 
in 0.8mM Ca2+ (around 0.26 mN).  Interestingly, in EHMs cultured in 1.2 – 2.0mM Ca2+, there was 
an observed drop in forces when extracellular Ca2+ went beyond 2.8mM. This drop appears more 
clearly in figure 5.4.1-3. The dotted line in this graph indicates the highest forces observed in all 
EHMs which were generally observed at 2.8mM Ca2+. It is apparent that beyond 2.8mM Ca2+, the 
        
























EHM contractile forces drop steadily for EHMs cultured in 1.2mM – 2.0mM Ca2+. This drop is 
most pronounced in EHMs cultured in 2.0mM Ca2+. From this graph, we can also determine that 
concentration of Ca2+ which gave rise to 50% of maximal forces (EC50).  These respective EC50 
values are presented in table 5.4.1-2.  
 
Figure 5.4.1-3 Forces of EHMs treated with different calcium concentrations as percentage of forces at 2.8mM Ca2+ 
 
EC50 (mM) 
0.4mM Ca2+ 0.8mM Ca2+ 1.2mM Ca2+ 1.6mM Ca2+ 2.0mM Ca2+ 
0.25 0.53 0.55 0.4 0.57 
 
Table 5.4.1-2 EC50 values of EHMs cultured in different calcium concentrations 
 
EHMs cultured in 0.8mM, 1.2mM and 2.0mM Ca2+ had similar EC50 at about 0.5mM but 
those cultured in 1.6mM Ca2+ had lower EC50 at 0.4mM and those cultured in 0.4mM Ca2+ had 
lowest EC50 values of 0.25mM. When force frequency response was analyzed, the following 
chart was obtained (figure 5.4.1-4). The chart show similar responses of EHMs cultured in media 
containing Ca2+: there was slight increase in forces when frequency of stimulation was increased 
from 1 Hz to 2 Hz. However, a drop in forces was observed when this stimulation frequency was 
   




























further increased from 2Hz to 3 Hz. EHMs cultured in 2.0mM Ca2+ showed the highest increase in 
forces (about 7.9%) when the stimulation frequency was increased from 1Hz to 2Hz. 0.4mM and 
0.8mM Ca2+ groups followed next with a force increase of about 3.5-4.0% while the 1.2mM and 
1.6mM Ca2+ group did not show much change in force with only about 1.4-1.5% increase. When 
the stimulation frequency was increased from 2Hz to 3Hz, similar trend was observed. 2mM Ca2+ 
EHM group showed the least drop in forces at about 9.2%, followed by the 0.8mM group at 




Figure 5.4.1-4 Force frequency response of EHMs cultured in different concentrations of calcium 
 
Responses to Isoprenaline improved in EHMs cultured in increasing Ca2+ concentrations 
from 0.8mM – 1.6mM. Only EHMs cultured in 2.0mM Ca2+ do not follow this trend, showing level 
of response similar to EHMs cultured in 0.8mM Ca2+.  This trend was also observed for carbachol 
response. % change of force after treatment with Isoprenaline, as well as after carbachol 
treatment was plotted to give figure 5.4.1-6. 
Force frequency response






























Figure 5.4.1-6 Carbachol response of EHMs cultured in different calcium concentrations 
 
Hudson 2D protocol (for details please see chapter 3) was employed to test the efficacy 
of different Wnt inhibitors in directing hESCs towards ventricular cardiomyocytes. The Wnt 
inhibitors used were IWP4 (5µM) and IWR1 (2.5µM or 5µM)  on day 3-12 of differentiation. 
Shown in figure 5.4.2-1 is the luciferase expression per cell from flasks treated with 
different Wnt inhibitors. The result indicated that 2.5µM IWR1 gave the highest RFU per total 





























































 IWR1 did not significantly improve MYL2 positive fraction 5.4.2.
247 
 




Figure 5.4.2-1 Different Wnt inhibitors did not significantly affect luciferase expression per cell (proxy for ventricular 
cardiomyocytes fraction).  
Negative control was the luciferase expression from wild type H9-derived cardiomyocytes 
 
Figure 5.4.2-2 shows that 5µM IWP4 gave the highest fraction of CMs positive for 
mCherry expression (about 55.3%) in comparison with 2.5µM IWR1 (about 50.8%) and 5µM 
IWR1 (about 51.7%). However, these differences were not found to be statistically significant. 
Mcherry positive fraction was normalized to alpha-actinin positive fraction (cardiomyocytes) to 
plot figure 5.4.2-3. 2.5µM IWR1 gave the highest mCherry to α-actinin-positive ratio and this was 
significantly higher than the 5µM IWP4 group. However, the result was puzzling as the 
mCherry(+) to α-actinin(+) ratio was more than 100%. 
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 Effect of select drugs on EHMs maturity 5.4.3.
Control Gemfibrozil Metformin  
 
10 µM 2 µM 
  
100 µM 20 µM 
  




IBMX Endothelin-1 Nor-adrenaline 




10 µM 1 nM 100 nM 
   
100 µM 10 nM 1000 nM 
   
  




Shown below is the luciferase expression of EHMs treated with Endothelin-1, at different 
time-points. There is general up-regulation of luciferase expression in EHMs treated with 1nM 
and 10nM ET-1 for the acute phase of drug treatment, with 1nM showing the highest level of 
expression followed by 10nM group. This trend, however, changes for the chronic phase, with 
1nM group showing the highest drop in luciferase expression, followed by 10nM and 0.1nM 
group. In fact, the 0.1nM group showed very little changes in luciferase expression throughout 
the study.  
 
 
Figure 5.4.3-1 Luciferase expression of EHMs treated with different concentrations of Endothelin-1 
 
 
Figure 5.4.3-2 Forces of EHMs treated with different Endothelin-1 concentrations 
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Up to 2.0mM Ca2+, EHMs in all groups showed increasing forces with increasing Ca2+ 
concentration, with 1nM group generating the highest forces of contraction, followed by 0.1nM 
and 10nM group. This data is not correlated with the luciferase data. However, from 2.0 – 
2.8mM Ca2+, a slight dip in forces was observed for EHMs in 0.1-1nM groups, owing to 
arrhythmic contractions. The EHMs in these groups recovered to the level of contraction before 
the dip once extracellular Ca2+ concentration was increased to 3.2mM. Due to this dip, EC50 
calculations using normalization to 4.0mM Ca2+ cannot be done, since in this experiment, the 
forces at 4.0mM Ca2+ were not the maximal forces. Therefore, a straight line was drawn to 
indicate the 50% percentile of forces and the corresponding Ca2+ concentrations recorded as 
EC50 values. From the graph, treatment with Endothelin-1 seems to shift EC50 values to the 
right slightly (by 0.5-1mM Ca2+), indicating that the drug helped to reduce the EHMs sensitivity to 
extracellular Ca2+ concentrations. EC50 value of EHMs treated with 0.1nM ET-1 was the largest at 
0.75mM, followed by 10nM Endothelin-1 group at 0.73nM and 1nM at 0.7mM. The control 
EHMs EC50 value was at 0.65mM.  
 
 
Figure 5.4.3-3 Force frequency response of EHMs treated by different concentrations of Endothelin-1 
    
   



















EHMs from all groups exhibited similar force-frequency trend: there is a slight increase in 
force as stimulation frequency was increased from 1 – 2 Hz, and a slight decrease as frequency 
was further increased to 3 Hz. This does not indicate positive force frequency response (1-2Hz), 
however, as all EHMs could not be paced at 1Hz. The lowest frequency at which all EHMs could 
be paced was 2 Hz. Thus all EHMs still exhibited negative force frequency response, with 0.1nM 
group showing almost identical response to 10nM group and 1nM group showing almost 
identical response to the control group.  
There was also no apparent difference in the responses to Isoprenaline from EHMs 
treated with all concentration of ET-1 to control group. Increase in forces after Isoprenaline 
addition, as well as the difference between Isoprenaline-induced and carbachol-induced forces, 




Figure 5.4.3-4 Isoprenaline-carbachol response of EHMs treated with different concentrations of Endothelin-1 
 
 



































           
Noradrenaline 
EHMs treated with 10-100nM Noradrenaline (NA) showed up-regulation of G.Luc for the 
first two days of treatment, while those treated with 1000nM showed a slight down-regulation. 
Beyond 48 hours of treatment, there was a down-regulation of luciferase expression in all EHMs. 
This down-regulation continued until day seven for 10nM NA while in EHMs treated with higher 
concentrations of NA at 100 and 1000nM, there is an up-regulation, with 1000nM group 
expressing higher level of luciferase than 100nM group. Beyond seven days of treatment, 
luciferase expression dropped for 100nM and 1000nM groups to reach similar level whereas, for 
the 10nM group, the expression increased slightly. After 10 days of treatment with NA, EHMs 
from all groups expressed similar levels of luciferase. From this data, one could expect similar 
levels of forces generated by all EHMs 10 days after drug treatment.  
 





































Figure 5.4.3-7 Luciferase expression of EHMs treated with different concentrations of Noradrenaline 
 
Indeed, as evident from graph 6.4.3-9, the forces of EHMs treated with different 
concentrations of NA beat at very similar level to one another at about 0.57mN and this force 
was lower than the control group at about 0.88mN. From 0 – 2.4mM calcium, EHMs treated with 
10nM and 100nM NA beat at almost identical forces. The EHMs treated with 1000nM NA beat at 
higher forces <2.4mM calcium but at 2.4mM, they beat at almost identical force as the EHMs 
from other groups. There was a dip in forces when Ca2+ was further increased from 2.4 – 2.8mM, 
with the 10nM NA-treated group showing the largest dip in force.  
Similar to treatment with ET-1, treatment of EHMs with NA seems to reduce EHMs 
sensitivity to extracellular calcium concentrations. EHMs treated with 10nM and 100nM NA 
showed the lowest sensitivity to extracellular calcium, with EC50 value of about 0.95mM. This 
was followed by the 1000nM NA group with EC50 value of 0.8mM. The control group has EC50 
value of 0.65mM. 
 
  





















Figure 5.4.3-8 Forces of EHMs treated with different concentrations of Noradrenaline 
 
       
 
Figure 5.4.3-9 Force frequency response of EHMs treated with different concentrations of Noradrenaline 
 
Force frequency response of EHMs treated with NA was similar to those treated with ET-
1. All EHMs could not be paced at 1Hz. Thus all the forces were normalized to the forces 
generated at 2Hz of stimulation. Here, we see that EHMs treated with 10nM and 1000nM NA 
showed negative force frequency behavior, with 1000nM group showing exactly the same 
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Force frequency response of EHMs
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behavior as the control group. EHMs treated with 100nM NA showed a mixed response at 3Hz of 
stimulation, some replicates showed negative while others showed positive force frequency 
behavior. Figure 5.4.3-11 shows that Isoprenaline and carbachol responses of EHMs treated with 
10nM and 1000nM NA did not differ very much from the control group. Only the 100nM NA 
group seems to stand out, showing higher response to isoprenaline and carbachol. To further 
analyze this, the increase in forces after isoprenaline addition, as well as the difference between 
isoprenaline-induced and carbachol-induced forces was tabulated and the difference analyzed 
with ANOVA using Bonferroni's multiple comparison test. The result indicated that there is a 
statistically significant difference in the response to isoprenaline in 100nM NA-treated EHMs in 
























































Figure 5.4.3-13 Luciferase expression of EHMs treated with different concentrations of IBMX 
 
There is general up-regulation in G.Luc expression for the first 72 hours for all IBMX 
concentrations tested: 10µM group showed the highest level of increase, followed by the 1µM 
and 100µM group. The higher concentrations groups, however, showed reduced expression of 
G.Luc from day 3-7 of drug treatment whereas the 1µM group did not show much change. This 
Gaussia Luciferase expression
























(w.r.t forces at 0.8mM Ca2+)
after Isoprenaline treatment











Figure 5.4.3-12 Response to Isoprenaline 































resulted in a dose-dependent expression of G.Luc after seven days of drug treatment: 1µM 
showing the highest luciferase expression, followed by 10µM and 100µM. It is worthy of note 
however, that all IBMX-treated EHMs expressed lower luciferase than the control group. Beyond 
day 7, luciferase expression dropped for control, 1µM and 10µM groups; whereas for the 100µM 
group, there was a slight increase in luciferase expression. Nevertheless, after 10 days of drug 
treatment, similar trend was observed as that after seven days of drug treatment: there was 
IBMX dose-dependent luciferase expression, with 1µM group showing highest expression of 




Figure 5.4.3-14 Forces of EHMs treated with different concentrations of IBMX 
 
The contraction force data above seems to recapitulate the G.Luc expression data, 
whereby EHMs treated with the least dose of IBMX (1µM) beat with the highest forces, followed 
by the higher doses of 10µM and 100µM. The 10µM group showed higher variability in the 
beating forces and also a dip in forces owing to arrhythmia when extracellular calcium was 
increased from 1.2mM – 1.6mM. Arrhythmia ceased when calcium was further increased from 
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1.6mM – 2.0mM and forces returned to the level of 1.2mM Ca2+ when extracellular calcium was 
about 2.4mM. The slight dip in forces owing to arrhythmia occurred at higher concentration of 
extracellular calcium for the 1µM and 100µM IBMX group (2.0mM – 2.8mM).  
Only EHMs treated with 1µM IBMX showed right-shifted EC50 value, from about 
0.65mM of the control group to about 0.72mM. EHMs treated with 10µM and 100µM IBMX had 
EC50 value of about 0.62mM and about 0.63mM respectively. There is a generally negative force 
frequency response for EHMs treated with all concentrations of IBMX, with the 100µM group 
showing the most negative response, followed by the 1µM group and 10µM group.  
 
 
Figure 5.4.3-15 Force frequency response of EHMs treated with different concentrations of IBMX 
 
There were also no statistically significant differences in the responses to isoprenaline 
from all EHM groups. However, there were statistically significant differences in the responses to 
carbachol from the 100µM group, in comparison with the control and 1µM group. The negative 
value for the 100µM group was due to the highly arrhythmic contractions after isoprenaline 
treatment.  
Force frequency response of EHMs
treated with different [IBMX]





















Figure 5.4.3-16 Isoprenaline and Carbachol response from EHMs treated with different concentrations of IBMX 
 
                       
 
Metformin 
Unlike EHMs treated with NA, EHMs treated with Metformin did not show a dip in G.Luc 
expression three days after treatment with the drug. There was only a slight dip 48 hours after 
treatment in EHMs treated with 2µM Metformin. EHMs treated with higher concentrations of 































































Figure 5.4.3-17 Reduction in contratile forces in 









(w.r.t forces at 0.8mM Ca2+)
after Isoprenaline treatment











Figure 5.4.3-18 Response to Isoprenaline 
stimulation in IBMX-treated EHMs 
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Metformin (20µM and 200µM) showed continued increase of G.Luc expression in the first 48 
hours of treatment with the drug. This increase of G.Luc expression was maintained from day 2 – 
7 of drug treatment, with more G.Luc being expressed in EHMs treated with higher Metformin 
concentrations. From day 7-10 post treatment, there was a drop in luciferase expression, with 
EHMs treated with 2µM Metformin showing same rate of reduction in expression as the control 
group; and the 20µM and 200µM EHM groups showing higher rate of reduction.  
 
 
Figure 5.4.3-19 Luciferase expression of EHMs treated with different concentrations of Metformin 
 
Surprisingly, despite consistently showing higher G.Luc expression in the first week of 
drug treatment, EHMs treated with 200µM Metformin beat with lower forces than EHMs 
treated with lower dosage of the drug. Also, despite the low levels of G.Luc expression 
throughout 10 days of treatment, EHMs treated with 2µM Metformin beat with the highest 
forces among all Metformin-treated EHMs, beating almost with similar forces as the control 
group. EHMs treated with 200µM Metformin beat with very similar forces to EHMs treated with 
20µM Metformin.  
Gaussia Luciferase expression



















Figure 5.4.3-20 Forces of EHMs treated with different concentrations of Metformin 
 
EC50 values of Metformin-treated EHMs were also shifted to the right (by about 0.02 – 
0.08mM increase) of the control group (about 0.65mM), with 2µM Metformin-treated EHMs 
having EC50 value of about 0.70mM; 20µM Metformin-treated EHMs at about 0.73mM and 
200µM Metformin-treated EHMs at about 0.67mM. 
 
 
Figure 5.4.3-21 Force frequency response of EHMs treated with different concentrations of Metformin 
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The force frequency response in EHMs treated with Metformin is similar to EHMs 
treated with NA: there is a generally negative force frequency response, in control, 2µM and 
200µM Metformin-treated groups. 2µM Metformin-treated group has the highest drop in forces 
as frequency of stimulation was increased to 3Hz, followed by the 200µM group and the control 
group. There is a mixed response in the 20µM Metformin-treated group, resulting in the average 
of slightly positive force-frequency response. There were no significant differences in the 


















































EHMs treated with Gemfibrozil showed a dose-dependent G.Luc expression for the first 
seven days of drug application, with the smallest dosage of 10µM resulting in EHMs secreting 
the most G.Luc, followed by 100 µM and 1000µM. In fact, the signal from 1000µM group is more 
than twice lower the 100µM group. For the 10µM and 100µM groups, after initial increase in 
G.Luc expression after 48 hours of treatment, there was a decrease in G.Luc expression between 
48 – 72 hours of drug treatment. This resulted in little difference in the G.Luc expression level on 
the third day, in comparison with the first day. For the 1000µM group, however, there was a 
drop in expression from 24 – 48 hours of drug treatment and this drop continued further from 
48 – 72 hours of treatment. From day 3-7, there was a general increase in G.Luc expression for 
all EHMs from all Gemfibrozil treated groups. From day 7 – 10, there was a general decrease in 
G.Luc expression for all EHMs from all experimental groups, with the 10µM group showing the 
sharpest rate of decrease. Similar to result obtained on the 7th day of treatment, the 1000 µM 
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Figure 5.4.3-24 Response to Isoprenaline stimulation 





























Figure 5.4.3-23 Reduction in forces  Metformin-





Figure 5.4.3-25 Gaussia Luciferase expression of EHMs treated with different concentrations of Gemfibrozil 
 
The G.Luc data was somewhat recapitulated in the contractile force data. EHMs treated 
with 100 µM Gemfibrozil beat with the highest forces, although there was an arrhythmic drop in 
force from 2.0 – 2.4 mM Ca2+. Beyond 2.4 mM Ca2+, arrhythmia stopped and the force recovered 
to the level at 2.0 mM Ca2+ when extracellular Ca2+ concentration was increased to 3.2 mM. 
There was also a very slight drop in forces owing to arrhythmia from 2.0 – 2.4 mM Ca2+ in the 
1000 µM group. The EC50 values of Gemfibrozil-treated EHMs were generally right-shifted, 
indicating that treatment with the drug resulted in lowered extracellular Ca2+ sensitivity. The 
extent of shift, however, was not dosage dependent as EC50 (10µM) is about 0.8mM, EC50 (100µM) is 
about 0.7mM and EC50 (1000µM) is about 0.75mM.  
Increasing frequency of stimulation from 2Hz – 3Hz resulted in no change of contractile 
forces in the EHMs treated with 10 µM and 100 µM Gemfibrozil. This is in contrast with the 
control and 1000 µM groups, which showed negative force-frequency relationship. 
























Figure 5.4.3-27 Force frequency response of Gemfibrozil-treated EHMs 
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Despite the apparent difference in responses to carbachol treatment between the 100µM 
and 1000µM groups, there were no statistically significant differences in the responses to 
isoprenaline and carbachol stimulations in the experimental groups.  
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Figure 5.4.3-30 Increase in Gemfibrozil-treated 



























Figure 5.4.3-29 Reduction in Gemfibrozil-treated 




In this chapter, the effect of extracellular calcium on CM maturation in EHM format was 
investigated. From section 5.4.1, it is apparent that ventricular CMs (mCherry bright cells) need 
extracellular calcium for proper growth and survival. EHMs cultured in calcium free media 
showed no observable mCherry (mChr) expression and no observable beating. Despite the 
presence of a few ventricular CMs in EHMs cultured in 0.4mM Ca2+, the contractile forces were 
negligible for these EHMs. Increasing the extracellular Ca2+ to 0.8mM appeared to increase MYL2 
expression by 2-fold in comparison to 0.4mM Ca2+, and 10-fold in comparison with 0mM Ca2+. 
This was evident from the G.Luc expression level that was about 1.93x and about 9.53x the level 
observed from EHMs cultured in 0.4mM Ca2+ and calcium free media respectively. Increasing the 
extracellular Ca2+ further to 1.2mM further improved MYL2 expression by about 1.47 fold 
leading to maximal contraction force of 0.54 ± 0.008 mN (mean ± SEM) vs 0.27 ± 0.042 mN in 
EHMs cultured in 0.8mM Ca2+. It is interesting to note that the observed contractile forces were 
not proportional to MYL2 expression levels.  
Increasing the extracellular Ca2+ further to 1.6mM and 2.0mM did not seem to benefit 
the EHMs further in terms of MYL2 expression levels and contractile forces. There was only 
about 1.13-fold more MYL2 in EHMs cultured in 1.6mM and 2.0mM Ca2+ and this did not 
translate to higher contractile forces. In fact, culturing EHMs in 2.0mM Ca2+ seemed to have a 
negative effect – these EHMs beat arrhythmically with reduced forces when extracellular Ca2+ 
was > 2.8mM in the organ bath (figure 5.4.1-2); they also showed poorer response to 
isoprenaline treatment (figure 5.4.1-7). Considering the CMs inside the EHMs were only 30 days 




which means that their contractility depends mostly on calcium fluxes between the cytosol and 
extracellular fluid (Katz and Lorell, 2000). In view of the report that in the failing hearts, fetal 
transcriptomes are re-activated (Katz and Lorell, 2000), the effects seen here could parallel to 
the decreased response to beta-adrenergic receptor stimulation seen in heart failure (Wynne et 
al., 1993), possibly due to changes in the excitation-contraction machinery instead of limitation 
of cAMP generation (Laurent et al., 2001).  
The second part of this chapter looked into whether IWR1 conferred ventricular subtype 
specificity during cardiac differentiation as has been reported before (Karakikes et al., 2014; 
Weng et al., 2014). The knock-in cell line is an excellent tool for these types of studies as 
mCherry expression faithfully represents MYL2 gene expression. Thus the ventricular CMs 
fraction can be easily identified by the mCherry positive cell population. This approach 
eliminates false positives or negatives from conventional FACS staining approach. Indeed, CMs 
from the same population fixed in different fixatives such as 90% methanol, 70% ethanol or 4% 
paraformaldehyde have showed different levels of MYL2 positive fraction, leading to 
overestimation or underestimation of the true MYL2 positive fraction in the cell suspension (own 
unpublished data). Therefore, as a measure of success for different subtype differentiation 
protocols, live-cell FACS was used to determine the absolute mCherry positive fraction from the 
CMs cell suspension. 
Using this method there was no statistically significant difference between flasks 
differentiated with 5 µM IWP4 or IWR1 at 2.5 and 5 µM concentrations. Although 2.5µM IWR1 
was shown to generate significantly more mCherry positive cells when data was normalized to α-
actinin positive fraction, this data was not reliable as the ratio went above 100%, indicating that 
the α-actinin positive fraction was underestimated during FACS. This is not surprising since FACS 
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necessitates CM monolayer trypsinization before fixation and staining. A number of CMs might 
have been killed during the trypsinization process leading to an underestimation of α-actinin 
positive fraction. Furthermore, each flask was divided into 2 fractions after trypsinization (one 
half was used for mCherry live FACS and the other for fixation and staining with α-actinin). The 
cell suspension may have been divided unequally during this process. Furthermore, Karakikes 
(2014) and Weng (2014) employed hypoxic conditions either for maintaining undifferentiated 
hPSCs (Karakikes et al., 2014) or during differentiation between day 0 – 8 (Weng et al., 2014). It 
is possible that the transition between hypoxic to normoxic or vice versa enhanced the 
ventricular subtype specification. Further experiments are necessary before any conclusions can 
be made. 
Finally the third part of this chapter looks into the different effects that certain cardio-
active select drugs (noradrenaline, endothelin-1, IBMX, Metformin and Gemfibrozil) might have 
on EHMs generated from knock-in CMs. Since NA, ET-I and IBMX have been reported to have 
hypertrophic effects on the heart (Bupha-Intr et al., 2012; Kaddoura et al., 1996; Korth, 1978; 
Newling et al., 1989; Reuter, 1983; Reuter and Scholz, 1977) the analysis for these 3 drugs will be 
combined.  
Combining the luciferase graphs of ET-1, NA and IBMX, the data suggest that ET-1 
produced most pronounced response after 7 days of treatment, followed by IBMX and NA (figure 
5.5.1-1). When we look at 5.5.1-1 and -2 side by side, it is apparent that luciferase expression 
cannot be the proxy of contractile forces as the 2 graphs do not correlate. Thus contractile forces 
might not be proportional to the level of MYL2 expression alone. The EC50 values also indicated 
that treatment with NA rendered the EHMs less sensitive to extracellular calcium concentrations, 
followed by treatment with ET-1 and IBMX. Finally, the responses to isoprenaline are generally 
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dose-dependent for ET-1 and IBMX, but not for NA for which 100nM showed the maximal 
response (figure 5.5.1-3). Chronic treatment with NA has been reported to result in 
desensitization of adrenoreceptors resulting in reduced response during isoprenaline stimulation, 
similar to that observed in heart failure (Wynne et al., 1993). This dose-dependent reduced 
response to isoprenaline stimulation was also observed in EHMs treated with ET-1 and IBMX 







Figure 5.5.1-1 Combined luciferase expression of EHMs treated with different hypertrophic-inducing drugs 
 
                      
    
Figure 5.5.1-2 Combined EHM contractile forces treated with different hypertrophic-inducing drugs 
 





























Highest contractile forces of drug-treated  EHMs
  
















































[EC50 values (mM Ca2+)] 
[NA]  
[EC50 values (mM Ca2+)] 
[IBMX] 
[EC50 values (mM Ca2+)] 
(0.65) 
0.1nM (0.75) 10 nM (0.95) 1 µM (0.72) 
1 nM (0.7) 100 nM (0.95) 10 µM (0.62) 
10 nM (0.73) 1000 nM (0.8) 100 µM (0.63) 
 
Table 5.5.1-1 Summary of EC50 values 
 
 
                 
 





Figure 5.5.1-4 Summary of carbachol response 













































































































Combining the luciferase graph of EHMs treated with Metformin and Gemfibrozil, it is 
apparent that EHMs treated with Metformin expressed higher level of luciferase than those 
treated with Gemfibrozil. Metformin displayed a very interesting trend. From day 1 to day 7, 
luciferase expression was proportional to the concentration of Metformin in the culture media 
(EHMs treated with higher concentrations of Metformin expressed more luciferase). But by the 
10th day of treatment, the luciferase expression level for 2 µM Metformin-treated EHMs was 
very similar to the 200 µM Metformin-treated ones; with those treated with 20 µM Metformin 
expressing slightly lower level of luciferase. It can be inferred from this data that MYL2 gene 
expression should be rather similar in these EHMs on day 10.  
 




Gemfibrozil, on the other hand displayed a more straightforward trend: EHMs treated 
with increasing dose of Gemfibrozil expressed decreasing amount of luciferase for a good 9 days 
of treatment. On the 10th day however, the level of luciferase expression for EHMs treated with 
10 µM and 100 µM fell to the same level. Thus it could be implied that chronic treatment with 
       
 





















       
Control
 








increasing concentrations of Gemfibrozil led to decreasing expression of MYL2 gene, at least 
when Gemfibrozil concentration was >100 µM.  
Yet the EHMs beating force profiles were quite different from expected. EHMs treated 
with 2µM Metformin beat with the strongest forces, almost similar to the control level, whereby 
those treated with the higher concentrations of Metformin (20 µM and 200 µM) beat with lower 
forces. Although the mean forces of EHMs treated with 20 µM and 200 µM Metformin appeared 








Gemfibrozil contractile forces also did not seem to follow the luciferase expression trend. 
From 0 mM – 1.6 mM Ca2+, 100 µM Gemfibrozil-treated EHMs beat with stronger forces than 
their 10 µM counterparts. From 2.0mM – 3.2mM Ca2+, however, 100 µM Gemfibrozil-treated 
EHMs exhibited arrhythmia, which was not observed with EHMs treated with 10 µM, or 1000 
µM of the drug. 
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[EC50 values (mM Ca2+)] 
[Metformin] 
[EC50 values (mM Ca2+)] 
[Gemfibrozil]  
[EC50 values (mM Ca2+)] 
 (0.65) 
2 µM (0.70) 10 µM (0.8) 
20 µM (0.73) 100 µM (0.7) 
200 µM (0.67) 1000 µM (0.75) 
 
Table 5.5.1-2 Summary of EC 50 values of EHMs treated with Metformin and Gemfibrozil 
 
 
In general, EHMs treated with Gemfibrozil showed a more right-shifted EC50 values and 
better isoprenaline response (table 5.5.1-2) than the Metformin treated ones (EC50 = about 0.7 
– 0.8mM vs 0.67 – 0.73mM Ca2+ respectively).  
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The effects seen with Gemfibrozil treatment could stem from the fact that this drug is a 
peroxisome proliferator–activated receptor alpha (PPARα) agonist. Chronic PPARα stimulation 
has been associated with increased MYL2 transcription as well as cardiac hypertrophy (Finck et 
al., 2002; Hamano et al., 2001) and moderate systolic dysfunction (Finck, 2007). Furthermore, in 
presence of high concentrations of circulating lipids, chronic stimulation of PPARα could result in 
uncontrolled fatty acid oxidation, toxic lipid intermediate accumulation, and reactive oxygen 
species accumulation which might lead to cellular degeneration, necrosis and cardiomyopathic 
remodeling (Finck, 2007; Pruimboom-Brees et al., 2006). Furthermore, since Gemfibrozil has 
been reported to inhibit mitochondrial respiration (Nadanaciva et al., 2007); this might lead to 
mitochondrial dysfunction and subsequent cell death. Altogether, these might explain the 
functional decline in EHMs treated with increasing doses of Gemfibrozil.    
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Human pluripotent stem cells (hPSCs) hold great potential in cardiovascular research. 
However, these potentials cannot yet be fully realized due to a number of persistent technical 
challenges. Published methods of cardiomyocyte (CM) differentiation from hPSCs were found 
here to be non-robust and non-reproducible, necessitating rounds of optimizations in this and 
other laboratories before success can be anticipated from the protocols. In addition, current 
differentiation protocols generate a mixture of phenotypically immature CMs displaying nodal-
lie, atrial-like and ventricular-like action potentials (Mummery et al., 2012). These fetal-stage 
CMs might not be optimal for downstream applications as they behave differently (reviewed in 
Chapter 2 section 2.2.3) from their adult counterparts (reviewed in Chapter 4 section 4.2.1). The 
current study has three main objectives: to develop a robust and reproducible CM 
differentiation protocol; to generate an MYL2-knock-in reporter line which would facilitate the 
enrichment for the ventricular CM subtype and to improve the maturation of hESCs-derived CMs 
in vitro. 
The MYL2-knock-in reporter line was successfully generated through TALEN-mediated 
homologous recombination (HR). TALEN technology was empirically demonstrated to improve 
HR efficiency from a reported ratio of 26:1 stable transfected clones to HR events (Zwaka and 
Thomson, 2003), to about 18.8:1 in H9 background and about 3.7:1 in induced PSCs MBJ6 
background. The reporter line was also shown to be pluripotent with no gross chromosomal 
aberrations. In addition, functional validation experiments demonstrated that the reporter line 
was functional as designed. Each knocked-in reporter (mCherry, neomycin resistance and 
Gaussia luciferase) was expressed in significant correlation to MYL2 gene (p ≤ 0.05 for G. Luc; p ≤ 
0.01 for mCherry and p ≤ 0.001 for NeoR), as well as to each other (table 4.4.4-1). Ventricular 
CMs (vCMs) fraction could be monitored in real time through the qualitative mCherry signal as 
283 
 
well as quantitative G. luciferase signal. Furthermore, the vCM fraction could be enriched 
through G418 selection of up to 50µg/ml and live cell FACS for mCherry positive cell population.  
Removal of the floxed selection cassette PGK-Hygromycin was shown to enhance 
mCherry reporter expression, as evident from the significantly higher mean mCherry 
fluorescence intensity from H9VC16 CMs versus that from H9V15 CMs (figure 3.4.6-7). The utility 
of the cell line was also tested in pilot studies to develop a vCM differentiation protocol, and in 
drug screening using the knock-in CMs in EHMs format. The novel MYL2-knock-in reporter line 
was demonstrated to provide a simple yet effective read-out for MYL2 positive fraction, 
eliminating potential under- or overestimation seen with conventional immunohistochemistry 
methods. From the drug screening study, it was learned that G.luc and mCherry reporter 
expressions could be used to indicate the drug effects on CM viability as well as MYL2 gene 
expression, yet they cannot be used as proxy for EHM contractile forces.  
Through nine iterations, a set of robust and reproducible monolayer and embryoid body-
based differentiation protocols were finally obtained. All differentiated embryoid bodies (EBs) 
beat by day 9 of differentiation, giving a differentiation efficiency of 100%. Monolayer based 
differentiation gave beating monolayers of CMs with >80% success rate from all differentiation 
efforts. Furthermore, in this study, a simple yet efficient CM trypsinization protocol has been 
successfully developed to improve CM viability post digestion and consequently CM yield.  
In vitro aging, in conjunction with auxotonic stretching and IGF1, VEGF and FGF 
treatment enhanced the CM maturation in the EHMs as determined by the mRNA and miRNA 
profiles. Electrical stimulation also seemed to improve CM maturation in the EHMs, as evident 
from the higher level of expression as well as enhanced organization and alignment of MYL2; 
decrease in hypersensitivity to extracellular calcium; enhanced response to isoprenaline and 
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carbachol stimulation and improvement in force-frequency behavior. However, increasing 
preload by 10% did not seem to enhance CM maturation. Including calcium at 1.2mM – 1.6mM 
was demonstrated to be beneficial for force development of the CMs, yet this approach also did 
not enhance maturation of CMs in the EHMs.  
Despite the encouraging level of maturation seen in in vitro aging as well as electrical 
stimulation experiments, additional work is still required to further enhance the maturation level 
in these CMs as they are still far from the maturation level seen in adult CMs in vivo. So far, it 
seems that the electrical stimulation approach is the most promising. However, the electrical 
stimulation parameters need to be further optimized to minimize cell death and maximize CM 
maturation. In addition, further work is also required to assess CM maturation from 
electrophysiological and ultrastructural angles.  
There are a number of publications on electrical stimulation for enhancement of CM 
maturation in vitro yet each approach uses different stimulation parameters as well as 
maturation parameters (Deng et al., 2000; Hirt et al., 2014; Martherus et al., 2010; Nunes et al., 
2013). It would be useful for the field to develop a gold standard protocol to measure CM 
maturation. Once this gold standard is established, one can then work on optimizing in vitro CM 
maturation protocol. With a CM maturation protocol at hand, the engineering of a biomimetic 
ventricular cardiac tissue model with properties close to that of the ventricular myocardium of 
the heart in vivo would be feasible. Then, not only drug screening assays for cardiotoxicity will 
more representative of the in vivo data, cell therapy for the treatment of heart failure patients 
will also be closer to reality. The novel MYL2 knock-in reporter line described here in this thesis, 
however, provides a starting point from which a homogenous population of ventricular 
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Appendix from Chapter 4 
 
 
1. Appendix 4.1 








2. Appendix 4.2  
qPCR data from EHMs at different time points. Each reading was normalized to GAPDH 
followed by their corresponding expression on day 18, when cardiomyocytes were 
trypsinized to generate EHMs 
 




Appendix from Chapter 5 










































30 vs. Day 
45) 
ABCB1 1.14E-05 4.61661 4.55E-04 2.71356 1.20E-03 2.40381 5.18E-03 1.92054 5.32E-01 1.12886 1.64E-02 1.70131 
AC002480.3 6.10E-06 5.2387 4.85E-05 3.7524 2.80E-05 4.07968 2.16E-01 1.2841 6.69E-01 0.919777 1.07E-01 1.39609 
AC007308.6 2.21E-05 12.2754 1.55E-04 7.44393 3.18E-03 3.82299 4.73E-03 3.21093 6.90E-02 1.94715 1.59E-01 1.64904 
AC009518.2 2.85E-05 6.53199 1.13E-04 4.9785 5.12E-03 2.60488 4.08E-03 2.5076 2.72E-02 1.91122 3.09E-01 1.31204 
ACAP1 7.86E-06 5.5113 2.19E-04 3.23229 6.57E-04 2.77604 5.88E-03 1.98531 4.66E-01 1.16436 2.26E-02 1.70507 
ACP5 1.24E-06 4.36822 5.85E-05 2.66034 3.95E-05 2.78063 9.40E-03 1.57094 7.64E-01 0.956738 5.44E-03 1.64198 
ACSF2 1.31E-05 2.49519 6.17E-04 1.7904 1.25E-04 2.03356 1.00E-01 1.227 2.88E-01 0.880425 1.41E-02 1.39365 
ACTBL2 1.06E-06 12.9633 3.21E-04 3.92055 3.80E-05 5.7898 7.36E-03 2.23899 1.41E-01 0.677148 5.00E-04 3.30651 
ALOX12B 3.18E-05 9.09617 1.26E-04 6.58968 9.75E-03 2.77637 2.41E-03 3.27629 1.57E-02 2.37349 3.10E-01 1.38037 
ANKEF1 8.71E-09 4.68473 1.75E-06 2.50893 1.17E-06 2.60747 5.79E-05 1.79665 6.86E-01 0.962208 3.28E-05 1.86722 
ANKRD1 6.10E-06 4.01505 6.78E-06 3.95386 7.50E-05 2.87502 6.05E-02 1.39653 7.14E-02 1.37525 9.25E-01 1.01548 
APOA1 1.82E-05 3.72316 3.92E-05 3.34686 6.89E-04 2.35139 2.04E-02 1.58338 6.17E-02 1.42335 5.43E-01 1.11243 
ARHGDIG 4.03E-06 5.54545 4.80E-05 3.7114 2.08E-04 3.01984 8.10E-03 1.83634 2.97E-01 1.22901 5.65E-02 1.49416 
ATP1B4 2.81E-07 4.64269 3.82E-08 6.44844 1.09E-05 2.87848 3.49E-03 1.6129 6.30E-05 2.24022 2.73E-02 0.719971 
ATP4A 5.95E-07 15.9215 4.32E-05 5.84238 6.18E-05 5.4485 1.31E-03 2.92218 7.86E-01 1.07229 2.09E-03 2.72517 
ATP6V1G2 7.47E-06 3.15114 4.41E-05 2.57626 3.72E-04 2.08516 1.08E-02 1.51122 1.45E-01 1.23552 1.63E-01 1.22315 
BAIAP3 1.22E-05 3.82974 2.09E-03 2.04857 2.50E-04 2.59018 3.81E-02 1.47856 1.85E-01 0.790897 3.11E-03 1.86947 
BEX1 5.81E-06 6.56057 4.01E-05 4.60161 1.90E-03 2.56432 1.12E-03 2.55841 2.00E-02 1.79448 1.27E-01 1.42571 
BNIP3P1 4.88E-06 3.11241 1.02E-05 2.86069 3.82E-05 2.48358 1.04E-01 1.2532 2.91E-01 1.15184 5.22E-01 1.08799 
C19orf67 2.31E-06 15.8353 4.88E-05 7.33253 3.11E-05 8.13028 4.03E-02 1.94769 7.26E-01 0.90188 2.13E-02 2.15959 
C4orf26 2.38E-05 11.6733 1.99E-04 6.85999 7.12E-03 3.20158 2.24E-03 3.64611 3.97E-02 2.14269 1.32E-01 1.70165 
C6orf52 1.35E-07 5.35412 6.95E-07 4.16806 6.16E-05 2.43107 8.78E-05 2.20237 1.75E-03 1.7145 8.30E-02 1.28456 
CADM4 9.37E-08 2.58254 5.29E-07 2.22671 3.14E-07 2.32344 1.68E-01 1.11152 5.65E-01 0.958367 6.30E-02 1.1598 
CCDC24 1.25E-05 4.54457 1.68E-04 3.09285 1.95E-04 3.03097 5.39E-02 1.49938 9.16E-01 1.02041 6.49E-02 1.46938 
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CDH13 8.75E-06 4.1952 5.41E-06 4.52033 1.64E-04 2.80775 3.88E-02 1.49415 1.78E-02 1.60995 6.71E-01 0.928074 
CHRNA3 5.88E-08 10.0702 3.98E-05 3.27104 7.46E-06 4.14258 2.43E-04 2.43089 1.84E-01 0.789612 3.19E-05 3.07859 
CLYBL 1.36E-06 3.22288 1.77E-05 2.44645 4.32E-05 2.24985 9.74E-03 1.43248 4.82E-01 1.08738 3.57E-02 1.31737 
COX7A1 2.06E-06 15.2092 2.11E-06 15.1012 7.31E-04 4.04377 6.10E-04 3.76115 6.35E-04 3.73444 9.80E-01 1.00715 
CTB-50L17.16 4.12E-06 5.55631 2.09E-05 4.23456 4.47E-04 2.73948 3.27E-03 2.02823 4.18E-02 1.54575 1.79E-01 1.31213 
CTD-2619J13.17 1.35E-06 12.3388 2.30E-05 6.45722 5.69E-04 3.5842 4.01E-04 3.44254 3.64E-02 1.80158 2.38E-02 1.91085 
DDX3Y 3.78E-09 34.0993 1.59E-08 21.7597 6.15E-06 5.51093 1.54E-06 6.18758 2.28E-05 3.94847 4.29E-02 1.56708 
DIO2 1.86E-06 6.03355 1.41E-06 6.35077 6.44E-04 2.5304 5.92E-04 2.38443 3.79E-04 2.50979 7.84E-01 0.95005 
DMKN 2.62E-07 3.22638 5.47E-07 2.9716 3.60E-06 2.45895 1.80E-02 1.3121 7.91E-02 1.20848 4.18E-01 1.08574 
EIF1AY 5.32E-08 27.2418 3.67E-07 15.4491 6.25E-05 4.93401 1.69E-05 5.52123 5.28E-04 3.13114 3.53E-02 1.76333 
ENO3 1.16E-06 4.22773 1.47E-06 4.08923 2.72E-04 2.20847 7.07E-04 1.91432 1.05E-03 1.85161 8.16E-01 1.03387 
ENSG00000240742 1.26E-05 8.01131 2.23E-04 4.48549 2.73E-03 2.9207 2.44E-03 2.74294 1.25E-01 1.53576 4.62E-02 1.78605 
EPCAM 3.14E-09 6.26896 3.44E-08 4.31559 2.04E-07 3.42244 8.49E-05 1.83172 4.11E-02 1.26097 3.36E-03 1.45263 
ETFB 5.39E-06 2.82595 5.25E-05 2.2512 6.39E-05 2.21123 6.15E-02 1.278 8.82E-01 1.01807 7.98E-02 1.25531 
FAM167A 9.16E-08 9.16323 2.24E-06 5.01394 6.99E-06 4.1902 6.65E-04 2.18682 3.05E-01 1.19659 4.09E-03 1.82755 
FAM19A5 3.64E-07 7.59408 3.41E-06 5.03988 9.89E-06 4.24882 6.83E-03 1.78734 3.50E-01 1.18618 3.89E-02 1.5068 
FBXO2 5.64E-06 11.0022 2.66E-05 7.62067 1.22E-05 9.1197 5.07E-01 1.20642 5.25E-01 0.835627 2.06E-01 1.44373 
FDXR 1.21E-05 3.80416 9.98E-04 2.20585 9.13E-05 2.90573 1.31E-01 1.30919 1.23E-01 0.759138 7.05E-03 1.72458 
FSD1 7.36E-08 5.75801 3.28E-06 3.31841 3.06E-06 3.34723 1.49E-03 1.72023 9.48E-01 0.991391 1.33E-03 1.73517 
GAPDH 7.10E-06 2.92059 1.62E-05 2.66796 6.58E-05 2.31626 9.09E-02 1.26091 2.83E-01 1.15184 4.85E-01 1.09469 
GAPDHP60 9.88E-06 2.98236 8.66E-05 2.36129 3.66E-05 2.57958 2.96E-01 1.15614 5.17E-01 0.915378 1.05E-01 1.26302 
GAPDHP70 3.39E-06 4.62319 5.67E-05 3.09532 8.16E-05 2.95562 2.05E-02 1.5642 7.85E-01 1.04726 3.37E-02 1.49361 
GBP2 1.28E-09 3.3382 1.47E-07 2.15286 1.47E-07 2.15314 1.66E-05 1.55039 9.98E-01 0.99987 1.65E-05 1.55059 
H2AFY2 1.88E-06 2.21845 2.32E-05 1.84302 3.59E-06 2.10807 5.42E-01 1.05236 1.26E-01 0.874266 4.30E-02 1.20371 
HMGB3P24 2.14E-06 9.0969 6.78E-05 4.58336 1.47E-04 4.0188 4.25E-03 2.26359 5.75E-01 1.14048 1.18E-02 1.98477 
HOXB1 3.47E-06 12.5006 2.43E-05 7.79493 2.08E-04 4.97263 6.26E-03 2.51388 1.29E-01 1.56757 1.12E-01 1.60368 
HSPA8P16 5.41E-06 6.53032 2.11E-05 5.06759 1.25E-03 2.68959 1.57E-03 2.428 1.26E-02 1.88415 2.59E-01 1.28865 
IL17REL 8.79E-08 10.6704 4.46E-06 4.94586 1.71E-05 4.00055 1.81E-04 2.66723 2.58E-01 1.2363 1.20E-03 2.15744 
IL1A 5.27E-10 13.0307 4.96E-09 8.00911 5.20E-07 3.77256 4.78E-07 3.45408 5.50E-05 2.12299 1.76E-03 1.62699 
INADL 5.98E-10 2.51444 5.91E-10 2.51665 5.02E-09 2.12814 2.62E-03 1.18152 2.53E-03 1.18256 9.84E-01 0.999124 
KBTBD8 5.30E-08 3.81304 5.15E-06 2.33469 6.21E-06 2.29625 2.53E-04 1.66055 8.65E-01 1.01674 3.30E-04 1.63321 
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KLHDC9 1.33E-08 4.73245 2.38E-06 2.54493 8.84E-07 2.80865 2.30E-04 1.68495 3.33E-01 0.906103 5.27E-05 1.85956 
KCNV2 3.82E-06 7.094 7.45E-06 6.21401 1.57E-03 2.62459 7.19E-04 2.7029 2.01E-03 2.36761 5.49E-01 1.14161 
KRT8P10 5.23E-06 5.16695 6.58E-05 3.47761 2.14E-04 2.95818 1.20E-02 1.74667 4.02E-01 1.17559 5.63E-02 1.48577 
LBX1-AS1 1.30E-05 16.0649 6.14E-04 5.86141 1.09E-03 5.14409 7.16E-03 3.12298 7.13E-01 1.13945 1.40E-02 2.74079 
LIN28B 4.18E-08 7.98286 1.94E-07 5.98674 6.38E-06 3.5167 1.49E-04 2.26998 3.72E-03 1.70237 7.30E-02 1.33342 
LINC00880 2.44E-06 9.03613 6.20E-05 4.73182 4.36E-04 3.4189 1.42E-03 2.64299 1.85E-01 1.38402 1.69E-02 1.90965 
LYPD6B 1.01E-06 6.26932 6.96E-06 4.5081 7.35E-06 4.46915 7.99E-02 1.4028 9.61E-01 1.00872 8.69E-02 1.39068 
MASP1 1.96E-08 5.21344 5.05E-07 3.33345 2.60E-06 2.77449 1.07E-04 1.87906 1.15E-01 1.20146 1.57E-03 1.56398 
MGARP 1.93E-05 3.12479 5.12E-05 2.77946 2.62E-04 2.32439 7.09E-02 1.34435 2.52E-01 1.19578 4.46E-01 1.12424 
MRAP2 4.76E-05 4.9846 2.90E-05 5.4615 1.21E-03 2.93665 4.25E-02 1.69737 2.10E-02 1.85977 7.00E-01 0.912679 
MSX2 3.66E-07 5.16021 1.10E-05 3.18311 5.56E-05 2.63626 6.08E-04 1.95739 2.10E-01 1.20743 5.82E-03 1.62112 
MT1E 1.05E-05 6.03937 1.17E-05 5.91063 5.62E-04 3.1018 1.11E-02 1.94705 1.33E-02 1.90555 9.23E-01 1.02178 
MT1G 7.32E-06 20.7795 9.02E-06 19.4478 8.79E-03 3.38685 3.41E-04 6.13534 4.58E-04 5.74215 8.56E-01 1.06847 
MT1X 5.21E-06 8.92182 1.74E-05 6.85436 2.34E-04 4.17513 1.07E-02 2.1369 7.03E-02 1.64171 3.09E-01 1.30163 
NAP1L2 2.91E-06 3.53265 8.45E-05 2.40098 9.86E-06 3.03733 2.85E-01 1.16308 1.08E-01 0.790491 1.51E-02 1.47133 
OGDHL 8.14E-06 4.37152 4.91E-04 2.50889 3.41E-04 2.62057 1.37E-02 1.66816 8.08E-01 0.957384 8.79E-03 1.74241 
P2RY14 2.36E-05 4.65296 1.57E-06 7.72124 4.72E-03 2.17779 3.39E-03 2.13656 6.73E-05 3.54546 3.06E-02 0.602618 
PDE6B 3.86E-06 3.13647 1.75E-05 2.6476 3.14E-05 2.49318 9.39E-02 1.25802 6.41E-01 1.06194 2.03E-01 1.18465 
PDHA2 1.92E-06 3.77241 1.50E-05 2.91645 6.01E-04 2.00249 6.73E-04 1.88386 1.80E-02 1.45641 8.38E-02 1.29349 
PFKP 1.62E-05 2.65793 1.21E-04 2.18051 1.11E-04 2.19773 1.55E-01 1.2094 9.51E-01 0.992165 1.40E-01 1.21895 
PGK1 7.34E-07 3.37134 2.70E-06 2.90062 6.65E-06 2.6374 5.15E-02 1.27828 4.16E-01 1.0998 2.08E-01 1.16228 
PLEKHB1 5.59E-06 3.52621 1.38E-04 2.41935 1.42E-04 2.41276 2.28E-02 1.46148 9.85E-01 1.00273 2.36E-02 1.4575 
PLS1 1.80E-09 4.46696 1.20E-08 3.4952 1.06E-06 2.24563 2.44E-06 1.98917 1.38E-04 1.55644 9.08E-03 1.27802 
PODXL2 1.58E-06 4.28701 2.31E-05 2.99744 3.81E-05 2.82448 1.53E-02 1.5178 6.91E-01 1.06124 3.17E-02 1.43022 
PPL 1.72E-06 5.07621 1.96E-04 2.6296 2.18E-05 3.46861 4.02E-02 1.46347 1.19E-01 0.758113 2.03E-03 1.93041 
PROM1 1.22E-05 5.75012 6.76E-05 4.25336 3.59E-04 3.27193 2.44E-02 1.75741 2.51E-01 1.29995 1.91E-01 1.3519 
PRRX2 4.33E-07 5.57336 4.36E-06 3.89389 4.59E-04 2.22723 7.93E-05 2.50237 3.47E-03 1.74831 3.66E-02 1.43131 
PTPRR 7.34E-07 3.37246 1.01E-06 3.24521 2.63E-05 2.309 6.27E-03 1.46058 1.15E-02 1.40546 7.39E-01 1.03921 
RP11-433O3.1 6.31E-08 7.47562 4.36E-06 3.7382 5.07E-06 3.66168 4.87E-04 2.04158 8.90E-01 1.0209 6.11E-04 1.99979 
RAB38 9.51E-08 4.13154 1.49E-07 3.88804 7.75E-06 2.48665 6.19E-04 1.66149 1.58E-03 1.56356 5.83E-01 1.06263 
RASL10B 2.80E-07 3.53243 1.22E-05 2.35907 3.99E-05 2.12483 5.62E-04 1.66246 3.46E-01 1.11024 2.92E-03 1.49739 
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RND2 2.50E-08 7.33715 2.20E-07 5.02414 6.30E-07 4.28369 1.88E-03 1.71281 2.54E-01 1.17285 1.56E-02 1.46038 
RP11-15G8.1 3.65E-06 9.05731 2.01E-05 6.28843 3.44E-04 3.75087 3.67E-03 2.41472 5.43E-02 1.67653 1.57E-01 1.44031 
RP11-224O19.2 1.76E-06 5.71049 1.07E-06 6.24995 1.30E-04 2.97883 3.53E-03 1.91703 1.46E-03 2.09813 6.18E-01 0.913686 
RP11-44D5.1 6.20E-10 8.4361 5.42E-09 5.69702 1.91E-07 3.44214 2.20E-06 2.45083 3.82E-04 1.65508 2.38E-03 1.48079 
RP11-451J24.1 1.49E-05 3.31339 1.71E-04 2.48089 7.19E-04 2.13461 1.43E-02 1.55223 3.42E-01 1.16222 8.23E-02 1.33557 
RP11-516A11.1 5.63E-06 3.82797 1.51E-04 2.53902 1.34E-04 2.57339 2.49E-02 1.48752 9.32E-01 0.986644 2.12E-02 1.50766 
RP11-545E17.3 3.23E-07 4.59722 1.13E-06 3.8419 8.85E-07 3.97379 2.86E-01 1.15689 8.00E-01 0.966811 1.95E-01 1.1966 
RP11-6F2.5 3.09E-06 9.07699 1.76E-04 4.10474 9.21E-05 4.59504 1.49E-02 1.97539 6.42E-01 0.893297 6.36E-03 2.21134 
RPS4Y1 1.03E-10 49.2956 4.71E-10 29.5483 1.12E-07 7.49891 1.02E-07 6.5737 2.46E-06 3.94034 7.03E-03 1.66831 
SDSL 1.04E-05 4.88471 1.23E-03 2.45577 3.07E-04 2.93864 2.32E-02 1.66224 3.72E-01 0.835683 4.44E-03 1.98908 
SELP 1.80E-05 11.2539 1.11E-03 4.37196 1.34E-04 6.88294 1.44E-01 1.63504 1.74E-01 0.635188 1.15E-02 2.57411 
SLC31A1P1 1.74E-05 2.34529 1.87E-04 1.91669 7.50E-05 2.06358 2.67E-01 1.13652 5.14E-01 0.92882 9.26E-02 1.22361 
SPESP1 4.51E-07 10.4255 2.24E-06 7.35279 3.45E-04 3.1201 1.13E-04 3.3414 1.62E-03 2.35659 1.19E-01 1.4179 
SPOCD1 1.36E-06 6.25492 9.10E-06 4.50737 1.47E-05 4.18019 4.73E-02 1.49633 6.84E-01 1.07827 9.67E-02 1.38771 
SRP14-AS1 5.43E-06 3.20257 6.04E-05 2.44862 2.99E-05 2.63508 1.68E-01 1.21536 5.90E-01 0.929237 6.70E-02 1.30791 
TCTE1 1.38E-05 14.2269 2.96E-04 6.46904 2.63E-03 4.00936 2.91E-03 3.54841 1.78E-01 1.61348 3.72E-02 2.19922 
TM7SF2 1.88E-05 3.68764 1.24E-04 2.86928 2.14E-04 2.68421 8.70E-02 1.37382 7.01E-01 1.06894 1.66E-01 1.28522 
TMEM38A 3.42E-06 3.98764 8.04E-06 3.54284 3.06E-05 2.98861 8.02E-02 1.33428 2.80E-01 1.18545 4.46E-01 1.12555 
TOM1L1 2.06E-06 3.15889 1.49E-06 3.28163 1.77E-05 2.50289 7.44E-02 1.2621 4.25E-02 1.31114 7.53E-01 0.962599 
TPST2P1 3.57E-06 6.3466 3.92E-04 2.96834 7.23E-05 3.79339 2.64E-02 1.67307 2.47E-01 0.782503 3.02E-03 2.1381 
TREML3P 7.04E-07 7.67641 4.90E-06 5.32442 2.85E-05 3.99267 5.14E-03 1.92262 1.54E-01 1.33355 7.73E-02 1.44173 
TSPAN8 6.99E-06 8.18671 1.78E-04 4.32413 8.29E-04 3.3353 3.73E-03 2.45457 3.12E-01 1.29648 2.45E-02 1.89326 
TXLNG2P 9.57E-06 40.0012 3.90E-05 23.7001 6.31E-03 5.02966 6.88E-04 7.95306 5.08E-03 4.71207 2.64E-01 1.68781 
USP9Y 5.40E-11 20.6186 8.89E-11 17.9851 5.35E-07 3.53664 7.70E-09 5.82999 1.80E-08 5.08537 2.53E-01 1.14643 
UTY 3.37E-08 25.5746 1.69E-07 15.9971 1.02E-04 4.12208 5.00E-06 6.2043 7.61E-05 3.88083 5.81E-02 1.5987 
VAMP8 5.68E-06 2.53686 7.02E-06 2.48528 5.60E-05 2.0665 7.96E-02 1.22761 1.10E-01 1.20265 8.50E-01 1.02075 
WFDC1 3.06E-05 16.3989 1.92E-05 18.9769 6.24E-04 7.03703 4.90E-02 2.33037 2.49E-02 2.69672 7.10E-01 0.864148 
ZFY 7.32E-09 47.044 2.55E-08 30.5435 2.41E-06 8.88194 1.51E-05 5.29659 2.10E-04 3.43883 8.46E-02 1.54023 
ZIC1 4.08E-06 21.1973 5.74E-05 9.91206 5.78E-04 5.66583 2.39E-03 3.74125 1.25E-01 1.74945 4.52E-02 2.13854 
ZNF157 5.45E-06 5.6896 1.17E-04 3.45512 4.29E-04 2.87913 5.42E-03 1.97615 3.75E-01 1.20005 2.81E-02 1.64672 













































COL6A6 1.84E-08 -46.12 5.34E-08 -31.80 1.74E-05 -6.87 9.45E-06 -6.71 6.80E-05 -4.63 1.61E-01 -1.45 
ADAMTS5 9.41E-09 -7.15 1.10E-08 -6.94 1.70E-06 -3.27 4.04E-05 -2.19 5.67E-05 -2.12 8.09E-01 -1.03 
SMOC2 4.58E-08 -10.41 7.80E-08 -9.26 4.66E-05 -3.17 1.75E-05 -3.29 4.47E-05 -2.92 4.93E-01 -1.12 
RORB 1.24E-06 -10.35 1.40E-06 -10.06 7.73E-04 -3.10 2.56E-04 -3.34 3.11E-04 -3.25 9.02E-01 -1.03 
SOX9 5.94E-09 -6.73 1.04E-09 -9.45 2.01E-06 -2.94 1.24E-05 -2.29 4.35E-07 -3.21 1.06E-02 1.40 
RP11-
152P17.2 1.10E-09 -9.06 2.86E-09 -7.50 1.97E-06 -2.91 4.97E-07 -3.11 2.99E-06 -2.58 1.12E-01 -1.21 
CILP2 1.04E-07 -14.36 3.33E-07 -10.79 8.09E-04 -2.73 5.37E-06 -5.27 3.12E-05 -3.96 1.87E-01 -1.33 
TGFBR3 1.33E-09 -6.44 9.70E-10 -6.81 8.40E-07 -2.72 1.75E-06 -2.37 9.32E-07 -2.50 5.60E-01 1.06 
SEMA3F 1.82E-06 -5.60 3.14E-06 -5.10 2.72E-04 -2.69 1.51E-03 -2.08 3.80E-03 -1.89 6.01E-01 -1.10 
NCAM2 4.84E-10 -10.99 2.55E-09 -7.78 5.47E-06 -2.63 5.09E-08 -4.17 8.50E-07 -2.96 9.43E-03 -1.41 
B4GALT1 3.19E-08 -5.09 2.74E-08 -5.21 6.18E-06 -2.62 9.00E-05 -1.94 6.63E-05 -1.99 8.34E-01 1.02 
HMGB1P21 5.88E-06 -5.40 6.18E-06 -5.36 9.09E-04 -2.55 2.55E-03 -2.12 2.76E-03 -2.10 9.65E-01 -1.01 
NFATC2 3.78E-05 -5.45 2.50E-05 -5.90 4.32E-03 -2.50 7.35E-03 -2.18 4.07E-03 -2.36 7.44E-01 1.08 
ANGPTL1 7.34E-05 -5.57 6.10E-06 -9.53 7.80E-03 -2.48 9.68E-03 -2.25 2.95E-04 -3.84 6.23E-02 1.71 
HSPA5 1.08E-07 -5.29 7.16E-08 -5.66 3.94E-05 -2.48 9.67E-05 -2.13 4.59E-05 -2.28 6.07E-01 1.07 
ADAMTS4 1.63E-07 -6.26 2.56E-07 -5.78 1.55E-04 -2.43 4.62E-05 -2.58 9.93E-05 -2.38 5.98E-01 -1.08 
TTYH2 1.16E-08 -4.96 1.91E-09 -6.67 5.19E-06 -2.40 1.49E-05 -2.07 5.36E-07 -2.78 1.22E-02 1.35 
COLEC12 1.01E-09 -8.84 2.75E-09 -7.26 1.11E-05 -2.40 9.87E-08 -3.69 5.18E-07 -3.03 9.42E-02 -1.22 
CTD-2369P2.2 2.08E-09 -4.46 2.21E-09 -4.42 5.50E-07 -2.40 7.35E-06 -1.86 8.39E-06 -1.84 9.15E-01 -1.01 
C6 5.29E-07 -7.35 8.08E-08 -11.00 8.95E-04 -2.38 5.82E-05 -3.08 3.40E-06 -4.61 4.50E-02 1.50 
BAI3 1.46E-07 -8.19 4.65E-08 -10.48 6.12E-04 -2.34 1.11E-05 -3.50 1.99E-06 -4.48 1.65E-01 1.28 
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RNF24 5.21E-11 -5.41 4.98E-10 -3.93 8.01E-08 -2.33 3.80E-08 -2.32 4.58E-06 -1.69 3.62E-04 -1.38 
KIAA1211 3.95E-08 -4.06 2.64E-08 -4.29 6.31E-06 -2.33 1.35E-04 -1.74 5.98E-05 -1.84 5.81E-01 1.06 
CBLN1 7.54E-07 -5.01 1.10E-06 -4.72 2.86E-04 -2.32 3.22E-04 -2.16 6.06E-04 -2.03 6.97E-01 -1.06 
HSD11B1 2.93E-06 -4.49 1.96E-06 -4.78 4.87E-04 -2.32 1.70E-03 -1.93 8.76E-04 -2.06 7.00E-01 1.07 
PXDNL 1.74E-05 -5.35 2.40E-05 -5.05 5.34E-03 -2.24 1.93E-03 -2.39 3.07E-03 -2.26 7.92E-01 -1.06 
DCLK1 4.58E-07 -5.64 6.07E-07 -5.38 5.20E-04 -2.22 7.69E-05 -2.54 1.21E-04 -2.42 7.59E-01 -1.05 
GAS7 1.99E-09 -4.63 3.74E-09 -4.24 1.90E-06 -2.20 1.54E-06 -2.11 5.28E-06 -1.93 2.93E-01 -1.09 
TBX18 2.94E-06 -5.25 2.87E-05 -3.68 1.75E-03 -2.19 4.29E-04 -2.40 1.35E-02 -1.68 6.84E-02 -1.43 
MBNL3 3.99E-06 -4.69 3.90E-06 -4.71 1.44E-03 -2.17 8.45E-04 -2.16 8.15E-04 -2.17 9.83E-01 1.00 
GAREM 1.46E-10 -4.03 3.53E-10 -3.61 9.32E-08 -2.13 2.52E-07 -1.89 1.68E-06 -1.69 8.15E-02 -1.12 
BNC2 7.83E-07 -4.26 1.91E-07 -5.29 3.47E-04 -2.10 2.79E-04 -2.03 2.78E-05 -2.52 1.36E-01 1.24 
IL32 1.17E-06 -4.23 1.03E-05 -3.16 5.77E-04 -2.06 3.13E-04 -2.06 1.05E-02 -1.54 6.15E-02 -1.34 
DOCK9 5.31E-09 -4.02 2.86E-08 -3.27 5.15E-06 -2.03 3.43E-06 -1.98 9.17E-05 -1.61 2.58E-02 -1.23 
LHFPL2 2.81E-10 -5.45 5.72E-10 -4.89 2.49E-06 -2.03 3.76E-08 -2.69 1.25E-07 -2.41 1.70E-01 -1.11 
KLF2 5.08E-06 -4.56 4.21E-06 -4.70 2.96E-03 -2.02 5.80E-04 -2.26 4.40E-04 -2.33 8.65E-01 1.03 


















































             
ABCC9 6.43E-08 -11.39 1.88E-07 -8.95 2.29E-06 -5.51 1.77E-03 -2.07 1.94E-02 -1.62 2.01E-01 -1.27 
AC011526.1 3.50E-06 -4.18 1.13E-05 -3.54 8.50E-05 -2.75 2.05E-02 -1.52 1.30E-01 -1.29 3.09E-01 -1.18 
ADAMTS2 6.25E-07 -3.79 4.18E-06 -3.00 6.82E-06 -2.84 3.64E-02 -1.33 6.59E-01 -1.06 7.99E-02 -1.26 
ADAMTS7 5.07E-07 -4.81 1.33E-06 -4.16 7.72E-06 -3.28 1.98E-02 -1.46 1.18E-01 -1.27 3.25E-01 -1.16 
ANKHD1 1.70E-06 -2.69 9.77E-06 -2.28 1.19E-05 -2.24 9.55E-02 -1.20 8.66E-01 -1.02 1.27E-01 -1.18 
APBA1 4.21E-10 -3.22 1.08E-09 -2.92 3.53E-08 -2.16 1.14E-05 -1.49 1.40E-04 -1.35 9.15E-02 -1.10 
APOLD1 1.57E-08 -5.12 1.07E-08 -5.44 1.09E-06 -2.94 2.40E-04 -1.74 1.02E-04 -1.85 5.77E-01 1.06 
ARHGAP23 7.37E-09 -5.49 1.39E-08 -4.97 8.08E-08 -3.87 5.36E-03 -1.42 3.08E-02 -1.28 3.47E-01 -1.10 
ARHGAP28 5.75E-10 -5.09 2.51E-09 -4.12 3.00E-07 -2.45 1.06E-06 -2.08 2.66E-05 -1.68 1.85E-02 -1.23 
ARHGEF28 6.52E-09 -9.66 1.45E-07 -5.39 7.91E-07 -4.15 5.41E-05 -2.32 7.61E-02 -1.30 1.07E-03 -1.79 
AVPR1A 6.66E-08 -84.64 5.44E-07 -37.06 8.73E-07 -31.38 1.09E-02 -2.70 6.18E-01 -1.18 2.72E-02 -2.28 
CHST2 7.69E-07 -3.73 3.20E-06 -3.12 8.47E-05 -2.22 1.39E-03 -1.68 1.76E-02 -1.41 1.75E-01 -1.19 
CILP 9.98E-11 -44.44 4.37E-10 -27.34 4.00E-09 -14.71 1.43E-05 -3.02 1.69E-03 -1.86 7.96E-03 -1.63 
CLEC2B 1.05E-07 -4.08 2.42E-06 -2.80 1.87E-06 -2.87 7.63E-03 -1.42 8.02E-01 1.03 4.84E-03 -1.46 
COL1A1 7.58E-08 -16.63 5.98E-07 -9.93 2.15E-06 -7.52 2.87E-03 -2.21 2.09E-01 -1.32 3.06E-02 -1.68 
COL5A1 2.79E-05 -3.01 2.35E-05 -3.07 6.52E-04 -2.13 4.09E-02 -1.41 3.17E-02 -1.44 8.89E-01 1.02 
CRIM1 1.69E-07 -4.41 5.22E-06 -2.86 8.36E-06 -2.71 1.81E-03 -1.62 6.78E-01 -1.05 3.79E-03 -1.54 
CSPG4 1.23E-06 -3.61 1.56E-05 -2.68 2.35E-05 -2.57 1.97E-02 -1.41 7.40E-01 -1.04 3.61E-02 -1.35 
CTDSP2 7.01E-08 -2.58 4.12E-07 -2.22 1.31E-06 -2.03 5.71E-03 -1.27 2.35E-01 -1.09 5.32E-02 -1.16 
DAB2 1.36E-09 -4.51 6.44E-09 -3.67 6.45E-07 -2.30 2.47E-06 -1.96 7.19E-05 -1.60 2.08E-02 -1.23 
DACH1 1.93E-07 -10.66 1.05E-06 -7.40 6.61E-06 -5.24 3.45E-03 -2.04 9.90E-02 -1.41 8.30E-02 -1.44 
DOCK6 8.87E-08 -6.74 1.81E-07 -5.92 7.97E-06 -3.36 5.14E-04 -2.00 2.26E-03 -1.76 3.90E-01 -1.14 
DTNBP1 4.63E-07 -3.59 2.21E-06 -2.98 6.77E-06 -2.64 2.03E-02 -1.36 3.12E-01 -1.13 1.27E-01 -1.21 
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ECM2 1.43E-06 -11.99 3.08E-06 -9.95 2.19E-04 -4.19 1.30E-03 -2.86 4.79E-03 -2.38 4.64E-01 -1.21 
EFCAB14 6.97E-11 -4.54 2.69E-10 -3.80 1.89E-09 -3.04 2.57E-05 -1.49 2.80E-03 -1.25 1.06E-02 -1.20 
EFNA5 2.12E-08 -3.06 2.33E-07 -2.43 2.18E-06 -2.03 1.63E-04 -1.51 3.35E-02 -1.19 9.05E-03 -1.26 
EIF4EBP2 3.22E-10 -2.48 1.66E-09 -2.18 3.95E-09 -2.05 6.18E-04 -1.21 1.57E-01 -1.06 8.29E-03 -1.14 
ELK3 1.68E-07 -3.67 8.83E-07 -3.01 2.11E-05 -2.21 4.82E-04 -1.66 1.23E-02 -1.36 8.45E-02 -1.22 
ENPEP 1.52E-08 -4.82 1.14E-07 -3.65 5.18E-07 -3.05 8.04E-04 -1.58 1.01E-01 -1.20 1.80E-02 -1.32 
EPAS1 3.60E-09 -7.40 9.59E-09 -6.20 1.01E-06 -3.19 1.06E-05 -2.32 8.91E-05 -1.94 1.38E-01 -1.19 
F2RL2 1.40E-08 -8.29 4.92E-08 -6.52 2.78E-06 -3.52 4.79E-05 -2.36 7.14E-04 -1.85 9.92E-02 -1.27 
FAM101B 2.69E-07 -3.24 7.79E-06 -2.30 2.41E-05 -2.09 1.01E-03 -1.55 3.52E-01 -1.10 5.34E-03 -1.41 
FAM110B 5.03E-10 -5.50 9.65E-09 -3.64 5.40E-07 -2.40 4.19E-07 -2.29 2.47E-04 -1.52 2.66E-04 -1.51 
FAM13C 2.17E-07 -5.39 6.46E-07 -4.53 2.32E-05 -2.83 6.98E-04 -1.90 5.86E-03 -1.60 2.37E-01 -1.19 
FAM89A 7.61E-07 -4.46 1.63E-06 -3.99 8.04E-06 -3.23 4.09E-02 -1.38 1.56E-01 -1.24 4.44E-01 -1.12 
FGD5 4.67E-10 -6.84 4.01E-10 -7.03 2.71E-08 -3.71 2.39E-05 -1.84 1.60E-05 -1.89 7.60E-01 1.03 
FMNL3 1.72E-10 -5.96 2.03E-09 -4.13 7.18E-08 -2.74 4.86E-07 -2.17 1.90E-04 -1.50 4.42E-04 -1.44 
GLIS2 1.58E-06 -3.28 9.38E-06 -2.68 3.32E-05 -2.36 1.87E-02 -1.39 3.09E-01 -1.14 1.20E-01 -1.22 
GPR153 3.12E-08 -5.82 3.77E-08 -5.64 4.76E-06 -2.91 1.22E-04 -2.00 1.81E-04 -1.94 7.96E-01 -1.03 
GPRC5B 4.34E-08 -4.07 5.58E-08 -3.94 3.84E-06 -2.46 3.32E-04 -1.66 5.69E-04 -1.60 7.40E-01 -1.03 
HECA 7.97E-10 -3.75 7.49E-09 -2.92 2.64E-07 -2.14 2.47E-06 -1.75 4.74E-04 -1.36 2.26E-03 -1.29 
HEG1 1.69E-08 -5.28 6.69E-08 -4.30 2.11E-06 -2.82 1.04E-04 -1.87 2.23E-03 -1.53 7.98E-02 -1.23 
HNRNPA3 5.38E-10 -3.13 1.25E-08 -2.34 3.70E-09 -2.59 4.42E-03 -1.21 7.52E-02 1.11 1.77E-04 -1.34 
HSPE1P26 3.76E-05 -3.05 3.60E-05 -3.06 1.53E-03 -2.02 2.32E-02 -1.51 2.19E-02 -1.52 9.74E-01 1.01 
INF2 2.35E-07 -2.77 2.22E-07 -2.79 3.70E-06 -2.17 1.37E-02 -1.28 1.20E-02 -1.29 9.44E-01 1.01 
ITGA8 9.27E-08 -3.93 1.36E-06 -2.86 7.78E-07 -3.03 2.93E-02 -1.30 5.71E-01 1.06 1.03E-02 -1.38 
ITGA9 6.21E-07 -3.45 2.15E-05 -2.35 5.45E-06 -2.70 5.16E-02 -1.28 2.54E-01 1.14 6.09E-03 -1.46 
ITPRIPL2 1.12E-06 -3.42 1.01E-05 -2.66 1.44E-04 -2.07 1.40E-03 -1.65 5.73E-02 -1.29 5.83E-02 -1.28 
KCNJ8 9.37E-07 -5.94 7.27E-06 -4.24 2.07E-05 -3.63 1.42E-02 -1.64 3.84E-01 -1.17 7.03E-02 -1.40 
KIAA1462 1.84E-08 -5.36 2.02E-08 -5.28 4.95E-07 -3.39 1.39E-03 -1.58 1.76E-03 -1.56 8.93E-01 -1.02 
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KIAA0922 5.93E-06 -2.77 1.12E-04 -2.09 1.46E-04 -2.04 2.41E-02 -1.36 8.47E-01 -1.02 3.43E-02 -1.33 
KIAA2018 2.38E-08 -2.76 5.34E-07 -2.11 3.22E-07 -2.20 6.24E-03 -1.25 5.78E-01 1.04 2.30E-03 -1.30 
LMBR1L 8.20E-07 -2.71 1.31E-06 -2.59 1.05E-05 -2.15 3.10E-02 -1.26 7.32E-02 -1.20 6.33E-01 -1.05 
LRRC32 8.40E-08 -4.60 1.57E-06 -3.13 5.15E-06 -2.75 8.73E-04 -1.67 2.73E-01 -1.14 6.29E-03 -1.47 
MAML2 1.19E-07 -2.99 1.39E-06 -2.36 2.62E-06 -2.24 5.58E-03 -1.34 5.38E-01 -1.06 1.73E-02 -1.27 
MEGF9 1.54E-08 -3.41 1.68E-08 -3.38 1.48E-06 -2.19 1.45E-04 -1.56 1.75E-04 -1.54 9.03E-01 -1.01 
MFHAS1 5.36E-08 -2.83 5.81E-08 -2.81 7.49E-07 -2.23 8.67E-03 -1.27 1.05E-02 -1.26 9.16E-01 -1.01 
MICALL1 1.81E-08 -3.27 1.06E-08 -3.48 1.20E-06 -2.20 2.88E-04 -1.49 8.63E-05 -1.59 4.36E-01 1.06 
MXRA5 8.02E-10 -9.81 1.91E-08 -5.44 2.59E-07 -3.73 2.58E-06 -2.63 5.53E-03 -1.46 2.26E-04 -1.80 
NOTCH1 2.86E-07 -8.49 2.86E-06 -5.46 2.72E-06 -5.51 3.51E-02 -1.54 9.61E-01 1.01 3.21E-02 -1.56 
OLFML2A 1.94E-05 -3.08 1.11E-04 -2.52 5.66E-04 -2.13 2.83E-02 -1.45 2.75E-01 -1.18 1.96E-01 -1.22 
PCDHGA10 4.51E-09 -3.54 6.47E-08 -2.66 5.83E-07 -2.20 3.72E-05 -1.61 2.23E-02 -1.21 2.20E-03 -1.33 
PCDHGB6 6.34E-07 -2.50 7.88E-06 -2.03 8.27E-06 -2.02 2.75E-02 -1.24 9.67E-01 -1.00 2.97E-02 -1.23 
PCDHGC3 2.51E-08 -5.48 3.97E-08 -5.09 4.04E-07 -3.66 4.48E-03 -1.50 1.42E-02 -1.39 5.30E-01 -1.08 
PDGFRB 1.88E-06 -4.43 1.60E-05 -3.28 1.09E-04 -2.61 4.99E-03 -1.70 1.57E-01 -1.26 7.36E-02 -1.35 
PLAGL1 4.60E-08 -6.56 1.93E-07 -5.14 4.79E-06 -3.27 2.72E-04 -2.01 5.83E-03 -1.57 9.26E-02 -1.28 
PXDN 4.39E-08 -4.84 6.13E-08 -4.61 6.26E-06 -2.62 1.69E-04 -1.85 3.38E-04 -1.76 6.61E-01 -1.05 
RAPH1 1.43E-09 -6.01 3.97E-09 -5.10 5.25E-08 -3.57 1.36E-04 -1.68 2.47E-03 -1.43 9.80E-02 -1.18 
ROBO4 3.16E-08 -15.73 1.12E-07 -11.44 1.14E-06 -6.94 1.13E-03 -2.27 2.19E-02 -1.65 1.18E-01 -1.37 
RP1-79C4.4 3.20E-06 -7.94 9.17E-06 -6.40 6.04E-05 -4.52 2.81E-02 -1.76 1.47E-01 -1.41 3.53E-01 -1.24 
RP11-238F2.1 5.32E-07 -38.03 1.00E-06 -30.38 8.07E-05 -8.48 7.58E-04 -4.49 2.40E-03 -3.59 5.05E-01 -1.25 
RP11-458N5.1 1.40E-05 -3.51 3.19E-04 -2.40 2.31E-04 -2.49 5.18E-02 -1.41 8.26E-01 1.04 3.48E-02 -1.46 
RP11-483C6.1 4.57E-06 -4.69 4.99E-06 -4.62 3.48E-04 -2.58 5.24E-03 -1.82 6.07E-03 -1.79 9.36E-01 -1.01 
RP11-488L18.10 1.33E-06 -4.20 1.96E-05 -2.95 5.99E-04 -2.06 3.72E-04 -2.04 2.69E-02 -1.43 2.96E-02 -1.42 
RP5-1085F17.3 4.65E-06 -3.24 1.47E-05 -2.83 3.58E-04 -2.05 5.21E-03 -1.58 3.26E-02 -1.38 3.26E-01 -1.14 
RUNX1 1.37E-07 -4.79 1.15E-07 -4.92 4.39E-06 -3.02 3.22E-03 -1.58 2.21E-03 -1.63 8.31E-01 1.03 
SASH1 1.75E-08 -4.42 1.42E-07 -3.37 1.08E-05 -2.19 1.43E-05 -2.02 8.83E-04 -1.54 1.58E-02 -1.31 
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SCAMP4 1.11E-07 -3.74 2.87E-07 -3.33 1.02E-06 -2.88 2.65E-02 -1.30 1.87E-01 -1.15 2.73E-01 -1.12 
SEPP1 1.08E-07 -5.37 1.50E-06 -3.65 5.65E-05 -2.41 6.43E-05 -2.23 8.00E-03 -1.52 1.21E-02 -1.47 
SF3A2 4.68E-06 -3.01 3.89E-05 -2.40 4.31E-05 -2.38 8.30E-02 -1.26 9.37E-01 -1.01 9.51E-02 -1.25 
SGK223 1.12E-06 -7.73 1.06E-05 -5.05 2.07E-05 -4.51 1.97E-02 -1.71 5.79E-01 -1.12 5.42E-02 -1.53 
SH2B3 1.86E-09 -3.88 2.30E-09 -3.77 2.85E-07 -2.31 1.44E-05 -1.68 2.35E-05 -1.63 7.11E-01 -1.03 
SLC43A3 8.92E-08 -5.28 4.72E-07 -4.11 2.60E-05 -2.54 1.11E-04 -2.08 2.73E-03 -1.62 7.01E-02 -1.29 
SLC7A1 1.74E-05 -3.55 8.74E-05 -2.88 3.12E-04 -2.48 4.95E-02 -1.43 3.77E-01 -1.16 2.25E-01 -1.23 
SORBS3 1.21E-06 -3.21 3.15E-06 -2.88 1.83E-05 -2.41 2.76E-02 -1.33 1.41E-01 -1.20 3.61E-01 -1.11 
SPON1 4.46E-06 -9.28 3.99E-06 -9.52 7.16E-05 -5.19 3.88E-02 -1.79 3.23E-02 -1.83 9.20E-01 1.03 
STAB1 1.71E-05 -3.82 4.59E-05 -3.32 1.53E-03 -2.17 7.34E-03 -1.76 3.09E-02 -1.53 4.37E-01 -1.15 
SULT1C4 6.92E-07 -3.09 1.35E-05 -2.29 4.03E-05 -2.09 3.06E-03 -1.48 3.84E-01 -1.10 1.52E-02 -1.35 
TDO2 4.94E-06 -6.34 4.22E-06 -6.54 4.53E-05 -4.28 8.45E-02 -1.48 6.57E-02 -1.53 8.86E-01 1.03 
TENC1 3.06E-07 -5.12 4.44E-07 -4.83 9.32E-06 -3.17 5.27E-03 -1.62 1.12E-02 -1.52 6.79E-01 -1.06 
TMTC2 1.83E-10 -2.69 1.75E-09 -2.23 7.88E-09 -2.01 2.04E-05 -1.34 2.69E-02 -1.11 8.56E-04 -1.21 
TP53I11 1.05E-08 -5.49 4.46E-08 -4.40 1.23E-06 -2.92 8.20E-05 -1.88 2.25E-03 -1.51 5.92E-02 -1.25 
TRAM2 1.21E-10 -4.01 1.74E-10 -3.83 8.45E-09 -2.54 5.61E-06 -1.58 1.53E-05 -1.51 4.28E-01 -1.05 
TSPAN14 6.39E-10 -3.47 1.01E-09 -3.30 1.38E-08 -2.54 2.38E-04 -1.37 9.89E-04 -1.30 3.90E-01 -1.05 
UNC5C 4.27E-08 -4.42 2.10E-07 -3.57 8.67E-06 -2.39 1.04E-04 -1.85 2.70E-03 -1.49 6.54E-02 -1.24 
UNKL 3.56E-05 -2.72 2.95E-05 -2.78 3.58E-04 -2.15 1.15E-01 -1.27 8.91E-02 -1.30 8.83E-01 1.02 
USP31 5.65E-09 -3.27 1.90E-07 -2.33 2.54E-07 -2.27 2.50E-04 -1.44 7.36E-01 -1.02 4.28E-04 -1.40 
VSTM4 1.14E-06 -2.88 2.70E-06 -2.63 3.82E-05 -2.07 8.43E-03 -1.39 3.97E-02 -1.27 4.03E-01 -1.09 
VWF 1.12E-07 -11.85 2.45E-07 -9.88 2.25E-06 -6.26 6.33E-03 -1.89 3.51E-02 -1.58 3.58E-01 -1.20 
WASF2 1.25E-10 -3.27 1.41E-10 -3.23 6.13E-09 -2.28 1.13E-05 -1.44 1.62E-05 -1.42 7.82E-01 -1.01 
ZC3HAV1L 1.50E-07 -3.47 3.73E-07 -3.12 1.87E-06 -2.63 1.70E-02 -1.32 1.12E-01 -1.19 3.03E-01 -1.11 
ZNF469 1.27E-07 -14.81 4.82E-06 -6.49 2.48E-06 -7.41 7.10E-03 -2.00 5.39E-01 1.14 2.34E-03 -2.28 
ZNF697 5.14E-09 -4.36 8.89E-08 -3.07 5.20E-06 -2.11 3.18E-06 -2.07 9.71E-04 -1.46 1.57E-03 -1.42 











































ABCA6 2.81E-08 -5.60 1.80E-09 -9.35 2.00E-08 -5.93 6.34E-01 1.06 2.36E-03 -1.58 1.03E-03 1.67 
ADNP 1.26E-08 -2.38 2.46E-08 -2.26 3.97E-08 -2.17 1.23E-01 -1.09 5.12E-01 -1.04 3.42E-01 -1.06 
AGO2 9.32E-08 -3.16 8.40E-08 -3.20 5.46E-07 -2.63 5.85E-02 -1.20 4.63E-02 -1.22 8.95E-01 1.01 
ARHGAP17 2.40E-06 -2.72 1.26E-06 -2.91 2.78E-06 -2.68 8.90E-01 -1.01 4.46E-01 -1.09 5.30E-01 1.07 
ARHGAP32 3.47E-07 -2.28 2.25E-07 -2.37 2.35E-07 -2.36 6.56E-01 1.03 9.60E-01 -1.00 6.20E-01 1.04 
ARHGAP6 4.53E-08 -2.82 1.25E-08 -3.23 2.44E-08 -3.01 4.04E-01 1.07 3.45E-01 -1.07 9.05E-02 1.15 
ARHGDIA 6.15E-06 -2.49 3.82E-06 -2.61 3.14E-05 -2.15 1.89E-01 -1.16 9.21E-02 -1.21 6.66E-01 1.05 
ARHGEF15 3.20E-05 -5.39 2.18E-05 -5.80 2.07E-04 -3.89 1.85E-01 -1.39 1.12E-01 -1.49 7.60E-01 1.08 
ARHGEF17 1.14E-05 -2.45 3.53E-06 -2.76 3.22E-05 -2.23 4.01E-01 -1.10 7.86E-02 -1.24 3.09E-01 1.12 
ARID1B 2.80E-10 -2.56 3.94E-11 -3.08 3.74E-10 -2.49 5.53E-01 -1.03 3.02E-04 -1.24 8.02E-04 1.21 
ASXL2 4.64E-08 -2.15 4.21E-08 -2.17 2.62E-08 -2.25 4.40E-01 1.04 5.18E-01 1.04 8.97E-01 1.01 
ATP13A1 6.04E-06 -2.16 8.24E-07 -2.57 3.26E-06 -2.28 5.74E-01 1.05 1.91E-01 -1.13 7.43E-02 1.19 
BCL2 1.23E-07 -5.64 4.61E-07 -4.57 6.05E-07 -4.39 8.83E-02 -1.29 7.68E-01 -1.04 1.45E-01 -1.23 
BMP8A 1.40E-07 -7.67 2.38E-05 -3.33 3.88E-07 -6.32 2.52E-01 -1.21 2.10E-03 1.90 2.92E-04 -2.30 
BRD3 5.37E-07 -2.34 7.40E-08 -2.81 4.04E-07 -2.40 7.56E-01 1.02 6.25E-02 -1.17 3.58E-02 1.20 
C15orf39 1.23E-06 -4.11 1.85E-07 -5.51 9.93E-07 -4.24 8.28E-01 1.03 8.37E-02 -1.30 5.72E-02 1.34 
C18orf54 9.91E-06 -3.46 9.05E-06 -3.50 1.29E-05 -3.34 8.21E-01 -1.04 7.61E-01 -1.05 9.37E-01 1.01 
CAMK4 1.72E-06 -3.25 8.31E-06 -2.72 1.09E-05 -2.64 1.11E-01 -1.23 8.13E-01 -1.03 1.64E-01 -1.19 
CASC7 7.76E-09 -3.83 2.92E-08 -3.26 2.99E-08 -3.26 6.79E-02 -1.18 9.76E-01 -1.00 7.16E-02 -1.17 
CASP2 1.41E-07 -2.46 3.35E-07 -2.29 7.98E-08 -2.59 4.86E-01 1.05 1.06E-01 1.13 3.22E-01 -1.08 
CBL 4.56E-10 -2.98 1.61E-09 -2.64 1.90E-09 -2.60 1.93E-02 -1.15 7.72E-01 -1.01 3.28E-02 -1.13 
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CCBE1 2.77E-06 -3.87 7.68E-07 -4.67 1.70E-06 -4.15 6.38E-01 1.07 4.25E-01 -1.13 2.16E-01 1.21 
CD36 8.24E-09 -36.43 6.70E-09 -39.12 1.16E-08 -32.44 6.00E-01 -1.12 4.03E-01 -1.21 7.47E-01 1.07 
CDC25B 8.47E-08 -2.82 3.01E-08 -3.14 1.81E-07 -2.62 3.61E-01 -1.08 3.82E-02 -1.20 1.89E-01 1.11 
CENPP 1.51E-05 -2.34 2.01E-05 -2.28 3.79E-05 -2.16 4.64E-01 -1.09 6.16E-01 -1.06 8.12E-01 -1.03 
CIC 4.01E-06 -3.85 1.12E-06 -4.64 3.02E-06 -4.00 7.93E-01 1.04 3.40E-01 -1.16 2.32E-01 1.21 
CNOT6 1.52E-07 -2.18 4.89E-07 -2.00 8.95E-08 -2.27 5.16E-01 1.04 6.60E-02 1.13 1.98E-01 -1.09 
COL5A3 1.97E-05 -3.34 5.97E-06 -3.93 2.46E-05 -3.24 8.56E-01 -1.03 2.44E-01 -1.21 3.19E-01 1.18 
COL6A3 6.44E-06 -2.92 7.36E-06 -2.88 1.57E-05 -2.65 4.50E-01 -1.10 5.21E-01 -1.09 9.07E-01 -1.01 
CRAMP1L 1.32E-06 -2.58 5.79E-07 -2.80 4.96E-07 -2.85 3.17E-01 1.10 8.67E-01 1.02 4.00E-01 1.08 
CREB3L1 7.69E-08 -7.65 3.27E-07 -5.85 1.51E-07 -6.73 4.11E-01 -1.14 3.75E-01 1.15 1.03E-01 -1.31 
CREB3L2 4.83E-11 -4.04 2.44E-11 -4.43 8.08E-11 -3.79 2.37E-01 -1.07 1.19E-02 -1.17 1.07E-01 1.10 
CRTC3 2.51E-09 -2.19 3.74E-10 -2.55 4.04E-09 -2.12 4.30E-01 -1.03 9.60E-04 -1.21 3.87E-03 1.17 
CTD-3099C6.9 2.87E-06 -2.48 2.33E-04 -1.75 4.28E-06 -2.39 7.10E-01 -1.04 7.72E-03 1.37 3.93E-03 -1.42 
DIAPH1 1.11E-07 -2.25 4.37E-08 -2.43 8.93E-08 -2.29 7.89E-01 1.02 3.63E-01 -1.06 2.47E-01 1.08 
DYRK1B 4.26E-06 -2.52 1.57E-06 -2.78 1.88E-06 -2.73 4.44E-01 1.08 8.61E-01 -1.02 3.52E-01 1.10 
EBF1 1.60E-07 -11.65 5.81E-07 -8.69 9.04E-07 -7.91 7.35E-02 -1.47 6.42E-01 -1.10 1.62E-01 -1.34 
EGFR 2.76E-06 -2.70 1.70E-06 -2.84 1.63E-06 -2.86 6.12E-01 1.06 9.66E-01 1.00 6.42E-01 1.05 
EHD2 8.55E-08 -4.14 1.78E-07 -3.75 1.73E-07 -3.76 3.95E-01 -1.10 9.73E-01 1.00 3.77E-01 -1.10 
ELMO1 1.47E-07 -3.38 1.91E-07 -3.28 9.74E-07 -2.74 5.37E-02 -1.23 9.20E-02 -1.19 7.59E-01 -1.03 
ENG 5.41E-06 -4.20 8.97E-06 -3.90 4.91E-06 -4.26 9.30E-01 1.01 5.95E-01 1.09 6.56E-01 -1.08 
EPN1 2.73E-05 -2.16 2.15E-05 -2.20 2.78E-05 -2.15 9.87E-01 -1.00 8.36E-01 -1.02 8.49E-01 1.02 
FAM122C 1.27E-05 -2.42 4.66E-06 -2.68 1.47E-05 -2.39 9.03E-01 -1.01 3.27E-01 -1.12 3.87E-01 1.10 
FAM174B 4.36E-06 -3.15 2.13E-06 -3.43 7.10E-06 -2.97 6.63E-01 -1.06 2.79E-01 -1.16 5.04E-01 1.09 
FAM193A 9.18E-07 -2.22 4.45E-07 -2.35 1.39E-06 -2.14 6.72E-01 -1.03 2.46E-01 -1.10 4.46E-01 1.06 
FAM214A 5.07E-07 -2.16 1.09E-06 -2.04 1.11E-06 -2.04 4.15E-01 -1.06 9.87E-01 -1.00 4.24E-01 -1.06 
FBXL7 1.72E-08 -3.63 7.23E-08 -3.08 2.21E-08 -3.52 7.20E-01 -1.03 1.29E-01 1.15 7.00E-02 -1.18 
FTX 1.58E-05 -3.07 5.08E-05 -2.68 6.53E-05 -2.61 2.77E-01 -1.18 8.50E-01 -1.03 3.62E-01 -1.15 
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GPC4 6.19E-08 -9.06 1.89E-08 -11.81 2.03E-07 -7.13 1.62E-01 -1.27 9.07E-03 -1.66 1.25E-01 1.30 
GSK3B 2.37E-09 -2.02 1.16E-07 -1.63 1.54E-09 -2.08 4.49E-01 1.03 3.83E-05 1.28 1.16E-04 -1.24 
HEBP1 1.25E-05 -2.11 1.01E-06 -2.64 7.21E-06 -2.21 6.36E-01 1.05 8.10E-02 -1.19 3.47E-02 1.25 
HIPK2 2.49E-09 -3.98 5.74E-10 -4.88 1.50E-09 -4.26 3.79E-01 1.07 9.30E-02 -1.15 1.87E-02 1.23 
HMBOX1 6.58E-06 -2.22 9.70E-05 -1.81 9.41E-06 -2.16 7.54E-01 -1.03 8.46E-02 1.19 4.87E-02 -1.23 
HNRNPD 1.15E-07 -2.46 7.50E-08 -2.56 1.54E-07 -2.40 7.24E-01 -1.03 3.80E-01 -1.07 5.92E-01 1.04 
HSPG2 1.75E-05 -6.46 1.54E-05 -6.64 1.39E-05 -6.77 8.48E-01 1.05 9.34E-01 1.02 9.14E-01 1.03 
HUWE1 1.15E-07 -1.94 8.67E-09 -2.34 7.05E-08 -2.01 5.41E-01 1.03 1.16E-02 -1.17 3.81E-03 1.21 
INO80D 1.76E-08 -2.43 1.37E-06 -1.79 7.65E-08 -2.16 6.50E-02 -1.12 6.52E-03 1.21 2.18E-04 -1.36 
INSR 2.32E-07 -2.38 2.50E-07 -2.36 8.16E-07 -2.15 1.83E-01 -1.11 2.09E-01 -1.10 9.32E-01 -1.01 
JMY 3.70E-08 -2.36 7.29E-09 -2.72 7.24E-08 -2.23 3.84E-01 -1.06 6.69E-03 -1.22 3.37E-02 1.15 
KCNMB2 8.51E-06 -3.21 5.21E-06 -3.41 1.94E-05 -2.91 4.93E-01 -1.10 2.72E-01 -1.17 6.64E-01 1.06 
KCNQ3 9.10E-06 -3.15 6.22E-06 -3.31 1.36E-05 -3.01 7.34E-01 -1.05 5.04E-01 -1.10 7.39E-01 1.05 
KIAA0430 7.52E-08 -2.53 5.41E-08 -2.61 1.12E-07 -2.44 6.16E-01 -1.04 3.61E-01 -1.07 6.71E-01 1.03 
KMT2A 1.07E-09 -2.82 1.23E-09 -2.78 1.06E-09 -2.82 9.81E-01 1.00 7.90E-01 1.01 8.08E-01 -1.01 
KMT2C 5.34E-09 -2.59 5.20E-08 -2.15 1.37E-08 -2.39 1.66E-01 -1.08 8.22E-02 1.11 5.97E-03 -1.20 
LAMC3 2.85E-07 -4.43 7.91E-08 -5.40 1.21E-07 -5.05 3.20E-01 1.14 6.00E-01 -1.07 1.42E-01 1.22 
LARP1 5.71E-08 -2.74 7.33E-09 -3.41 3.25E-08 -2.90 4.55E-01 1.06 4.72E-02 -1.18 1.19E-02 1.24 
LATS1 1.17E-09 -2.52 8.48E-09 -2.15 6.54E-09 -2.20 1.20E-02 -1.15 6.86E-01 1.02 5.75E-03 -1.17 
MAML1 2.20E-08 -2.33 1.81E-09 -2.93 1.43E-08 -2.42 5.35E-01 1.04 5.71E-03 -1.21 1.88E-03 1.25 
MAP1B 1.14E-06 -2.22 1.13E-06 -2.23 2.36E-06 -2.10 4.79E-01 -1.06 4.69E-01 -1.06 9.86E-01 1.00 
MAPK7 8.35E-05 -2.16 5.76E-05 -2.23 3.58E-05 -2.33 5.24E-01 1.08 7.15E-01 1.05 7.82E-01 1.03 
MAST4 3.39E-09 -2.88 1.62E-08 -2.49 1.22E-08 -2.55 6.33E-02 -1.13 6.72E-01 1.03 2.95E-02 -1.16 
MBTPS2 6.00E-08 -2.11 6.05E-08 -2.11 7.46E-08 -2.08 7.79E-01 -1.02 7.87E-01 -1.02 9.91E-01 -1.00 
MEX3A 5.08E-08 -2.45 5.81E-08 -2.42 4.14E-07 -2.08 2.47E-02 -1.18 3.41E-02 -1.17 8.60E-01 -1.01 
MGRN1 1.17E-05 -3.51 2.20E-06 -4.46 4.70E-06 -3.98 4.28E-01 1.14 4.81E-01 -1.12 1.49E-01 1.27 
MIR3682 1.33E-05 -3.68 1.68E-05 -3.56 1.58E-05 -3.60 8.85E-01 -1.02 9.57E-01 1.01 8.42E-01 -1.03 
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MIR4435-1HG 2.90E-07 -2.09 1.00E-05 -1.67 1.68E-07 -2.18 5.27E-01 1.04 1.37E-03 1.30 4.20E-03 -1.25 
MYO10 3.28E-09 -5.42 4.85E-09 -5.10 2.47E-08 -4.04 8.83E-03 -1.34 2.88E-02 -1.26 5.22E-01 -1.06 
NDST1 1.68E-07 -3.52 1.85E-07 -3.48 1.10E-06 -2.84 5.72E-02 -1.24 7.00E-02 -1.22 9.09E-01 -1.01 
NFAT5 2.26E-09 -2.99 2.43E-08 -2.40 6.96E-09 -2.68 8.46E-02 -1.12 8.32E-02 1.12 2.94E-03 -1.25 
NOTCH2NL 3.51E-07 -2.53 2.94E-07 -2.58 4.90E-07 -2.46 7.12E-01 -1.03 5.71E-01 -1.05 8.41E-01 1.02 
NOTCH3 1.40E-06 -5.14 1.22E-05 -3.70 1.19E-06 -5.28 8.70E-01 1.03 4.91E-02 1.43 6.58E-02 -1.39 
NOTCH4 7.59E-09 -7.63 6.07E-09 -7.97 8.80E-08 -4.99 4.79E-03 -1.53 2.56E-03 -1.60 7.26E-01 1.04 
NOVA1 8.17E-06 -2.08 6.87E-07 -2.58 4.85E-06 -2.17 6.44E-01 1.04 7.51E-02 -1.19 3.28E-02 1.24 
NR2C2 7.83E-10 -2.20 2.00E-09 -2.06 8.04E-10 -2.20 9.59E-01 -1.00 1.17E-01 1.07 1.07E-01 -1.07 
OAS3 5.69E-06 -2.94 4.89E-07 -3.99 5.12E-06 -2.97 9.23E-01 1.01 3.58E-02 -1.34 3.01E-02 1.36 
OGFRL1 2.05E-07 -3.04 1.40E-07 -3.17 5.59E-07 -2.74 2.71E-01 -1.11 1.34E-01 -1.16 6.55E-01 1.04 
OLFML1 9.37E-06 -3.16 1.90E-06 -3.89 1.20E-05 -3.07 8.31E-01 -1.03 1.13E-01 -1.27 1.61E-01 1.23 
OLFML2B 3.73E-07 -7.42 1.36E-07 -9.15 5.78E-07 -6.82 6.33E-01 -1.09 1.17E-01 -1.34 2.53E-01 1.23 
PABPC1P3 3.16E-05 -2.49 3.63E-06 -3.16 3.43E-05 -2.47 9.48E-01 -1.01 7.55E-02 -1.28 8.45E-02 1.27 
PABPC1P4 1.35E-06 -2.46 1.26E-07 -3.13 6.68E-07 -2.63 4.72E-01 1.07 7.76E-02 -1.19 2.10E-02 1.27 
PABPC3 3.56E-07 -2.76 2.37E-07 -2.88 2.11E-06 -2.34 8.34E-02 -1.18 3.67E-02 -1.23 6.45E-01 1.04 
PAK2 8.71E-10 -2.21 5.76E-10 -2.28 1.40E-09 -2.14 3.87E-01 -1.04 1.15E-01 -1.07 4.34E-01 1.03 
PCBP2 7.87E-09 -2.90 3.51E-09 -3.15 6.72E-09 -2.94 8.05E-01 1.02 3.05E-01 -1.07 2.11E-01 1.09 
PCDHB13 2.24E-06 -3.00 8.44E-07 -3.36 9.55E-07 -3.31 4.02E-01 1.10 8.98E-01 -1.02 3.38E-01 1.12 
PCDHB16 4.14E-07 -3.28 1.78E-07 -3.64 4.14E-07 -3.28 9.98E-01 -1.00 3.43E-01 -1.11 3.44E-01 1.11 
PCDHB9 4.95E-06 -3.11 5.90E-06 -3.05 6.17E-06 -3.03 8.44E-01 -1.03 9.69E-01 -1.01 8.75E-01 -1.02 
PCDHGB7 1.29E-05 -2.60 2.96E-05 -2.39 3.84E-05 -2.34 3.85E-01 -1.11 8.39E-01 -1.02 5.00E-01 -1.09 
PCGF2 9.19E-05 -2.60 1.95E-05 -3.12 5.22E-05 -2.77 6.74E-01 1.07 4.43E-01 -1.12 2.45E-01 1.20 
PDK4 2.74E-05 -3.28 1.34E-04 -2.69 1.22E-04 -2.72 2.72E-01 -1.20 9.44E-01 1.01 2.45E-01 -1.22 
PEAK1 1.55E-09 -3.42 1.82E-08 -2.65 7.44E-09 -2.89 2.14E-02 -1.18 1.97E-01 1.09 1.90E-03 -1.29 
PEAR1 3.00E-06 -3.52 3.25E-07 -4.83 1.37E-06 -3.91 4.51E-01 1.11 1.45E-01 -1.23 3.84E-02 1.37 
PIP5K1C 1.00E-07 -4.07 6.68E-08 -4.31 1.30E-07 -3.93 7.48E-01 -1.04 4.08E-01 -1.10 6.06E-01 1.06 
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PLEKHH2 1.61E-07 -3.72 1.26E-07 -3.84 1.12E-06 -2.95 5.03E-02 -1.26 2.91E-02 -1.30 7.63E-01 1.03 
PLXNA2 1.22E-07 -2.94 3.02E-08 -3.44 1.16E-07 -2.96 9.50E-01 1.01 9.96E-02 -1.16 8.94E-02 1.17 
PREX2 8.73E-07 -6.91 2.13E-06 -5.85 1.86E-06 -5.99 4.51E-01 -1.15 8.96E-01 1.02 3.79E-01 -1.18 
PRKD2 5.25E-07 -2.66 2.50E-07 -2.87 2.12E-06 -2.34 1.70E-01 -1.14 4.08E-02 -1.23 4.14E-01 1.08 
PRRC2C 8.01E-09 -2.48 2.98E-08 -2.23 3.00E-08 -2.23 7.31E-02 -1.11 9.89E-01 -1.00 7.48E-02 -1.11 
PTPN12 2.19E-09 -2.77 7.22E-09 -2.49 7.22E-09 -2.49 6.93E-02 -1.11 1.00E+00 1.00 6.93E-02 -1.11 
RAB11B 1.28E-05 -2.31 1.22E-06 -2.91 6.33E-06 -2.46 5.45E-01 1.07 1.37E-01 -1.18 4.79E-02 1.26 
RBM33 5.35E-07 -2.43 6.97E-06 -1.98 8.38E-07 -2.33 6.35E-01 -1.04 6.12E-02 1.18 2.59E-02 -1.23 
RBMS2 1.44E-09 -3.06 9.96E-10 -3.19 5.80E-10 -3.38 1.08E-01 1.10 3.13E-01 1.06 5.01E-01 1.04 
RFX7 9.33E-08 -2.85 3.01E-07 -2.54 5.71E-07 -2.40 5.38E-02 -1.19 4.84E-01 -1.06 1.79E-01 -1.12 
RGMB 1.11E-08 -3.31 4.29E-09 -3.71 4.94E-08 -2.82 5.38E-02 -1.17 3.56E-03 -1.31 1.54E-01 1.12 
RMI1 9.81E-08 -3.02 8.09E-08 -3.08 9.34E-07 -2.42 2.35E-02 -1.25 1.51E-02 -1.27 8.08E-01 1.02 
RNF152 1.41E-07 -3.78 5.99E-07 -3.17 8.94E-07 -3.03 5.72E-02 -1.25 6.73E-01 -1.05 1.19E-01 -1.19 
RP11-175O19.4 6.00E-07 -2.36 1.09E-05 -1.89 7.46E-07 -2.31 8.16E-01 -1.02 2.43E-02 1.22 1.59E-02 -1.25 
RP11-214K3.21 2.40E-05 -3.94 1.86E-04 -2.96 1.25E-04 -3.12 2.26E-01 -1.26 7.76E-01 1.05 1.44E-01 -1.33 
RP11-252A24.7 1.59E-05 -2.24 3.97E-06 -2.54 6.65E-06 -2.42 4.59E-01 1.08 6.43E-01 -1.05 2.39E-01 1.14 
RP11-575G13.2 3.09E-05 -4.09 7.18E-06 -5.19 3.51E-05 -4.00 9.19E-01 -1.02 2.04E-01 -1.30 2.39E-01 1.27 
RP11-690G19.3 1.35E-06 -2.52 7.23E-07 -2.68 4.10E-06 -2.28 2.97E-01 -1.10 1.07E-01 -1.17 5.23E-01 1.06 
RP11-720L2.3 2.86E-05 -3.85 2.01E-05 -4.06 6.47E-05 -3.42 5.32E-01 -1.13 3.70E-01 -1.19 7.76E-01 1.05 
RP11-730G20.2 2.20E-07 -2.63 7.72E-08 -2.91 3.34E-07 -2.53 6.32E-01 -1.04 9.94E-02 -1.15 2.18E-01 1.11 
RP11-73M18.8 2.46E-05 -2.85 9.20E-05 -2.47 7.90E-05 -2.51 3.76E-01 -1.14 9.11E-01 1.02 3.22E-01 -1.16 
RP11-91J3.1 2.47E-05 -5.24 3.35E-05 -4.97 6.68E-05 -4.40 4.47E-01 -1.19 5.99E-01 -1.13 8.09E-01 -1.06 
RPS6KA2 5.09E-08 -2.80 7.77E-09 -3.43 9.33E-08 -2.64 4.41E-01 -1.06 4.48E-03 -1.30 1.86E-02 1.22 
SCN7A 4.82E-07 -9.97 3.14E-08 -20.10 2.94E-07 -11.19 5.83E-01 1.12 1.52E-02 -1.80 5.54E-03 2.02 
SCUBE2 1.64E-05 -2.40 7.91E-06 -2.57 2.02E-05 -2.35 8.63E-01 -1.02 4.35E-01 -1.09 5.39E-01 1.07 
SEMA5A 1.29E-06 -2.29 3.70E-05 -1.79 1.01E-06 -2.34 8.02E-01 1.02 6.97E-03 1.31 1.10E-02 -1.28 
SETBP1 8.19E-07 -2.23 1.06E-06 -2.19 7.73E-07 -2.24 9.51E-01 1.00 7.46E-01 1.03 7.92E-01 -1.02 
303 
 
SETD5 1.42E-06 -2.42 1.09E-06 -2.48 1.51E-06 -2.41 9.46E-01 -1.01 7.43E-01 -1.03 7.94E-01 1.02 
SFRP2 6.16E-08 -5.11 1.97E-07 -4.29 7.76E-08 -4.93 7.65E-01 -1.04 2.68E-01 1.15 1.69E-01 -1.19 
SH3D19 2.09E-06 -2.65 1.11E-05 -2.26 6.33E-06 -2.38 3.15E-01 -1.11 6.24E-01 1.05 1.48E-01 -1.17 
SHANK3 1.92E-07 -6.09 9.43E-08 -6.93 1.80E-07 -6.16 9.42E-01 1.01 4.36E-01 -1.13 3.96E-01 1.14 
SKI 7.31E-07 -4.34 1.40E-07 -5.63 3.54E-07 -4.84 4.37E-01 1.12 2.90E-01 -1.16 8.15E-02 1.30 
SLC26A7 1.36E-06 -9.33 6.88E-06 -6.61 6.48E-06 -6.69 1.59E-01 -1.39 9.58E-01 1.01 1.46E-01 -1.41 
SNX29 5.87E-08 -2.00 7.50E-09 -2.33 2.73E-08 -2.11 3.14E-01 1.05 7.69E-02 -1.10 1.19E-02 1.16 
SRRM1 4.16E-06 -1.99 2.68E-05 -1.76 1.98E-06 -2.10 4.88E-01 1.06 3.84E-02 1.20 1.31E-01 -1.13 
SYVN1 1.66E-08 -4.16 1.25E-08 -4.33 2.19E-08 -4.01 6.94E-01 -1.04 4.21E-01 -1.08 6.74E-01 1.04 
TAF1C 9.15E-06 -2.41 5.07E-06 -2.55 1.59E-05 -2.29 6.40E-01 -1.05 3.32E-01 -1.11 6.04E-01 1.06 
TATDN2 1.92E-09 -2.50 1.54E-09 -2.54 1.72E-08 -2.10 4.22E-03 -1.19 2.12E-03 -1.21 6.99E-01 1.02 
TET3 6.27E-09 -3.65 4.79E-09 -3.77 4.03E-08 -2.96 1.77E-02 -1.23 8.02E-03 -1.28 6.65E-01 1.03 
TGFB1 4.99E-05 -2.17 3.54E-06 -2.81 2.41E-05 -2.32 5.71E-01 1.07 1.17E-01 -1.21 4.33E-02 1.29 
TIAL1 2.12E-08 -2.59 4.76E-08 -2.41 2.19E-08 -2.58 9.64E-01 -1.00 2.97E-01 1.07 2.78E-01 -1.07 
TMEM131 8.52E-08 -2.17 4.34E-08 -2.28 6.05E-08 -2.22 6.61E-01 1.03 6.62E-01 -1.03 3.88E-01 1.05 
TTYH3 1.11E-05 -3.10 7.88E-06 -3.23 6.38E-06 -3.32 6.32E-01 1.07 8.52E-01 1.03 7.69E-01 1.04 
UBN2 1.34E-06 -2.22 2.37E-05 -1.81 1.05E-06 -2.27 8.08E-01 1.02 1.45E-02 1.26 2.26E-02 -1.23 
ULK1 2.99E-06 -3.34 4.38E-07 -4.33 1.22E-06 -3.75 3.87E-01 1.12 2.92E-01 -1.15 7.01E-02 1.29 
USP42 1.02E-08 -2.23 1.66E-09 -2.59 4.73E-09 -2.37 2.41E-01 1.06 9.63E-02 -1.09 1.09E-02 1.16 
WDR26 1.48E-08 -2.35 8.86E-08 -2.06 4.19E-08 -2.17 1.63E-01 -1.08 3.39E-01 1.06 2.98E-02 -1.14 
WNK1 1.07E-08 -2.69 4.98E-08 -2.35 2.01E-08 -2.54 3.64E-01 -1.06 2.27E-01 1.08 4.78E-02 -1.14 
WWC3 5.70E-08 -2.75 5.66E-08 -2.75 3.32E-07 -2.34 5.07E-02 -1.17 4.98E-02 -1.17 9.92E-01 1.00 
ZFP36L1 4.63E-08 -3.78 2.09E-08 -4.20 9.10E-08 -3.47 3.90E-01 -1.09 6.85E-02 -1.21 2.85E-01 1.11 
ZFPM1 7.54E-07 -3.29 1.07E-06 -3.16 1.03E-06 -3.17 7.50E-01 -1.04 9.63E-01 1.01 7.15E-01 -1.04 
ZNF154 3.15E-05 -2.36 1.79E-04 -2.02 4.67E-05 -2.28 7.60E-01 -1.04 3.34E-01 1.13 2.13E-01 -1.17 
ZNF318 1.72E-07 -2.01 8.42E-08 -2.11 1.44E-07 -2.03 8.27E-01 1.01 5.12E-01 -1.04 3.87E-01 1.05 
ZNF37BP 4.44E-06 -2.61 5.32E-05 -2.08 1.32E-05 -2.35 3.50E-01 -1.11 2.77E-01 1.13 5.76E-02 -1.25 
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MMP3 7.95E-07 96.25 4.85E-05 19.29 5.96E-03 4.77 2.12E-05 20.17 7.35E-03 4.04 3.08E-03 4.99 
HSPA6 3.13E-08 69.84 4.56E-08 60.08 1.35E-02 2.50 1.74E-07 27.95 2.79E-07 24.04 6.12E-01 1.16 
SLC16A6 1.68E-06 50.71 1.88E-04 10.41 1.71E-02 3.31 2.54E-05 15.32 1.43E-02 3.15 2.05E-03 4.87 
AIM1L 8.30E-08 43.04 1.02E-05 10.13 1.44E-04 5.59 1.61E-05 7.70 5.81E-02 1.81 3.18E-04 4.25 
NLGN4Y 1.81E-09 36.83 1.42E-08 19.46 6.90E-06 4.99 3.80E-07 7.38 1.59E-05 3.90 5.82E-03 1.89 
CLDN6 3.83E-08 32.62 1.14E-06 12.16 7.57E-04 3.33 1.29E-06 9.81 2.27E-04 3.66 1.80E-03 2.68 
IL1RN 2.39E-06 31.82 5.75E-04 6.43 1.25E-02 3.19 5.27E-05 9.96 7.85E-02 2.01 1.00E-03 4.95 
EREG 4.61E-11 31.19 2.06E-09 11.20 3.22E-07 4.43 8.71E-09 7.04 1.51E-05 2.53 5.99E-06 2.78 
CTSF 2.10E-10 28.11 4.82E-09 12.05 1.75E-06 4.06 3.05E-08 6.92 9.66E-06 2.97 9.17E-05 2.33 
KIRREL3 2.60E-07 27.93 1.17E-05 9.56 6.87E-04 4.06 2.45E-05 6.88 1.04E-02 2.36 2.66E-03 2.92 
INSC 2.12E-06 26.96 7.34E-05 9.48 2.08E-02 2.69 2.96E-05 10.04 3.39E-03 3.53 1.05E-02 2.84 
ANKRD66 2.05E-06 26.72 6.58E-04 5.52 3.43E-02 2.41 1.91E-05 11.08 3.17E-02 2.29 6.78E-04 4.84 
HNRNPA1P45 8.74E-07 26.67 3.05E-04 5.63 3.91E-04 5.34 2.94E-04 4.99 8.68E-01 1.05 3.84E-04 4.74 
HNF4A 1.72E-05 26.09 4.57E-04 9.25 1.84E-02 3.49 5.49E-04 7.47 4.01E-02 2.65 3.07E-02 2.82 
CRHBP 8.60E-10 25.57 5.28E-08 8.98 7.68E-05 2.81 2.23E-08 9.09 1.36E-05 3.19 3.51E-05 2.85 
ZNF667-AS1 9.28E-06 24.69 3.42E-04 8.35 4.54E-03 4.38 9.17E-04 5.63 1.22E-01 1.91 1.68E-02 2.96 
ZFP28 3.70E-06 23.76 8.37E-05 9.54 7.04E-03 3.43 1.60E-04 6.93 1.29E-02 2.78 2.30E-02 2.49 
PRKY 1.84E-06 23.51 1.54E-05 12.52 4.43E-03 3.44 8.90E-05 6.84 1.96E-03 3.64 7.50E-02 1.88 
KRT42P 6.19E-06 23.51 4.30E-04 7.00 1.20E-02 3.25 2.03E-04 7.23 5.86E-02 2.15 6.66E-03 3.36 
RP11-744K17.9 7.88E-06 23.39 3.91E-04 7.51 2.08E-02 2.96 1.70E-04 7.91 2.91E-02 2.54 1.10E-02 3.11 
FRG1B 1.81E-06 22.51 4.32E-05 9.23 3.49E-03 3.53 1.08E-04 6.37 1.12E-02 2.61 1.65E-02 2.44 
ZNF229 2.40E-08 21.36 2.90E-07 11.07 3.09E-04 3.10 1.22E-06 6.88 6.11E-05 3.57 7.89E-03 1.93 
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HECW1 2.81E-05 21.14 3.68E-04 9.55 6.86E-02 2.46 2.91E-04 8.59 7.31E-03 3.88 8.04E-02 2.22 
ZNF506 2.95E-05 20.61 1.30E-04 12.86 1.62E-02 3.53 1.30E-03 5.83 9.48E-03 3.64 2.77E-01 1.60 
GRK1 7.42E-06 20.59 1.29E-03 5.17 6.05E-03 3.66 4.98E-04 5.62 3.53E-01 1.41 2.49E-03 3.98 
KRBOX1 3.80E-06 20.37 7.47E-04 5.17 1.77E-02 2.70 7.35E-05 7.56 7.38E-02 1.92 1.59E-03 3.94 
COL26A1 2.49E-08 20.25 7.78E-07 8.58 2.54E-05 4.45 1.10E-05 4.55 7.38E-03 1.93 1.27E-03 2.36 
CAT 2.18E-08 20.21 1.38E-07 12.38 1.80E-04 3.25 1.58E-06 6.23 3.03E-05 3.81 3.04E-02 1.63 
AC006262.6 9.48E-06 20.19 3.42E-04 7.34 7.21E-03 3.62 5.95E-04 5.58 7.59E-02 2.03 1.74E-02 2.75 
SHD 6.97E-06 19.95 1.38E-04 8.57 2.50E-03 4.34 1.11E-03 4.60 7.68E-02 1.98 3.39E-02 2.33 
GRIA1 4.73E-08 19.67 2.20E-06 7.67 5.46E-04 2.99 2.22E-06 6.59 9.35E-04 2.57 9.46E-04 2.56 
TRIM4 8.74E-06 19.53 2.87E-04 7.38 2.55E-02 2.69 1.62E-04 7.26 1.59E-02 2.74 1.91E-02 2.65 
TMCO5B 3.24E-06 19.51 3.36E-05 10.11 2.72E-03 3.77 3.22E-04 5.17 1.04E-02 2.68 6.42E-02 1.93 
KDM5D 2.78E-09 19.45 1.47E-08 12.64 1.21E-04 2.73 9.39E-08 7.13 1.15E-06 4.63 2.10E-02 1.54 
CAMKV 3.41E-06 19.29 5.35E-05 9.02 3.03E-03 3.70 3.13E-04 5.22 1.77E-02 2.44 3.69E-02 2.14 
LYPD4 6.80E-06 19.18 5.31E-04 5.99 1.05E-02 3.13 2.60E-04 6.13 8.55E-02 1.91 6.01E-03 3.20 
RP11-329E24.6 2.64E-06 19.18 4.34E-04 5.28 3.65E-03 3.44 1.80E-04 5.57 1.96E-01 1.54 1.63E-03 3.63 
FGF10-AS1 2.91E-06 19.16 1.45E-05 12.12 4.22E-03 3.39 1.82E-04 5.66 1.89E-03 3.58 1.73E-01 1.58 
ZNF558 2.72E-07 18.91 3.31E-06 9.83 3.50E-03 2.68 7.08E-06 7.06 2.61E-04 3.67 2.24E-02 1.92 
LINC00839 1.66E-07 18.70 6.13E-06 7.64 9.34E-04 3.10 9.54E-06 6.03 2.65E-03 2.47 2.82E-03 2.45 
AC008132.13 7.69E-07 18.60 1.44E-04 5.28 9.67E-03 2.50 1.39E-05 7.43 1.89E-02 2.11 7.24E-04 3.52 
GDF2 6.08E-07 17.54 2.59E-04 4.41 4.81E-03 2.69 1.72E-05 6.53 8.29E-02 1.64 2.50E-04 3.98 
TRH 9.52E-09 17.46 1.15E-06 6.01 2.09E-03 2.12 1.01E-07 8.25 8.76E-05 2.84 7.22E-05 2.91 
SIGLEC9 9.41E-07 16.89 4.98E-05 6.41 1.27E-02 2.36 1.48E-05 7.15 3.38E-03 2.71 4.07E-03 2.64 
RP11-258B16.1 4.69E-07 16.70 1.14E-04 4.80 1.21E-03 3.20 3.71E-05 5.22 1.32E-01 1.50 4.00E-04 3.48 
TFAP2C 1.15E-05 16.33 5.34E-04 5.98 7.06E-02 2.10 9.26E-05 7.78 1.11E-02 2.85 1.37E-02 2.73 
RP11-388N2.1 5.09E-06 16.02 6.09E-05 8.31 2.58E-02 2.39 7.86E-05 6.71 2.12E-03 3.48 5.98E-02 1.93 
AOC4P 1.11E-05 15.87 1.22E-04 8.28 1.12E-02 3.04 4.85E-04 5.22 1.30E-02 2.72 8.08E-02 1.92 
LINC00955 1.74E-05 15.33 3.78E-03 3.99 2.51E-02 2.67 4.11E-04 5.75 2.74E-01 1.50 2.77E-03 3.84 
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DMBX1 2.21E-05 15.30 3.88E-04 7.05 6.80E-02 2.20 2.18E-04 6.97 7.87E-03 3.21 5.41E-02 2.17 
RP1-29C18.8 1.80E-05 15.26 1.12E-03 5.25 3.75E-02 2.45 2.94E-04 6.22 5.34E-02 2.14 1.13E-02 2.91 
C9orf117 4.25E-07 15.23 1.45E-05 6.65 1.53E-03 2.94 2.61E-05 5.18 5.73E-03 2.26 5.19E-03 2.29 
RGS13 4.39E-08 15.14 4.59E-06 5.53 3.82E-03 2.12 5.49E-07 7.14 3.89E-04 2.61 2.61E-04 2.74 
SSX5 1.36E-05 15.08 5.88E-04 5.73 3.80E-02 2.37 2.02E-04 6.35 2.48E-02 2.42 1.59E-02 2.63 
KRT14 1.11E-05 14.83 2.52E-04 6.62 2.94E-03 3.88 1.87E-03 3.82 1.33E-01 1.71 3.27E-02 2.24 
SLC2A2 1.37E-05 14.73 3.00E-05 11.81 1.73E-02 2.77 4.26E-04 5.32 1.24E-03 4.27 5.25E-01 1.25 
ZNF562 8.73E-09 14.54 4.64E-08 9.80 4.77E-05 3.07 1.05E-06 4.74 1.74E-05 3.19 3.22E-02 1.48 
TYW3 3.12E-06 14.46 1.89E-05 9.09 9.69E-03 2.63 9.46E-05 5.51 1.18E-03 3.46 1.33E-01 1.59 
FOLR2 2.36E-06 14.29 1.75E-04 5.25 1.85E-02 2.29 3.77E-05 6.25 1.21E-02 2.30 4.04E-03 2.72 
QPCT 2.80E-06 14.21 2.95E-05 7.89 6.04E-03 2.80 1.24E-04 5.08 3.60E-03 2.82 6.04E-02 1.80 
HSD3BP2 5.31E-06 13.81 1.52E-04 6.11 2.01E-02 2.39 1.04E-04 5.77 9.21E-03 2.55 1.91E-02 2.26 
ZNF667 1.96E-05 13.76 1.13E-03 4.99 7.20E-02 2.08 1.77E-04 6.61 2.65E-02 2.40 1.27E-02 2.76 
RP11-1018N14.2 3.44E-07 13.64 1.47E-04 3.94 6.95E-03 2.23 5.94E-06 6.12 2.76E-02 1.77 1.75E-04 3.46 
STAU2-AS1 8.56E-06 13.63 1.67E-04 6.50 4.21E-02 2.16 1.01E-04 6.30 4.68E-03 3.00 3.65E-02 2.10 
HOXA11-AS 6.65E-06 13.53 1.44E-04 6.36 8.38E-03 2.85 3.12E-04 4.76 2.20E-02 2.24 2.96E-02 2.13 
AC005077.12 1.53E-05 13.53 1.64E-04 7.32 5.22E-03 3.45 1.64E-03 3.92 4.34E-02 2.12 8.98E-02 1.85 
RP11-66B24.2 2.79E-05 13.47 5.46E-04 6.22 6.64E-02 2.17 2.99E-04 6.21 1.22E-02 2.87 5.03E-02 2.17 
CRYZ 2.84E-07 13.43 4.73E-06 7.06 7.86E-03 2.15 4.20E-06 6.24 2.05E-04 3.28 1.35E-02 1.90 
RP11-521O16.2 5.04E-06 13.27 2.13E-04 5.49 9.19E-03 2.70 1.94E-04 4.92 3.28E-02 2.03 1.14E-02 2.42 
AQP8 3.28E-06 13.00 2.57E-04 4.85 8.24E-03 2.61 1.17E-04 4.98 4.68E-02 1.86 4.38E-03 2.68 
HOXA10 1.90E-07 12.86 5.87E-07 9.82 2.43E-03 2.39 5.59E-06 5.37 2.84E-05 4.10 2.19E-01 1.31 
ALOX5 8.53E-06 12.74 7.73E-04 4.50 1.98E-03 3.74 1.92E-03 3.41 5.55E-01 1.20 5.54E-03 2.83 
RP11-423G4.7 2.17E-07 12.67 8.59E-05 3.88 2.19E-03 2.44 7.29E-06 5.19 4.84E-02 1.59 1.41E-04 3.27 
STC1 1.84E-07 12.62 6.71E-06 5.83 2.44E-04 3.24 3.63E-05 3.89 1.53E-02 1.80 3.06E-03 2.17 
TUSC5 8.44E-06 12.50 5.96E-05 7.68 4.69E-03 3.14 7.71E-04 3.97 1.27E-02 2.44 1.33E-01 1.63 
CPNE7 6.58E-06 12.45 2.73E-04 5.24 5.03E-03 3.01 5.02E-04 4.13 8.44E-02 1.74 1.29E-02 2.38 
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LYZL4 5.84E-06 12.15 4.67E-04 4.54 5.26E-03 2.92 4.04E-04 4.17 1.49E-01 1.56 5.48E-03 2.67 
AC092071.1 3.19E-05 11.67 3.61E-04 6.35 6.05E-02 2.14 3.89E-04 5.45 8.21E-03 2.96 9.83E-02 1.84 
FOXQ1 3.12E-05 11.55 5.64E-04 5.66 6.45E-02 2.10 3.54E-04 5.49 1.31E-02 2.69 5.68E-02 2.04 
HOXA11 1.16E-07 11.47 3.13E-06 5.78 3.62E-03 2.11 2.11E-06 5.43 2.33E-04 2.74 3.89E-03 1.98 
APOA2 1.51E-05 11.40 2.33E-03 3.70 1.61E-02 2.57 5.21E-04 4.43 2.61E-01 1.44 3.80E-03 3.08 
DLX6 1.80E-05 11.03 9.51E-05 7.33 9.25E-03 2.87 1.15E-03 3.85 1.14E-02 2.56 2.13E-01 1.51 
ZNF680 6.16E-06 10.68 6.38E-05 6.27 2.13E-02 2.20 1.20E-04 4.85 2.76E-03 2.84 7.61E-02 1.70 
GPR128 1.95E-09 10.67 1.54E-08 7.02 1.06E-04 2.20 6.07E-08 4.86 1.38E-06 3.20 6.07E-03 1.52 
FGFBP1 1.37E-05 10.66 1.80E-03 3.70 3.31E-02 2.18 2.31E-04 4.89 1.02E-01 1.70 4.37E-03 2.88 
VAC14-AS1 1.05E-05 10.62 5.38E-04 4.46 9.93E-03 2.63 5.04E-04 4.04 9.21E-02 1.70 1.18E-02 2.38 
UBTFL8 1.15E-05 10.47 2.08E-03 3.48 4.00E-02 2.07 1.56E-04 5.07 9.79E-02 1.69 2.89E-03 3.01 
CTC-559E9.5 1.25E-05 10.29 2.12E-04 5.42 9.22E-03 2.67 6.90E-04 3.85 3.26E-02 2.03 4.84E-02 1.90 
FSTL5 4.16E-06 10.29 1.64E-05 7.51 2.36E-02 2.07 6.49E-05 4.96 4.03E-04 3.62 2.46E-01 1.37 
RP11-343H19.1 1.18E-07 10.23 1.08E-05 4.36 5.68E-05 3.41 7.51E-05 3.00 1.98E-01 1.28 6.00E-04 2.35 
BTBD7P1 9.64E-07 10.15 1.75E-04 3.74 1.73E-03 2.66 7.97E-05 3.82 1.51E-01 1.41 8.52E-04 2.72 
KRT222 3.38E-07 10.09 1.52E-04 3.34 1.07E-04 3.51 2.41E-04 2.87 8.01E-01 -1.05 1.63E-04 3.02 
CCDC60 6.50E-06 10.08 3.72E-04 4.30 8.51E-03 2.52 2.98E-04 4.01 7.06E-02 1.71 8.59E-03 2.35 
RP11-311F12.1 1.10E-05 10.03 3.56E-04 4.69 3.27E-02 2.10 1.75E-04 4.77 1.59E-02 2.23 2.08E-02 2.14 
PRSS21 1.92E-05 10.03 2.63E-04 5.50 1.55E-02 2.52 7.50E-04 3.98 2.44E-02 2.18 7.02E-02 1.82 
SIGLEC11 6.90E-06 9.91 1.53E-04 5.07 6.03E-03 2.66 4.50E-04 3.73 3.41E-02 1.91 2.89E-02 1.95 
RPL7P38 1.18E-05 9.89 1.21E-03 3.74 7.12E-03 2.73 8.26E-04 3.62 2.91E-01 1.37 5.48E-03 2.64 
RP11-399K21.11 1.25E-05 9.88 2.86E-04 4.96 2.62E-02 2.20 2.55E-04 4.49 1.54E-02 2.26 3.35E-02 1.99 
TPM3P1 6.64E-07 9.41 2.70E-05 4.59 6.01E-03 2.12 1.64E-05 4.44 3.18E-03 2.16 4.98E-03 2.05 
CTC-378H22.2 3.89E-06 9.85 7.15E-05 5.30 1.92E-03 2.99 6.02E-04 3.29 4.39E-02 1.77 3.10E-02 1.86 
AP1M2 1.11E-05 9.84 6.68E-04 4.12 5.02E-03 2.87 1.07E-03 3.42 2.25E-01 1.43 9.88E-03 2.39 
PRODH 1.50E-06 9.72 5.59E-04 3.22 1.15E-03 2.90 2.33E-04 3.36 6.44E-01 1.11 4.88E-04 3.01 
AC113167.2 1.44E-06 9.71 1.85E-04 3.81 8.01E-03 2.19 3.81E-05 4.43 3.18E-02 1.74 1.61E-03 2.55 
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RP11-60L3.1 1.40E-08 9.54 3.65E-07 5.18 1.80E-05 3.01 5.62E-06 3.17 2.78E-03 1.72 1.27E-03 1.84 
RP11-930P14.1 5.85E-06 9.51 4.66E-04 3.92 5.08E-03 2.64 4.18E-04 3.60 1.53E-01 1.48 5.51E-03 2.43 
CTD-2337J16.1 5.63E-06 9.39 2.43E-04 4.34 1.24E-02 2.28 1.72E-04 4.13 2.81E-02 1.91 1.15E-02 2.16 
ADIRF 4.22E-06 9.31 3.46E-05 5.93 1.38E-02 2.18 1.06E-04 4.27 1.90E-03 2.72 9.48E-02 1.57 
LRRC15 2.05E-06 9.28 9.55E-04 3.01 1.15E-03 2.93 3.77E-04 3.17 9.08E-01 1.03 4.55E-04 3.08 
AC007403.3 1.75E-06 9.16 7.96E-05 4.34 2.79E-03 2.52 1.25E-04 3.63 3.34E-02 1.72 6.64E-03 2.11 
COMT 6.11E-08 9.09 1.87E-06 4.82 4.37E-04 2.35 3.86E-06 3.87 9.13E-04 2.05 2.23E-03 1.88 
ANGPT4 5.93E-06 9.01 5.27E-04 3.72 1.54E-02 2.18 1.52E-04 4.13 5.70E-02 1.71 4.87E-03 2.42 
TUBBP5 8.38E-06 8.85 1.59E-03 3.20 4.00E-03 2.76 8.99E-04 3.21 5.75E-01 1.16 2.38E-03 2.76 
CTSV 1.61E-09 8.73 4.40E-07 3.54 1.05E-06 3.19 1.95E-06 2.74 3.63E-01 1.11 5.69E-06 2.47 
HOXD10 1.92E-05 8.69 7.74E-05 6.36 3.00E-02 2.13 3.96E-04 4.08 2.48E-03 2.99 2.90E-01 1.37 
AP000696.2 1.87E-05 8.61 4.09E-03 2.97 4.00E-02 2.02 2.91E-04 4.27 1.93E-01 1.47 2.84E-03 2.90 
RP11-382E9.1 2.10E-05 8.45 9.84E-04 3.84 3.05E-02 2.12 4.40E-04 3.99 5.72E-02 1.81 1.67E-02 2.20 
BX255923.3 6.14E-06 8.31 3.18E-04 3.88 1.31E-02 2.18 1.85E-04 3.82 3.71E-02 1.78 9.52E-03 2.14 
CTC-327F10.1 1.33E-05 8.25 2.03E-03 3.13 2.53E-02 2.09 2.86E-04 3.95 1.51E-01 1.50 3.66E-03 2.63 
S100A6 1.26E-08 8.13 1.65E-07 5.13 4.17E-05 2.52 2.14E-06 3.23 1.97E-04 2.04 4.83E-03 1.58 
TMEM179 1.28E-06 7.96 4.83E-04 2.92 5.81E-03 2.11 4.23E-05 3.77 1.40E-01 1.38 4.41E-04 2.73 
RP11-909M7.3 6.35E-07 7.94 1.71E-05 4.37 1.74E-03 2.31 4.23E-05 3.44 6.31E-03 1.89 8.95E-03 1.82 
ANKRD22 1.11E-05 7.89 1.39E-04 4.74 2.58E-02 2.02 2.21E-04 3.90 6.24E-03 2.35 6.88E-02 1.67 
PRSS33 3.87E-06 7.74 6.65E-04 3.11 4.84E-03 2.34 2.42E-04 3.30 2.32E-01 1.33 1.87E-03 2.49 
RP11-27M9.1 2.05E-06 7.21 3.91E-04 3.00 4.49E-04 2.94 1.03E-03 2.45 9.26E-01 1.02 1.20E-03 2.40 
CRABP1 1.06E-06 7.70 3.73E-05 4.06 2.16E-03 2.32 7.48E-05 3.32 1.55E-02 1.75 7.55E-03 1.90 
KB-1568E2.1 1.18E-05 7.70 6.97E-04 3.54 1.49E-02 2.19 4.04E-04 3.52 8.19E-02 1.62 1.04E-02 2.17 
CHRNA9 1.02E-06 7.67 9.92E-05 3.48 2.65E-03 2.25 5.95E-05 3.40 4.75E-02 1.54 1.90E-03 2.20 
CYP3A7 1.64E-05 7.65 2.59E-04 4.40 4.97E-03 2.67 1.92E-03 2.86 8.03E-02 1.65 5.72E-02 1.74 
AC079776.1 1.17E-07 7.49 9.37E-06 3.64 1.49E-04 2.58 2.77E-05 2.90 4.87E-02 1.41 7.26E-04 2.05 
LGI1 9.09E-06 7.48 1.52E-03 2.97 3.63E-03 2.61 1.12E-03 2.87 5.96E-01 1.14 2.82E-03 2.51 
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C1orf167 9.74E-06 7.43 4.47E-04 3.63 2.09E-02 2.02 2.25E-04 3.67 3.41E-02 1.80 1.31E-02 2.05 
RP11-492E3.2 1.05E-06 7.36 1.14E-04 3.34 1.50E-03 2.38 1.04E-04 3.09 1.05E-01 1.40 1.68E-03 2.20 
MEG9 5.20E-07 7.10 3.26E-04 2.64 1.34E-04 2.95 3.98E-04 2.40 5.40E-01 -1.12 1.51E-04 2.69 
KRT8P35 1.93E-05 7.01 2.91E-04 4.15 1.14E-02 2.29 1.03E-03 3.06 3.86E-02 1.81 6.27E-02 1.69 
PRR7-AS1 1.54E-05 6.89 3.34E-03 2.68 1.32E-02 2.18 6.50E-04 3.16 4.19E-01 1.23 2.65E-03 2.57 
AQP10 8.99E-07 6.87 9.11E-05 3.24 6.74E-04 2.51 1.75E-04 2.74 1.85E-01 1.29 1.68E-03 2.12 
ZBBX 9.07E-07 6.79 9.51E-05 3.20 3.02E-04 2.75 4.13E-04 2.46 4.22E-01 1.16 1.62E-03 2.12 
ADCY8 9.45E-07 6.61 5.31E-04 2.55 1.43E-03 2.26 9.20E-05 2.92 5.27E-01 1.12 2.43E-04 2.60 
RP11-460N16.1 2.39E-06 6.57 9.19E-06 5.13 3.00E-03 2.23 1.86E-04 2.94 1.38E-03 2.30 2.34E-01 1.28 
SORL1 1.31E-05 6.50 2.52E-03 2.66 1.65E-02 2.04 4.19E-04 3.19 2.75E-01 1.31 2.81E-03 2.44 
THPO 1.30E-05 6.45 2.76E-03 2.62 6.29E-03 2.33 1.08E-03 2.77 6.22E-01 1.13 2.54E-03 2.46 
GAS8 8.92E-06 6.42 1.10E-03 2.86 2.97E-03 2.49 1.34E-03 2.58 5.42E-01 1.15 3.93E-03 2.24 
AC006994.2 3.78E-06 6.37 1.65E-04 3.39 1.08E-03 2.61 1.06E-03 2.44 2.26E-01 1.30 9.74E-03 1.88 
RN7SL357P 4.84E-08 6.23 1.39E-06 3.72 2.09E-04 2.14 4.86E-06 2.92 1.30E-03 1.74 2.18E-03 1.67 
HSPA1A 7.69E-07 6.09 1.28E-04 2.84 2.62E-03 2.02 3.96E-05 3.02 6.64E-02 1.41 8.37E-04 2.15 
PDZD7 8.22E-06 5.96 3.05E-03 2.37 2.02E-03 2.51 1.78E-03 2.38 7.99E-01 -1.06 1.15E-03 2.51 
RP11-342M1.3 3.35E-06 5.84 2.55E-04 2.97 7.10E-04 2.60 1.37E-03 2.25 4.98E-01 1.14 4.57E-03 1.97 
CLDND2 7.49E-06 5.83 6.22E-04 2.88 3.25E-03 2.31 9.41E-04 2.53 3.11E-01 1.25 5.81E-03 2.03 
TRIM55 3.89E-07 5.17 3.93E-05 2.76 4.76E-04 2.13 6.47E-05 2.43 9.48E-02 1.30 1.07E-03 1.87 
HSPA1B 2.29E-06 5.13 1.00E-03 2.25 7.14E-04 2.34 7.43E-04 2.19 8.28E-01 -1.04 5.18E-04 2.27 
RALYL 1.23E-06 5.00 1.19E-05 3.57 1.60E-03 2.02 1.23E-04 2.47 4.01E-03 1.76 5.42E-02 1.40 
TTC39A 1.82E-08 4.72 6.18E-07 3.01 2.05E-05 2.15 7.82E-06 2.19 6.49E-03 1.40 9.01E-04 1.57 
MLPH 2.11E-07 4.71 9.39E-05 2.26 7.06E-05 2.33 1.68E-04 2.03 8.33E-01 -1.03 1.22E-04 2.08 
GPC2 5.80E-07 4.69 7.18E-05 2.53 7.51E-04 2.00 7.90E-05 2.34 1.24E-01 1.26 1.03E-03 1.85 
ZFR2 6.94E-06 4.46 3.29E-04 2.62 1.65E-03 2.18 1.71E-03 2.05 3.08E-01 1.20 1.11E-02 1.70 
WNT5B 3.03E-07 4.20 1.65E-05 2.59 1.27E-04 2.13 1.64E-04 1.97 1.35E-01 1.22 2.19E-03 1.62 
PRDX2P4 1.20E-07 3.72 1.06E-04 1.91 3.33E-05 2.09 1.43E-04 1.78 3.90E-01 -1.10 4.00E-05 1.95 
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Fold-Change                       





(D30 vs. D90) 
Fold-Change                       





(D30 vs. D90) 
Fold-Change                       
(D30 vs. D90) (Description) 
BCL6B -25.60 Day 30 down vs Day 90 GATAD2B -2.82 Day 30 down vs Day 90 ZNFX1 -2.19 Day 30 down vs Day 90 
ARHGAP29 -13.69 Day 30 down vs Day 90 RPS6KA2 -2.80 Day 30 down vs Day 90 EPHA5 -2.18 Day 30 down vs Day 90 
RORB -10.35 Day 30 down vs Day 90 CYBRD1 -2.73 Day 30 down vs Day 90 CNOT6 -2.18 Day 30 down vs Day 90 
PLSCR4 -9.92 Day 30 down vs Day 90 FOXP1 -2.73 Day 30 down vs Day 90 ZDHHC9 -2.16 Day 30 down vs Day 90 
FGD5 -6.84 Day 30 down vs Day 90 UNKL -2.72 Day 30 down vs Day 90 ASXL2 -2.15 Day 30 down vs Day 90 
TSHZ3 -6.43 Day 30 down vs Day 90 GALNT10 -2.65 Day 30 down vs Day 90 SNX30 -2.15 Day 30 down vs Day 90 
KCNJ8 -5.94 Day 30 down vs Day 90 SNRK -2.64 Day 30 down vs Day 90 AEBP2 -2.15 Day 30 down vs Day 90 
GPC6 -5.34 Day 30 down vs Day 90 LATS2 -2.54 Day 30 down vs Day 90 FBXO11 -2.13 Day 30 down vs Day 90 
HEG1 -5.28 Day 30 down vs Day 90 BMPR2 -2.50 Day 30 down vs Day 90 CTDSPL -2.12 Day 30 down vs Day 90 
KLF3 -5.09 Day 30 down vs Day 90 RELA -2.49 Day 30 down vs Day 90 UBE2J1 -2.10 Day 30 down vs Day 90 
RUNX1 -4.79 Day 30 down vs Day 90 RORA -2.48 Day 30 down vs Day 90 MDM4 -2.10 Day 30 down vs Day 90 
MBNL3 -4.69 Day 30 down vs Day 90 MEX3A -2.45 Day 30 down vs Day 90 ZC3H12C -2.06 Day 30 down vs Day 90 
FAT4 -4.57 Day 30 down vs Day 90 CDK19 -2.42 Day 30 down vs Day 90 TBC1D8B -2.05 Day 30 down vs Day 90 
ZNF697 -4.36 Day 30 down vs Day 90 IRF2BP2 -2.39 Day 30 down vs Day 90 IP6K1 -2.04 Day 30 down vs Day 90 
BNC2 -4.26 Day 30 down vs Day 90 KLF12 -2.36 Day 30 down vs Day 90 UBE2R2 -2.04 Day 30 down vs Day 90 
TRPS1 -4.24 Day 30 down vs Day 90 MBNL2 -2.34 Day 30 down vs Day 90 HK1 2.15 Day 30 up vs Day 90 
ZFPM2 -4.21 Day 30 down vs Day 90 ZBTB44 -2.33 Day 30 down vs Day 90 TIPARP 2.30 Day 30 up vs Day 90 
TET3 -3.65 Day 30 down vs Day 90 RPS6KA3 -2.32 Day 30 down vs Day 90 ZFHX4 2.64 Day 30 up vs Day 90 
TGFBR2 -3.63 Day 30 down vs Day 90 TNS1 -2.31 Day 30 down vs Day 90 PFKP 2.66 Day 30 up vs Day 90 
NR2F2 -3.59 Day 30 down vs Day 90 RNF38 -2.26 Day 30 down vs Day 90 MYLK 2.71 Day 30 up vs Day 90 
PEAK1 -3.42 Day 30 down vs Day 90 ABL2 -2.26 Day 30 down vs Day 90 EPHA7 3.23 Day 30 up vs Day 90 
ULK1 -3.34 Day 30 down vs Day 90 TIMP3 -2.26 Day 30 down vs Day 90 SYT14 5.52 Day 30 up vs Day 90 
ZFPM1 -3.29 Day 30 down vs Day 90 PPP3R1 -2.26 Day 30 down vs Day 90 CYBB 8.40 Day 30 up vs Day 90 
CREB5 -3.09 Day 30 down vs Day 90 GAB2 -2.23 Day 30 down vs Day 90 TRHDE 8.71 Day 30 up vs Day 90 
ASAP1 -2.96 Day 30 down vs Day 90 PAK2 -2.21 Day 30 down vs Day 90 FSTL5 10.29 Day 30 up vs Day 90 
PKD2 -2.89 Day 30 down vs Day 90 NR2C2 -2.20 Day 30 down vs Day 90 
   ZBTB7A -2.85 Day 30 down vs Day 90 PHLPP2 -2.19 Day 30 down vs Day 90 
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Fold-Change                       







Fold-Change                       







Fold-Change                       
(D30 vs. D90) (Description) 
BCL6B -25.5965 Day 30 down vs Day 90 TCF7L1 -2.97118 Day 30 down vs Day 90 HMBOX1 -2.22313 Day 30 down vs Day 90 
RORB -10.3475 Day 30 down vs Day 90 NFIA -2.93904 Day 30 down vs Day 90 NR2C2 -2.2011 Day 30 down vs Day 90 
NFIB -8.09729 Day 30 down vs Day 90 PKD2 -2.88517 Day 30 down vs Day 90 EPHA5 -2.18236 Day 30 down vs Day 90 
TSHZ3 -6.42572 Day 30 down vs Day 90 ZBTB7A -2.85341 Day 30 down vs Day 90 CNOT6 -2.18194 Day 30 down vs Day 90 
APBB2 -5.62895 Day 30 down vs Day 90 FOXP1 -2.72602 Day 30 down vs Day 90 ASXL2 -2.15156 Day 30 down vs Day 90 
PRRX1 -5.56372 Day 30 down vs Day 90 FOXJ2 -2.71467 Day 30 down vs Day 90 AEBP2 -2.14562 Day 30 down vs Day 90 
RUNX1 -4.78903 Day 30 down vs Day 90 TP53INP2 -2.70208 Day 30 down vs Day 90 MDM4 -2.09508 Day 30 down vs Day 90 
ZNF697 -4.35972 Day 30 down vs Day 90 CCND1 -2.68979 Day 30 down vs Day 90 AHR -2.06683 Day 30 down vs Day 90 
BNC2 -4.25529 Day 30 down vs Day 90 BMPR2 -2.50171 Day 30 down vs Day 90 NFYA -2.02035 Day 30 down vs Day 90 
TRPS1 -4.24474 Day 30 down vs Day 90 RELA -2.49423 Day 30 down vs Day 90 SETD7 -2.01176 Day 30 down vs Day 90 
ZFPM2 -4.20865 Day 30 down vs Day 90 RORA -2.47789 Day 30 down vs Day 90 TMEM100 2.04343 Day 30 up vs Day 90 
ELK4 -4.12117 Day 30 down vs Day 90 INO80D -2.43012 Day 30 down vs Day 90 ELAVL2 2.22349 Day 30 up vs Day 90 
TET3 -3.64749 Day 30 down vs Day 90 FOXO3 -2.40099 Day 30 down vs Day 90 BAMBI 2.58174 Day 30 up vs Day 90 
NR2F2 -3.59439 Day 30 down vs Day 90 ARID5B -2.39598 Day 30 down vs Day 90 POLR3G 2.70467 Day 30 up vs Day 90 
RGMB -3.31117 Day 30 down vs Day 90 IRF2BP2 -2.39273 Day 30 down vs Day 90 DKK1 3.0768 Day 30 up vs Day 90 
ZFPM1 -3.28907 Day 30 down vs Day 90 KLF12 -2.36267 Day 30 down vs Day 90 FOXF2 7.45493 Day 30 up vs Day 90 
E2F7 -3.24071 Day 30 down vs Day 90 MAML1 -2.33308 Day 30 down vs Day 90 ALX4 12.5154 Day 30 up vs Day 90 
CREB5 -3.09017 Day 30 down vs Day 90 ZBTB44 -2.32786 Day 30 down vs Day 90       
TP53INP1 -3.02878 Day 30 down vs Day 90 RPS6KA3 -2.31955 Day 30 down vs Day 90   






























































hsa-let-7a-5p 2.16E-02 13.29  4.48E-02 1.75  3.34E-01 1.02  8.39E-02 12.27  1.80E-01 1.66  6.17E-01 11.54  
hsa-let-7b-5p 7.85E-01 -1.27 2.97E-01 -1.62 1.00E+00 -0.94 7.42E-01 -0.33 1.96E-01 -1.61 3.90E-01 0.35  
hsa-let-7c-5p 1.53E-03 3.13  9.21E-03 2.07  3.92E-02 0.66  1.04E-01 2.47  4.49E-01 2.66  3.52E-01 1.06  
hsa-let-7f-5p 2.13E-02 4.94  2.75E-02 3.80  4.90E-01 0.41  5.97E-04 4.53  5.77E-04 10.52  7.91E-01 1.14  
hsa-let-7g-5p 1.24E-01 2.41  2.01E-02 5.53  1.97E-02 4.28  4.00E-01 -1.87 9.84E-01 2.37  3.96E-01 -3.11 
hsa-miR-1 3.12E-02 4.53  7.97E-01 -0.32 5.85E-01 -0.24 2.31E-02 4.76  6.88E-01 -1.06 1.01E-02 4.85  
hsa-miR-100-5p 2.09E-01 2.58  5.00E-01 1.11  9.86E-01 0.79  1.25E-01 1.79  3.90E-01 1.25  4.57E-01 1.47  
hsa-miR-1225-3p 6.38E-01 -10.44 2.79E-02 -12.77 2.84E-01 -11.77 5.13E-01 1.33  1.45E-01 -2.00 5.08E-02 2.33  
hsa-miR-125b-5p 9.63E-02 2.83  4.17E-02 4.91  9.09E-01 0.98  3.38E-02 1.84  8.51E-03 15.25  7.32E-01 -2.09 
hsa-miR-126-3p 4.85E-01 10.96  4.51E-01 -1.16 3.23E-01 -1.11 5.24E-02 12.07  7.77E-01 -1.04 9.49E-02 12.12  
hsa-miR-133a-3p 8.09E-01 1.50  9.85E-02 -1.91 3.97E-01 -0.57 2.12E-01 2.07  3.03E-01 -2.54 3.26E-02 3.42  
hsa-miR-143-3p 7.70E-01 0.06  7.82E-02 -0.98 4.63E-01 -0.72 6.30E-01 0.78  1.91E-01 -1.20 9.77E-02 1.04  
hsa-miR-146b-5p 1.31E-02 13.60  9.15E-03 13.60  3.18E-01 0.44  5.46E-02 13.16  3.81E-02 9162.23  1.00E+00 0.00  
hsa-miR-181a-5p 7.30E-02 2.79  3.17E-01 1.03  7.90E-01 0.48  6.15E-02 2.31  3.59E-01 1.47  3.01E-01 1.76  
hsa-miR-181b-5p 4.81E-01 -0.42 3.29E-01 1.07  1.02E-01 2.23  3.05E-01 -2.65 4.13E-01 -2.22 7.88E-01 -1.50 
hsa-miR-1973 1.32E-02 -13.78 4.41E-01 -11.33 4.65E-01 -10.70 2.72E-02 -3.08 9.52E-01 -1.55 3.30E-02 -2.45 
hsa-miR-199a-3p 4.35E-02 13.20  2.41E-01 2.26  8.74E-01 0.22  2.42E-02 12.98  2.07E-01 4.09  2.63E-01 10.94  
hsa-miR-199b-3p 2.55E-02 13.31  4.68E-02 3.24  5.90E-01 0.49  3.47E-02 12.83  6.78E-02 6.73  6.61E-01 10.07  
hsa-miR-199b-5p 4.63E-01 12.18  3.19E-01 -0.22 3.71E-01 0.09  6.03E-02 12.08  8.90E-01 -1.24 4.82E-02 12.39  
hsa-miR-208b-3p 4.31E-01 12.18  9.51E-01 1.12  1.67E-01 -0.74 1.37E-02 12.92  7.71E-02 3.65  3.84E-01 11.05  
hsa-miR-21-5p 8.06E-01 1.11  4.64E-01 0.53  6.74E-01 0.38  4.39E-01 0.73  6.92E-01 1.11  2.63E-01 0.58  
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hsa-miR-210-3p 3.39E-01 0.88  4.08E-01 -0.63 9.07E-01 0.20  3.06E-01 0.68  2.43E-01 -1.78 4.09E-02 1.51  
hsa-miR-222-3p 9.91E-01 -0.43 1.76E-01 -0.82 6.14E-01 -0.63 5.57E-01 0.20  2.85E-01 -1.14 1.23E-01 0.39  
hsa-miR-26a-5p 4.23E-02 13.82  2.56E-01 1.88  8.13E-01 1.01  2.88E-02 12.81  2.62E-01 1.83  2.40E-01 11.94  
hsa-miR-26b-5p 6.54E-01 0.42  4.67E-01 1.02  8.83E-01 0.73  7.07E-01 -0.30 4.69E-01 1.22  7.71E-01 -0.59 
hsa-miR-302a-5p 1.00E-01 -2.04 2.15E-01 -1.40 4.89E-01 1.88  6.87E-03 -3.92 1.93E-02 -9.66 5.64E-01 -0.65 
hsa-miR-30a-5p 4.57E-01 11.35  6.85E-01 -0.95 4.69E-01 -1.21 8.87E-02 12.56  6.98E-01 1.20  1.80E-01 12.30  
hsa-miR-30c-5p 7.47E-01 2.89  9.39E-01 1.49  1.78E-01 -1.10 5.75E-02 3.99  8.20E-02 6.02  7.65E-01 1.40  
hsa-miR-30d-5p 1.84E-01 1.82  4.47E-01 0.63  2.58E-01 0.93  7.41E-01 0.89  2.22E-02 -1.23 1.65E-02 1.19  
hsa-miR-30e-5p 6.42E-01 -10.22 1.23E-01 -12.80 1.60E-01 -11.92 2.96E-01 1.71  8.48E-01 -1.83 2.28E-01 2.58  
hsa-miR-320a 6.80E-01 -0.50 2.75E-01 2.34  8.19E-01 -0.14 4.48E-01 -0.36 1.04E-01 5.58  4.53E-01 -2.84 
hsa-miR-3609 1.76E-02 2.63  4.01E-01 1.65  6.77E-01 1.17  1.59E-02 1.46  5.93E-01 1.39  5.38E-02 0.98  
hsa-miR-3687 6.39E-01 -10.22 1.40E-01 -12.12 1.43E-01 -12.51 2.68E-01 2.30  9.75E-01 1.32  2.62E-01 1.90  
hsa-miR-425-5p 1.13E-01 2.45  3.74E-01 2.30  3.66E-01 1.63  3.64E-01 0.82  9.93E-01 1.60  3.66E-01 0.14  
hsa-miR-4461 6.54E-03 -3.23 1.86E-03 -2.66 1.22E-01 -1.47 1.05E-01 -1.76 3.62E-02 -2.28 7.38E-01 -0.57 
hsa-miR-4485 1.27E-01 -2.14 3.60E-02 -2.82 1.49E-02 -3.26 3.27E-01 1.13  6.71E-01 1.36  5.59E-01 0.68  
hsa-miR-4521 2.70E-02 13.17  9.79E-02 3.22  3.74E-01 0.65  8.83E-02 12.52  3.26E-01 5.91  4.21E-01 9.96  
hsa-miR-5096 6.84E-02 -3.60 1.19E-01 -3.08 9.77E-02 -3.01 7.34E-01 -0.59 6.52E-01 -1.05 8.84E-01 -0.52 
hsa-miR-6087 4.20E-04 -5.73 6.10E-03 -4.12 1.48E-02 -3.58 9.06E-02 -2.15 6.38E-01 -1.45 2.07E-01 -1.62 
hsa-miR-619-5p 2.58E-02 -14.07 4.15E-02 -13.53 1.30E-02 -14.27 8.82E-01 0.20  5.70E-01 1.67  7.10E-01 -0.55 
hsa-miR-6723-5p 3.40E-02 -1.09 5.78E-01 0.41  9.68E-01 1.48  1.25E-02 -2.57 5.21E-01 -2.10 5.44E-02 -1.50 
hsa-miR-7641 2.01E-02 -1.61 2.39E-02 -1.48 6.27E-01 -0.31 2.27E-02 -1.30 2.61E-02 -2.26 8.19E-01 -0.13 
hsa-miR-99a-5p 6.13E-01 -0.71 4.07E-01 -0.49 5.01E-01 0.59  8.78E-01 -1.30 6.69E-02 -2.11 1.26E-01 -0.22 




        Appendix 5 - 9 Dot plots of different miRNAs that are expressed differentially in d90 and d30 EHMs 
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Miscellaneous Appendix - 1 List of primers 
 
1. MYL2f   : 5’-CTG TAT GAG CAA GCA ATG GTG CCG-3’ 
2. MYL2r   : 5’-GTG ACA GAA AAC AGA GGC CTC CCC-3’ 
3. SeqPrmr1  : 5’-CAC AGC AGG TGG AAA GTG AA-3’ 
4. SeqPrmr2  : 5’-ATG CAC TTT TCC TTC CTT GC-3’ 
5. SeqPrmr3  : 5’-TAC TCG GGG GAG AGA GAT GA-3’ 
6. SeqPrmr4  : 5’-TCC GCT TCC TTC TTG TCA CT-3’ 
7. SeqPrmr5  : 5’-AGT TCA CTG CAG CCT CGA C-3’ 
8. SeqPrmf1  : 5’-TGG CAA GGG CAA TAT AAG TG-3’ 
9. SeqPrmf2  : 5’-TTA TAC CCC CAC ACC AAT CC-3’ 
10. SeqPrmf3  : 5’-TGG GTG GCT ATG GGT ACT TC-3’ 
11. SeqPrmf4  : 5’-GCC TGG ATG TGA GTT GAC CT-3’ 
12. Phlox5   : 5’-aga Gat AAC TTC GTA TAG CAT ACA TTA TAC GAA GTT ATG CTG CAG GAA TTC TAC CGG GTA G-3’ 
13. Phlox3   : 5’-tct cAT AAC TTC GTA TAA TGT ATG CTA TAC GAA GTT ATA AGC AAT AGT AAA GAG CCT TCA G-3’ 
14. SAC-Primer1-1  : 5'-CCA CGG AGA AGA GAA GGA CG-3’ 
15. SAC-Primer1-2  : 5’-GCA CAT CAT CAC CCA CGG AGA AGA GAA-3’ 
16. SAC-Primer2-1  : 5’-TCC GCC TCA GAA GCC ATA GA-3’ 
17. SAC-Primer2-2  : 5’-CAG CTG GTT CTT TCC GCC TC-3’ 
18. SAC-Primer3-1  : 5’-AGA GAT AAC TTC GTA TAG CAT ACA T-3’ 
19. SAC-Primer3-2  : 5’-AAG AAC CAG CTG AGA GAT AAC TTC GTA TAG CAT ACA T-3’ 
20. SAC-Primer4-1  : 5’-TCT CAT AAC TTC GTA TAA TGT ATG C-3’ 
21. SAC-Primer4-2  : 5’-ACC ACT CTG CAA TCT CAT AAC TTC GTA TAA TGT ATG C-3’ 
22. SAC-Primer5-1  : 5’- CCC TGC CCT CAT CTC TCT C-3’ 
23. SAC-Primer5-2  : 5’-TTG CAG AGT GGT CCC TGC CCT CAT CTC TCT C-3’ 
24. SAC-Primer6-1  : 5’-ACC AGG TTC TTG TAG TCC AAG TT-3’ 
25. SAC-Primer6-2  : 5’- GTG ATG ATG TGC ACC AGG TTC TTG TAG TC-3’ 
26. Reverse Primer C     : 5’– AAC TGA GGG GAC AGG ATG TC – 3’ 
27. Forward primer Phlox-M : 5’– CTC GTC CGA GGG CAA AGG AA – 3’  
28. Forward primer L-Phlox : 5’– TTG CCC CTC CCC CGT GCC TT – 3’  
29. Reverse primer L-Phlox : 5’– CAA AGG CCT ACC CGC TTC CA – 3’  
30. Seq-hyg-f1                : 5’– CAT TCT GCA CGC TTC AAA AG – 3’ 
31. Seq-hyg-f2                  : 5’– CGA GGA CTG CCC CGA AGT CC – 3’  
32. Seq-hyg-r1                : 5’– TGA CAG GAA AAA CTT CCA TTT T – 3’  
33. Seq-hyg-r2             : 5’– GGC CCA AAG CAT CAG CTC – 3’  
34. TAL-5                          : 5’– CAC CAT GGG AAA ACC TAT TCC TAA TCC – 3’ 
35. TAL-3                           : 5’– TTA TCA GAA GTT GAT CTC GCC GTT – 3’  
36. MYL2KI-F   :5’-GGT GCG GTA GTG AGT TTG GT-3’ 
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37. MYL2KI-R    :5’-CTT CAG CTT CAG CCT CTG CT-3’ 
38. Nde508F   :5’-TGC ACC TGT GGT CTC AGC TAC-3’ 
39. Nde508R   :5’-TGG TTC AGG AGG ACT CTG ATT T-3’ 
40. Nde500F   :5’-AGG CAA AGG CAG ATG AGC TA-3’ 
41. Nde500R   :5’-GGG ACT CTT GCA GCC ATA AC-3’ 
42. Puro Phlox 5  : 5'- AGA GAT AAC TTC GTA TAG CAT ACA TTA TAC GAA GTT ATG CTG CAG GAA TTC TAC CGG GTA GGG GA-3' 
43. Puro Phlox 3  : 5'- TCT CAT AAC TTC GTA TAA TGT ATG CTA TAC GAA GTT ATG GCC ACA ACT CCT CAT AAA GA-3' 
44. Cherry-F     : 5’- CCCCGTAATGCAGAAGAAGA-3’  
45. Cherry-R     : 5’- TTGACCTCAGCGTCGTAGTG-3’ 
46. KIgDNA-F    : 5’- GTCCTTAGCACGTGTTGCTG-3’  
47. KIgDNA-R    : 5’- AGGAAAGGACAGTGGGAGTG-3’ 
48. KIhomo-F     : 5’- CATTGCAGGTTGACCAGATG-3’  
49. KIhomo-R     : 5’- CAAGGCCCTCTAAATGCTTG- 3’ 
50. MYL-tcp-F  : 5’- ATTCTTCTCGGGAGGCAGTG-3’ 
51. MYL-spl-seq-R  : 5’- AGGTCCAGGGTTCTCCTCC -3’ 
52. qPCR-KI-R  : 5’- GCCGTCCTCGAAGTTCATCA -3’ 
53. MYL2-KI-R  : 5’- CTTCAGCTTCAGCCTCTGCT-3’ 
54. MYL-tcp-R  : 5’- GCAGGAGCAAGGTGAGATGA-3’ 
55. Neo-F   : 5’-ATGCCTGCTTGCCGAATATC-3’ 
56. Neo-R   : 5’-TCAGCAATATCACGGGTAGCC-3’ 
57. Luc-F   :5’-TCGTCGACATTCCTGAGATTCC-3’ 
58. Luc-R   :5’-TCTTGAGCAGGTCAGAACACTG-3’ 
59. Seq-puro-F  :5’-CTG GAC CAC GCC GGA GAG-3’ 





Miscellaneous Appendix - 2 Materials 
 
1. Cell lines 
Name Cat. No Company 
HES3 and H9  WiCell Research Institute, Inc 
MBJ5 and MBJ6  In-house  (by Manasi and  
Dr. Vinod Verma) 
EmbryoMax® Primary Mouse Embryo Fibroblasts, Not 
Mytomycin C Treated, Strain CF1, passage 3   
PMEF-CFL Millipore 
MEF (DR4) Mouse Embryonic fibroblasts SCRC-1045 ATCC 
HFF-1 Human Foreskin Fibroblasts SCRC-1041 ATCC 
EmbryoMax® Primary Mouse Embryo Fibroblasts, 
Hygromycin resistant, passage 3   
PMEF-HL Millipore 
Normal Human Dermal Fibroblasts (neonatal skin) CC-2509 Lonza 
Puromycin-Resistant Mouse Embryonic Fibroblasts, Day 
E13.5 
00325 Stemcell technologies 
2. Cell culture and differentiation components    
Name Cat. No Company 
Dulbecco’s Modified Eagle’s Medium (DMEM) 11965-092 Gibco, Life Technologies 
Fetal Bovine Serum 10270-106 Gibco, Life Technologies 
DMEM:F12 10565-018 and 11330-032 Gibco, Life Technologies 
KnockOut™ Serum Replacement (KOSR) 10828-028 Gibco, Life Technologies 
BD Matrigel hESC-qualified Matrix 354277 BD Biosciences 
BD Matrigel Matrix Growth Factor Reduced  354230 BD Biosciences 
Non-Essential Amino Acids solution (100x) 11140-050 Gibco, Life Technologies 
Penicillin-Streptomycin-Glutamine (100X) 10378-016 Gibco, Life Technologies 
Human recombinant bFGF 13256029 Gibco, Life Technologies 
RPMI 1640 Medium, GlutaMAX™ Supplement 61870-036 Gibco, Life Technologies 
Sodium Pyruvate (100 mM) 11360-070 Gibco, Life Technologies 
Penicillin-Streptomycin (10,000 U/mL) 15140-122 Gibco, Life Technologies 
B-27® Supplement (50X), serum free 17504-044 Gibco, Life Technologies 
B-27® Supplement, minus insulin A1895601 Gibco, Life Technologies 
Iscove’s liquid medium without L-Glutamine F 0465 Biochrom, Merck Millipore 
Recombinant Albumin A9731 Sigma 
Bovine Serum Albumin A3311 Sigma 
L-Glutamine (200 mM) 25030-081 Gibco, Life Technologies 
mTeSR™1 05850 Stemcell Technologies 
Geneticin® Selective Antibiotic (G418 Sulfate) 10131-027 Gibco, Life Technologies 
G418 Sulfate 345812 Calbiochem 
Puromycin Dihydrochloride A11138-03 Gibco, Life Technologies 
Hygromycin B 400050 CAlbiochem 
BMS453 3409 Tocris Bioscience 
rh-Dkk1 1096-DK R&D systems 
bFGF 130-093-841 Miltenyi Biotech 
Activin-A 338-AC R&D systems 
BMP4 314-BP R&D systems 
IGF-1 AF-100-11 Peprotech 
VEGF AF-100-20 Peprotech 
FGF AF-100-18B Peprotech 
TGF-β1 AF-100-21C Peprotech 
Lipid Mixture 1, Chemically Defined L0288 Sigma 
Type I, Bovine Soluble Collagen CS019 Collagen Solutions LLC 






3. Chemicals, small molecules and enzymes 
Name Cat. No Company 
Collagenase I C0130 Sigma 
NAOH   
CaCl2   
Y27632 04-0012-10 Stemgent 
2-Mercaptoethanol (55mM) 21985-023 Gibco, Life Technologies 
L-Ascorbic acid 2-phosphate sesquimagnesium salt hydrate A8960-5G Sigma 
DPBS, no calcium, no magnesium 14190-144 Gibco, Life Technologies 
DPBS, calcium, magnesium 14040-133 Gibco, Life Technologies 
DPBS, calcium, magnesium, glucose, pyruvate 14287-080 Gibco, Life Technologies 
Goat Serum, New Zealand origin 16210-064 Gibco, Life Technologies 
IWP4 04-0036 Stemgent 
IWR1 I0161-5MG Sigma 
CHIR99021 04-0004 Stemgent 
Dimethyl sulfoxide (DMSO) D2650 Sigma 
Roti ® -Histofix 4% P087.5 Carl Roth 
TRIzol® Reagent 15596-026 Ambion, Life Technologies 
Sodium Lactate   
Isoprenaline hydrochloride I5627 Sigma 
Gemfibrozil G9518 Sigma 
0.25% Trypsin with EDTA 25300-054 Gibco, Life Technologies 
DNAse  260913 Calbiochem 
Hoechst 33342, Trihydrochloride, Trihydrate H3570 Invitrogen, Life Technologies 
Triton X-100 T8787 Sigma 
Expand High FidelityPLUS PCR System 03300242001 Roche 
Expand Long Template PCR System 11681834001 Roche 
Taq DNA Polymerase, native 18038042 Invitrogen, Life Technologies 
10x DreamTaq Buffer B65 Thermo Scientific 
X-Gal Solution, ready-to-use R0941 Thermo Scientific 
DNAse I recombinant, RNAse free 04716728001 Roche 
Phusion Green Hot Start II High-Fidelity DNA Polymerase (2 
U/µL) 
F-537L Thermo Scientific 
DpnI R0176S NEB 
EcoRI-HF® R3101S NEB 
NheI-HF® R3131S NEB 
SalI-HF® R3138S NEB 
NdeI R0111S NEB 
NotI-HF® R3189S NEB 
HindIII R0104S NEB 
SpeI R0133S NEB 
Mitomycin-C  Kyowa Hakko Kirin 
BglII R0144S NEB 
  
4. Antibodies and Kits   
Name Cat. No Company 
IgG1 control MAB002 R&D systems 
α-Actinin A7811 Sigma 
SOX2  MAB2018 R&D 
OCT4 AF1759 R&D 
NANOG  R&D 
SSEA-4 AB16287 Abcam 
TRA-1-60 AB16288 Abcam 
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Goat anti mouse Alexa 488 A11001 Invitrogen, Life technologies 
Goat anti rabbit Alexa 546 A11010 Invitrogen, Life technologies 
Goat anti mouse Alexa 546 A11003 Invitrogen, Life technologies 
Goat anti rabbit Alexa 488 A11008 Invitrogen, Life technologies 
DNeasy Blood & Tissue Kit (250) 69506  Qiagen 
First Strand cDNA Synthesis Kit K1612 Thermo scientific 
iQ™ SYBR® Green Supermix 170-8880 Biorad 
QIAquick Gel Extraction Kit 28706  Qiagen 
QIAquick PCR Purification Kit 28106  Qiagen 
TOPO® TA Cloning® Kit for Subcloning, with One Shot® 
TOP10 chemically competent E. coli cells 
K4500-01 Invitrogen, Life Technologies 
RNeasy Mini Kit  74106  Qiagen 
Wizard® SV Gel and PCR Clean-Up System A9282 Promega 
QIAprep Spin Miniprep Kit 27106  Qiagen 
PureLink® HiPure Plasmid Filter Maxiprep Kit K2100-17 Invitrogen, Life Tehcnologies 
 
5. Equipments   
Name Company 
Kryo 750 Plus Planer 
CASY cell counter and analyzer Roche 
Gene Pulser Xcell™ Electroporation Systems Biorad 
Veriti® Thermal Cycler Applied Biosystems, Life Technologies 
Stratalinker® UV Crosslinker Stratagene 
                                                              
6. Software   
Name Company 
Partek® Flow® and Genomics Suite® Partek Inc. 
Graphpad Prism  Graphpad Software 
 
 
